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Abstract  
Atrial fibrillation is common in older people, and is associated with increased mortality 
and stroke. Patients with atrial fibrillation/flutter (AF) also commonly have frailty, which 
is associated with increased risk of a range of further adverse clinical outcomes. 
However, there is a lack of evidence on the burden and management of AF in people 
with frailty.  
A study using the primary care electronic health records of 536,955 patients aged ≥65 
years was conducted to investigate the burden of frailty and AF amongst older people, 
and their associations with clinical outcomes. 
A systematic review and meta-analysis was completed to establish the current 
knowledge base, and to inform the quantitative analyses.  Baseline characteristics 
were described and compared between those with and without AF as well as by frailty 
category according to the electronic frailty index. Rates of all-cause mortality, stroke, 
bleeding (intracranial and gastrointestinal), transient ischaemic attack (TIA), and falls 
were calculated per 1000 person-years, and compared with the non-AF patient 
population. 
Cox proportional hazards modelling was used to determine unadjusted and adjusted 
risk for each clinical outcome and mortality, and presented as hazard ratios (HR) 
alongside 95% confidence intervals.  The association between oral anticoagulation 
(OAC) prescription stratified by frailty category with clinical outcomes was investigated 
using Cox proportional hazards modelling. 
At baseline, 61,177 (11.4%) patients had AF. People with AF had a higher burden of 
frailty than those without (89.5% vs. 55.3%) and had higher rates of mortality, stroke, 
TIA and bleeding. Of patients with AF and eligible for OAC, it was prescribed in 53.1% 
(41.7% in robust, mild frailty 53.2%, moderate 55.6%, severe 53.4%). OAC was 
associated with a 19% reduction in all-cause mortality (HR 0.81, 95%CI 0.77-0.85) and 
22% reduction in stroke (HR 0.78, 0.67-0.92). There was no statistically significant 
difference in rates of bleeding between those prescribed and not prescribed OAC. 
For the first time in a large representative cohort of older people, this study quantified 
the burden of AF and frailty, and their association with a range of clinical outcomes. 
This study found no evidence that OAC should be withheld on the basis of concomitant 
frailty.  
vi 
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Chapter 1 – Frailty and the heart 
 
Globally, there are 962 million people over the age of 60 years, which is 
anticipated to rise to 2.1 billion in the next thirty years.2 This remarkable 
demographic shift is likely to have far-reaching cultural, social and economic 
consequences, and alongside these, a substantial burden of ill-health in the 
form of multiple long-term conditions.  
 
A person with disability has a long-term restriction in their ability to perform an 
activity.3 Disability-free life expectancy is the average number of years an 
individual is expected to live free of disability, assuming that current patterns of 
mortality and disability continue.4 In the United Kingdom in 2016, disability-free 
life expectancy was 63 years, followed by 16 years with disability in men and 20 
years in women.5 
 
Multimorbidity is the coexistence of two or more long-term conditions in an 
individual.6 Providing healthcare to a growing population of older people with 
multimorbidity and disability is a major challenge for healthcare systems, 
because there is the potential for substantial increases in the requirement for 
healthcare provision, and associated costs.7 However, there is limited evidence 
that ‘more healthcare’ will necessarily improve outcomes.8 There is a clear need 
to identify patients that are likely to benefit from medical interventions in order to 
maximise their utility. Chronological age alone is not an adequate, or equitable, 
metric for clinical decision making,9 and so frailty has been proposed as a 
framework for a more individualised approach to patient management. Frailty is 
a condition in which there is a decline in biological reserves and deterioration in 
physiological mechanisms, which render the person vulnerable to a range of 
adverse outcomes.10 Frailty provides an insight into biological age and is more 
useful than chronological age in predicting adverse events including death.11 
 
2 
 
In this thesis, I will investigate the implications of frailty on outcomes and 
thromboembolism prevention for older people with a common long-term 
cardiovascular condition, atrial fibrillation (AF). Within this chapter I will provide 
a broad overview of frailty, discuss frailty in the context of cardiovascular 
disease, and then specifically in AF. In Chapter 2, a systematic review of the 
literature will be reported, followed by a summary of the data sources that could 
be considered for use in the study. The methodology and results of the 
quantitative analysis will be detailed in Chapters 4 to 8, and these will be 
critically discussed in the context of the literature in Chapter 9.  
 
1.1 Aims and objectives 
This thesis will investigate the impact of frailty on clinical outcomes in older 
people with AF. The aims and objectives below have been informed by a 
systematic review of the literature reported in Chapter 2. 
 
Aims 
1. To establish the prevalence of AF and frailty in people aged 65 years and 
over 
2. To describe the clinical characteristics of people with AF at different 
levels of frailty 
3. To identify whether prescription of oral anticoagulation (OAC) differs by 
frailty category in people with AF 
4. To determine whether frailty modifies the association between OAC use 
and clinical outcomes. 
 
  
3 
 
Research questions 
1. What is the population prevalence of AF in older people with different 
levels of frailty? 
2. What differences are there in the clinical characteristics of people with 
AF, compared to those without? 
3. Is frailty associated with different OAC prescribing in patients with AF? 
4. Is OAC prescription associated with similar efficacy and safety endpoints 
for older people with different levels of frailty?  
 
Objectives 
To use ResearchOne primary care electronic health record data to:  
1. establish the population prevalence of atrial fibrillation, stratified by 
electronic frailty index categories. 
2. report prescription rates of OAC in patients with AF by frailty category 
3. estimate the association between frailty and OAC prescription. 
4. report rates of clinical outcomes (stroke, death and major bleeding) by 
frailty category and OAC prescription status.  
5. investigate the association between OAC and clinical outcomes (stroke, 
death and major bleeding), and whether the association is modified by 
frailty. 
 
  
4 
 
1.2 Frailty 
Over time, damage accumulates at a cellular level as a part of the ageing 
process. This leads to a gradual deterioration in function, and a reduction in 
homeostatic mechanisms across a range of organ systems.12 In health, there is 
considerable physiological redundancy to most body systems. For example, 
humans have substantially more renal nephrons than are required for survival, 
which compensates for age-related deterioration.13 However, in people with 
frailty there is acceleration of the loss of biological reserves, leading to failure of 
homeostatic mechanisms and vulnerability to a range of adverse clinical 
outcomes as a result of stressor events.10  
 
Physiological regulatory systems are dynamic and interconnected, and 
therefore the loss of adaptive capacity that characterises frailty tends to have 
effects across multiple organ systems.10, 13 These changes have been 
described in skeletal muscle, the brain, and in the endocrine, immune, 
cardiovascular, respiratory and renal systems.10 
 
Frailty may explain the differential vulnerability to adverse outcomes of people 
of the same chronological age.11, 14-16 Frailty has important prognostic 
implications, as people with frailty are at a greater risk of nursing home 
admission and of all-cause mortality than those without frailty.11, 17 However, 
frailty is considered to have greater reversibility than disability,18-20 and there is 
now an increased focus on frailty prevention in mid-life,3 and on identifying 
patients at risk of frailty through National Health Services (NHS) general 
practices with the aim of improved holistic patient care.21, 22 In particular, more 
accurate prognostication may help with clinical decision making regarding 
therapies where risk is ‘up front’, and benefits are in the long term.23 The British 
Geriatric Society (BGS) recommends routine assessment for frailty during all 
encounters with health and social care professionals.24 Within primary care, 
NHS England have introduced a contractual obligation for general practices to 
identify patients with moderate or severe frailty under their General Medical 
Service contract.25 This is in-keeping with an international consensus that 
patients aged over 70 years should be screened for frailty.26   
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1.2.1 Epidemiology of frailty 
In community-dwelling adults aged 65 years or older, the overall weighted 
prevalence of frailty was 10.7% (95% confidence interval [95% CI] 10.5% to 
10.9%) in a meta-analysis of 21 studies.27 However, estimates ranged from 
4.0% to 59.1%, as a result of variation between studies in the definition and 
measurement of frailty, and differences in the inclusion and exclusion criteria. 
Frailty was more common in women than men (9.6% compared with 5.2%, 
p<0.001).27 Amongst hospital inpatients aged 65 years or older, the prevalence 
of frailty has increased over time, and is estimated to have reached 14% in 
2013.28 Given that this estimate included elective admissions, who may have a 
different frailty profile from non-elective admissions, this may be an 
underestimate of the true burden amongst inpatients.29 The authors suggest 
that at least 4,000 patients with frailty are admitted per month to hospitals in 
England.28 
 
Frailty is more common with increasing age. Just 3.2% of participants in the 
Cardiovascular Health Survey aged 65 to 70 years were identified as frail, 
compared with 25.7% of those aged 85 to 89 years.30 In Europe, 25% of the 
population are aged 60 years or over, but this is projected to increase to 35% by 
2050.31 As the population ages, the overall burden of frailty is likely to increase 
substantially over coming years. 
 
1.2.2 Models of frailty 
There are two well established conceptual frameworks for frailty: the phenotype 
and the cumulative deficit models.32 These will now be discussed, followed by 
an outline of the frailty measures that are in common clinical use. 
 
1.2.2.1 Phenotype model 
The phenotype model is based upon the premise that patients with frailty share 
a set of physical characteristics, and that these can be summarised.14 It was 
developed in a secondary analysis of the Cardiovascular Health Study, which 
was a prospective, community based cohort st
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years or older.33 The cardinal characteristics that defined the phenotype were 
identified through clinical consensus, and are listed in Table 1. Those with three 
or more factors were defined as frail, those with one or two as intermediate or 
‘pre-frail’, and those with no factors as not frail.30 In the original study 7% of 
participants were categorised as frail, 47% as pre-frail, and 46% as not frail. 
 
Table 1: The five indicators included in the phenotype model 
Indicator Definition 
Weight loss Unintentional loss of ≥10 lbs or ≥5% of body weight 
in prior year 
Poor endurance 
exhaustion 
Self-reported “exhaustion” 
Low activity Males: <384 kilocalories per week; females: <270 
kilocalories per week 
Slow gait speed Time to walk 15 feet, cut-off stratified by gender and 
height 
Weak grip strength Lowest 20% of the population, stratified by gender 
and body mass index.30 
 
Patients in the frail group had worse clinical outcomes than the intermediate or 
non-frail groups. Compared with the non-frail group, frailty at baseline was 
associated with an 80% higher risk of falls (adjusted hazard ratio [HR] 1.8, 
95%CI 1.5 to 2.2a), 40% increased risk of worsened mobility (HR 1.4, 1.2 to 
1.6), 80% risk of worsened activities of daily living (ADL) disability (HR 1.8, 1.5 
to 2.2), 30% increased risk of hospitalisation (HR 1.3, 1.1 to 1.5), and 60% 
increased risk of death (HR 1.6, 1.3 to 2.1) at 7 years.30 
 
 
a Each HR adjusted for age, gender, indicator for minority cohort, income, smoking 
status, blood pressure, fasting glucose, albumin, creatinine, carotid stenosis, 
history of heart failure, cognitive function, major electrocardiographic abnormality, 
use of diuretics, problem with independent activities of daily living, self-report 
health measure, and depression measure. 
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The Cardiovascular Health Study was originally designed to investigate 
coronary heart disease and stroke. This gives rise to two key limitations in its 
use for developing a frailty model. Firstly, patients with Parkinson’s disease, 
previous stroke, cognitive impairment or depression were excluded.10 Secondly, 
the constituent parts of the phenotype model were contingent upon data that 
were collected in the original trial, for a purpose for which it was not designed, 
and did not include factors such as cognitive impairment.10 Despite this, in an 
external validation study there was an independent association between each of 
slow gait speed, low physical activity and weight loss with the outcomes of 
chronic disability, long-term nursing home stay, injurious fall and death.34 
However, there was not an independent association between these outcomes 
and weak grip strength or self-reported exhaustion. Concerns have also been 
expressed over how to operationalise the phenotype model in primary care, due 
to the need for evaluation of muscle strength and gait speed, and also the 
existence of a ‘ceiling effect’ in the case of disabling conditions.32 
 
1.2.2.2 Cumulative deficit model 
The cumulative deficit model considers the ‘building blocks’ of frailty to be 
additive, and is based upon the idea that “the more things individuals have 
wrong with them, the higher the likelihood that they will be frail”.35 In the 
cumulative deficit model, deficits are considered to be abnormal signs, 
symptoms, laboratory values, disease states and disabilities. The number of 
deficits identified can be summed and expressed as a proportion of the total to 
create a frailty index. This reflects the view that the accumulation of deficits 
contribute to the likelihood of frailty.10, 36 Three rules are used for the inclusion of 
variables in a frailty index: the variable must be biologically sensible; 
accumulate with age; and not saturate too early.37  
 
The original frailty index consisted of 92 items from the cross-sectional and 
longitudinal components of the Canadian Study of Health and Ageing.38 The 
statistical properties of the model were explored in detail in the original paper, 
and were consistent with probability models seen in complex systems with in-
built redundancy, which is in-keeping with the concept of frailty as a condition 
with a reduction in homeostatic reserve.10 Subsequent work, such as a study 
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using data from the National Population Health Survey of Canada, has shown 
that it is possible to reduce the number of potential deficits in the model from 92 
to 36 variables whilst maintaining validity.39 This lower number of variables is 
more practical for use in routine clinical practice, and the electronic frailty index 
(eFI) of 36 variables was subsequently developed for routine use within general 
practice computing systems.11 The eFI will be discussed in detail in section 
1.2.7.3.  
 
Although the two models of frailty are not mutually exclusive, the cumulative 
deficit model has been shown to more precisely evaluate the probability of 
death than the phenotype model,40 and allows a graded approach to evaluating 
frailty in a number of different clinical settings.32 
 
1.2.3 Comprehensive geriatric assessment 
In clinical practice, the identification and impact assessment of frailty is typically 
achieved using the evidence based holistic evaluation known as comprehensive 
geriatric assessment (CGA).12 It is used in order to provide a tailored approach 
to care for patients with complex health and care needs, and should include 
medical, psychological, functional and social needs assessments. This is a 
multi-disciplinary process, typically making use of the expertise of a geriatrician, 
general practitioner, specialist nurse, nurse, physiotherapist, occupational 
therapist and a social worker.12 Other specialists may also be involved, such as 
a pharmacist or other medical specialist. 
 
This multi-dimensional evaluation aims to systematically formulate a list of 
problems, including identifying frailty. It is an important part of developing a 
management plan that addresses health and care needs, guided by patient-
centred prioritisation.14 Use of a CGA as part of inpatient care has been shown 
to be associated with improved outcomes for older people with frailty, including 
improved rates of independent survival and lower functional decline following 
hospital discharge.12, 41 Some frailty measures, such as the multi-dimensional 
prognostic index or the Canadian Study of Health and Ageing Clinical Frailty 
Scale are only recommended for use following a CGA.36, 41, 42 
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1.2.4 Frailty instruments 
A subjective label of ‘frailty’ from a clinician, even without using formal criteria, is 
associated with increased healthcare utilisation and a greater number of 
geriatric syndromes.43 However, clinical assessment in the absence of a 
structured CGA lacks sensitivity in identifying individuals with frailty, with one 
study finding that general practitioner global judgement had a sensitivity of 0.67, 
and specificity of 0.77 compared with the phenotype model.44 To improve 
diagnostic accuracy it is recommended that validated tools are used alongside 
clinical judgement to identify patients with frailty.24, 61 However, there is no 
consensus on which tool should be used,45 and a recent systematic review 
identified 67 frailty instruments to select from.46 
 
The BGS recommend slow gait speed, the PRISMA 7 questionnaire, and the 
timed-up-and-go test as reasonable frailty assessments for general use, and the 
Edmonton Frail Scale when elective surgical intervention is under 
consideration.24 Whilst these population-based frailty scores have limitations in 
the acute setting,47 various tools have been used successfully in acute 
myocardial infarction,48-50 and a hospital frailty risk score has been developed 
as a systematic screening tool for inpatients.29 Some of the commonly used 
instruments are outlined below. 
 
1.2.5 Multidimensional frailty assessment instruments 
These instruments test components across different dimensions of a patient’s 
health and care, as in the comprehensive geriatric assessment. 
 
1.2.5.1 Edmonton Frail Scale 
Ten domains are included to assess cognition, health (two domains), 
hospitalisation, social support, nutrition, mood, function, and continence. Mild 
frailty is diagnosed with a score of 8-9 of a possible 17.51 Moderate frailty is 
defined as a score of 10-11, and severe as a score of 12 or more.52 The scale 
was developed in a population of community dwelling people aged 65 years or 
over who were referred for specialist geriatric assessment. It was shown to 
have good correlation with the geriatrician’s clinical impression of frailty formed 
following a one-hour comprehensive geriatric assessment. By comparison, the 
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Edmonton Frail Scale takes considerably less time, and does not require 
specialist training.51 
 
1.2.5.2 PRISMA-7 questionnaire 
This simple, seven-item, self-completed questionnaire is used to identify 
patients with moderate or severe disability.53 The questions included are: 
1. Are you more than 85 years old? 
2. Are you male? 
3. In general, do you have any health problems that require you to limit your 
activities? 
4. Do you need someone to help you on a regular basis? 
5. In general, do you have any health problems that require you to stay at 
home? 
6. In case of need, can you count on someone close to you? 
7. Do you regularly use a cane, a walker or a wheelchair to move about? 
 
A score of three or more is the cut-off for significant disability, which has a 
sensitivity of 78%, and specificity of 75% compared with the Functional 
Autonomy Measurement system, which is a 29-item scale from which the 
PRISMA-7 questionnaire was derived.54 Although it was originally developed to 
identify disability, PRISMA-7 is recommended by the British Geriatric Society for 
recognising frailty.24, 41 Advantages include the simplicity of the test, and that 
patients can complete the questionnaire at home, without the need for a visit to 
a healthcare provider.24 
 
1.2.6 Simple frailty instruments 
These instruments rely on a single assessment, rather than spanning multiple 
dimensions of care. Three commonly used tests are briefly summarised. 
 
1.2.6.1 Timed-up-and-go test 
The original ‘get-up and go’ test was devised as an assessment of balance in 
the elderly.55 Adding a timed element gave additional power to quantify 
functional mobility that could be used to evaluate change over time.56 An 
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individual that takes more than 30 seconds to stand from a chair, walk 3 metres, 
turn around, walk back and be seated is considered to have mobility problems.  
 
1.2.6.2 Gait speed 
Various cut-off values for identifying frailty are used in the literature, which are 
associated with varying sensitivity and specificity values.57 Compared with the 
phenotype model, a gait speed of less than 0.8 metres per second (m/s) had a 
sensitivity of 0.99 and specificity of 0.64 for identifying frailty.44 There are also 
survival implications of a reduced gait speed, as it has been shown to be an 
independent predictor of all-cause mortality in older people.58 In a recent meta-
analysis, the HR for survival per each 0.1 m/s faster gait speed was 0.88 (95% 
CI 0.87 to 0.90).57 
 
1.2.6.3 Grip strength 
Low grip strength is predictive of functional decline and mortality in community-
dwelling adults.52 In a prospective cohort study of 142,861 patients, grip 
strength was inversely associated with all-cause mortality: a reduction of 5 kg in 
grip strength was associated with a 16% increase in all-cause mortality (HR 
1.16, 95% CI 1.13 to 1.20).59 
 
1.2.7 Using routinely collected data to identify frailty 
These tools use routinely collected data to identify patients with frailty. They are 
not subject to the limitations of inter-operator reliability, and as they can be 
calculated automatically within existing data structures, their use tends to result 
in a low additional burden on the healthcare professional to calculate the 
score.29 
 
1.2.7.1 QMortality 
QMortality is a risk prediction algorithm to estimate short term risk of death and 
assess frailty.25 The authors identified 180,132 deaths from 4.4 million person-
years of observation. They combined the predicted one-year risks of unplanned 
hospital admission (QAdmission) and mortality to classify patients into frailty 
groups: 2.7% were classified as severely frail (these were either in the highest 
2% in the cohort in predicted risk of death or in the top 2% at greatest risk of 
hospital admission in the next year), 9.4% as moderately frail (in the top 10% of 
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either risk of death or of hospital admission), 43.1% as mildly frail (in the top 
50% of either risk of death or of hospital admission), and 44.8% as fit (the 
remainder).25 
 
1.2.7.2 Hospital Frailty Risk score 
The hospital frailty risk score is a recent addition to the available screening 
tools. It was developed in a cohort (n=22,139) of patients aged 75 years or 
older who had been discharged from hospital.29 A cluster analysis was 
performed to identify cohorts of patients that had similar characteristics in terms 
of the clinical codes assigned during their admission, number of hospital bed-
days, and the cost of their admission, alongside a set of candidate clinical 
codes for frailty that were  defined a priori. The hospital frailty risk score was 
calculated using coefficients from a logistic regression model, where 
membership of the frail cluster was the binary dependent variable, and the set 
of clinical codes as binary predictor variables. These were weighted based upon 
their prevalence amongst patients in the cohort that were determined as frail, 
and the score was created. Patients were categorised into frailty risk groups by 
their score: low risk (score of less than 5), intermediate risk (score of 5-15), and 
high risk (score of greater than 15).  
 
People with high frailty risk had a 70% higher adjusted risk of 30-day mortality 
than those in the low-risk group (OR 1.71, 95% CI 1.68 to 1.75). They had a six-
fold higher adjusted odds of a long hospital stay (OR 6.03, 5.92 to 6.10) and 
48% higher risk of emergency readmission within 30 days (1.48, 1.46 to 1.50).29 
 
1.2.7.3 Electronic frailty index (eFI) 
The eFI uses routinely available primary care electronic health record (EHR) 
data. It was developed using a cohort of 931,541 patients aged 65 to 95 years 
registered with a practice that was enrolled in ResearchOne or The Health 
Improvement Network (THIN) research databases. The authors used the 
cumulative deficit model as a theoretical framework.11 36 deficits were identified 
that met the three criteria of being biologically plausible, increased in 
prevalence with age, and did not saturate too early.37 The included deficits are 
listed in Table 2. These deficits are identified within EHR by 2,171 Clinical 
Terms Version 3 (CTV-3) codes (discussed further in section 3.2.4.1). 
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Table 2: The 36 deficits included in the electronic frailty index 
Disease state Symptoms/signs 
Arthritis Dizziness 
Asthma/COPD Dyspnoea 
Atrial fibrillation Falls 
Cerebrovascular disease Memory/cognitive problems 
Chronic kidney disease Polypharmacy 
Diabetes Sleep disturbance 
Foot problems Weight loss and anorexia 
Fragility fracture Urinary incontinence 
Heart failure  
Hypertension Abnormal laboratory values 
Hypotension/syncope Anaemia and haematinic deficiency 
Ischaemic heart disease  
Osteoporosis Disability 
Parkinsonism and tremor Activity limitation 
Peptic ulcer Housebound 
Peripheral vascular disease Hearing impairment 
Respiratory disease Mobility/transfer problems 
Skin ulcer Requirement for care 
Thyroid disease Social vulnerability 
Urinary system disease Visual impairment 11, 60 
 
The deficits for each patient are summed and expressed as a proportion of the 
maximum possible. Population quartiles were used to categorise patients as 
being fit, or having mild frailty, moderate frailty or severe frailty, as shown in 
Table 3. The eFI showed good discrimination for outcomes of mortality and 
nursing home admission, and moderate discrimination for hospitalisation.  
The research paper describing the development and validation of the eFI was 
published in 2016,11 and has since been integrated into the electronic health 
record systems SystmOne, EMISWeb, and Vision EHR.60 Use of the eFI is 
supported in National Institute for Health and Care Excellence (NICE) 
guidance.61 The score can be calculated automatically from data within primary 
care records, and this integration into existing GP record systems allows wide-
spread access to the tool. Real-life usage of the eFI to identify patients with 
frailty in primary care has been described as simple, quick, acceptable to staff, 
and useful.62  
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1.3 Frailty and cardiovascular disease 
An increasing proportion of patients have co-existing cardiovascular disease 
and frailty. This is partly as a consequence of improvements in life expectancy, 
but also in improved treatments and survival following index cardiovascular 
presentations.63 There is evidence that manifest or subclinical frailty is an 
important consideration across a range of cardiovascular conditions,64 and it is 
possible that increased recognition of frailty may facilitate improved clinical 
decision making and clinical management of patients with increasingly complex 
health and care needs.65, 66 A recent position paper by the Acute Cardiovascular 
Care Association called for an increased focus on defining the targeted utility of 
frailty measurement in patients with cardiovascular disease, which they identify 
as an area of unmet research need.23 Below I will discuss the implications of 
age and frailty on cardiovascular disease in general in the context of the 
existing literature, followed by a more detailed section on AF, which will be the 
focus of the remainder of the thesis. 
 
1.3.1 The ageing heart 
Anatomical and physiological changes in the heart and vasculature that occur 
with ageing result in deterioration over time. Key age-related changes that have 
been observed include: 
• Diastolic impairment secondary to myocyte loss and increased size of 
remaining cells 
• Disruption of electrical conducting tissue and sclerosis of valves, due to 
calcification 
• Hypertrophy as a result of collagen changes 
• Reduced heart rate responsiveness to adrenergic stimulation 
• Hypertension as a consequence of thickening or decreased compliance 
of arterial walls.67 
The mechanisms driving these changes are complex. Key factors include 
oxidative stress, inflammation, non-enzymatic glycation, and genetic changes.67 
It is thought that these insults cumulatively result in molecular and cellular 
damage that ultimately reduce physiological reserve.10 
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1.3.2 Acute coronary syndrome 
Older people account for an increasing proportion of acute coronary syndrome 
presentations: 12.9% of entries into the Myocardial Ischaemia National Audit 
Project (MINAP) are now for patients aged 85 years or older,68 although the true 
number of admissions to hospital due to acute coronary syndrome is likely to be 
higher due to under-recording in the registry.69-71 
 
A treatment paradox has emerged, whereby older people who are at highest 
risk of mortality are less likely to receive contemporary, evidence-based 
treatment and tend to have poorer clinical outcomes.71-74 Frailty is common in 
patients with acute coronary syndrome, and is a risk factor for mortality.48, 75-77 
Trials are ongoing to establish the optimal care strategy in patients with frailty 
and acute coronary syndrome,214, 215 who were under-represented in the 
evidence that underpins clinical guideline recommendations,68, 78 and who may 
not be best served by single-organ orientated care strategies.21 
 
1.3.3 Heart failure 
In the UK, the mean age at first diagnosis of heart failure is 77.0 years (SD 
12.9).79 Three-quarters of patients with heart failure also meet diagnostic criteria 
for frailty, which is associated with increased functional decline, all-cause 
mortality, and hospital readmission in patients with heart failure.80-87 As in acute 
coronary syndrome, patients with heart failure and frailty are underrepresented 
in clinical trials.88  
 
Clinical decisions regarding therapy for long-term potential prognostic gain may 
be particularly challenging in patients with frailty. An example concerning 
patients with heart failure is when considering patients for cardioverter 
defibrillator implant. This device is designed to provide protection against 
sudden arrhythmic death. However, the prognostic benefit for patients with 
frailty may be attenuated by a relatively higher non-arrhythmic mortality,89, 90 
who also have higher complication and mortality rates following implantation.91-
93 In order to identify patients that are most likely to benefit, case selection is of 
key importance. Frailty could be a helpful addition to aid in this clinical decision 
making.23 
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Age should not necessarily be a barrier to defibrillator implant,94 as rates of 
appropriate shocks are similar across age categories.95 Instead, defibrillator 
specific risk scores alongside frailty assessment are advised,90, 96-100 particularly 
when deciding between resynchronisation pacing, which is associated with 
symptomatic improvement and left ventricular remodelling in older people,101 
and a defibrillator alone, which does not improve symptoms.216, 217 In younger 
people with advanced heart failure, there is evidence that frailty status can be 
improved with a left ventricular assist device implant or cardiac transplant.102, 103 
 
1.3.4 Valvular heart disease 
In Europe, valvular heart disease is predominantly degenerative and age-
related.67, 104 By way of example, aortic stenosis affects 9.8% of people over 80 
years of age, many of whom are also frail.105 Once patients are symptomatic of 
their aortic stenosis their prognosis without intervention is poor, however 
conventional surgery carries a high risk of major complications in older 
people.106, 107 The advent of trans-catheter aortic valve intervention has 
provided a therapeutic option for patients that are deemed too high risk for 
conventional surgery, and is associated with good clinical outcomes.108 
Although the procedure is associated with an increased risk of post-procedural 
mortality and delirium in patients with frailty,109 trans-catheter aortic valve 
intervention is often the only viable treatment option in this vulnerable group, 
and it is likely that percutaneous options will play an increasing role in patients 
with frailty and mitral valve disease in the future.110, 111 
 
1.3.5 Stroke 
There were 84,184 patients admitted to hospitals in England, Wales and 
Northern Ireland with stroke between 2015 and 2016.112 Although over 80% of 
strokes occur in those aged 65 years or older, older people with stroke are less 
likely to receive effective treatment and have poorer outcomes,113 suggesting 
that there may be a high burden of potentially avoidable morbidity and mortality. 
Pre-stroke health status has been shown to be a more important determinant of 
outcome than age,114 raising the concept of frailty as an important 
consideration.115 Frailty is independently associated with increased mortality 
and care home admission following stroke,116, 117 and frailty status may be a 
greater determinant of clinical outcome than the currently available optimal 
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medical therapy for hyper-acute stroke.118 Stroke in the context of AF is 
discussed in greater detail in section 1.4.5. 
 
 
1.4 Atrial fibrillation 
Atrial fibrillation is a condition characterised by disorganised electrical activity in 
the atria, causing irregularity of the pulse. It is the most common arrhythmia 
encountered clinically, with a lifetime risk of one in four for adults over the age 
of 40 years.119  
 
1.4.1 Pathophysiology of atrial fibrillation 
The pathogenesis of AF is understood to involve rapidly firing ectopic foci, 
usually within the pulmonary veins, that are propagated within abnormal atrial 
tissue which acts as a substrate for the arrhythmia.120, 121 At a cellular level, AF 
is initiated and perpetuated by pro-arrhythmic mechanisms such as triggered 
activity, in addition to re-entry of electrical excitation.122 At a macroscopic level, 
the organised contraction of sinus rhythm is replaced by a chaotic fibrillation. 
This leads to a loss of atrio-ventricular synchrony and reduction in efficiency, 
but also the possibility of stasis of blood that can allow thrombus formation. This 
often occurs within the left atrial appendage (Figure 1).123 Subsequent 
thromboembolism may then cause cerebral infarction leading to a stroke, or 
infarction elsewhere.123-125 Atrial flutter is a more ‘organised’ rhythm that 
commonly coexists with or precedes AF, and also carries an elevated stroke 
risk.126 
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Over time, oxidative stress promotes remodelling of the electromechanical 
activity of the atria.127, 128 The persistence of AF leads to further chamber 
dilatation and interstitial fibrosis, which in turn increases the burden of atrial 
substrate, thereby sustaining the arrhythmia.127, 129 
Figure 1: Diagram of the heart, showing the anatomical location of the left 
atrium and the left atrial appendage. Artist: Bryony Cousins 
Left atrial appendage 
Left atrium 
Left 
ventricle 
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1.4.2 Epidemiology of atrial fibrillation 
Atrial fibrillation affects 2-3% of the population of Europe.130 In the UK, age and 
sex standardised prevalence of AF was 3.3% (95% CI 3.27% to 3.32%) in 
2016.131 The incidence of AF appears to be increasing over time. In the UK, the 
age-adjusted incidence of AF per 1000 person-years was 1.11 (95% CI, 1.09 to 
1.13) in 1998–2001, 1.33 (1.31 to 1.34) in 2002–2006, and 1.33 (1.31 to 1.35) in 
2007–2010.132 The incidence and prevalence of AF is higher with increasing 
age.131, 132 The prevalence of the risk factors for developing AF are also 
increasing over time.130 Considering these factors alongside population ageing, 
it is likely that the prevalence of AF will continue to increase. Indeed, AF has 
been described as an ‘epidemic’.130 
 
Globally, hypertension  and increasing age are thought to be the most 
significant risk factors for AF.133-135 Other risk factors for AF include heart 
failure, coronary artery disease, valvular heart disease, obesity, diabetes 
mellitus and chronic kidney disease.126  
 
Atrial fibrillation is associated with a range of adverse outcomes, including 
stroke, heart failure, unplanned hospital admission and death.126, 136, 137 For 
example, in a nationwide cohort study of patients admitted to hospital in 
Sweden, AF was associated with  a greater risk of mortality compared with 
controls up to 14 years following admission.136 In women, AF was associated 
with a two-fold increased risk of all-cause mortality compared with controls 
(adjusted HR 2.2, 95% CI 2.0 to 2.3) in patients aged under 65 years. There 
was a 70% increased risk in women with AF aged 65 to 74 years (HR 1.7, 1.67 
to 1.78), and 40% (HR 1.4, 1.42 to 1.46) in women with AF aged 75 to 85 years. 
The mortality disadvantage associated with AF was lower for men than women 
(corresponding figures for men were 1.8 (1.69 to 1.84), 1.4 (1.33 to 1.40), and 
1.2 (1.22 to 1.26) respectively).136 In these data, there was a reduction in the 
mortality disadvantage associated with AF with increasing age. 
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1.4.3 Patterns of atrial fibrillation 
Atrial fibrillation is commonly classified according to the pattern of arrhythmia:  
• Paroxysmal – this describes episodes that last up to seven days, or 
required cardioversion treatment within that time to restore sinus rhythm. 
• Persistent – episodes that last longer than seven days 
• Long-standing persistent – continuous AF lasting for one year or more, 
where the intention is to restore sinus rhythm (a rhythm control strategy) 
• Permanent – where a decision has been made to accept AF rather than 
attempt to restore sinus rhythm (a rate control strategy)126 
 
However, patients often move between categories,138 and the natural history of 
AF is that the disease pattern frequently progresses from paroxysmal to 
persistent to permanent over time.139 
 
1.4.4 Diagnosis of atrial fibrillation 
Common symptoms of AF include palpitations, fatigue, breathlessness, anxiety 
and depressed mood, symptoms which may prompt the patient to present to 
healthcare services.130 Patients may also present with a complication of AF, 
such as heart failure or stroke, as it is possible to have AF with no associated 
symptoms.130 
 
During a clinical examination, palpation of the pulse may reveal an irregularly 
irregular rhythm, which would raise the suspicion of AF.140 The heart rhythm 
should then be evaluated with a 12-lead electrocardiogram (ECG), which would 
show irregular R-R intervals and absent discernible distinct P waves if the 
patient was in AF at the time.126 If there is a suspicion of paroxysmal AF a more 
prolonged period of ECG monitoring may be required to detect an episode, 
such as an ambulatory ECG monitor (which records a prolonged surface ECG), 
an event recorder (which is activated by the patient when symptoms occur) or 
an implantable loop recorder, which is placed anteriorly to the pre-pectoral 
fascia through a small incision and makes recordings automatically when an 
arrhythmia is detected by the device or when it is activated by the patient.126, 140 
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As many episodes of AF are ‘silent’,130 meaning that they occur without 
symptoms, the European Society of Cardiology (ESC) recommend opportunistic 
screening for AF in patients aged 65 years or older, in patients that present with 
a transient ischaemic attack or ischaemic stroke, and as part of the routine 
follow-up of pacemakers and implantable cardioverter defibrilators.126 In 
England, NICE recommend investigating for AF as part of the assessment of a 
symptomatic patient.140 There is currently no consensus on population-based 
screening for AF,130 although this is a rapidly developing area. Watches are now 
being marketed that include technology that may identify episodes of AF,141 
although this function has not been approved in the UK as yet. 
 
Management of AF centres upon two key considerations: the prevention of 
thromboembolic consequences such as stroke, and treatment of the arrhythmia 
itself.126, 140 These will be discussed in sections 1.4.5 and 1.4.7 respectively.  
 
1.4.5 Thromboembolism in atrial fibrillation 
There is strong evidence that AF confers a state of blood stasis, endothelial 
dysfunction and clotting activation, thus fulfilling Virchow's triad of criteria for 
thrombus formation, Figure 2.124, 125  
 
Figure 2: Virchow's triad of criteria for thrombus formation 
Endothelial 
dysfunction
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The formation of thrombus in the fibrillating atria leads to the potential of 
embolism, which may occlude a distal blood vessel. In the brain, this causes 
cerebral ischaemia, and potentially infarction.125, 142 If the symptoms and signs 
related to cerebral ischaemia resolve within 24 hours, this is known as a 
transient ischaemic attack (TIA).143 However, if they persist for longer than 24 
hours then the criteria for a diagnosis of stroke are met.143 
 
Although the risk of stroke is elevated in patients with AF, appropriate use of 
oral anticoagulation (OAC) has been shown to reduce the risk of stroke by 
64%.144 Yet despite good evidence of the efficacy of OAC a recent study using 
UK primary care records showed that OAC was prescribed in just 55% of 
eligible patients.145 Indeed, of 15,807 patients that were admitted to hospital 
with a stroke in the context of a known history of AF in England, Wales, and 
Northern Ireland in 2017/18, 42.4% of these were not prescribed OAC.146 This 
suggests that there is a potential for reducing the population burden of stroke in 
patients with AF through appropriate use of OAC for stroke prophylaxis.140 
There is also the potential of significant cost savings to health and care 
services, as stroke disease has an annual estimated cost of £3.6 billion for the 
first five years following admission in England Wales and Northern Ireland, and 
a mean cost per patient of £46,039.112 
 
1.4.6 Oral anticoagulation for stroke prophylaxis in atrial fibrillation 
Until 2012, warfarin was the only commonly used OAC in the UK.154 Warfarin 
has a narrow therapeutic window, and requires blood test monitoring to guide 
dose-adjustment.147 The first direct oral anticoagulant (DOAC) medication came 
onto the formulary in the UK in 2012, and there are now four such agents 
available: apixaban, edoxaban, rivaroxaban and dabigatran.148 Each has been 
shown to be non-inferior to warfarin in stroke reduction, Table 4.  
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Table 4: Rates of stroke or systemic embolism in patients with AF 
reported in the literature 
Study, year (ref) Warfarin, compared 
with: 
Patients 
enrolled 
Stroke or systemic 
embolism,  
rate per 100 person-years 
Warfarin DOAC No 
OAC 
ROCKET AF.  
2011 149 
Rivaroxaban 20mg OD 14,143 2.4 2.1 - 
RE-LY.  
2009 150 
Dabigatran 150mg BD* 18,113 1.7 1.5 - 
Dabigatran 110mg BD   1.5 - 
ENGAGE AF-
TIMI 48. 2013 151 
Edoxaban 60mg OD 21,105 1.5 1.2 - 
ARISTOTLE.  
2011 152 
Apixaban 5mg BD 18,201 1.6 1.3 - 
Abbreviations  OAC: oral anticoagulation; DOAC: direct OAC; OD: once daily; BD: 
twice daily           
* in renal impairment 
Intention to treat analysis reported from the clinical trials. 
 
The current guidance on when OAC should be considered for stroke 
prophylaxis in patients with AF will be discussed below. 
 
1.4.6.1 Considerations in valvular atrial fibrillation 
AF is traditionally dichotomised into valvular (usually considered as 
moderate/severe mitral stenosis or mechanical heart valves) and non-valvular 
AF.126, 153 Valvular AF is associated with a particularly high stroke risk, requiring 
more intensive anticoagulation using warfarin.154 This is in part because in 
mitral stenosis, AF-related endothelial damage and dilatation of the left atrium 
tends to be more pronounced than in a non-stenotic valve,125 and left atrial 
dilatation is associated with further blood stasis and propensity to thrombosis.155 
None of the DOAC agents are currently licenced for use in valvular AF.154 
Where a patient has a prosthetic heart valve, there is clear guidance for OAC 
directed for the specific valuvlar indication.156 Where a patient has AF and OAC 
is not indicated for the prosthetic valve, for example in the case of a bio-
prosthetic aortic valve, then OAC should still be considered for AF 
thromboprophylaxis. 
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1.4.6.2 Assessment of stroke risk in non-valvular atrial fibrillation 
Guidelines from NICE140 and the ESC126 recommend that the decision whether 
or not to commence OAC in people with non-valvular AF should be based upon 
an objective stroke-risk scoring system, specifically the CHA2DS2-VASc 
score.157 There were four thromboembolic risk scoring systems identified in a 
recent meta-analysis.158 These were the Framingham,159 ABC,160 CHADS2,161 
and CHA2DS2-VASc scores.157 Each will be summarised in turn. 
 
The Framingham score includes age, sex, systolic blood pressure, use of 
antihypertensives, evidence of left ventricular hypertrophy on ECG, prevalent 
cardiovascular disease, smoking status, current or previous AF, and 
diabetes.159 These were combined in order to predict the probability of stroke at 
10 years. The score was developed using stroke data collected in the 1960’s 
and 1970’s and has tended to over-estimate stroke risk in contemporary 
cohorts.162 This prompted the development of the revised Framingham risk 
score in which left ventricular hypertrophy was removed, and other factors such 
as coronary artery calcium score, and blood markers including c-reactive 
protein were included.163 A c-statistic gives an indication of model performance, 
where a value of 0.5 means that the model is no better than random chance 
and a value of 1 identifies a model that perfectly predicts patients that will 
experience an event.164 In this case, the authors reported that the revision of the 
Framingham score resulted in a modest improvement in the c-statistic from 0.65 
in the original, to 0.72 in the revised model.163 
 
The ABC (age, biomarker, clinical history) stroke risk score includes age, N-
terminal fragment B-type natriuretic peptide, high-sensitivity cardiac troponin, 
and prior history of stroke or TIA.160 The score was developed using data from 
the ARISTOTLE trial,152 and validated using data from the STABILITY trial.165 
The authors report a c-statistic of 0.68 in the derivation cohort, and 0.66 in the 
external validation cohort. Again, these c-statistics show only a modest model 
performance. 
 
The components of the CHADS2 score are congestive heart failure, 
hypertension, age 75 years or older, type 2 diabetes, and previous stroke or TIA 
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(for either of which two points are allocated).161 The performance of the model 
was assessed in a meta-analysis of 14 studies, and a pooled c-statistic of 0.69 
(95% CI 0.66 to 0.73) was reported.158 One particular weakness of the CHADS2 
score was a tendency to misclassify patients as low risk, and so OAC 
prescription was not advised. For example, in the validation study the stroke 
rate in patients with a CHADS2 score of zero was 1.9 (1.2 to 3.0) per 100 
person-years.161 The CHA2DS2-VASc score was developed, and includes the 
additional risk factors of vascular disease (defined as prior myocardial 
infarction, peripheral arterial disease or aortic plaque) and sex. As in CHADS2, 
two points were allocated for previous thromboembolism. Older age was given 
additional weighting, with two points allocated for patients aged 75 years or 
older, Table 5. 
Table 5: Assessment of stroke risk using CHA2DS2-VASc 
Criteria Value Points 
Age <65 years old 0 
65-74 years old +1 
≥ 75 years old +2 
Sex Male 0 
Female +1 
Congestive heart failure history Yes / no +1 
Hypertension history Yes / no +1 
Stroke / TIA / thromboembolism history Yes / no +2 
Vascular disease history Yes / no +1 
Diabetes mellitus history Yes / no +1 
Abbreviation  TIA: transient ischaemic attack 
 
In the validation study, no patients with a score of zero had a stroke. Stroke 
rates increased with increasing score up to 5.5 per 100 person-years (95% CI 
0.91 to 27.0) in patients with a score of nine.157 The authors went on to estimate 
what the stroke risk would have been in the absence of OAC, assuming that 
warfarin provides a 64% reduction in stroke risk.144 In this model, a CHA2DS2-
VASc score of 9 was associated with a stroke risk of 15.2 per 100 person-years, 
Table 6.157 
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Table 6: Stroke or Other Thromboembolism Events per Patient Year Based 
on the CHA2DS2-VASc Scoring System, adapted from Lip et al.157 
CHA2DS2-VASc score Adjusted annual stroke or thromboembolism events 
per 100 person-years* 
0 0 
1 1.3 
2 2.2 
3 3.2 
4 4.0 
5 6.7 
6 9.8 
7 9.6 
8 6.7 
9 15.2 
* adjusted for warfarin use to give theoretical thromboembolism rates without 
therapy, assuming that warfarin provides a 64% reduction in risk.144 
 
In a meta-analysis of 17 studies, the c-statistic for prediction of stroke using 
CHA2DS2-VASc was 0.67 (95% CI 0.64 to 0.70).158 On the basis of their meta-
analysis, the authors suggest that there is little difference between the four 
scores. At present, CHA2DS2-VASc is recommended in national and 
international guidelines,126, 167, 168 and is widely used.169 NICE guidelines state 
that OAC should be considered in men with a CHA2DS2-VASc score of one, and 
should be offered to men or women with a CHA2DS2-VASc of two or more.140 
 
1.4.6.3 Assessment of bleeding risk in non-valvular atrial fibrillation 
Both ESC and NICE guidelines recommend that bleeding risk should be 
assessed, and that risk factors for bleeding should be modified alongside a 
decision to commence OAC, but that a high bleeding risk should not generally 
result in withholding OAC.126, 167 Four commonly used scores for estimating 
bleeding risk in patients taking warfarin and the evidence supporting their use 
are summarised in Table 7.170  
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There are few scores that have been validated in patients that are prescribed a 
DOAC. One example is the ABC-bleeding score, which was developed as part 
of a nested prospective biomarker study of 8,705 participants in the ENGAGE 
AF-TIMI 48, which was a multinational, randomized trial of the oral factor Xa 
inhibitor edoxaban in patients with AF and CHADS2 score two or more. The 
score includes age, prior bleeding, haemoglobin, baseline high-sensitivity 
troponin T, and growth differentiation factor-15.175 However, the biomarkers 
tested are not currently in routine clinical use for this purpose, and the score 
offered limited risk discrimination with a c-statistic of 0.65 in the validation 
study.158 
 
NICE guidelines currently recommend the HAS-BLED score,167 which was first 
published in 2010.171 Two recent meta-analyses have concluded that HAS-
BLED has the best evidence for predicting bleeding risk.158, 176 However, the 
meta-analyses are limited by the fact that various classification systems for 
major bleeding were used in the included studies, leading to clinical 
heterogeneity. 
 
In patients that are unable to take OAC because it contraindicated or not 
tolerated, a left atrial appendage occlusion device is a potential option, and was 
formally commissioned by NHS England in June 2018.177 These devices 
physically block the connection between the appendage and the left atrium, 
preventing thrombus the appendage from entering the circulation. 
 
1.4.7 Arrhythmia management in atrial fibrillation 
There are two strategies for management of the AF itself. The first is rate 
control, whereby the presence of AF is ‘accepted’, and arrhythmia modifying 
drugs such as beta blockers, calcium channel blockers and digoxin are used to 
moderate the tendency to tachycardia. The second is rhythm control, where the 
aim is to restore sinus (‘normal’) rhythm.126, 167 Initial therapies include 
pharmacological or electrical cardioversion, with the option of longer-term 
arrhythmia-modifying medication. Should these options be unsuccessful in 
maintaining sinus rhythm and the patient is symptomatic, more invasive therapy 
such as pulmonary vein isolation can be considered.126, 167 
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At present, guidelines from the ESC and NICE would suggest a rhythm control 
strategy only to improve symptoms where a rate control strategy has been 
unsuccessful.126, 167 This is supported by evidence that generally there is no 
mortality advantage to a rhythm control strategy,178 although there is recent trial 
evidence that an invasive rhythm control strategy carries a mortality advantage 
in the specific group of patients with AF and severe left ventricular systolic 
impairment.179 
 
A recent meta-analysis has shown an improved quality of life in patients treated 
with a rhythm control strategy using the short-form 36-item health survey (SF-
36) physical component summary score.178, 180 However, all of the eight studies 
included were at high risk of bias, partly due to incomplete blinding.178 There 
was no difference in stroke risk between the two groups, and there were more 
adverse treatment events in the rhythm control group than the rate control 
group. 
 
1.5 Atrial fibrillation and frailty 
This chapter has described the association between AF, mortality, and 
morbidity including stroke. Whilst OAC is effective in reducing the risk of stroke, 
it is not prescribed in 45% of patients with a CHA2DS2-VASc score of two or 
more, and would therefore be considered eligible for treatment.145 Older people, 
who tend to have the highest baseline risk of stroke, are often not prescribed 
OAC.145, 181-183 A possible factor in OAC decisions is frailty, which will form part 
of the literature review.  
 
Frailty and AF are particularly common in older people, and the two conditions 
frequently co-exist.11, 184 However, clinical guidelines tend to focus upon single-
organ conditions, and take little account of frailty.126, 140 Indeed, the absence of 
applicable guidance may reflect the existing uncertainty as to whether frailty 
should inform judgements in management of AF and OAC.185 This uncertainty 
suggests that shared decision making has an important role. Shared decision 
making is characterised by a partnership between the patient and clinician, and 
joint deliberation of therapeutic options based on the knowledge and experience 
that each brings to the consultation.186 As the prevalence of AF and of frailty are 
increasing,131, 187 and each condition is associated with a substantial burden of 
 
 
32 
morbidity and mortality,10, 136 effective management of patients with AF and 
frailty is of vital importance. This thesis will seek to help address the current lack 
of evidence in the epidemiology and management of patients with AF and 
frailty. 
 
1.6 Summary 
• Frailty is a condition characterised by decreased physiological reserves 
and a vulnerability to adverse outcomes from a relatively minor stressor 
event. It is considered using two main theoretical frameworks: the 
cumulative deficit and phenotype models. 
• There are a range of different measures that can be used to identify 
frailty, including bedside assessments, scoring systems, and models 
derived from primary care records. 
• Frailty is associated with adverse outcomes, including all-cause mortality 
and nursing home admission. This has been demonstrated in unselected 
populations, and also in a number of common cardiovascular conditions.  
• Patients with frailty have a different risk and benefit profile for clinical 
interventions compared to patients without frailty, which should be 
considered when recommending treatment. How this applies to AF will 
be investigated in this thesis. 
• AF is common and is associated with an increased risk of clinical 
outcomes including stroke. Guidelines suggest that stroke risk should be 
estimated using the CHA2DS2-VASc score to guide the appropriate 
prescription of OAC, which can substantially reduce stroke risk. 
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1.7 Conclusion 
In this chapter I have provided a summary of frailty as a concept, and some of 
the ways that it may be operationalised clinically using frailty measures. The 
association between frailty and common cardiovascular conditions has been 
described, followed by a more in-depth exploration of AF. The existing evidence 
base on frailty and AF will be synthesised in a systematic review of the literature 
in the next chapter. In Chapter 3 the data sources will be summarised that are 
available to explore the association between frailty and AF, which will be the 
focus for the rest of the thesis.   
 34 
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Chapter 2 - Literature review 
Atrial fibrillation and older people with frailty:  
a systematic review and meta-analysis 
 
2.1 Abstract    
Background 
Despite a large and growing population of older people with frailty and atrial 
fibrillation (AF), there is a lack of guidance on optimal AF management in this 
high-risk group. 
 
Objective 
To synthesise the existing evidence base on the association between frailty, AF 
and clinical outcomes. 
 
Methods 
A systematic review of studies examining the association between validated 
measures of frailty, AF, and clinical outcomes, and meta-analysis of the 
association between frailty and oral anticoagulation (OAC) prescription. 
 
Results 
20 studies (30,883 patients) were included, all observational. Fifteen were in 
hospital, four in the community, and one in nursing home care. Risk of bias was 
low to moderate. AF prevalence was between 3% and 38%, and frailty 
prevalence varied by setting from 6% in a community-based cohort to 100% of 
patients with AF in a nursing home. In people with AF, frailty was associated 
with increased stroke incidence, all-cause mortality, symptom severity, and 
length of hospital stay.  
 
Meta-analysis of six studies showed that frailty was associated with decreased 
OAC prescription at hospital admission (pooled adjusted OR 0.45 [95%CI 0.22-
0.93], 3 studies), but not at discharge (pooled adjusted OR 0.40 [95%CI 0.13-
 36 
1.23], 3 studies). A community-based study showed increased OAC prescription 
associated with frailty (OR 2.33 [95%CI 1.03-5.23]). 
 
Conclusion 
Frailty is common, and is associated with adverse clinical outcomes in patients 
with AF. There is evidence of an association between frailty status and OAC 
prescription, with a different direction of effect in community compared with 
hospital cohorts. Despite the majority of care for older people being provided in 
the community, there is a lack of evidence on the association between frailty, 
AF, anticoagulation and clinical outcomes to guide optimal care in this setting.  
 
2.2 Introduction 
As discussed in Chapter 1, it is increasingly recognised that frailty is a more 
useful approach to guide care in older people than chronological age,10 and can 
help guide more individualised treatments with advancing multi-morbidity and 
polypharmacy.219 The prevalence of patients with frailty and AF is growing,187 
making optimal management an important goal for older people, clinicians, 
health services and social care.23, 26, 78 However, the optimal treatment strategy 
for people with AF and frailty is unclear. The objective of this review is to 
synthesise the existing evidence base on the association between frailty, atrial 
fibrillation and clinical outcomes, with a particular focus on OAC. 
 
2.3 Methods 
The review was conducted according to meta-analysis of observational studies 
in epidemiology (MOOSE) guidelines, and reported using Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) 
recommendations.220, 221  
 
2.3.1.1 Protocol and registration 
The review protocol was registered with the international prospective register of 
systematic reviews (PROSPERO), record number CRD42018092951.222 
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2.3.1.2 Eligibility criteria 
Studies that used a measure that is reported within the published literature to 
identify frailty in populations with AF (permanent, paroxysmal or persistent) or 
atrial flutter were considered eligible. Reviews, case reports, case series and 
conference proceedings were excluded. Studies were limited to those in the 
English language. 
 
2.3.1.3 Information sources 
We searched CINAHL, Cochrane, Embase, Medline, and Web of Science from 
inception of each until October 2017. The search strategy was developed with 
Mrs Deidre Andre, Research Librarian at the University of Leeds, and is outlined 
in Table 8. 
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Table 8: Search strategy for Ovid Medline. Rows combined with 'OR', 
columns combined with 'AND' 
atrial fibrillation/  frail elderly/ 
atrial fibrillation*.tw.  (frail* or sarcop?eni* or prefrailty).tw. 
auricular fibrillation*.tw.  sarcopenia/ 
atrium fibrillation*.tw. Geriatric Assessment/ 
catheter ablation/ "comprehensive geriatric 
assessment".tw. 
atrial ablation*.tw. (multimorbid* or multi-morbid*).tw. 
(electric* adj2 ablation*).tw. (multidisease? or multi-disease? or 
(multiple adj (ill* or disease? or 
condition? or syndrom* or 
disorder?))).tw. 
catheter ablation*.tw. geriatric syndrom*.tw. 
(radiofrequency adj2 ablation*).tw. cumulative deficit*.tw. 
pulmonary vein isolation*.tw. Phenotype model*.tw. 
exp Anti-Arrhythmia Agents/  ((Edmonton or Fried) adj5 (index* or 
indicator* or score* or scale* or tool* or 
test* or model* or phenotype* or criteri* 
or marker* or method* or instrument* or 
assess* or exam* or evaluat* or 
measure* or screen* or diagnos* or 
detect* or identif*)).tw. 
Atrial Flutter/ (Gait speed* or walking speed* or grip 
strength*).tw. 
atrial flutter.tw. exp hand strength/ 
atrium flutter.tw. ("Timed up and go test*" or tugt or gug or 
"get up and go").tw. 
Tachycardia, Ectopic Atrial/ frail elderly/ 
((atrial or atrium or auricular) adj2 
(tachycardia* or tachyarrhythmia*)).tw.  
(frail* or sarcop?eni* or prefrailty).tw. 
antiarrhythmi*.tw. sarcopenia/ 
anti-arrhythmi*.tw. Geriatric Assessment/  
exp Anticoagulants/  "comprehensive geriatric 
assessment".tw. 
anticoagulant*.tw. (multimorbid* or multi-morbid*).tw. 
antithrombotic*.tw. (multidisease? or multi-disease? or 
(multiple adj (ill* or disease? or 
condition? or syndrom* or 
disorder?))).tw. 
Symbols:  * = Truncation. This identifies variant endings for the stem word  
? = Wildcard. This allows a different character (or no character) to identify variant 
spellings of words. 
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2.3.1.5 Study selection 
Two independent reviewers (Dr Oliver Todd [OT] and I [CW]) screened titles 
and abstracts for potentially eligible studies, and assessed full text articles 
against the eligibility criteria. All disagreements were resolved through 
consensus. Reasons for exclusion of articles at the full-text review stage were 
collated using Covidence.223  
 
2.3.1.6 Data extraction 
Data from the included studies was extracted using a pro forma including 
author, year of publication, study period, study design, country, setting, patient 
characteristics (age, sex, prevalence of co-morbidities, ethnicity), frailty 
measure, AF prevalence and outcomes assessed. Where frailty status was 
dichotomised, the threshold used by the study author was used. Data for meta-
analysis were extracted by two independent reviewers (CW and OT). 
 
2.3.1.7 Outcomes 
The primary outcome was OAC prescription by frailty status. Secondary 
outcomes included: ischaemic and haemorrhagic stroke; all-cause mortality; 
disability; care home admission; hospitalisation; and haemorrhagic events. 
 
2.3.1.8 Risk of bias in individual studies 
The Newcastle-Ottawa checklist was used by two authors (CW and OT) to 
independently assess risk of bias,224, 225 with an adapted scale for cross-
sectional studies.226 Studies were assessed on the domains of selection, 
comparability, exposure and outcome. Studies rated as moderate or good were 
considered as having low risk of bias. 
 
2.3.1.9 Synthesis of results 
Two authors (CW and OT) extracted adjusted odds ratios (ORs) with 95% CIs 
for dichotomous data. OR for frail vs. non-frail were used; when the reverse was 
reported by the authors, then an inverse OR was calculated. We synthesised 
data for meta-analysis by generic inverse variance random-effects modelling 
summarised as an odds ratio using RevMan 5.3 software.227 Random effects 
modelling was selected because we anticipated that the classification of frailty 
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status may be based on different instruments, and to allow for clinical 
heterogeneity. Adjusted data were prioritised because they account for 
confounding variables and are considered more reliable. Unadjusted ORs were 
not included in the meta-analysis. 
2.4 Results 
2.4.1 Study selection 
 
Figure 3: Preferred reporting items for systematic reviews and meta-
analyses (PRISMA) diagram of the included studies228 
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The review is summarised in Figure 3. The search identified 1,839 studies, of 
which 165 were retrieved for full-text review. A common reason for exclusion at 
the stage of full-text review was ‘no focus on frailty’, which includes studies that 
were identified because they used the word frailty, but in a different context 
such as ‘shared frailty model’, or included the term ‘frail elderly’ in the abstract, 
but did not investigate frailty as such. In total, 20 studies met the eligibility 
criteria and were included in this review; six within a meta-analysis,181, 190, 193, 197, 
210, 212 and fourteen in a narrative synthesis.1, 189, 191, 194, 198-203, 206, 209, 211, 213 All 
were observational studies. 
 
2.4.2 Study characteristics 
Twelve cross-sectional 189, 190, 193, 197, 198, 200, 202, 203, 206, 209, 212, 213 and eight cohort 
studies were included,1, 181, 191, 194, 199, 201, 210, 211 with a total of 30,883 
participants, Table 9. 15 studies were based in hospital,1, 181, 189-191, 193, 194, 197-200, 
203, 209-211 and five were community-based,201, 202, 206, 212, 213 one of which 
involved nursing home residents.213 Thirteen studies were conducted in 
Europe,1, 189, 191, 193, 194, 197-200, 206, 209, 212, 213 three in Australia,210, 211, 213 three in 
North America,190, 201, 202 and one in Taiwan.203 
 
2.4.3 Risk of bias within studies 
Overall, the included studies were moderate to low risk of bias, Table 10. The 
six studies included in the meta-analysis were judged at low risk of bias overall, 
with risk identified in two studies regarding ascertainment of outcome181 and 
follow-up duration.181, 210 However, these did not relate to the specific meta-
analysis question of OAC and frailty associations. 
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Table 9: Summary of included studies 
Study  Setting Age 
criteria 
Mean 
[median] 
age 
Country Measure of 
frailty 
n 
 
Prospective cross-sectional studies 
Bo, 2015 193 Hospital ≥65 81.7 Italy GFI 513 
Denoël, 2014 200 Hospital ≥75 NR Belgium ISAR 995 
Donoghue, 
2014 206 
Community  ≥50 70.7 Republic 
of 
Ireland 
GU&G,  
Gait speed 
4525 
Frewen, 2013 
166 
Community ≥50 63.8 Republic 
of 
Ireland 
Fried 
criteria 
4890 
Hess, 2013 202 Outpatients ≥18 [75] USA Fried 
criteria 
10,096 
Hung, 2013 203 Hospital ≥75 [75] Taiwan GU&G  401 
Mlynarska, 2017 
209 
Hospital none 72.7 Poland TFI 132 
O’Caoimh, 2017 
213 
Nursing home  none [84] Republic 
of 
Ireland 
CFS 225 
Polidoro, 2013 
198 
Hospital none 79.3 Italy Frailty 
index37 
140 
Retrospective cross-sectional studies 
Annoni, 2016 189 Hospital  ≥65 84.6 Italy Robinson 
criteria 192 
1619 
Induruwa, 2017 
197 
Hospital ≥75 85.3 England CFS 419 
Lefebvre, 2016 
190 
Hospital ≥80 85.9 Canada CFS 682 
Prospective cohort studies 
Bo, 2017 199 Hospital ≥65 81.6 Italy GFI 452 
Doucet, 2008 1 Hospital >65 84.7 France GU&G  209 
Gullón, 2017 194 Hospital >75 85 Spain FRAIL 
scale 
804 
Magnani, 2016 
201 
Community 70-79 N/A USA Health 
ABC 
battery 
2753 
Nguyen, 2016 
210 
Hospital ≥65 84.7 Australia Reported 
EFS 
302 
Nguyen, 2016 
211 
Hospital ≥65 84.7 Australia Reported 
EFS 
302 
Perera, 2009 181 Hospital ≥70 82.7 Australia Modified 
EFS 
207 
Retrospective cohort study 
Pilotto, 2016 191 Community, 
previous 
hospitalisation 
≥65 84.4 Italy MPI 1287 
Abbreviations  EFS: Edmonton Frail Scale, GFI: Groningen frailty indicator, GU&G: get-
up-and-go test, MPI: multidimensional prognostic index, MPI-SVaMA: MPI based on 
standardized multidimensional assessment schedule for adults and aged persons, NR: not 
reported, TFI: Tilburg Frailty Index. Further detail in Table 15, page 58. 
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  Table 10: R
isk of bias assessm
ent  
 The N
ew
castle-O
ttaw
a Scale w
as used for quality assessm
ent, adapted for cross-sectional studies.[25, 26] A m
axim
um
 of one star is aw
arded for 
each heading under selection and outcom
e, and tw
o stars under com
parability. The total possible is seven stars for cross-sectional studies. G
ood: 
≥5; m
oderate: 3-4; poor ≤2. For cohort studies, the total possible is nine stars. G
ood: ≥7; m
oderate: 5-6; poor ≤4 
 C
ross-sectional studies 
 
Selection 
C
om
parability 
O
utcom
e 
Total 
 
R
epresentative of 
exposed cohort 
Selection of non-
exposed cohort 
Ascertainm
ent 
of exposure 
C
ontrols and 
adjusted 
Ascertainm
ent 
of outcom
e 
Statistical 
test 
Annoni, 2016 189 
1 
1 
1 
1 
0 
1 
5 
Bo, 2015 193 
1 
1 
1 
2 
1 
1 
7 
D
enoël, 2014 200 
1 
1 
1 
2 
0 
1 
6 
D
onoghue, 2014 206 
1 
1 
1 
2 
1 
1 
7 
Frew
en, 2013 166 
1 
1 
1 
2 
0 
1 
6 
H
ess, 2013 202 
1 
1 
1 
2 
1 
1 
7 
H
ung, 2013 203 
1 
1 
1 
2 
1 
1 
7 
Induruw
a, 2017 197 
1 
1 
1 
2 
1 
1 
7 
Lefebvre, 2016  190 
1 
1 
1 
2 
1 
1 
7 
M
lynarska, 2017  12, 209 
1 
1 
1 
1 
1 
1 
6 
O
’C
aoim
h, 2017 11, 17, 
213 
1 
1 
1 
1 
0 
1 
5 
Polidoro, 2013 25, 198 
1 
1 
1 
1 
1 
1 
6 
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Pilotto 
2016 191 
Perera 
2009 181 
N
guyen 
2016 211 
N
guyen  
2016 210 
M
agnani  
2016 201 
G
ullón, 
2017
194 
D
oucet 
2008
1 
Bo  
 2017
199 
  C
ohort studies 
 
1  1 1 1 1 1 1 1 
R
epresentative 
of exposed 
cohort  
Selection 
0 1  1  1  1  0  1  1  
Selection of 
non -exposed 
cohort 
1 1 1 1 1 1  1  1  
Ascertainm
ent 
of exposure 
1 1 1 1 1 1 1 1 
O
utcom
e not 
present at 
start  
2 2 2 2 2 2 1 2 
C
ontrols and 
adjusted  
C
om
parability 
1 0 1 1 1 1 1 1 
Ascertainm
ent 
of outc om
e  
O
utcom
e  
1  0  0  0  1  1  0  0  
W
as follow
-up 
long enough 
1  1  0  0  0  1  0  0  
Adequate 
follow
- up 
8 7 7 7 8 8 6 7  
Total  
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2.4.4 Participant characteristics 
Amongst patients with AF the mean age was 83.3 years (reported in 16 
studies1, 166, 181, 189-191, 193, 194, 197, 198, 203, 206, 209-211), range 58 to 101 years (6 
studies194, 197, 198, 210, 211), and 48.2% female (18 studies1, 181, 189-191, 193, 194, 197-199, 
202, 203, 206, 209-213). Excluding a large registry of outpatients,202 56.8% of 
participants were female.  
 
Eight studies also included patients without AF.166, 189, 198, 200, 201, 203, 206, 213 The 
mean age of the whole cohort (those with AF and those without) was 68.5 years 
(reported in 6 studies166, 189, 198, 201, 203, 206), range 56 to 96 (2 studies198, 206). 
50.3% were female (7 studies166, 189, 198, 201, 203, 206, 213), Table 11. 
 
2.4.5 Assessment of frailty 
Of the thirteen measures of frailty used, the timed-up-and-go test56, clinical 
frailty scale36, and Edmonton frail scale51 were most common (3 studies each). 
 
2.4.6 Prevalence of atrial fibrillation 
AF prevalence was reported in six studies, but not stratified by frailty status.189, 
200, 203, 206, 212, 213 It varied by setting from 3% in community-dwellers,206, 212 to 
38% in nursing home residents.213 In three studies of older patients admitted 
acutely to hospital, AF was identified in 14%,200 17%,203 and 24%189, Table 11. 
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2.4.7 Atrial fibrillation and frailty 
Sixteen studies reported the prevalence of frailty in patients with AF.181, 189-191, 
193, 194, 197-200, 202, 203, 209-211, 213 This varied between populations, affecting 6% in a 
registry of outpatients aged ≥18,202 and 100% in a nursing home population,213 
Table 12. In older people admitted to hospital, AF was strongly associated with 
being frail (adjusted OR 4.09, 95% CI 1.51 to 11.07, adjusted for age, sex, 
hypertension, diabetes, stroke, myocardial infarction and heart failure).198  
 
Hung et al found that whilst there was no difference in frailty between those 
admitted to a geriatric unit with AF and without, AF was an independent risk 
factor for falls (adjusted OR 1.98 [95%CI 1.08 to 3.63], adjusted for 
benzodiazepine use, paroxysmal subgroup of AF, hypertension, polypharmacy 
and age).203 However, the tendency to fall may have increased AF case-
detection through use of ambulatory electrocardiography. Magnani et al showed 
that age-related decline in physical performance in community-dwellers was 
accelerated by approximately four years for those with AF compared to those 
without.201  
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Table 12: Reported prevalence and definitions of frailty in included 
studies 
Study  Mean age 
[median], 
patients 
with AF 
Frailty definition Frailty prevalence 
Measure Cut-point Whole 
cohort 
Patients 
with AF 
Annoni 189 84.6 Robinson 
criteria 192 
≥4 NR 57.3% 
Bo 193 81.7 GFI ≥4 - 77.5% 
Bo 199 81.6 GFI ≥4 - 75.4% 
Denoël 200 NR ISAR ≥2 NR 84% 
Donoghue 
206 
70.7 GU&G  
Gait speed 
Comparison was made between 
groups with AF and without AF, no 
threshold was used 
Doucet 1 84.7 GU&G  Comparison was made between 
those prescribed OAC and those 
that weren’t. 
Frewen  166 63.8 Fried criteria ≥1 NR NR 
Gullón 194 85 FRAIL scale ≥3 - 50.3% 
Hess 202 [75] Fried criteria ≥3 - 6.0% 
Hung  203 82.6 GU&G  >10 
seconds 
87% 83% 
Induruwa 
197 
85.3 CFS 5-8 - 67.3% 
Lefebvre 190 85.9 CFS ≥7 - 25.4% 
Magnani 201 N/A Health ABC 
PPB 
Scores were compared over time for 
the same individuals, and the effect 
of developing AF estimated 
Mlynarska 
209 
72.7 TFI ≥5 - 60% 
Nguyen 210 84.7 Reported 
EFS 
≥8 - 53.3% 
Nguyen 211 84.7 Reported 
EFS 
≥8 - 53.3% 
O’Caoimh 
213 
[84] CFS ≥5 
≥7* 
- 
- 
100% 
85.8% 
Perera 181 82.7 Modified 
EFS 
≥8 - 64% 
Pilotto 191 84.4 MPI ≥2 - 61.4% 
Polidoro 198 79.3 Frailty 
index37 
0.25 77.9% 88.6% 
* Threshold of 5 used by the authors. Results for a threshold of 7 also reported 
in this table for comparison purposes.       
Abbreviations  CFS: clinical frail scale, EFS: Edmonton frail scale, GFI: 
Groningen frailty indicator, GU&G: get up and go, ISAR: Identification of seniors 
at risk, MPI: multidimensional prognostic index, N/A: not-applicable, NR: not 
reported, PPB: physical performance battery, OAC: oral anticoagulant, TFI: 
Tilburg frailty indicator 
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  Table 13: Studies reporting the association betw
een frailty and O
A
C
 status 
Study 
Association: frailty 
and O
AC
 
prescription 
Tim
e of assessm
ent 
n= 
U
nadjusted O
R
 
(95%
 C
I) 
Adjusted O
R
 
(95%
 C
I) 
Lefebvre, 2016 190 
Less use 
H
ospital adm
ission 
682 
0.45 (0.31-0.65) 
0.29 (0.16-0.54) 
Induruw
a, 2017 197 
Less use 
H
ospital adm
ission 
419 
N
R
 
0.77 (0.70–0.85) 
Perera, 2009 181 
Less use 
H
ospital adm
ission 
220 
N
R
 
0.34 (0.17-0.68) 
H
ospital discharge 
220 
N
R
 
0.12 (0.06-0.23) 
D
enoël, 2014 200 
N
o difference 
H
ospital adm
ission 
142 
O
R
 1.12 (0.50-2.96) 
N
R
 
Bo, 2015 193 
N
o difference 
H
ospital discharge 
430 
N
R
 
0.80 (0.41–1.57) 
N
guyen, 2016 210  
N
o difference 
H
ospital discharge 
302 
0.58 (0.36-0.93) 
0.66 (0.40–1.10) 
D
oucet, 2008 1 
N
o difference 
H
ospital discharge 
209 
N
R
 
N
R
 
Frew
en, 2013 212 
M
ore use 
C
om
m
unity sam
ple 
118 
N
R
 
2.33 (1.03-5.23) 
Abbreviations:   N
R
: not reported, O
R
: odds ratio. Adjustm
ents are detailed in Table 14, page 57 
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2.4.8 Atrial fibrillation, frailty and anticoagulation 
2.4.8.1 Hospital cohorts 
Eight studies were in a hospitalised population with AF, Table 13.1, 181, 190, 193, 197, 
199, 200, 210 Five were methodologically similar, reported adjusted OR for the 
association between frailty and OAC, and were included in the meta-analysis, 
Figure 4.181, 190, 193, 197, 210 Two studies reported OR at admission,190, 197 and two 
at discharge.193, 210 One study reported both.181  
 
At hospital admission: Meta-analysis showed that people with frailty had lower 
odds of OAC prescription than those without frailty (pooled adjusted OR 0.45 
[95%CI 0.22 to 0.93].181, 190, 197 One study reported an unadjusted OR, and was 
not included in the meta-analysis. This showed no association between OAC 
prescription and frailty (unadjusted OR 1.12 [0.50 to 2.96].200 The later was a 
small study using a brief screening tool with limited predictive validity 
(Identifying Seniors at Risk).229 
 
At hospital discharge: Meta-analysis showed that frailty had no statistically 
significant association with OAC prescription (pooled adjusted OR 0.40 [95% CI 
0.13 to 1.23]).181, 193, 210 One study used propensity score analysis and whilst it 
was not included in the meta-analysis, it also found no association between 
frailty and OAC prescription after matching.199  
 
2.4.8.2 Community cohorts 
In contrast to the hospital cohorts, a study using a nationally representative 
community sample found that people with frailty had an increased odds of OAC 
prescription compared to people without frailty (adjusted OR 2.33 [95%CI 1.03 
to 5.23], adjusted for age, sex and education).166 In a study of nursing home 
residents with AF and frailty, 70% of participants were eligible for OAC 
according to a bespoke risk based decision support aid incorporating stroke and 
bleeding risk.213 However, just 17% were prescribed OAC. A separate study 
found that advanced age, very short life expectancy, difficult/impossible 
management of therapy, fear of bleeding, and harm greater than benefit were 
commonly reported reasons for not prescribing OAC in older patients.193
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Figure 4: Forest plot to show
 the association betw
een fr ailty and anticoagulation status at 
adm
ission, at discharge, and in the com
m
unity 
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2.4.9 Direct oral anticoagulation prescription 
Across five studies, DOAC was prescribed in between 5.4% and 20.6% of those 
anticoagulated.190, 193, 194, 197, 210 This was stratified by frailty status in one study, 
but it only included 11 patients on DOAC.197  
 
2.4.10 Age, co-morbidity, and oral anticoagulation 
Six studies reported the association between increasing age and OAC 
prescription,166, 190, 193, 197, 210 five of which adjusted for other factors, Table 
14.166, 190, 193, 197, 210 Increased age was independently associated with reduced 
OAC prescription in four studies (adjusted OR range 0.71 [0.59 to 0.84] to 0.98 
[0.97 to 0.98]),190, 193, 197, 210 but not in the fifth (adjusted OR 1.02 [0.97 to 
1.07]).166 Finally, a study published in 2008 showed patients prescribed 
antiplatelet medications instead of OAC tended to be older (mean 86.5 vs 82.9 
years, p<0.01).1  
 
Two studies reported the association between Charlson co-morbidity score and 
OAC prescription. One showed that an increased adjusted score was 
independently associated with not being prescribed OAC.193 The second 
showed no statistically significant difference in score between those prescribed 
OAC and those that were not.200  
 
2.4.11 Oral anticoagulation and outcomes 
One study noted a greater incidence of cardio-embolic stroke among individuals 
with frailty compared to those without frailty (12.3 vs. 3.9%, p<0.05). However, 
the incident cases of stroke were not stratified by OAC prescription due to a 
small number of events.181 Patients with AF and frailty also had a higher six-
month mortality compared to those with AF without frailty (unadjusted RR 2.8 
[95%CI 1.2 to 6.5]).181 Nguyen et al showed no difference in stroke or major 
bleeding by frailty status in patients with AF, which the authors suggest may be 
related to careful patient selection and OAC management.210   
 
Doucet et al found no difference in clinical outcomes (stroke, death, major 
bleeding) at 3 months between patients with AF who were prescribed OAC 
compared with an antiplatelet.1 The prevalence of falls post-discharge was 
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higher in the aspirin compared to the OAC group (18.6% vs. 7.5%, p<0.02) 
despite similar pre-admission falls history. This may suggest that clinicians were 
aware of an increased falls risk in these individuals that was not captured by the 
study. Physicians tended to overestimate the risk of bleeding, and 
underestimate the risk of thrombosis compared with objective scores.  
 
2.4.12 Frailty and mortality in atrial fibrillation 
Three studies report the association between frailty and mortality in patients 
with AF. However, the different representations of risk and durations of follow-
up did not allow pooling for meta-analysis. Perera et al identified increased 
mortality in patients with AF and frailty compared to patients with AF but not 
frailty (unadjusted RR 2.8 [95%CI 1.2 to 6.5]).181 Nguyen et al report increased 
six-month mortality associated with frailty, (adjusted HR 2.33 [95%CI 1.31 to 
4.14], adjusted for age, gender, comorbidity, CHAD2DS2-VASc, HAS-BLED, 
delirium, OAC, digoxin or psychotropic medication) and that length of stay was 
3.1 days longer in individuals with frailty compared to those without.211 During a 
mean follow-up period of 301 days Bo et al found that in patients with AF, frailty 
was associated with an increased risk of mortality compared to non-frail patients 
(adjusted OR 2.77 [95% CI 1.44 to 5.33], adjusted for OAC, ADL dependence, 
serum albumin and readmission).199 A further study found that functional status, 
but not frailty (FRAIL scale), was independently associated with inpatient 
mortality.194  
2.5 Discussion 
This systematic review included 20 research articles. Although the search 
period commenced at the inception of each included database, the articles that 
met the inclusion criteria were published between 2013 and 2017. Six studies 
were included in a meta-analysis of the association between frailty status and 
OAC prescription in patients with AF. At hospital admission frailty was 
associated with decreased OAC prescription, but there was no statistically 
significant association at discharge. A community-based study found that frailty 
was associated with increased OAC prescription. 
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We report evidence that in patients with AF, frailty is associated with increased 
stroke incidence,181 medium-term mortality,181, 211 symptom severity,209 and 
length of hospital stay.211 One study showed frailty was not associated with 
stroke or major bleeding.210 Having AF was associated with a greater chance of 
being frail, 198 having falls,203 and physical performance decline201 compared to 
people without AF, suggesting that AF itself may be a marker of frailty. There 
was a lack of data on clinical outcomes stratified by both frailty and OAC 
status.1, 181, 210  
 
The different association between frailty and OAC prescription among hospital 
and community cohorts was striking. The findings at hospital admission are 
reflective of prescribing patterns in the community, albeit in a subgroup who 
have been hospitalised, with potential for different characteristics. The absence 
of a statistically significant association between OAC prescription and frailty 
status at discharge may be because hospitalisation allowed more complete 
case ascertainment and prescription of therapy. However, survivorship bias is 
also a potential factor, whereby fitter patients are more likely to survive to 
discharge. Furthermore, hospitalisation in the context of frailty is a potential 
marker of nearing end of life, so de-prescribing decisions could be influenced 
accordingly.230 
 
In a community study with a relatively young population and low AF prevalence, 
frailty was associated with an increased OAC prescription rate.166 In contrast, in 
a nursing home population with a relatively high prevalence, just 25% of the 
eligible population were prescribed OAC.213 Competing risks are likely to be 
influencing prescribing behaviour in this vulnerable population. 
 
There are concerns that clinical guidelines tend to relate to single-organ 
pathology,23, 219 and the trial evidence on which they are based frequently 
excludes people with frailty, including of DOACs.149-152 Furthermore, CHA2DS2-
VASc has not been validated for use in the oldest old or people with frailty.231 In 
the absence of trial evidence, observational data can offer insights into current 
practice and patient outcomes. However, this review identified a lack of 
research in a community setting using validated frailty measures, despite 
growing evidence that a greater mortality risk is carried by measures of 
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biological than chronological age.10, 11 There is therefore a limited evidence 
base to guide management in this high-risk population in whom bleeding 
complications may be more common and more problematic than in the general 
population.232, 233  A risk-treatment paradox exists, whereby those at the highest 
risk of stroke are not more likely to receive anticoagulation.183, 234 Whether frailty 
should influence OAC prescribing, including through incorporation into AF 
decision-support tools, is currently unknown. 
 
2.5.1 Strengths of the review 
To my knowledge, this is the first systematic review to summarise current 
evidence for the management of AF in older people with frailty. We have used a 
robust search strategy, risk of bias assessment and methods pre-specified in a 
published protocol. We were able to present pooled adjusted estimates of the 
association between OAC prescription and frailty, and included data on DOAC 
use, reflecting recent prescribing trends. However, the small proportion of 
patients that were taking DOAC in the included studies despite its increasing 
role reinforces the need for contemporary research.235 
 
2.5.2 Limitations of the review 
A range of frailty measures were used and frailty status was dichotomised as in 
the source studies. This may have introduced additional clinical heterogeneity in 
the meta-analysis. This, in combination with the relatively low number of 
participants in the included studies (ranging from 118 to 682 participants) as 
well as variation in the confounders used between the studies is likely to have 
contributed to the high measure of statistical heterogeneity (I2 greater than 
80%). Therefore, the estimates should be interpreted with a degree of caution. 
We have reported adjusted and unadjusted estimates where available, and 
importantly these show similar direction of associations. 
 
Whilst we have reported OAC prescription at different time points, this was 
without access to individual patient data, so we cannot exclude misclassification 
error. Frailty was often diagnosed in an acute hospital setting, although 
guidance suggests frailty assessment is best performed in the community.24  
Most studies excluded patients with cognitive or major sensory impairment due 
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to the necessity for informed consent, and so may not be representative of the 
overall frail population. Some studies required participants to complete a 
physical task, which may exclude those with advanced frailty.  
As with any meta-analysis of observational data there are risks of confounding 
by indication and other systemic biases that are incompletely accounted for. 
Further observational data in a community setting with complementary 
qualitative work would contribute to our understanding of current practice, but 
with susceptibility to bias. A randomised trial may ultimately be needed to help 
quantify efficacy and safety endpoints in a frail population. 
 
2.6 Conclusion 
At hospital admission frailty was associated with decreased OAC prescription. 
However, there was no statistically significant association at the time of 
discharge. A single study in a community setting showed that frailty was 
associated with increased OAC prescription. There is evidence that in patients 
with AF, frailty is associated with increased stroke incidence, mortality, 
symptom severity, and length of hospital stay. There was a lack of evidence 
with which to evaluate the impact of frailty on the association between OAC 
prescription and clinical outcomes. 
 
Although anticoagulation is largely initiated and managed in primary care, there 
is a lack of evidence to guide optimal care in this setting for patients with AF 
and frailty. This may in part explain a gap between current guidelines and 
clinical practice in management of these patients, particularly in relation to OAC 
prescription. 
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Chapter 3 - Potential electronic health record data sources 
3.1 Introduction 
Clinical record keeping is central to safe and effective patient care at an 
individual level, but the secondary use of these routinely collected data for 
research has the additional potential to improve patient care for the population.  
 
The use of large observational datasets for research may significantly add to 
current understanding of the epidemiology and clinical outcomes of patients 
with a wide range of conditions. The large number of participants, long follow-up 
duration and broad inclusion criteria are advantages, and may complement 
knowledge gained from clinical trials, which tend to be more restricted in scale 
and in the participants that are included.236 Observational data may allow 
researchers to evaluate ‘real world’ experience, generate hypotheses, and 
develop an understanding of the associations between exposures and 
outcomes.237, 238 However, care must be taken to consider confounding and 
other forms of bias, and due regard given to governance and consent.239 The 
increasing use of routinely collected health and social care data in observational 
research presents a particular opportunity for research involving older people, 
who tend to be under-represented in randomised controlled trials and other 
types of research.240 
  
The quantitative analysis in this thesis will use routinely collected electronic 
health record (EHR) data from primary care, supplied by ResearchOne. This 
chapter will provide a summary of the EHR data sources with potential to 
address the research questions of the thesis, followed by a discussion of the 
definitions and code lists that are needed to make use of EHR for research 
purposes. 
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3.2 Electronic health records 
Examples of EHR data sources that are available to researchers in the UK are 
shown in Figure 5.241  
 
Figure 5: Examples of electronic health records available in the UK 
Abbreviations  CPRD: Clinical Practice Research Datalink; THIN: The Health 
Improvement Network. 
 
Primary care databases have the advantage of holding relatively 
comprehensive longitudinal clinical data from a large, unselected population. 
The datasets are likely to be representative of the overall population, but in the 
absence of linkage to another source may under-represent secondary care 
diagnoses, and may lack data resolution.242 Other data sources may hold high 
resolution data for a very specific and single-issue remit, such as 
EudraVigilance, which is the system for managing and analysing information 
relating to adverse drug reactions operated by the European Medicine 
Agency.241  
 
Disease registries contain highly detailed information relevant to the particular 
condition of interest, but are not representative of the overall population that 
have not been diagnosed with that condition. As clinical data sources are 
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increasingly computerised, patient-level datasets are being linked across 
traditional boundaries of care services, which also allows more robust and 
comprehensive ascertainment of exposures and outcomes from across 
secondary care and some disease registries.243 
 
Whilst the availability of EHR has benefits to researchers, concerns have been 
expressed by patients and clinicians regarding the governance and consent 
arrangements for this secondary use of EHR, and it has been suggested that 
these concerns may prove to be a barrier to further implementation.239 In 
particular, there are risks of patient privacy violations associated with data 
breaches.238, 244 However, the impact of these is mitigated in the research arena 
by the use of anonymised or pseudonymised datasets and stringent data 
security policies.243, 245-247 In fact, it may be that the greater risk to confidentiality 
is from inappropriate access of identifiable patient records in the clinical 
environment,248 rather than from research breaches. A summary of primary 
care, secondary care, and registry datasets will now follow. 
 
3.2.1 Primary care datasets 
There are over 300 million consultations annually in primary care in the UK,249 
and 96% of practices have been using EHR since 1996.250, 251 The use of EHR 
has a range of advantages including improved quality of care, guideline 
adherence, and financial efficiencies.244 This huge repository of data has also 
allowed a proliferation in research using EHR in recent years. Indeed, 
publications using three large primary care databases have increased at an 
annual rate of 18.7% over twenty years.252  
 
Despite differences in the coding and structure of different primary care 
datasets, there is evidence that analyses can be externally validated across 
databases with differences in population characteristics, data definitions, 
recording, quality and completeness having only a minimal impact on 
findings.253 Examples of international datasets include the Information System 
for the Development of Primary Care Research database, which includes 
records representing 80% of the Catalan population,254 and the Snow Agent 
surveillance system for infectious diseases in Norway,255 amongst others.256 In 
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the UK, there are four key primary care datasets for research, and each will be 
briefly outlined below. 
 
3.2.1.1 ResearchOne  
This research database is derived from the TPP SystmOne clinical database.257  
SystmOne holds the health and care records of over 26 million patients, and 
these are made available within the ResearchOne database if healthcare 
providers ‘opt-in’ to making pseudonymised records available for research. 
Individual patients have the right to ‘opt-out’. The eFI was developed using 
ResearchOne, and validated using the THIN database.11 The ResearchOne 
database will be discussed in detail in section 4.4. 
 
3.2.1.2 Clinical Practice Research Datalink (CPRD) 
The research service CPRD is a governmental, not-for-profit organisation. They 
provide research access to two main primary care research databases, CPRD 
GOLD and CPRD Aurum.243 The databases contain data from two different 
clinical computing systems, and are offered separately due to differences in the 
structure and coding of the data between the two. Both databases offer routine 
data linkage with Hospital Episode Statistics (HES), death registration data from 
the Office for National Statistics (ONS), Mental Health Dataset and deprivation 
scores. Access to patient-level datasets is provided for research following 
protocol approval from an independent scientific advisory committee. 
 
The current iteration of CPRD built upon previous databases, the Value Added 
Medical Products dataset (established in 1987), and subsequently the General 
Practice Research Database (established in 1993), which expanded to become 
CPRD in 2012.258 CPRD GOLD contains data contributed by 674 general 
practices in the UK that use Vision® software. In 2015, there were 4.4 million 
patients that were alive and registered in CPRD GOLD with records that meet 
their quality criteria (approximately 6.9% of the UK population).258 CPRD Aurum 
contains data contributed by practices using EMIS Web® software. They provide 
anonymised primary care records from 738 general practices (10% of practices 
in England), with EHR from over 19 million patients. Of these, seven million are 
alive and currently contributing (13% of the population of England).259 
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3.2.1.2.1 Clinical research using LInked Bespoke studies and Electronic health 
Records (CALIBER) 
The CALIBER programme was established in 2012, and provides linkage of 
CPRD data with multiple other EHR sources, including MINAP, secondary care 
data, and cause-specific mortality.247 The programme are also developing links 
between datasets such as UK Biobank and MINAP to support bespoke 
investigator-led cohort studies. All projects must be approved by the CPRD 
Independent Scientific Advisory Committee. The CALIBER programme hold 
EHR of 10 million patients, but the specific numbers for each dataset are not 
published. 
 
3.2.1.3 The Health Improvement Network (THIN) 
Like CPRD GOLD, the THIN database collects data from practices that use 
Vision® software dating back to 1987 in some cases.260 Patients may appear in 
either or both research database. In 2012, it was found that of 781 practices 
that were submitting data to CPRD or THIN, 41.9% (327) submitted data to 
both.260 The THIN database contains anonymised primary care records from 
562 general practices covering 6.5% of the UK population.245 It currently holds 
the EHR of 11.1 million patients, of whom 3.7 million are active. Data from THIN 
are linked with postcode based socioeconomic and environmental indicators, 
and are increasingly being linked with secondary care datasets, but the 
proportion of records in which linked data are available is not reported.260 
 
3.2.1.4 QResearch 
QResearch was developed as a collaboration between the University of 
Nottingham and the primary care software company Egton Medical Information 
Systems (EMIS).260 It is now a not-for-profit collaboration between the 
University of Oxford and EMIS. QResearch contains pseudonymised health 
records of over 30 million patients across 1500 general practices using the 
EMIS clinical computer system.246 The entire database has been linked to 
cause of death data, cancer and hospital data at individual patient level, and 
data linkages extend back to 1993. Data are available to researchers following 
protocol approval by the data controller for QResearch and the linked datasets, 
supported by the advice from a Scientific Advisory Committee.246 
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3.2.2 Secondary care datasets 
Historically, uptake of EHR in secondary care has lagged behind primary care. 
However, hospital records are increasingly being computerised.250 As in primary 
care, the original purpose of data collection is often for another purpose such as 
clinical administration or audit, but datasets are increasingly available for 
research, and may be linked to general practice records.247 Using secondary 
care datasets alone would miss patients that were not admitted to hospital. 
 
3.2.2.1 Hospital Episode Statistics 
Hospital Episode Statistics (HES) is a data warehouse containing data of all 
admissions, outpatient appointments and attendances at accident and 
emergency in NHS hospitals in England. Each HES record includes clinical, 
demographic, administrative and geographical information. The clinical 
information comprises of primary and secondary diagnoses, coded using the 
International Statistical Classification of Diseases and Related Health Problems 
10th Revision (ICD-10) by hospital coding departments.261, 262 HES are 
collected predominantly to enable healthcare analysis for the NHS, government, 
statutory bodies, and providers. However, data extracts can be obtained for 
research use from the NHS Digital Secondary Use Service. 
 
3.2.3 Clinical registry data 
Clinical registries are often designed to collect data for the evaluation of 
disease-specific care and outcomes. Registry data tend to be prospectively 
acquired which has advantages in terms of reliability, and includes variables 
that are considered relevant to the particular condition of interest. However, 
registries are potentially subject to selection bias. For example, there is 
evidence that there is under-reporting of myocardial infarction in MINAP 
compared with general practice records from CPRD and HES,242 and patients 
that are not included may be systematically different from those that are.263  
 
A recent systematic review identified 15 registries of patients with AF, with a 
wide range of different designs, inclusion criteria and duration of follow-up.264 
One example is the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation 
(GARFIELD-AF), which is a large, industry-funded registry of patients with a 
  
 
69 
new diagnosis of non-valvular atrial fibrillation, and aims to evaluate the 
management and outcomes of those with an indication for OAC.265 57,262 
patients from 1048 centres in 35 countries worldwide were recruited over five 
sequential cohorts between December 2009 and August 2016. Follow up is 
planned of between two- and eight-years following diagnosis. 
 
The TuRkish Atrial Fibrillation cohort is a population-based, whole-country 
cohort of patients with AF, extracted from a health insurance database in 
Turkey.266  It was the first cohort of its kind, and aims to study patterns, causes 
and impact of therapy on AF incidence and outcomes. 
 
The Guidance on Risk Assessment in Stroke Prevention for Atrial Fibrillation 
(GRASP-AF) tool was developed by PRIMIS, which is a part of the School of 
Medicine at the University of Nottingham. It is incorporated into general practice 
computer systems to aid clinicians in case-finding and care management, in 
particular by identifying patients with possible or probable AF in whom it 
calculates an estimated stroke risk using CHA2DS2-VASc. The tool also 
identifies patients that are potentially eligible but not currently prescribed OAC, 
and estimates the number of strokes across the general practice list that may 
potentially be preventable by instigating OAC. The tool assists practices with 
providing evidence of compliance with the Quality Outcomes Framework, and 
data that is useful for comparison of performance between practices and clinical 
commissioning groups.145, 267 
 
3.2.4 Data definitions in electronic health records 
Information in EHR are commonly coded rather than kept as free-text. Coding 
offers greater consistency, and makes data storage and analysis more efficient. 
In clinical practice, free-text data may be available alongside the coded data, 
which provides additional context. However, in EHR research this ‘free text’ 
data is often not available, and if it is available then it is challenging to analyse 
at scale. Clinical coding structures tend to be based upon internationally 
accepted classifications, such as the World Health Organisation’s International 
Classification of Diseases, currently in version 11 (ICD-11),262 which is 
commonly used for coding clinical data in secondary care. Clinical coding within 
primary care will now be discussed. 
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3.2.4.1 Read codes 
In 1986, Dr James Read published his innovative system of using hierarchical 
four-byte codes for clinical coding.268 Subsequent iterations were Clinical Term 
Versions 2, and then 3. In 2002, CTV-3 was merged with the College of 
American Pathologists’ Systematized Nomenclature of Medicine Reference 
Terminology (SNOMED RT) to create SNOMED Clinical Terms (SNOMED CT), 
which has now replaced previous versions in much of the UK.251, 268, 269 
 
The Read clinical classification was purchased by the UK Department of Health 
in 1990, which gave the opportunity for comprehensive and standardised 
clinical coding.270 This has brought benefits for clinical care including by 
identifying patients with a particular condition for clinical review and enabling a 
concise summary of their past medical history. There are also population level 
benefits, such as estimating the burden of a particular disease in a local area, 
and clinical coding has also been used in establishing remuneration for clinical 
practice that is in line with NHS England objectives set out in the Quality 
Outcomes Framework.  
 
Coded primary care records have also allowed a proliferation of research 
making secondary use of these data. Whilst researchers have often used 
clinical codes, advances in machine learning are allowing increasingly 
sophisticated uses to be made of data that were difficult to clean and utilise at 
scale for research, such as free text, in a rapidly advancing field of ‘deep 
learning’.271 
 
3.2.4.2 Code-lists 
One challenge associated with clinical coding is the large number of potential 
codes for a phenotypically similar entity. For example, AF could be coded as 
G5730 - AF; Xa7nl - controlled AF; X202R - lone AF, among others. This has 
implications for the reproducibility of research, as there is the potential for large 
variation in the clinical codes that are included or excluded for any given 
diagnosis, investigation, result or observation.  
 
Many publications that use EHR have published their code-lists, which is 
important for scrutiny and reproducibility of research. Open-access repositories 
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of code-lists have also been developed, including through CALIBER.247 
However, these are currently not available for CTV-3 codes, which is the coding 
structure used in ResearchOne. In the absence of a universally accepted set of 
codes that can be used to define a particular condition, there have been efforts 
made to increase the rigour of decision making processes using a rule-based 
phenotyping framework to develop and validate code-lists through 
consensus.272  
 
Ultimately, research datasets are reliant on the coding practices at the source of 
the data, which can be suboptimal. For example, in a cross-sectional analysis, a 
large proportion of heart disease events recorded in EHR were coded used 
terms that did not distinguish between angina and myocardial infarction, and 
that the use of more non-specific codes appeared to be increasing over time.273 
This poses a challenge for researchers using EHR, where more specific clinical 
information is often required to reach meaningful conclusions. Using linked 
datasets has the potential to increase the sensitivity and specificity of primary 
care records, for example through linkage to a disease specific registry, death 
certificate information or hospital admissions data.242 
 
Regardless of the source of the code-lists, it has been suggested that case 
definitions are reported transparently, and that researchers should consider 
undertaking a sensitivity analyses using different sets of clinical codes.273 There 
is scope for an increased transparency of reporting of code-lists. In a 
representative sample of 450 papers published using EHR data, only 19 (5.1%) 
were accompanied by a full set of published clinical codes.274  
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3.3 Summary 
• Primary care electronic health records allow for breadth of data across a 
large and representative population, but may under-report diagnoses 
made in secondary care.  
• Datasets linked between primary and secondary care are increasingly 
available. 
• There are four key primary care research databases available in the UK: 
ResearchOne, CPRD, THIN and QResearch. 
• There are multiple different clinical coding structures. Within the coding 
structure, code-lists are required to define each condition, investigation, 
observation and test of interest. These are integral to the validity of the 
research, and there is an increasing focus on transparency of code-lists. 
• At present, there is no code-repository for CTV-3 codes. 
 
3.4 Conclusion 
A range of data sources are available for EHR research in patients with AF. 
Registry data would have the advantage of high-resolution data that is highly 
specific to AF, but would have limited generalisability to the overall population. 
Secondary care data is limited to patients that have required hospital admission, 
and information about that admission. Importantly, neither of these sources 
include routine ascertainment of frailty status. Primary care data was selected 
for use in this thesis, as it is representative of the community-dwelling 
population, has breadth of data that enables estimation of frailty status using the 
eFI, and contains detailed information on repeat prescriptions. These three 
factors are integral to meeting the aims and objectives of this thesis, which were 
informed by the literature review. 
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Chapter 4 - Development of the research cohort data set 
 
4.1 Chapter introduction 
The quantitative analysis in this thesis was based upon an extract of patients 
aged 65 years or older from ResearchOne, a national, primary care based 
dataset. The aims were to establish the prevalence of AF and frailty; describe 
the clinical characteristics of people with AF at different levels of frailty; to 
identify whether prescription of OAC differs by frailty category in people with AF; 
and to determine whether frailty modifies the association between OAC use and 
clinical outcomes. The focus of this chapter will be the dataset, the extract that 
formed the analytical cohort, the selection of the variables that were studied, 
and data cleaning and coding. The analytical methods will be detailed in 
Chapter 5. 
 
4.2 Chapter summary 
The electronic health records of all patients aged 65 years or older on the 31st 
December 2015 who were in the ResearchOne database were included in this 
retrospective cohort study. The initial data extract consisted of 115.4 million 
rows of data, with clinical information mostly held in CTV-3 codes. Code-lists 
were developed to identify the clinical conditions of interest, and these were 
used to clean and code the dataset. 
 
The key exposures included AF, frailty, and OAC, and the outcomes of interest 
were all-cause mortality, stroke, intracranial bleeding and gastrointestinal 
bleeding. A wide range of co-variates and baseline characteristics are also 
reported. 
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4.3 Study design 
This was a retrospective cohort study of patients aged 65 or over on the 31st 
December 2015. 
 
4.4 Data 
Data used for the analysis were from ResearchOne, which is a health and care 
research database developed by The Phoenix Partnership (TPP) in 
collaboration with the University of Leeds and the UK Government’s Technology 
Strategy Board. It is run on a not-for-profit basis, and includes de-identified 
clinical and administrative data derived from the EHR of patients in England 
who are registered at a practice that use the TPP SystmOne clinical system.275 
There are a number of clinical settings that use SystmOne outside general 
practice including some providers of child health, community health, palliative 
care, Accident & Emergency and acute hospital services. Whilst data may be 
included in ResearchOne from each of these settings, formal comprehensive 
linkage from other databases is not available. 
 
As of 2016, there were 20.2 million patients registered in SystmOne, 
representing 35% of all patients in England.276 There were 2,552 general 
practices represented, and 11,160 general practitioners. The median list size 
was 7,080 (interquartile range, IQR, 4,214 to 10,553) of whom 524 (IQR 256 to 
895) were aged 75 years or older. Patients are included from all NHS England 
geographical regions in England (as of 2016) except for Lancashire, with 
coverage ranging from 5% of patients in Cheshire and Merseyside to 77% in the 
East of England.276 
 
The transfer of EHR data from SystmOne to ResearchOne is subject to the 
general practice ‘opting in’ to the research database. If they are part of a 
ResearchOne practice, individual patients also have the right to ‘opt out’ of their 
EHR being used for research purposes. 
  
ResearchOne was selected for this study because of the size and national 
coverage of the data set.276 Other similar resources are available, as outlined in 
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Chapter 3, but these tend to be costly, and ResearchOne has additional 
benefits such as pre-existing collaborative links with University of Leeds,275 and 
that it was used in the development of the eFI.11  
4.5 Housing and security 
Data were obtained following an application to TPP, which was reviewed 
internally by their research committee. Following approval, a data extract was 
prepared by a TPP analyst, and this was delivered through a secure data link. 
The flow of data is shown in Figure 6. 
 
 
Figure 6: Chart to illustrate data flow 
Abbreviations 
LIDA: Leeds Institute for Data Analytics 
VRE: Virtual Research Environment 
SQL: Structured Query Language 
CSV: Comma-Separated Values 
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All data were housed within a secure Virtual Research Environment (VRE). This 
is a ‘private cloud’ with limited, secure access and strict protocols for transfer of 
data in and out. The VRE is managed by a team of data analysts who are 
responsible for disclosure control, information classification, security, and back-
up arrangements. It is accredited to the international standard for information 
security management, ISO/IEC 27001:2013, and meets the requirements to 
store health data from NHS Digital, Public Health England and other NHS or 
social care organisations.277 A data management protocol was completed with 
input from the data services team, and was approved by the information 
governance manager for the Leeds Institute for Data Analysis (LIDA). A brief 
summary of this will follow. 
 
4.5.1 Extract from data management protocol 
4.5.1.1 Data Collection 
What data will you collect or create? Patient records will be extracted from the 
ResearchOne database. Long-term access will not be allowed, or required. 
Data will be accessible for up to 5 years.  
 
How will the data be collected or created? Data are extracted electronically from 
routine primary care records. Data will be transferred electronically.  
 
4.5.1.2 Documentation and Metadata 
What documentation and metadata will accompany the data? Some of the data 
will be coded using controlled terminologies such as ICD, British National 
Formulary (BNF) and Read, and the appropriate version of these terminologies 
will be stored with the data.  
 
4.5.1.3 Ethics and Legal Compliance 
How will you manage any ethical issues? The data are de-identified. Routine 
clinical data will be used. This does not require specific ethical review, as the 
research is limited to secondary use of information previously collected in the 
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course of normal care without the intention to use it for research at the time of 
collection. Patients are not identifiable to the research team. The ResearchOne 
database has NHS Research Ethics Committee and National Information 
Governance Board approval. The data will be saved securely on the university 
Integrated Research Campus (IRC).  
 
How will you manage copyright and Intellectual Property Rights issues? 
Research findings can be freely published without interference, regardless of 
the nature of the findings. Where the ResearchOne dataset contributes toward 
any publication or presentation the source must be acknowledged and a copy of 
any journal or conference publication submitted to the ResearchOne Project 
Committee.  
 
4.5.1.4 Storage and Backup 
How will the data be stored and backed up during the research? The University 
of Leeds IRC is a secure data management platform. The IRC handles a large 
volume and variety of data so that it can be used securely and efficiently in 
research. 
 
Data will be stored on a project-specific VRE on the IRC. The VRE enables data 
analysis through remote access into a secure virtual desktop, ensuring the data 
stays within the secure environment. Researchers sign an IRC User Agreement 
and undertake any required information governance training before being given 
access to the data through the VRE. Data cannot leave the environment without 
approval and intervention by the IRC Data Services Team, who check for 
unauthorised disclosure. Researchers disseminate non-disclosive findings or 
consented information – and publish these open access where possible. Data is 
subjected to volume-level snapshots periodically throughout the day and is 
synchronously replicated to a secondary data centre on campus.  
 
How will you manage access and security? IRC processes are based on 
international standards and legal requirements for the confidentiality, availability 
and integrity of data. Data handling procedures are determined by the IRC’s 
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Information Security Management System which has gained accredited 
certification to ISO/IEC 27001:2013 and has been assessed as satisfactory 
against the NHS Information Governance Toolkit. The main risk to data security 
is re-identification of data subjects, either accidentally or intentionally. The use 
of a VRE on the IRC significantly reduces this risk. Researchers are not able to 
introduce additional data to the VRE to enable jigsaw attacks to attempt re-
identification. Researchers are not able to download data from the VRE 
themselves, therefore preventing release of data that may be potentially 
identifiable. The platform itself has been designed to be secure in operation, 
has been penetration tested and undergoes regular patching and vulnerability 
scanning. Access control is strict and researchers can only access their own 
projects, and only in isolation from each other so they cannot leak data across 
projects.  
 
Researchers accessing the IRC are bound by an IRC User Agreement which 
details their responsibilities. Researchers are also bound by the terms and 
conditions of their contract with the University of Leeds, and its requirement to 
be bound by the statutes, ordinances and policies of the institution. Any outputs 
of data from the VRE will be verified by the IRC Data Services Team as 
compliant with relevant legislation, contracts and agreements which the project 
is bound by, in particular to the Data Protection Act 1998. Researchers are also 
bound by the ResearchOne confidentiality agreement which contains clauses 
which confer duties upon the institution and individual in relation to 
confidentiality and data protection.  
 
4.5.1.5 Selection and Preservation  
Which data are of long-term value and should be retained, shared, and/or 
preserved?  The data must be destroyed after five years by agreement with 
ResearchOne. The dataset is solely for use on projects that have approval from 
the ResearchOne Project Committee and relevant ethics and governance 
bodies.  
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What is the long-term preservation plan for the dataset? The data must be 
destroyed after five years by agreement with ResearchOne. The dataset is 
solely for use on projects that have approval from the ResearchOne Project 
Committee and relevant ethics and governance bodies.  
 
4.5.1.6 Data Sharing  
How will you share the data? This data must not be shared. Other researchers 
may apply to ResearchOne for the same data. The results of the research will 
be published in the academic literature, and will form an MD dissertation. The 
dataset is solely for use on projects that have approval from the ResearchOne 
Project Committee and relevant ethics and governance bodies.  
 
4.5.1.7 Responsibilities and Resources 
Who will be responsible for data management? The data will remain in the IRC, 
Leeds. Responsibility for good practice lies with each researcher using the 
dataset. The researchers are under the supervision of Professor Chris Gale, 
(Professor of Cardiovascular Medicine, University of Leeds and co-supervisor). 
 
4.6 Ethics 
This study was approved by the ResearchOne project committee under the 
terms of the National Research Ethics Service Research Ethics Committee 
North East approval of the research database (REC reference number 
11/NE/0184, Appendix B). This study was based on the secondary use of 
pseudonymised patient level data previously collected in the course of normal 
care, therefore under the Health and Social Care Act 2012, further NHS or 
University research ethics committee approval was not required. This was 
confirmed by Dr Alice Temple (Research Ethics Training and Development 
Officer, University of Leeds). The study was conducted in compliance with the 
Declaration of Helsinki.278 
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4.7 Data extract 
Data from the beginning of each patients’ EHR up until the date of data 
extraction were requested from ResearchOne by Professor Andrew Clegg, 
(Professor of Geriatric Medicine, University of Leeds and co-supervisor) in May 
2015. The study participants were all patients aged 65 years or older who were 
alive and registered at an included SystmOne practice on 31st December 2015. 
Variables requested by Prof Clegg were age, sex, socioeconomic status 
(Indices of Multiple Deprivation [IMD] score and Townsend quintile), eFI score, 
and all CTV-3 codes that identify a ‘recorded diagnosis of cardiovascular 
disease, comorbidities, medications, systolic and diastolic blood pressure, 
smoking status, residence (home/care home), incident cardiovascular event and 
mortality.’ 
 
The dataset was extracted by Dr Chris Bates (Director of Research & Analytics, 
TPP) and his team of analysts, and arrived in February 2018. Following analysis 
of the dataset, it became apparent that the data that were supplied did not meet 
the requested specifications, as only CTV-3 codes for the past medical history 
required for the calculation of the patient’s eFI were provided. An auxiliary data 
file was supplied in January 2019. 
 
The initial extract consisted of 115.4 million rows of data, which were delivered 
in tables that were accessed through Microsoft SQL Management Studio 2017. 
An Open DataBase Connectivity (ODBC) link was used to bring data into Stata 
(StataCorp LP. 2015. Stata Statistical Software: MP version 14. College Station, 
TX) for coding, cleaning, and analysis. Data were in the form of seven relational 
tables, with a common identifier, which was a patient identification number 
(patient ID). Table 16 shows a summary of the contents of each data table.  
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Table 16: Sum
m
ary of data tables that w
ere supplied by R
esearchO
ne 
Table nam
e 
C
ontents 
R
ow
s of data 
Patient details 
O
ne row
 per patient, containing date of birth, date of death, and gender 
570,131 
Address 
The indices of m
ultiple deprivation (IM
D
) rank and com
bined rurality indicator of the patient’s 
address, along w
ith the start and end date of residence at that address. O
ne row
 for each 
new
 address. 
1,353,172 
Additional coded data 
 
This table contained the clinical data. For each clinical encounter, m
ultiple clinical codes 
could be recorded w
ith each on a new
 row
 in the table. The C
TV-3 code associated w
ith a 
clinical entry, the textual definition of the C
TV-3 code, and any num
eric value (such as 
haem
oglobin, w
ith associated units and norm
al range) w
ere reported in the sam
e row
, along 
w
ith the date of the clinical entry and an event identification code.  
66,619,796 
C
are hom
e  
 
The addresses of providers registered w
ith the C
are Q
uality C
om
m
ission w
as used by 
R
esearchO
ne staff to identify a list of nursing hom
es. W
here a patient’s address m
atched 
this database, the start and end date of their residence at a nursing hom
e w
as recorded in 
this table. 
90,975 
Ethnicity 
Ethnicity w
as recorded using a C
TV-3 code w
ith an associated date of recording and 
definition. There could be m
any recordings per patient. 
1,001,341 
G
P registration history 
The general practice that the patient w
as registered w
ith w
as recorded w
ith an anonym
ous 
practice identification num
ber, w
ith the dates the patient as registered at the practice. 
723,330 
R
epeat m
edications 
The nam
e and dose of each drug that the patient as prescribed, w
ith the start and end dates 
associated w
ith that prescription. R
epeat prescriptions frequently had a review
 date and/or a 
m
axim
um
 num
ber of allow
ed issues of the prescription.  
44,998,666 
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4.8 Cleaning and coding 
Extensive data cleaning and coding was required in order to make use of the 
dataset, and a brief summary of the approach taken for each data table will 
follow. Each row of data contained a unique patient identification number, which 
allowed data from across tables to be combined. 
 
4.8.1 Patient details 
This table contained key demographic data and was directly imported into 
Stata. It included date of birth, date of death. A variable was labelled ‘Gender’, 
was treated as biological sex, as a binary code for male/female was provided 
with a single entry for the duration of the patient’s EHR. 
 
4.8.2 Address 
This table contained data on the IMD rank associated with a patient’s postal 
address. IMD is a measure of relative deprivation at a neighbourhood level 
(lower-layer Super Output Areas with an average of 1,500 residents, based on 
2011 census data).279 The IMD is calculated using a weighted cumulative model 
based on seven domains of deprivation: 
 
1. Income Deprivation 
2. Employment Deprivation 
3. Education, Skills and Training Deprivation 
4. Health Deprivation and Disability 
5. Crime 
6. Barriers to Housing and Services 
7. Living Environment Deprivation279 
 
In some cases, multiple addresses were recorded for an individual over their 
EHR, with a range of different IMD ranks associated with them. This could have 
arisen from address changes over the course of a patient’s records. Whilst 
deprivation at an individual level is a dynamic state with consequences across 
the life-course,280 and there may be large variation between individuals in socio-
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economic status within a neighbourhood, the last recorded IMD was chosen as 
a proxy for the patient’s relative deprivation state. 
 
4.8.3 Additional Coded Data 
Coded data in the form of CTV-3 codes provide one row of data for every 
measurement, observation or diagnoses for every aspect of a GP visit for one 
person, Table 16. In the original data extract, this table was 66.6 million rows 
long, with hundreds of rows per patient. Much of this was not directly relevant to 
this research question. Therefore, the first step in cleaning was to identify CTV-
3 codes that were of relevance, and only retain data associated with these.  
 
The method for extracting relevant data out of this table was to firstly create a 
list of all relevant CTV-3 codes related to a particular diagnoses or clinical 
measurement, and secondly identify all patients with any occurrence of any of 
the CTV-3 codes and label them with the particular diagnoses or clinical 
measurement. An illustration of this process is provided in Figure 7, for the 
example of smoking status. 
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For each variable of interest, code-lists were developed by searching online 
repositories and papers with published code lists.273, 281 These were 
supplemented with codes identified from the Technology Reference data 
Update Distribution (TRUD). TRUD was searched using free-text, and 
subsequent review of the ‘parents and children’ of each identified code in the 
database browser software.269,b For example, pure sensory lacunar infarction is 
considered as a ‘child’ of lacunar infarction, which is in turn a ‘child’ of cerebral 
infarction within the CTV-3 coding structure, Figure 8. The specific variables 
that were used in the study will be detailed in section 4.10.
 
Figure 8: Example of the ‘parent’ and ‘child’ structure of CTV-3 codes 
 
b Clinical Terminology Browser version 1.04. NHS Information Authority and NHS 
digital 
Cerebral infarction
Anterior cerebral 
circulation infarction
Total anterior 
cerebral circulation 
infarction
Partial anterior 
cerebral circulation 
infarction
Lacunar infarction
Pure sensory 
lacunar syndrome
Pure motor lacunar 
syndrome
Pure motor lacunar 
infarction
Pure sensory 
lacunar infarction
Pure sensorimotor 
lacunar infarction
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The code lists that were used to define each condition of interest (and appeared 
in the dataset) are detailed in the appendix. 
 
4.8.3.1 Care Home  
The last entry recorded in this table for each patient was used to identify those 
that were recorded as being resident in a nursing home. This was identified by 
ResearchOne prior to the data extract. They identified nursing home residents 
through CTV-3 coded evidence of nursing home admission, or the patient’s 
postcode matching a postcode on the Care Quality Commission list of 
registered UK nursing homes.11 
 
4.8.3.2 Ethnicity 
For each individual, multiple different recordings were made for ethnicity. 
Entries included classifications of race, but also included religions, or a person’s 
status as a traveller. Where race data was available, this was summarised into 
top level ethnic category codes as defined by the NHS data dictionary, and 
detailed in Table 17.282 
Table 17: Ethnic category codes 
Ethnic category Example 
White British, Irish 
Mixed White and black Caribbean, white and black 
African, white and Asian 
Asian or Asian British Indian, Pakistani, Bangladeshi 
Black or black British Caribbean, African 
Other ethnic groups Chinese 
 
Where patients had multiple different categories recorded, the mode was used. 
As ‘white’ is the dominant category in the UK generally, it is possible that this is 
the default entry for individuals entering data. Therefore, where there were two 
equally commonly recorded categories, the non-white option was selected. This 
process has been previously developed for use with hospital episode statistics 
data, in which multiple ethnic categories occur per patient over the course of 
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their longitudinal healthcare records.283 After applying these rules, recording of 
ethnicity data remained unreliable with multiple conflicting recordings for each 
patient, and this variable was not carried forward to the analysis. 
 
4.8.3.3 General practice registration history 
A unique code identified the general practice that each patient was registered 
at, which allowed adjustment by general practice (section 5.6). The start and 
end date associated with each general practice code was supplied. Where 
patients had been registered at multiple different practices, the most recent (i.e. 
current practice) was included as a co-variate, as this practice was responsible 
for the medical management of the patient during the study period.  
 
The end date was also used to identify the end of the available follow-up data 
for that individual, which was used as the censorship date in survival analysis 
for patients that left the practice before the end of the study and had no 
recorded date of death. Censorship is discussed further in section 4.10.4.5. 
 
4.8.3.4 Repeat Medications 
Medication data were supplied in a table contained 45 million rows of data in 
free-text format, with no coded components. An anonymised extract from the 
medication table shows that the data input was inconsistent, with no coded 
elements, Table 18. 
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Table 18: Illustrative anonymised extract from the medications table 
Medication Start Date End Date Review 
Date 
Dose Quantity 
Amlodipine 
5mg tablets 
09/12/13 02/03/14 - Take one 
daily 
28 tablet 
Ticagrelor 
90mg tablets 
02/07/12 02/07/13 - Take ONE 
tablet 
TWICE a 
day 
1 pack of 56 
tablet(s) 
Fybogel 3.5g 
effervescent 
granules 
sachets plain 
SF (Reckitt 
Benckiser 
Healthcare 
(UK) Ltd) 
17/07/13 19/09/14 - ONE TO 
BE TAKEN 
TWICE A 
DAY, 
Orange 
2*30 sachet – 
3.5 
grams/sachet 
Doxazosin 4mg 
tablets 
11/01/07 - 12/01/16 1 Twice 
Daily 
56 tablets 
Missing data represented with a dash (-) 
 
Non-medicinal prescriptions, such as diabetes testing strips and bandages were 
also included in the medications table. For the calculation of polypharmacy as 
an eFI deficit, it was necessary to exclude such non-pharmaceutical items. This 
required further cleaning steps to separate out these data into medications and 
other treatments. The calculation of the eFI is discussed further in section 
4.10.1. 
 
Medications that were considered to be relevant to the research question were 
identified through clinical expertise, discussion with supervisors, and review of 
the recent literature. Medications were identified in the table using either generic 
or trade names, and so a comprehensive list was collated of alternative ways of 
prescribing each medication using the BNF.154 Where the intention was to 
report that a patient was taking a medication at the time of study entry, e.g. 
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calcium channel blocker, a binary entry was coded (on drug or not). For other 
drugs, such as OAC, more granularity was required and the coding incorporated 
date information in addition as detailed in section 4.10.3. 
 
4.9 Participants 
Patients who were in the ResearchOne database, and aged 65 years and over 
on 31st December 2015 were included. Patients who were identified as having 
AF, but without an associated date of that diagnosis were excluded from the 
analytical cohort. This is because they could not be classified as incident cases 
after study entry, or prevalent cases at study entry. Patients were categorised 
by whether they had a diagnosis of AF at the time of study entry or not. 
 
NICE guidelines recommend that in patients with AF, clinicians should ‘offer 
anticoagulation to people with a CHA2DS2-VASc score of two or above, taking 
bleeding risk into account.’140 On this basis, patients with AF were further 
grouped into those with a CHA2DS2-VASc of two or above, and those with a 
score of below two. The groups available for analysis are shown in Figure 9.
 
Figure 9: Categories of subgroups for analysis 
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As age is a component of CHA2DS2-VASc, patients aged 75 years or above 
have a minimum score of two points, and patients aged 65 to 75 years have a 
minimum score of one. Everyone in the cohort was 65 years or older, so a score 
of zero was not possible in this cohort. 
 
The group with a CHA2DS2-VASc score of two or more was further divided into 
patients that were prescribed OAC, and those that were not.  
 
4.10 Variables 
ResearchOne is a positive recording dataset, whereby new diagnoses, 
observations, and results are added to the record. The assumption was made 
for this study that the absence of an entry means that the condition or 
observation is absent, or not yet identified. 
 
4.10.1 Explanatory variable: frailty 
Frailty was identified using the eFI, as it is based upon a robust theoretical 
framework (the cumulative deficit model). It has undergone independent 
external validation, has excellent predictive validity for clinically important 
outcomes, with good to moderate discrimination. The eFI has been nationally 
implemented, which provides a link for translation of the findings of the thesis 
into clinical practice. Furthermore the eFI was originally created and validated in 
the ResearchOne dataset, and the supervisory team have substantial 
experience of the eFI.11  
 
A file of the CTV-3 codes used to define the deficits was obtained from Dr 
Clegg. The eFI score was calculated as recommended by the authors, as an 
equally weighted proportion of deficits present of the total possible.11 There 
were no time constraints to individual deficits with the exception of 
polypharmacy, which was defined as 5 or more medications prescribed in the 
preceding 12 months using chapters 1–15 of the BNF.154 
 
Dr Marlous Hall (Senior Epidemiologist in Cardiovascular Epidemiology, 
University of Leeds and lead supervisor) cleaned and de-duplicated the 
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medications table to exclude non-medicine prescriptions (e.g. bandages etc), 
and then calculated each patient’s eFI using all patient records up until the date 
of study entry, 31/12/2015, within Microsoft SQL.  
 
Frailty was then categorised as described in the original eFI validation 
publication: robust (0 to 0.12), mild (>0.12 to 0.24), moderate (>0.24 to 0.36) or 
severe (>0.36) frailty. The presence of AF as a component of the eFI and as 
part of the cohort definition, and of stroke as a component of the eFI and an 
outcome is potentially problematic due to mathematical coupling, which occurs 
when one variable is the whole or part of another.284 A previous study 
examining the impact of frailty on the association between systolic blood 
pressure and all-cause mortality used a modified eFI that excluded 
hypertension.285 However, the use of broad categories in the eFI is likely to 
mitigate any impact due to the need for multiple additional conditions to move 
from one frailty category to the next, and so the inclusion of AF in the eFI 
calculation is unlikely to have a large effect on the categorisation of frailty.285 
 
4.10.2 Exposure: atrial fibrillation or atrial flutter 
The AF cohort was defined by a list of 38 CTV-3 codes, Table 19. These were 
compiled using the process described in section 4.8.3. Patients were 
considered as having a history of AF if they had a recorded history of 
paroxysmal, persistent or permanent AF, or atrial flutter on or before the 31st 
December 2015. In the remainder of the thesis, AF will refer to both atrial 
fibrillation and atrial flutter as these frequently co-exist126 which may not be well 
reflected in primary care coding; both carry an elevated stroke risk;126 and the 
two have been previously grouped in a trial setting.152 
 
Codes associated with resolved AF or flutter were also included in the cohort 
definition, as there is evidence of ongoing risk of increased risk of 
thromboembolic sequelae in the long-term, even in the absence of recurrent 
recorded arrhythmia.286 
 
  
 
 
 
 
92 
Table 19: CTV-3 codes used to define the AF cohort 
CTV-3 code Definition 
G5730 Atrial fibrillation 
XaeUP Chronic atrial fibrillation 
XaOft Permanent atrial fibrillation 
XaOfa Persistent atrial fibrillation 
Xa2E8 Paroxysmal atrial fibrillation 
X202R Lone atrial fibrillation 
X202S Non-rheumatic atrial fibrillation 
Xa7nI Controlled atrial fibrillation 
XaEga Rapid atrial fibrillation 
G5731 Atrial flutter 
XaeUR Atypical atrial flutter 
XaeUQ Typical atrial flutter 
XaaUH Paroxysmal atrial flutter 
G573. Atrial fibrillation and flutter 
G573z Atrial fibrillation and flutter NOS 
XaDv6 H/O: atrial fibrillation 
Xafis Atrial fibrillation detected 
XaLFz Atrial fibrillation resolved 
XaIIT Atrial fibrillation monitoring 
XaMGD Atrial fibrillation annual review 
XaZdc Atrial fibrillation care pathway 
XaXrZ Referral to atrial fibrillation clinic 
XaMDG Atrial fibrillation monitoring first letter 
XaMDI Atrial fibrillation monitoring third letter 
XaMDH Atrial fibrillation monitoring second letter 
XaMDK Atrial fibrillation monitoring verbal invite 
XaMDF Atrial fibrillation monitoring administration 
XaMFn Atrial fibrillation monitoring telephone invite 
XE0Wk (Atrial fibrillation) or (atrial flutter) 
7936A Implantation of intravenous pacemaker for atrial fibrillation 
XaaaD Provision of written information about atrial fibrillation 
XaLFh Exception reporting: atrial fibrillation quality indicators 
XaLFi Excepted from atrial fibrillation quality indicators: Patient unsuitable 
XaLFj Excepted from atrial fibrillation quality indicators: Informed dissent 
XaNRA History of atrial flutter 
3272. ECG: atrial fibrillation 
2432. O/E - pulse irregularly irreg. 
3273. ECG: atrial flutter 
Abbreviations  H/O: history of; NOS: not otherwise specified; ECG: electrocardiogram 
 
  
 
 
 
 
93 
4.10.3 Exposure: Oral anticoagulation 
Prescription of OAC was identified from patient-level prescription data, using the 
process described in section 4.8.3.4. All OAC available for prescription in 
England and Wales at the time of the study were included: 
 
• Vitamin K antagonists – warfarin, acenocoumarol, phenindione 
• Direct inhibitors of activated factor X (factor Xa) – apixaban, 
edoxabanc,148 rivaroxaban 
• Direct thrombin inhibitors – dabigatran etexilate 
 
The terms used to search for OAC agents in the medications table are reported 
in Table 20. 
 
Table 20: Search terms used to identify oral anticoagulants 
Drug name Search terms 
Warfarin warfarin 
Apixaban apixaban, eliquis 
Edoxaban edoxaban, lixiana 
Rivaroxaban rivaroxaban, xarelto 
Dabigatran dabigatran, pradaxa 
Acenocoumarol acenocoumarol, sinthrome 
Phenindione phenindione 
Source: British National Formulary 287 
 
Parenteral anticoagulants were not included in this study, as this route is not 
routinely recommended in NICE guidance for prophylaxis of thromboembolism 
for patients with AF,288 and only recommended in rare, short-term situations in 
the ESC guidelines (such as during pregnancy, as low-molecular weight 
heparins do not cross the placenta; and during perioperative management or 
procedures such as catheter ablation).126, 289 As such, it is unlikely that patients 
in this cohort would have been taking parenteral OAC for a sustained period of 
 
c Edoxaban was approved by NICE in England and Wales in September 2015.  
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time during the study period. It is possible that patients were prescribed OAC 
prior to their diagnosis of AF for an alternative indication, such as pulmonary 
embolism or mechanical heart valve. These patients were not excluded. 
 
4.10.3.1 Doses 
International Normalised Ratio (INR) results were not available in this study, 
and so a patient prescribed a vitamin K antagonist was considered to be 
anticoagulated. DOAC regimens were considered as likely to be of a sufficient 
therapeutic dose for prophylaxis of thromboembolic events for patients with AF 
in this study (and therefore the patient ‘anticoagulated’) if the prescribed DOAC 
dose was at least as high as that recommended in the BNF for this purpose, 
regardless of initial indication. These are detailed in Table 21. It was assumed 
that the prescribed dosage was correct and accounted for any necessary dose 
reductions. It was not possible to verify this assumption using the data 
available. 
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Table 21: DOAC dosing regimens that were considered as therapeutic for 
patients with AF, and alternative possible indications for each dose 
Regimen British national formulary indications154  
Apixaban  
2.5mg BD Stroke and systemic embolism prophylaxis in NVAF, in 
patients with 2 or more of: age ≥ 80 years, body-weight < 61 
kg, or serum creatinine ≥ 133 mmol/L. 
Alternative indications: VTE prophylaxis following knee or hip 
replacement surgery; recurrent DVT or PE prophylaxis.  
5mg BD Stroke and systemic embolism prophylaxis in NVAF 
 
Edoxaban 
 
30mg OD Stroke and systemic embolism prophylaxis in NVAF in 
patients with body weight < 61kg 
Alternative indications: treatment or prophylaxis of DVT or 
PE in patients with body weight < 61kg. 
60mg OD Stroke and systemic embolism prophylaxis in NVAF 
Alternative indications: treatment or prophylaxis of DVT or 
PE  
 
Rivaroxaban 
 
15mg OD Stroke and systemic embolism prophylaxis in NVAF if 
creatinine clearance 15–49 mL/minute. 
Alternative indications: treatment of DVT or PE; prophylaxis 
of recurrent DVT or PE 
20mg OD Stroke and systemic embolism prophylaxis in NVAF  
Alternative indications: treatment or prophylaxis of DVT or 
PE  
15mg BD Initial treatment of DVT or PE 
 
 
Dabigatran 
 
110mg BD Stroke and systemic embolism prophylaxis in NVAF in 
patients aged ≥ 80 years, or in patients with moderate renal 
impairment, or increased risk of bleeding. 
Alternative indications: treatment of DVT or PE or 
prophylaxis of recurrent DVT or PE in patients aged ≥ 80 
years, or in patients with moderate renal impairment, or 
increased risk of bleeding 
150mg BD Treatment of DVT or PE or prophylaxis of recurrent DVT or 
PE.  
Abbreviations: DVT: deep vein thrombosis, NVAF: non-valvular AF, PE: 
pulmonary embolism, VTE: venous thromboembolism 
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4.10.3.2 Persistence and timings of exposure 
Vitamin K antagonists exhibit a highly variable half-life and have a narrow 
therapeutic window. In contrast, DOACs have a relatively short half-life (7-11 
hours for rivaroxaban, 9-11 hours for edoxaban, 10-14 hours for apixaban, 14-
17 hours for dabigatran).147 These characteristics mean that for both classes of 
OAC, rigorous concordance with therapy is needed to maximise efficacy and 
minimise treatment related harms.  
 
A proxy for persistence is the issue of a prescription, with the assumption that a 
patient is taking the medication if they are requesting a further supply. Previous 
studies have considered an OAC as discontinued if there was a gap between 
prescriptions of 60 days or more,290, 291 although most gaps between medication 
renewals were shorter than 30 days.291 Johnson et al defined a ‘discontinuation 
period’ as being twice the median duration of a single prescription (60 days for 
dabigatran, and 56 days for apixaban, rivaroxaban and vitamin K antagonist).195  
 
In this study, the association between OAC and clinical outcomes was initially 
modelled as ‘intention to treat’, with OAC status determined at the time of entry 
to the study (31/12/2015). A sensitivity analysis was completed that excluded 
patients that discontinued therapy during the study period, to emulate a ‘per 
protocol’ analysis. In this analysis, switching between OAC agents without a 
break of greater than 30 days was considered as persistent therapy, as used 
elsewhere.205 OAC was considered to be persistent if there were no gaps in 
treatment of 30 days or more. Although this is a ‘stricter’ definition of 
persistence than used in some studies reported in the literature (Table 22), 195, 
207 this has precedent in other recent studies,196, 205 and represents a more 
rigorous approach using the maximum granularity that is possible within the 
limitations of the data. 
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Table 22: Exam
ples of how
 persistence has been defined in the literature 
Study 
Setting 
D
esign 
Persistence definition 
Analysis 
Vinogradova, 
2018
188 
U
K prim
ary care: 
C
PR
D
 and Q
-
research 
R
etrospective, new
-
users 
G
ap of less than 30 days betw
een 
prescriptions. 
Persistence not quantified – patients censored 
w
hen O
AC
 discontinued or changed. 
Johnson, 
2016
195 
U
K prim
ary care: 
C
PR
D
 
R
etrospective, new
-
users 
G
ap of less than tw
ice the m
edian 
prescription duration betw
een 
prescriptions. 
Proportion of patients w
ho w
ere persistent over 
the course of follow
-up. 
C
um
ulative incidence rates of persistence. 
C
ox regression m
odels to report tim
e to non-
persistence. 
Beyer-
W
estendorf, 
2015
3, 196 
D
resden, G
erm
any: 
O
AC
 registry
204 
Prospective, new
 
users 
G
ap less than four w
eeks betw
een 
prescriptions. 
D
iscontinuation rates and tim
e-to-event analysis 
for discontinuation. 
W
illey, 2015
6, 
205 
U
SA: pharm
acy 
claim
s data 
R
etrospective, new
 
users 
G
ap less than 30 days betw
een 
prescriptions. For w
arfarin gap 
betw
een prescriptions of 60 days, 
and less than 42 days betw
een IN
R
 
tests. 
D
iscontinuation rates and m
ean tim
e to 
discontinuation. 
G
o, 2003
7, 207 
N
orthern C
alifornia, 
U
SA, ATR
IA 
cohort. 8-11, 208 
Prospective cohort 
study 
G
ap of less than 60 days betw
een 
w
arfarin prescriptions, unless an 
intervening IN
R
 m
easurem
ent 
every 42 days. 
M
ultivariable C
ox m
odels, incorporated tim
e-
dependent w
arfarin use data. 
A
bbreviations  ATR
IA: The AnTicoagulation and R
isk Factors In Atrial Fibrillation, IN
R
: International N
orm
alised R
atio, C
PR
D
: C
linical Practice 
R
esearch D
atalink 
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4.10.4 Outcomes 
It was shown in the introduction and literature review that AF is associated with 
an increased risk of stroke, and that this risk may be substantially reduced by 
the use of OAC.144 However, OAC also increases the risk of clinically significant 
bleeding. These considerations informed the choice of outcomes for this study, 
and mirrors those in clinical trials of DOAC versus warfarin,149-152 and in 
previous observational cohort work comparing the efficacy and safety of DOAC 
agents and warfarin.188 Mortality was included as an endpoint as it is definitive, 
objective, likely to be well represented in the dataset, and highly relevant in a 
population of older people with frailty.11 These endpoints are of importance to 
trialists and clinicians, but they are also key priorities for patients with AF. When 
937 patients with AF were asked which attributes of OAC they ranked most 
highly, the highest priority was stroke prevention, followed by major bleeding 
risk.292 
 
Only the first event of any outcome was considered per patient. This was to 
reduce bias caused by multiple recordings. By way of example – a GP may 
enter a code for stroke for a patient with a new hemiparesis and arrange 
hospital admission. The discharge letter may prompt a further stroke coded 
event, as would any subsequent follow-up clinic letter. In this scenario, the 
same index event could be coded on multiple occasions.  
 
For every condition or exposure of interest in the remainder of this chapter, the 
CTV-3 code list was derived using the process described in section 4.8.3. The 
code lists are detailed in Appendix C, limited to the codes that actually featured 
in the ResearchOne dataset. 
 
4.10.4.1 Mortality 
The data for date of death was supplied as part of the dataset from 
ResearchOne. This was entered onto the GP record at the General Practice. 
Linked data from the Office for National Statistics (ONS) were not available. 
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In order to comply with Health Research Authority guidance for confidentiality, 
the dataset from ResearchOne was supplied with dates of birth and death 
rounded to the first day of the month. For example, '01 Mar 1963', '15 Mar 1963' 
and '31 Mar 1963' would all be presented as '01 Mar 1963'.293 
 
4.10.4.2 Stroke 
Strokes were classified into haemorrhagic, ischaemic, and unspecified using the 
codes reported in the appendix, and rates of each subtype were reported. For 
modelling, the unspecified and ischaemic stroke groups were combined, to 
enable comparison with recent clinical trials as ‘efficacy’ endpoints.150, 152 
 
4.10.4.3 Bleeding 
There is a substantial variation in the literature in the definitions of major 
bleeding. For example, in the ATRIA study the authors considered bleeding as 
significant if it was fatal, required transfusion of two units of blood or was into a 
critical anatomical site,174 whereas in HEMORR2HAGES, bleeding in any site 
requiring hospital admission was included.172 In this study, it was not possible to 
quantify bleeding severity, whether a hospital admission was required, or any 
bleeding-related harms. Additionally, it is known that coding of inpatient 
bleeding events in primary care records is frequently incomplete.294 The safety 
outcomes were selected were gastrointestinal and intra-cranial bleeding (intra-
cerebral and sub-dural haemorrhage), as these were identified as being 
potentially life-threatening or life-changing.295-298 These endpoints were used to 
derive and validate the QBleed scores in primary care, suggesting that 
recording in primary care is likely to be adequate.297 
 
4.10.4.4 Secondary outcomes: falls and transient ischaemic attack 
The rates of falls and TIA were studied as secondary endpoints. It has been 
reported that AF is an independent risk factor for falls.203 A tendency to 
experience falls is associated with an increased risk of major bleeding in 
patients that are prescribed OAC,233, 299 suggesting that this is a useful outcome 
to study in a secondary analysis. The occurrence of TIA may be as a 
consequence of AF and herald subsequent stroke,300 and was included as a 
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secondary endpoint, with the caveat that diagnosis of a TIA in primary care has 
been shown to have limited correlation with the assessment of a specialist.300, 
301  
 
4.10.4.5 Censoring 
For all participants, outcome data were right-censored, with the last death 
recorded in ResearchOne on 1st April 2017. The last recorded event in the data 
was on 10th April 2017. The date of censor was therefore set to 11th April 2017 
for all outcomes. However, a patient record could be censored prior to this due 
to the occurrence of the event that is being investigated, death, or 
discontinuation of the medical record for another reason, such as moving away 
from a ResearchOne general practice.  
 
Some possible patient journeys are shown Figure 10, where the outcome of 
mortality is being investigated. Patient 1 survives the duration of the study and 
is considered censored at the end of the follow-up period. Patient 2 dies during 
the follow-up period, and so experiences an event of interest. Patient 3 dies 
prior to study entry, so is not represented in the cohort. 
 
 
Figure 10: Illustration of censoring in survival analysis 
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4.10.5 Baseline characteristics and co-variates 
Potential confounders were identified a priori on the basis of clinical 
understanding and relevant literature. These co-variates were included on the 
basis of the reported risk factors for AF,302 those that may influence prescribing 
decision, or because they increase the risk of bleeding.188, 297  
 
The list of baseline characteristics that are reported was intended to be 
inclusive, and therefore includes some variables that make up deficits in the 
eFI. However, only variables that were not part of the eFI were included in 
modelling as co-variates, to avoid collinearity. 
 
4.10.5.1 Co-variates 
The following variables were included for adjustment in all of the models, with 
the exception of cancer, which was only included as an additional adjustment 
for the outcome of death. 
 
Age 
Increasing age is associated with a higher hazard of death, and therefore a 
reduced probability of benefit from preventative or prophylactic therapy.303 Age 
at study entry was calculated, and included as a co-variate as a continuous 
variable. 
 
Sex 
Women tend to have a higher life expectancy than men, and women also have 
a greater burden of disability and frailty.7, 11 Sex is therefore an important 
confounder in this study. 
 
Smoking status 
Smoking is associated with a substantially increased death rate compared with 
people that have never smoked (HR 3.0; 99% CI 2.7 to 3.3 for women; 2.8, 2.4 
to 3.1 for men),304 and an increased risk of stroke.304, 305 In this study, smoking 
was considered as a binary exposure, where patients were categorised as 
having never smoked, or as having a smoking history if they were a current or 
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ex-smoker. Ideally, the number of pack years would have been used to quantify 
the exposure with greater granularity, but these data tend to be recorded poorly 
in primary care.306 
 
Socioeconomic status 
Higher levels of deprivation are associated with an increased incidence (and 
severity) of stroke,305 and all-cause mortality.280 The most deprived small area 
in England has an IMD rank of 1, and the least deprived is ranked 32,844. For 
this study, IMD was considered in nationally derived quintiles. Further detail on 
IMD is provided in section 4.8.2. 
 
General practice unique identification number 
There may be unobserved determinants of outcome that may be shared 
between patients at the same general practice, such as clinical protocols or 
coding, but also in the local environment and therefore to account for possible 
confounding, a pseudonymised GP practice ID variable was included in the 
survival analyses (detailed in section 5.6.2). 
 
Cancer 
Cancer is a competing risk for death, and is also a contraindication for some 
OAC. 154 There are also a vast number of CTV-3 codes associated with cancer, 
many of which are historical diagnoses that have now potentially been cured. 
To approach this issue, codes associated with cancer was identified using the 
Quality and Outcomes Framework (QOF) code list.307 These codes are likely to 
be well recorded in primary care, as remuneration of general practices is 
dependent on compliance with QOF, which has tended towards increased 
recording of incentivised conditions.251, 308 
 
4.10.5.1.1 Risk scores 
Stroke risk: CHA2DS2-VASC score 
A list of CTV-3 codes for defining the components of the score is not publicly 
available in NICE guidance or in the original research papers. Following 
correspondence with the clinical team at SystmOne,309 I was sent a list of CTV-
3 parent codes that is used within SystmOne to calculation the CHA2DS2-VASc 
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score, and has been approved by Professor Gregory Lip, who devised the 
score. The codes are reported in Appendix A. 
 
Bleeding risk; ATRIA score 
The ATRIA score was used to assess bleeding risk.310 Points are allocated on 
the basis of a past medical history of anaemia (3 points), severe renal disease 
(3 points), age ≥75 (2 points), previous diagnosis of haemorrhage (1 point), and 
hypertension (1 point). The scores are summed, then categorised as in Table 
23.  
 
Table 23: ATRIA risk score and risk of bleeding 
ATRIA risk score Risk category Annual risk of haemorrhage 
<4 Low 0.76% 
4 Intermediate 2.6% 
>4 High 5.8% 
 
 
Alternatives such as HAS-BLED (hypertension, abnormal renal/liver function, 
previous stroke/TIA, bleeding history or predisposition, labile international 
normalized ratio [INR], elderly [age ≥65], drugs/alcohol concomitantly)171 or 
HEMORR2HAGES (Hepatic or renal disease, ethanol abuse, malignancy, older 
[aged ≥75 years], reduced platelet count or function, re-bleeding risk, 
uncontrolled hypertension, anaemia, genetic factors [cytochrome P450 2C9 
single nucleotide polymorphism], excessive fall risk, and stroke)172 were 
considered, and whilst there is evidence that HAS-BLED has been shown to 
have the best predictive and discriminative performance of the three,311-313 
components including labile INR, reduced platelet function and genetic factors 
were not part of the requested dataset. In this study, ATRIA was approximated 
based upon previously defined CTV-3 code lists. In particular, the codes for 
chronic kidney disease were used (rather than severe renal disease) and eFI 
codes for hypertension and anaemia were used.  
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4.10.5.1.2 Past medical history 
Advanced liver disease – cirrhosis and varices 
The liver has an important role in the synthesis and regulation of important 
factors of blood coagulation. Chronic liver disease, and in particular cirrhosis of 
the liver, is associated with a coagulopathy.314 The portal hypertension 
associated with cirrhosis can lead to the development of oesophageal varices, 
which may bleed catastrophically, particularly in the presence of OAC.315 This 
may be a consideration for clinicians when considering OAC prescription. 
Codes were identified using TRUD. 
 
Alcohol excess 
High intake of alcohol is of relevant to clinicians initiating OAC, due to concerns 
about medication adherence, pharmacological interaction and falls.316 Alcohol 
excess may lead to decreased metabolism of warfarin through effects on the 
cytochrome P450 system, leading to an increased risk of haemorrhage, and 
there is a lack of data for concomitant alcohol excess and DOAC use.316 
Alcohol excess was identified through a GP recorded history of alcohol excess, 
rather than a quantification of alcohol intake. This is because a reported weekly 
intake is difficult to interpret in isolation. For example, it is not clear in 
ResearchOne whether a recorded value is ‘typical’ for an individual, and so may 
be misleading. A code selected by a clinician provides additional context. 
Text terms indicating chronic alcohol excess (e.g. alcohol abuse, alcoholism) or 
evidence of harm (e.g. alcohol-related coma, requirement for detoxification, or 
alcohol related organ damage) were searched in TRUD to identify patients with 
a history of alcohol excess. 
 
Anaemia  
Concomitant anaemia adds complexity when considering OAC. Anaemia may 
be the consequence of an occult bleeding process that may be worsened by 
OAC, and may be an adverse prognostic marker.317 The code list used in the 
eFI to identify anaemia was used.  
 
  
 
 
 
 
105 
Bleeding disorder 
The presence of a bleeding disorder affects anticoagulation decisions. 
Conditions were identified from the literature, and include von Willebrand’s 
disease, thrombocytopenia, Bernard–Soulier syndrome, Glanzmann’s disease, 
haemophilia, and factor deficiencies I, II, V, VII, X, XI, XII and XIII.318 Any 
condition coded as a “child” of  the term ‘bleeding disorder’ in the CTV-3 
hierarchy within TRUD was also included.154 Conditions were identified from the 
literature, and include von Willebrand’s disease, Thrombocytopenia, Bernard–
Soulier syndrome, hemorrhagiparous thrombocytic dystrophy, Glanzmann’s 
disease, haemophilia, and factor deficiencies I, II, V, VII, X, XI, XII and XIII.318 
Any condition coded as a “child” of the term ‘bleeding disorder’ in the CTV-3 
hierarchy within TRUD was also included. 
 
Bleeding events 
A previous history of bleeding events, such as a gastrointestinal (GI) or 
intracranial (IC) haemorrhage may be relative contraindications to OAC, 
depending on the aetiology. A history of haematuria or haemoptysis may also 
caution against anticoagulation. Code lists identifying these conditions were 
compiled using TRUD. 
 
Chronic kidney disease 
There is an independent, graded, inverse association between reduced 
estimated glomerular filtration rate and risk of death and cardiovascular 
events.319 The code list for identifying CKD as part of the eFI was used. 
 
Duration of atrial fibrillation 
The median duration of time between first recorded diagnosis of AF in the EHR 
and study entry was calculated for each patient, and expressed as a median 
with IQR for each analytical group.  
 
Falls 
Frequent falls increase the potential for major injury, the consequences of which 
may be worse in an anticoagulated patient.299 This may affect clinical decision-
making. The eFI code list was used to identify a history of falls.320  
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Hypertension 
Hypertension is a major risk factor for stroke and all-cause mortality.321 As it is a 
component of the eFI, blood pressure was not included in the modelling, but 
was reported as an average over two years. Classifying hypertension using 
observational data presents challenges, as there is often a concertina effect 
whereby the most unwell patients have their blood pressure measured more 
frequently, leading to an effect of regression to the mean. Techniques such as 
regression dilution corrected measures seek to account for this.322  
 
Hyperthyroidism 
Hyperthyroidism is an established risk factor for AF,323 and is reported for 
populations with and without AF using the code list from the eFI. 
 
Ischaemic heart disease and myocardial infarction 
Ischaemic heart disease is an important risk factor for AF,126 and is also a 
potential indication for alternative antiplatelet or anticoagulant therapy, 
particularly following an acute coronary syndrome.324 This may affect 
prescribing decisions regarding OAC for patients with concurrent AF. 
 
Memory loss 
Patients with cognitive impairment are less likely to be prescribed OAC, but 
benefits of therapy appear similar regardless of cognitive status.325 The 
discrepancy in prescribing may be due to concerns over therapy concordance. 
Code lists were used from the eFI. 
 
Nursing home 
The proportion living in a nursing home was reported for each analytical group. 
The process that was used to identify a nursing home is described in section 
4.8.3.1. 
 
Obesity 
Obesity is a risk factor for AF, stroke, and other cardiovascular diseases.326 
Codes were identified using TRUD. 
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Peptic ulcer 
Peptic ulcers are responsible for 36% of acute upper GI bleeds, with an 
associated case mortality of 8.9% for a hospitalised event.295 The presence of 
known peptic ulcer disease may impact on prescribing behaviour. Codes were 
identified using TRUD. 
 
Stroke and TIA 
A past history of ischaemic or unspecified stroke and TIA are reported. These 
are key components of stroke risk scores and will influence OAC decisions and 
risk of future stroke.289, 327 Codes were identified from the eFI code list and 
TRUD. 
 
Previous thromboembolic disease  
A previous diagnosis of pulmonary embolism or deep vein thrombosis would be 
an alternative indication for OAC.154 
 
Medications 
Oral, dispersible and rectal preparations of medications were included as these 
are likely to have the highest systemic absorption. Eye drops, for example, were 
not included.  
 
The medications groups that potentially increase bleeding risk or interact with 
anticoagulants were reported.297 The selection and timing of their inclusion was 
considered on clinical grounds, as described below, and on the basis of 
precedent within the literature.188 
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4.10.5.1.3 Medications in recent use 
A group of medications was compiled that may have been considered as a part 
of the decision-making process regarding OAC prescription,188 that were either 
usually for short-term use, or could be stopped or exchanged for an alternative 
medicine prior to commencing OAC. Use of medication in these groups was 
reported for the year prior to study entry: 
• Proton pump inhibitors 
• Macrolide antibiotics 
• Non-steroidal anti-inflammatory drugs (NSAID) 
• Corticosteroids 
• Statins 
 
4.10.5.1.4 Medications in concurrent use 
Concurrent prescription of an anti-platelet at the time of study entry was 
reported, as these independently act on the coagulation system, and are 
sometimes prescribed by clinicians according to an outdated perception that 
they are an alternative to OAC in thromboembolism prophylaxis for patients with 
AF.145 The antiplatelets included were those in common current use in the UK:  
• Aspirin 
• Adenosine diphosphate (ADP) receptor antagonists: Clopidogrel, 
Ticagrelor, Prasugrel 
• Adenosine re-uptake inhibitor: Dipyridamole 
 
Concurrent use of the anti-epileptic medications phenytoin and carbamazepine 
were also reported, as these are not readily exchangeable for an alternative 
drug and may influence clinician choice of OAC. The search terms used to 
identify the medications of interest from the ResearchOne medications table are 
shown in Table 24. 
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Table 24: Search terms used to identify medications of interest 
Drug class Drug name Search terms 
Antiplatelet Aspirin aspirin, micropirin, nu-seals, danamep, disprin, 
mandaprin 
Clopidogrel clopidogrel, plavix 
Ticagrelor ticagrelor, brilique 
Prasugrel prasugrel, efient 
Dipyridamole dipyridamole, attia, ofcram pr, persantin retard, 
trolactin, persantin 
Proton pump 
inhibitor 
Omeprazole omeprazole, losec, mepradec, mezzopram 
Esomeprazole esomeprazole, emozul, ventra, nexium 
Pantoprazole pantoprazole, pantoloc, 
Rabeprazole rabeprazole, pariet 
Lansoprazole lansoprazole, zoton fastab 
Macrolide 
antibiotics 
 
Azithromycin azithromycin, zithromax, zedbac 
Clarithromycin clarithromycin, klaricid, xetinin 
Erythromycin erythromycin, erythrolar, erythrocin, erythroped 
NSAID Aceclofenac aceclofenac, preservex 
Celecoxib celecoxib, celebrex 
Dexibuprofen dexibuprofen, seractil 
Dexketoprofen dexketoprofen, keral 
Diclofenac diclofenac , voltarol, dicloflex, econac, fenactol , 
volsaid, enstar, arthrotec, misofen, masidemen 
Etodolac etodolac, etolyn, etopan, lodine, eccoxolac 
Etoricoxib etoricoxib, arcoxia 
Fenoprofen fenoprofen 
Flurbiprofen flurbiprofen, strefen 
Ibuprofen ibuprofen, brufen, brufen, anadin, feminax 
express, ibucalm, nurofen 
Indometacin indomethacin, indocid, berlind 
Ketoprofen ketoprofen, oruvail, tiloket cr, larafen cr, valket 
Mefenamic Acid mefenamic acid, ponstan 
Meloxicam meloxicam 
Nabumetone nabumetone, relifex 
Naproxen naproxen, feminax ultra, naprosyn ec, vimovo 
Dexketoprofen dexketoprofen, skudexa 
Piroxicam piroxicam, feldene 
Sulindac sulindac 
Tenoxicam tenoxicam, mobiflex 
Tiaprofenic Acid tiaprofenic acid, surgam 
Tolfenamic Acid tolfenamic acid, clotam rapid 
Corticosteroid 
 
Hydrocortisone hydrocortisone, plenadren,  
Dexamethasone dexamethasone, glensoludex, neofordex, dexsol, 
martapan 
Betamethasone  
Statin Atorvastatin atorvastatin, lipitor 
Fluvastatin fluvastatin, dorisin xl, lescol xl, nandovar xl 
Pravastatin pravastatin 
Rosuvastatin rosuvastatin, crestor 
Simvastatin simvastatin, simvador, zocor, inegy, cholib 
Anti-epileptic Phenytoin phenytoin, epanutin 
Carbamazepine carbamazepine, carbagen, tegretol 
Abbreviation  NSAID: non-steroidal anti-inflammatory drug 
Source: British National Formulary287 
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4.11 Summary 
• The quantitative analysis is a retrospective cohort study using an extract 
of patients aged 65 years or older from ResearchOne 
• Code-lists were developed from existing sources and hand-searching to 
identify the clinical conditions of interest. These were used to clean and 
code the dataset. 
• The key exposures were AF, frailty, and OAC 
• The outcomes of interest were all-cause mortality, stroke, intracranial 
bleeding and gastrointestinal bleeding 
• A range of other co-variates and medications were also included, and 
were selected on the basis of clinical expertise and precedent in the 
existing literature. 
 
4.12 Conclusion 
This chapter has detailed the dataset from ResearchOne and the variables of 
interest, with a justification for the inclusion of each. My role was in deciding 
upon the variables to include, and then to derive the code-lists required to 
define them. Subsequently, I cleaned and coded the dataset using the process 
that has been described within this chapter. These preparatory steps were 
necessary to make use of this large dataset. For transparency, the CTV-3 
codes for each condition of interest are reported in Appendix C. 
 
The analytical methods that were used to examine the associations between 
AF, frailty and OAC with these outcomes will be the subject of Chapter 5.
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Chapter 5 - Analytical methods 
 
5.1 Chapter introduction 
The previous chapter included a summary of the dataset, and a discussion of 
the variables that were to be included in the analysis. This chapter will detail the 
approach that was taken to the analysis itself, with the aim of addressing the 
key objectives of this thesis. In brief, these were to establish the population 
prevalence of AF, and report prescription rates of OAC in patients with AF by 
eFI category. Next, to estimate the association between frailty and OAC 
prescription, and report the rates of clinical outcomes by eFI category and OAC 
status. Finally, to investigate the association between OAC and clinical 
outcomes (stroke, death and major bleeding), and whether the association is 
modified by frailty.  
 
5.2 Chapter summary 
This chapter sets out the methodological approach to the quantitative analysis 
of the thesis, building upon those described in Chapter 4. Baseline 
characteristics were reported for the whole cohort, and for patients with AF, and 
compared. Comparisons were also made by frailty category and OAC 
prescription status in patients with AF. The occurrence of clinical outcomes of 
interest by OAC status and frailty category were investigated and reported using 
standardised rates, and time to event analysis. Sensitivity analyses were 
completed to assess whether the findings were robust to a more specific 
definition of AF, and when accounting for persistence of OAC over the study 
period. 
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5.3 Descriptive statistics at study entry 
As discussed in section 4.10, ResearchOne is a positive recording database, 
meaning that missing data is difficult to assess, and can only three items could 
realistically be checked. There was no missing data for sex or age. Data were 
missing for IMD in 32,336 (6%) of records. As missing data were minimal and in 
a variable that was not integral to the analysis, these data were not imputed.328   
 
Two analytical groups were defined by the presence or absence of a recorded 
past medical history of AF at the time of study entry. This allowed AF 
prevalence in the whole cohort to be calculated. Prevalence of AF was then 
calculated by eFI category. 
 
The baseline characteristics of the whole cohort was reported. This was then 
stratified by AF status, and baseline characteristics were reported and 
compared, and the difference in proportions between the groups plotted in a 
forrest plot. The number of eFI deficits and the eFI category were calculated 
and compared between the groups with and without AF, and presented 
graphically.  
 
The cohort was then limited to just patients with AF. Risk scores (CHA2DS2-
VASc and ATRIA) were calculated for each patient as described in section 
4.10.5.1.1, and the group results were compared by eFI category. The 
prescription rates of medications of interest (section 4.10.5.1.3 and 4.10.5.1.4) 
and other baseline characteristics were compared by eFI category.  
 
Baseline characteristics, risk scores, and prescription rates of medications of 
interest for patients with AF that were prescribed OAC were reported and 
compared with those of patients with AF that were not prescribed OAC. The 
cohort was then limited to patients with a CHA2DS2-VASc score of two or more, 
and these comparisons were repeated, between patients who were and were 
not prescribed OAC. 
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For all comparisons, data distribution was assessed using histograms, and 
normally distributed data were summarised using mean and standard deviation, 
and compared using Student’s t-test. Non-parametric data were summarised 
using median and interquartile range and compared using the Mann–Whitney 
U-test. Categorical data were reported as a percentage, and proportions 
compared using Chi-square.  
 
5.4 Rates of outcome events 
Rates of the first event of each clinical outcome were reported (primary efficacy  
endpoints: all-cause mortality, stroke; primary safety endpoints; intracranial 
bleeding, gastrointestinal bleeding; secondary endpoints: TIA, falls). 
 
Participants had differing periods of follow-up due to censorship (section 
4.10.4.5). To account for this, the rate of each outcome event was reported per 
1000 person years.  
 
Rates were reported for each clinical outcome, and compared by:  
• AF status 
• Frailty category in patients with AF and without AF 
• CHA2DS2-VASC score for patients with AF 
• OAC prescription at baseline for patients with AF 
 
To test the assumption that that age was an important confounder, rates were 
also reported by age category in patients with AF.  
 
5.5 Prescription of oral anticoagulation in patients with AF 
Prescription rates of OAC were reported at study entry and compared between 
each of the subgroups detailed above. Additionally, the odds ratio for 
prescription of OAC by frailty category was calculated using logistic regression, 
to estimate the association between frailty status and OAC prescription. The 
results from un-adjusted and adjusted models are presented as odds ratios with 
95% confidence intervals. 
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The confounders included in the logistic regression model were identified 
through clinical consensus with the supervisory team. Adjustments were made 
for steroid, NSAID, macrolide antibiotic and PPI prescription in the previous 
year, concurrent antiplatelet prescription at time of study entry and GP practice. 
A further model was additionally adjusted for patient age, and past medical 
history of cancer, varices, GI bleed or IC bleed. An incremental model build was 
used in order to gain insight into the relative contribution of prescribed 
treatments and factors that relate to demographics and past medical history. 
 
5.6 Survival models 
The time to event was modelled for each outcome separately. Using survival 
analysis techniques gives the opportunity to incorporate time-to-failure and 
censorship information, which is not possible in other regression models. 
Survival analysis depends on two key concepts: the survivor function and the 
hazard function. The survivor function is the probability that the individual 
survives longer than a specified time, and the hazard function is the 
instantaneous potential for each unit of time for a failure event to occur, given 
survival up until that time point.329 
 
5.6.1 Kaplan-Meier survival curves 
Kaplan-Meier curves are used for a univariate nonparametric analysis of 
survival. Survival probabilities are estimated using a product limit formula, 
allowing curves to be drawn for each group (in this case frailty status), and 
compared with a log-rank test of the null hypothesis that there is a common 
survival curve between the two groups.330  
 
5.6.2 Cox proportional hazard model 
The Cox proportional hazard model is an example of a semiparametric model. 
These do not require assumptions about the distribution of failure times,331 and 
in this dataset time-to-event is unlikely to be normally distributed. This is 
because risks of mortality and stroke increase with age. The model produces a 
hazard ratio between groups, where failure represents occurrence of the 
outcome of interest. 
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The results are presented as hazard ratios with 95% confidence intervals. 
Where possible these are displayed graphically using forest plots, for ease of 
interpretation. The unadjusted estimates are presented throughout. Additionally, 
adjustments were made in each case for age, sex, smoking status, IMD quintile 
and GP practice identifier, as these were identified as likely confounders. For 
the clinical outcome of all-cause mortality, a recorded past medical history of 
cancer was included as a confounder in addition, as this may be an important 
competing risk of death in older people. 
 
5.6.2.1 Assumptions 
The integral assumption within a Cox model is that the hazard for an individual 
is proportional to that of another individual, and that this proportionality is 
independent of time. This assumption is tested graphically, where the 
assumption is said to have been met if the lines do not cross between 
categories in a graph of the hazards. It is also tested numerically using a 
goodness of fit test, which gives p-value for evaluating the proportional hazards 
assumption.332 Assumptions were tested for each outcome of interest. 
 
5.6.2.2 Nesting, interaction and stratification 
A multi-level approach was planned, using shared-frailty models to estimate and 
account for within-group correlation by general practice ID.333 Whilst the 
intention was to use the general practice code as a frailty variable in every 
survival model, this is a computationally intense process that was not possible 
within the VRE. Instead, the general practice code was included as a variable in 
the Cox proportional hazard model, to account for differences between 
practices. 
 
Frailty category was included as an interaction term in the Cox model, and 
results were stratified by frailty status. 
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5.7 Sensitivity analyses 
5.7.1 Restricting the cohort to a more specific definition of AF 
The CTV-3 codes that were used to define the AF cohort were critically 
reviewed for whether it was reasonable clinically to rely on them for a diagnosis 
of AF to be substantiated. This process was completed independently by two 
clinical researchers (myself, and Dr Oliver Todd). Disagreements were resolved 
through discussion. 
 
Of the 37 codes that were included in the main analysis to identify AF, five were 
identified as insufficiently specific to be the sole determinant of an AF diagnosis: 
 
• XaaaD: Provision of written information about atrial fibrillation 
• XaLFh : Exception reporting: atrial fibrillation quality indicators 
• XaLFi: Excepted from atrial fibrillation quality indicators: Patient 
unsuitable 
• XaLFj: Excepted from atrial fibrillation quality indicators: Informed dissent 
• 2432: O/E - pulse irregularly irreg. 
 
The use of these codes within the dataset was summarised. Two sub-groups of 
patients were defined from the original analytical cohort of patients with AF. 
These were: 
1. Excluded patients – these patients had AF identified only using one of 
the five codes listed above, and were excluded from the sensitivity 
analysis 
2. Reduced analytical cohort – the remaining patients, who were included in 
the sensitivity analysis. 
 
Baseline characteristics were reported and compared between the two 
subgroups. The rates of outcome events were calculated for each. The 
unadjusted and adjusted hazard ratios for each clinical outcome of interest were 
then reported for each subgroup to estimate the association between both frailty 
and OAC prescription. 
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5.7.2 Evaluating the intention to treat assumption 
In the preceding analyses, the association between OAC and clinical outcomes 
was evaluated by OAC status at the start of the study (intention to treat). It is 
possible that patients may discontinue therapy during the study, and there may 
be systematic differences between those that remain on therapy throughout the 
study compared with those that discontinue (such as adverse clinical outcomes 
that may be associated with treatment, including bleeding events). A second 
sensitivity analysis was undertaken to investigate whether the findings of the 
main analysis were robust to an analysis that accounts for persistence on 
therapy. 
 
The cohort of patients with AF was split into three: 
1. Patients that were not prescribed OAC during the study 
2. Patients that discontinued OAC during the study 
3. Patients that persisted on OAC throughout the study 
 
The baseline characteristics of patients in each group were described, and the 
rates of clinical outcome events reported in each. The association between 
OAC and clinical outcomes was evaluated separately for each of the three 
groups, and reported as hazard ratios with 95% confidence intervals.  
 
5.8 Summary 
• Baseline characteristics were reported and compared by AF status, frailty 
category, eligibility for OAC, and prescription of OAC. 
• Rates of clinical outcomes were reported for each sub-group, 
standardised to 1000 person-years. 
• Time to event analysis was used to estimate the association between 
frailty category and OAC status with clinical outcomes. 
• A sensitivity analysis was performed to investigate whether the results of 
the main analysis were robust to a more specific definition of AF, and 
when accounting for persistence on OAC. 
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5.9 Conclusion 
This chapter has detailed the analytical approach that was used in the 
quantitative component of the thesis. The results of these analyses will be 
presented over the next three chapters. The baseline characteristics and clinical 
outcomes for the whole analytical cohort will be reported in Chapter 6. The 
analytic cohort will then be restricted to patients with AF in Chapter 7, followed 
by a particular focus on the association between OAC prescription and clinical 
outcomes in patients with AF in Chapter 8.  
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Chapter 6 – Baseline characteristics and clinical outcomes for 
the whole cohort 
 
6.1 Chapter introduction 
This chapter will begin with a description of the derivation of the analytic cohort, 
followed by a summary of the baseline characteristics of the whole cohort, 
stratified by AF status. Clinical outcomes will be described using proportions, 
and rates standardised to 1000 person-years, and compared. 
 
6.2 Chapter summary 
In this cohort of 536,995 patients aged 65 years or older, 11.4% (61,177) had 
AF. The prevalence of AF was higher with increasing frailty category, and 
patients with AF had a greater burden of frailty and comorbidity than those 
without AF. Patients with AF experienced a higher incidence of adverse clinical 
outcomes during the follow-up period than those without AF, including all-cause 
mortality, stroke, and bleeding events. 
 
 
6.3 Participants and data 
6.3.1 Derivation of the analytic cohort 
The analytical cohort of 536,955 patients was derived from the full patient table, 
which was used to assess the cohort eligibility criteria. There were 31,243 
patients (5.5%) who were under the age of 65 years on the study entry date and 
were therefore excluded. Subsequently, the cohort was split into patients with a 
diagnosis of AF (n=61,177, 11.4%) and those without AF (n=475,778, 88.6%). 
Patients with AF recorded within their EHR, but without a date of AF diagnosis 
(n=96, 0.02%) were excluded from the cohort, Figure 11.334 
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Figure 11: Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) diagram to show the derivation of the 
analytic cohort 
 
 
6.3.2 Data available for analysis 
Data were included from a total of 384 general practices. The number of 
patients registered at each practice ranged from a minimum of 16 to a 
maximum of 8,670 (median 1923, IQR 1244 to 2788). One practice reported no 
patients with AF. Of the remaining 383 practices, the minimum number of 
patients with AF at each practice was two, and the maximum was 1,016 
(median 228, IQR 143 to 324). The minimum number of patients without AF at 
each practice was 13, and the maximum was 7,654 (median 1691, IQR 1089 to 
2508). 
 
In total, there were 671,135 person-years of follow-up. The minimum follow-up 
duration was 32 days, and maximum was 467 days. The mean follow-up 
duration was 15 months (456.5 days, SD 55.3). There were 74,238 person-
years of follow-up for those with AF compared to 596,896 person-years for 
those without AF. The mean follow-up duration was 443.2 days (SD 81.8) in 
patients with AF, and 458.2 days (SD 50.6) in patients without AF. The range 
was 32 to 467 days for both groups.  
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Whilst it is not possible to summarise missing clinical data, due to the positive 
recording nature of ResearchOne, it was possible to identify missing data for 
patient demographics. Data were missing for IMD in 32,336 patients (6.0%). 
IMD rank was missing in 3,466 (5.7%) patients with AF, and in 28,870 (6.1%) 
patients without AF. There were no missing sex or age data.  
 
6.3.3 Baseline characteristics 
Overall, the median age was 73.8 years (interquartile range [IQR] 69.0 to 80.5). 
On average, patients with AF were older than those without (79.7, 73.3 to 85.5 
years, compared with 73.1, 68.8 to 79.6 years). The difference in age 
distribution between patients with and without AF is shown in Figure 12. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No AF 
AF 
De
ns
ity
 
Age at study entry (years) 
Figure 12: Histogram of age at study entry by AF status 
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Overall, 290,764 (54.2%) of the cohort were women. Women made up a greater 
proportion of the patients without AF than the group with AF (262,777, 55.2% of 
patients without AF compared to 27,987, 45.8% of patients with AF). 
 
Postcode level deprivation as approximated by the IMD was similar for patients 
with AF and those without. In the AF group, 12.9% lived in the most deprived 
quintile, compared with 13.0% in the group without AF.  
 
Of the complete cohort, 218,865 patients (41%) were in the robust category, 
181,986 (34%) were classified as mildly frail, 91,411 (17%) as moderately frail, 
and 44,693 (8%) as severely frail, Figure 13. 
 
 
Figure 13: Histogram of frailty categories for the complete cohort, 
n=536,955 
 
The prevalence of AF was higher with increasing frailty category, affecting 2.9% 
(6,443) of patients in the robust category, 11.2% (20,352) of those with mild 
frailty, 22.2% (20,315) moderate, and 31.5% (14,067) severe frailty, Figure 14. 
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Figure 14: Bar chart to show the prevalence of AF by electronic frailty 
index category 
 
The prevalence of AF was higher with increasing age, from 5% of patients aged 
65 to 70 years to 24% of those aged 95 to 100, Table 25. 
 
Table 25: Prevalence of atrial fibrillation by age category 
Age category n= Patients with AF AF prevalence, %  
(95% confidence interval) 
³65 to <70 169,357 8,391 5.0 (4.9 to 5.1) 
³70 to <75 127,409 10,463 8.2 (8.1 to 8.4) 
³75 to <80 98,257 12,721 13.0 (12.7 to 13.2) 
³80 to <85 72,305 13,215 18.3 (18.0 to 18.6) 
³85 to <90 45,144 10,194 22.6 (22.2 to 23.0) 
³90 to <95 19,693 5,046 25.6 (25.0 to 26.2) 
³95 to <100 4,790 1,147 23.9 (22.7 to 25.2) 
Total 536,955 61,177 11.4 (11.3 to 11.5) 
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The group with AF had a higher burden of frailty than the group without AF. Of 
patients with AF, 89% (54,734) had mild, moderate or severe frailty, compared 
to 55% (263,356) of patients without AF. In patients with AF, 56% had moderate 
or severe frailty, compared with 21% of those without AF, Table 26. 
 
Table 26: Electronic frailty index category by AF status 
Frailty category Complete cohort 
n=536,955 
No history of AF 
n=475,778 
AF 
n=61,177 
Robust 218,865 (40.8%) 212,422 (44.7%) 6,443 (10.5%) 
Mild 181,986 (33.9%) 161,634 (34.0%) 20,352 (33.3%) 
Moderate 91,411 (17.0%) 71,096 (14.9%) 20,315 (33.2%) 
Severe 44,693 (8.3%) 30,626 (6.4%) 14,067 (23.0%) 
 
Overall, the median number of eFI deficits was 5 (IQR 3 to 8). Patients with AF 
had a median of 9 deficits (6 to 12) compared with 5 deficits (3 to 8) in patients 
without AF, Figure 15.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Number of electronic frailty index deficits by AF status at the time 
of study entry 
No AF 
AF 
Number of eFI deficits at study entry 
De
ns
ity
 
  
 
125 
The proportion of patients with a prior recorded history of every condition of 
interest was higher in patients with AF than those without (p<0.001 for each, 
Table 27). The greatest difference was in a recorded history of ischaemic heart 
disease, which was higher in patients with AF than those without (18.4% 
difference, 95% CI 18.0 to 18.8%, Figure 16). The next greatest difference was 
in history of heart failure (17.6% difference between those with AF and those 
without AF, 17.3 to 17.9%); hypertension (16.7%, 16.3 to 17.1%); and chronic 
kidney disease (15.9%, 15.6 to 16.3%). Each of the conditions mentioned 
above are also eFI deficits (shown in italics in Table 27). Valvular heart disease 
(11.3% difference, 95% CI 11.0 to 11.6%) and a history of stroke (8%, 7.8 to 
8.3%) were more common in patients with AF than those without, and are not 
conditions that form part of the eFI.  
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6.4 Clinical outcomes 
6.4.1 All-cause mortality 
Over the duration of follow-up, 24,254 deaths (4.5%) were recorded in the 
complete cohort. The all-cause mortality rate was 36.1 (95% CI 35.7 to 36.6) 
per 1000 person-years (/1000pys). 
 
Figure 17: Kaplan-Meier graph showing all-cause mortality by frailty 
category, with 95% confidence interval. n=536,955 
 
The all-cause mortality rate was higher with increased frailty category (Figure 
17), with a rate of 10.7 (95% CI 10.3 to 11.1) per 1000 person-years (/1000pys) 
in the robust group; 30.0 (29.3 to 30.7) /1000pys in the mild frailty group; 69.3 
(67.8 to 70.9) /1000pys in the moderate frailty group and 126.4 (123.4 to 129.5) 
/1000pys in the group with severe frailty.  
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Figure 18: Kaplan-Meier graph showing all-cause mortality by AF status, 
with 95% confidence interval. n=536,955 
 
All-cause mortality was also higher in patients with AF than in those without 
(Figure 18). In patients with AF there were 6,143 deaths (10.0%), conferring an 
all-cause mortality rate of 83.8 (81.7 to 85.9) /1000pys. In the group without AF 
there were 18,111 deaths (3.8%), with an all-cause mortality rate of 30.3 (29.9 
to 30.8) /1000pys. The difference in mortality rate observed in patients with AF 
compared to those without AF was statistically significant (p <0.001), Table 28. 
 
There was a 2.7-fold increased risk of death for those with AF compared to 
those without AF (HR 2.7, 95% CI 2.6 to 2.8). After adjustment for age, sex, 
IMD quintile and GP practice, the HR was 1.6 (1.55 to 1.64). Further adjustment 
for electronic frailty index category reduced the HR to 1.2 (1.18 to 1.26), 
suggesting that AF is associated with an increased risk of death, independent of 
baseline characteristics and frailty status. 
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6.4.2 Stroke 
There were 1,396 patients (0.26%) with an episode of ischaemic stroke, and 
1,639 (0.31%) with an episode of an unspecified stroke recorded during the 
follow-up period. After combining ischaemic and unspecified stroke categories, 
3,035 patients (0.57%) had a recorded stroke event over the follow-up period, 
with a stroke rate for the whole cohort of 4.5 (4.4 to 4.7) /1000pys. 
 
Figure 19:Kaplan-Meier graph showing incidence of first stroke event by 
frailty category, with 95% confidence interval. n=536,955 
 
Stroke rates were higher with increasing frailty category (Figure 19). In the 
robust group the rate was 2.4 (2.2 to 2.6) /1000pys; in the mild frailty group 4.8 
(4.5 to 5.1) /1000pys; in the moderate frailty group 7.3 (6.9 to 7.9) /1000pys, 
and in the severe frailty group 8.7 (8.0 to 9.6) /1000pys. 
 
The recorded stroke incidence was higher in patients with AF than in those 
without AF (Figure 20). In patients with AF, 617 (1.0%) patients had a recorded 
stroke event (279 ischaemic and 338 unspecified). The rate of unspecified or 
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ischaemic stroke was 8.5 (7.8 to 9.1) /1000pys. In patients without AF, there 
were 2,418 (0.51%) patients with a stroke event recorded (1,117 ischaemic and 
1,301 unspecified). The rate of unspecified or ischaemic stroke was 4.1 (3.9 to 
4.2) /1000pys.  
 
 
Figure 20: Kaplan-Meier graph showing first stroke event by AF status, 
with 95% confidence interval. n=536,955 
 
The unadjusted hazard ratio for stroke in patients with AF compared to those 
without AF was 2.1 (95% CI 1.9 to 2.2). After adjustment for sex, smoking 
status, IMD quintile, age and GP practice, the HR was 1.5 (1.4 to 1.6). Further 
adjustment for eFI category reduced the estimate further to 1.3 (1.2 to 1.4). This 
suggests that differences in baseline characteristics explain some of the 
variation in stroke outcome between patients with AF and those without, and 
that eFI further accounts for some of the difference. This also suggests that AF 
is associated with stroke, independently of eFI category and baseline 
characteristics.  
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6.4.3 Bleeding  
Overall, there were 3,236 (0.6%) patients with a recorded episode of GI bleed, 
conferring a rate of 4.8 (95% CI 4.7 to 5.0) /1000pys for first GI bleed events. 
The incidence of GI bleeding was higher with increased frailty category (Figure 
21), from a rate of 2.9 (2.7 to 3.2) /1000pys in the robust group; 5.0 (4.7 to 5.3) 
/1000pys in the mild frailty group, 7.5 (7.0 to 8.0) /1000pys in the moderate 
frailty group to 8.6 (7.8 to 9.4) /1000pys in the severe frailty group.  
 
 
Figure 21: Kaplan-Meier graph showing incidence of first gastrointestinal 
bleeding event by frailty category, with 95% confidence interval. 
n=536,955 
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The incidence of GI bleeds was higher in patients with AF than those without, 
(Figure 22) affecting 583 (1%) patients from the AF group, and 2,653 (0.6%) of 
the group without AF, The standardised rates were 8.0 (7.4 to 8.7) /1000pys in 
patients with AF, and 4.5 (4.3 to 4.6) /1000pys in patients without AF, p<0.001. 
 
 
Figure 22: Kaplan-Meier graph showing first gastrointestinal bleeding 
event by AF status, with 95% confidence interval. n=536,955 
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Intracranial (IC) bleeds were comparatively rare: 629 patients (0.1%) had a 
recorded event in the overall cohort, with a rate of first IC bleeding event of 0.94 
(0.9 to 1.0) /1000pys. The rate increased by frailty category (Figure 23), from 
0.53 (0.46 to 0.63) /1000pys in the robust group to 0.96 (0.84 to 1.10) /1000pys 
in the group with mild frailty; 1.4 (1.2 to 1.6) /1000pys in the moderate frailty 
group and 2.0 (1.6 to 2.4) /1000pys in the group with severe frailty. 
 
 
Figure 23: Kaplan-Meier graph showing incidence of first intracranial 
bleeding event by frailty category, with 95% confidence interval. 
n=536,955 
 
Intracranial bleeds occurred more frequently in the group with AF than in those 
without AF (Figure 24). There were 136 (0.22%) patients with a recorded 
episode of IC bleed in the AF group, and 493 (0.10%) in the group without AF. 
Rates of IC bleeding were 0.8 (0.76 to 0.90) /1000pys in patients without AF, 
and 1.9 (1.6 to 2.2) /1000pys in patients with AF, p<0.001.  
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Figure 24: Kaplan-Meier graph showing first intracranial bleeding event by 
AF status, with 95% confidence interval. n=536,955 
 
6.4.4 Falls 
Overall, 13,856 (2.6%) patients had a recorded fall during the follow-up period. 
The overall rate was 20.9 (95% CI 20.6 to 21.3) /1000pys, although this 
increased with increasing frailty category, and was 6.0 (5.7 to 6.3) /1000pys in 
the robust group, 18.4 (17.9 to 19.0) /1000pys in the group with mild frailty, 42.4 
(41.2 to 43.6) /1000pys in the group with moderate frailty and 67.1 (64.8 to 
69.4) /1000pys in the group with severe frailty. 
 
There were 2,707 (4.4%) patients with a recorded history of falls in the AF 
group, and 11,149 (2.3%) in the group without AF. Rates of falls was higher in 
patients with AF than those without: 37.72 (36.32 to 39.16) /1000pys in patients 
with AF, and 18.90 (18.5 to 19.25) /1000pys in patients without AF, p<0.001.  
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6.4.5 Transient ischaemic attack 
There were 372 (0.61%) patients with a recorded history of TIA in the AF group, 
and 1,992 (0.42%) in the group without AF. Overall, the first TIA event rate was 
3.5 (95% CI 3.4 to 3.7) /1000pys. Incidence of first TIA event was higher with 
increased frailty category, from 2.2 (2.0 to 2.3) /1000pys in the robust group; 3.5 
(3.3 to 3.8) /1000pys in the mild frailty group, 5.6 (5.2 to 6.1) /1000pys in the 
moderate frailty group to 6.5 (5.8 to 7.2) /1000pys in the severe frailty group.  
 
Rates of TIA was higher in patients with AF than those without: 5.09 (4.60 to 
5.63) /1000pys in patients with AF, and 3.34 (3.20 to 3.49) /1000pys in patients 
without AF, p<0.001 (Table 28). 
 
6.5 Summary of key findings 
• In this primary care cohort of 536,995 patients aged 65 years or older, 
the prevalence of AF was 11.4%. The prevalence was higher with 
increased eFI category, from 2.9% in the robust group to 31.5% of those 
with severe frailty. 
• The prevalence of AF was also higher with increased with age, from 5% 
of patients aged 65 to 70 years, to 24% of those aged 95 to 100 
• Patients with AF tended to be older, and with a higher burden of frailty 
than patients without AF.  
• A past medical history of every condition of interest was recorded more 
frequently in patients with AF than in those without AF. The difference 
was greater than 10% in the recorded history of ischaemic heart disease, 
heart failure, hypertension, chronic kidney disease and valvular heart 
disease. 
• AF was associated with higher all-cause mortality, incident stroke, 
gastrointestinal bleeding, intracranial bleeding, falls and transient 
ischaemic attack compared to people without AF.  
• AF was associated with an increased risk of mortality and stroke, 
independent of baseline characteristics and frailty status.  
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6.6 Conclusion 
In this cohort, the prevalence of AF at study entry was 11.4%. The prevalence 
was higher with increased electronic frailty index category and increased age. 
Patients with AF had a higher burden of frailty than those without AF, and AF 
was associated with adverse outcomes including all-cause mortality, stroke, 
bleeding events, falls and transient ischaemic attack compared to patients 
without AF. In Chapter 7, the analysis will be restricted to patients with AF to 
examine the characteristics of this group in greater detail, and evaluate the 
association between frailty and clinical outcomes. 
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Chapter 7 - Baseline characteristics, frailty status and clinical 
outcomes of patients with atrial fibrillation 
 
7.1 Chapter introduction 
This chapter will describe the clinical characteristics and frailty status of patients 
who had a diagnosis of AF at study entry. Risk scores for stroke and bleeding, 
and prescription rates of key medications will be reported. Standardised rates of 
mortality, stroke, bleeding events, falls, and transient ischaemic attack will be 
reported by electronic frailty index category. The association between each 
clinical outcome and frailty category will be estimated using a univariate and 
then multivariate Cox proportional hazards model, and survival differences 
shown using Kaplan-Meier curves. 
 
7.2 Chapter summary 
Among 61,177 patients with AF, patients in higher frailty categories tended to 
be older, with a higher proportion of women, a longer history of AF, a greater 
proportion living in a nursing home and higher levels of deprivation. 
 
Compared to the robust group, patients with AF and frailty had a significantly 
greater proportion with a past medical history of ischaemic heart disease, 
chronic kidney disease, hypertension, falls, and diabetes. Patients with frailty 
tended to have a greater risk score estimates for both bleeding and stroke, and 
were more frequently prescribed medications including statins, corticosteroids, 
non-steroidal anti-inflammatory drugs, macrolide antibiotics and proton pump 
inhibitors prior to study entry. Patients with frailty were also more commonly 
prescribed oral anticoagulation at the time of study entry.  
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Frailty and increased age were associated with higher rates of each clinical 
outcome of interest, including mortality, stroke, intracranial bleeding and 
gastrointestinal bleeding. The association between frailty and clinical outcomes 
was statistically significant for each frailty category compared to patients in the 
robust category for the outcome of mortality. For stroke and gastrointestinal 
bleeding, the relationship was only statistically significant for moderate and 
severe frailty. For intracranial bleeding, the difference between the robust 
category was only statistically significant for patients with severe frailty.  
 
Following adjustment, the difference in clinical outcome between different frailty 
categories was eliminated for stroke, but a difference between the robust group 
and the moderate and severe groups persisted for GI bleeding. Patients with 
severe frailty had a significantly higher risk of IC bleeding than the robust group 
after adjustment. Compared to the robust group, adjusted mortality risk was 
higher with every frailty category. 
 
7.3 Participants 
The analyses in this chapter are based on a cohort of patients with a diagnosis 
of AF documented in their EHR at the start of the study (n=61,177). Of these 
6,443 (10.5%) were in the robust category, 20,352 (33.3%) mild frailty, 20,315 
(33.2%) moderate frailty and 14,067 (23.0%) severe frailty. 
 
In total, there were 74,238 person-years of follow-up. The minimum follow-up 
duration was 32 days, and maximum was 467 days. The mean follow-up 
duration was 14.6 months (443 days, SD 82).  
 
According to frailty category, the mean follow-up duration was 15.2 months (461 
days, SD 41) in the robust group; 15.0 months (456 days, SD 57) in the group 
with mild frailty; 14.5 months (443 days, SD 83) in the group with moderate 
frailty; and 13.7 months (418 days, SD 113) in the group with severe frailty.  
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7.3.1 Baseline characteristics of patients with AF by frailty status 
There were differences in baseline characteristics at the time of study entry 
across the frailty categories. With increasing frailty category, patients tended to 
be older, with a higher proportion of women, a greater proportion living in a 
nursing home, and a higher measure of postcode level deprivation, Table 29. 
The duration of AF since the time of diagnosis was higher with increasing frailty 
category. The median age of patients with AF was 79.7 (IQR 73.3 to 85.5) 
years, and was higher with increasing frailty category, at 72.7 (68.8 to 78.2) 
years in the robust group, 77.1 (71.6 to 82.7) years in those with mild frailty, 
81.0 (75.4 to 86.2) years in those with moderate frailty, and 84.3 (79.1 to 89.0) 
years in those with severe frailty. 
 
Overall, 45.8% (n=27,987) of patients with AF were women. The proportion of 
women was greater with increasing frailty category. In the robust group, 35.6% 
(95% CI 34.4 to 36.8%, n=2,293) were women, increasing to 41.1% (40.4 to 
41.7%, n=8,355) of the group with mild frailty, 47.1% (46.4 to 47.8%, n=9,569) 
of the group with moderate frailty, and 55.2% (54.4 to 56.1%, n=7,770) of the 
group with severe frailty. In patients with AF, 8.6% (95% CI 8.4 to 8.8%, 
n=5,276) lived in a nursing home at study entry. The proportion living in a 
nursing home increased with frailty category, from 1.0% (0.8 to 1.3%, n=66) of 
patients in the robust category to 19.3% (18.7 to 20.0%, n=2,718) of patients in 
the severely frail category. 
 
Patients tended to have a longer history of AF with increasing frailty category. 
The median time from a diagnosis of AF to entry into the study was 4.8 (IQR 2.1 
to 9.4) years, but this ranged from 3.9 (1.8 to 7.7) years in the group with mild 
frailty to 5.8 (2.6 to 10.7) years in those with severe frailty. Neighbourhood level 
deprivation was higher in patients with increased frailty category. Overall, 12.9% 
(95% CI 12.6 to 13.2%, n=7,439) of patients with AF lived in the most deprived 
IMD quintile, and this increased from 8.8% (8.1 to 9.6%, n=532) in the robust 
group to 10.8% (10.3 to 11.2%, n=2,064) in those with mild frailty, 13.6% (13.2 
to 14.1%, n=2,619) in those with moderate frailty and 16.7% (16.0 to 17.3%, 
n=2,751) in the group with severe frailty, Table 29. 
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7.3.2 Risk scores 
For the cohort of patients with AF, the mean CHA2DS2-Vasc was 3.8 (SD 1.5). 
The average score was higher with increased frailty category, from 2.2 (0.98) in 
the robust group to 3.2 (1.2) in the group with mild frailty, 4.0 (1.3) in moderate 
frailty and 5.0 (1.4) in the group with severe frailty. The upper and lower 
adjacent values, the 25th and 75th percentile, and the median are shown visually 
in Figure 25. Of the patients with AF, 95.1% (n=58,204) had a CHA2DS2-Vasc 
score of 2 or more. 
 
 
Figure 25: Box plot showing CHA2DS2-Vasc score at study entry by 
electronic frailty index category 
 
The median ATRIA bleeding score was 3 (IQR 2 to 6). The median score 
increased with higher frailty categories, from 1 (0 to 2) in the robust group to 3 
(1 to 5) in the group with mild frailty, 4 (3 to 6) in moderate frailty and 6 (4 to 8) 
in the group with severe frailty, Figure 26.  
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Figure 26: Box plot showing ATRIA score at study entry by electronic 
frailty index category 
 
7.3.3 Past medical history 
There was a stepwise positive association between frailty category and a 
recorded history of each condition of interest except alcohol excess. The most 
common co-morbidity was hypertension, which was recorded in 67.6% (95% CI 
67.2 to 67.9%, n=41,340) of patients.  
 
Five conditions had a difference in prevalence between the robust group and 
the group with severe frailty of 40% or more. These were ischaemic heart 
disease (difference 51.4%, 95% CI 50.5 to 52.4%), chronic kidney disease 
(50.4%, 49.4 to 51.4%), hypertension (46.2%, 44.8 to 47.5%), falls (42.8%, 41.9 
to 43.7%), and diabetes (40.0%, 39.1 to 40.9%). These conditions were 
included in the eFI, but a similar pattern is seen in conditions outside the eFI, 
such as myocardial infarction (difference 22.6%, 95% CI 21.9 to 23.4%), 
transient ischaemic attack (15.3%, 14.6 to 16.4%), stroke (17.8%, 17.0 to 
AT
R
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18.5%), haematuria (11.2%, 10.4 to 12.1%), peptic ulcer (9.9%, 9.3 to 10.5%) 
and cancer (9.1% 8.1 to 10.1%), Figure 27. 
 
Figure 27: Chart showing percentage of patients with past medical history 
recorded of each condition of interest, by frailty category
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7.3.4 Medications 
Of the medications studied, statins were the most commonly prescribed among 
patients with AF. In the year prior to study entry, 59.7% (95% CI 59.3 to 60.0%, 
n=36,498) of patients had been prescribed a statin. Statins were prescribed 
more commonly with increasing frailty category from 37.4% (36.2 to 38.6%, 
n=2,410) of those in the robust category to 67.5% (66.7 to 68.3%, n=9,494) of 
the group with severe frailty, Figure 28 and Table 30. 
 
The proportion of patients prescribed a proton pump inhibitor (PPI) exhibited the 
greatest difference in prescription rate by frailty categories. A PPI was 
prescribed in the year prior to study entry in 16.4% (95% CI 15.5 to 17.3%, 
n=1,057) of patients in the robust category, 32.8% (32.2 to 33.5%, n=6,677) in 
mild, 43.7% (43.1 to 44.4%, n=8,885) in moderate, and 56% (55.3 to 56.9%, 
n=7,892) in the category of severe frailty. 
  
Each of the other drugs in the study showed a positive stepwise association 
between prescription rates and increased frailty status, including macrolide 
antibiotic, non-steroidal anti-inflammatory drugs (NSAID), corticosteroid, and 
statin in the year prior to study entry showed a positive stepwise association 
with increased frailty status, as did the prescription of anti-epileptic and anti-
platelet medication at study entry, Figure 28 and Table 30. 
 
Figure 28: Bar chart showing proportion of patients prescribed key 
medications of interest, by frailty status 
0 20 40 60 80
Proton pump inhibitor
Macrolide antibiotics
NSAID
Corticosteroid
Statin
Anti-platelet
Percentage
Robust Mild frailty Moderate frailty Severe frailty
  
 
148 
Oral anticoagulation was prescribed in 52.4% (95% CI 52.0 to 52.8%, 
n=32,079) of patients with AF. OAC was more commonly prescribed with 
increasing frailty category. This will be discussed in greater detail in Chapter 8, 
as will the association between OAC use and clinical outcomes.  
 
DOAC were prescribed in sub-therapeutic doses (as defined by the BNF and 
described in section 4.10.3) in 85 patients (0.14%, 95% CI 0.11 to 0.17%). The 
proportion prescribed sub-therapeutic doses of DOAC was highest in patients 
with severe frailty (0.23%, 95% CI 0.15 to 0.31, n=32, Chi-square p=0.015, non-
parametric test for trend p=0.017), Table 30. 
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Table 30: M
edication history of patients w
ith A
F, by frailty status  
Variable 
All 
n=61,177 
R
obust 
n=6,443 
M
ild frailty 
n=20,352 
M
oderate 
frailty 
n=20,315 
Severe frailty 
n=14,067 
p value 
for 
difference 
across 
categories 
p value for 
trend across 
categories a 
M
edications in the previous year, n (%
) 
 
 
 
 
 
 
Proton pum
p inhibitor 
24,511 (40.1) 
1,057 (16.4) 
6,677 (32.8) 
8,885 (43.7) 
7,892 (56.1) 
<0.001 
<0.001 
M
acrolide antibiotics 
427 (0.70) 
10 (0.16) 
90 (0.44) 
167 (0.82) 
160 (1.1) 
<0.001 
<0.001 
N
SAID
 
5,453 (8.9) 
284 (4.4) 
1,697 (8.3) 
1,903 (9.4) 
1,569 (11.2) 
<0.001 
<0.001 
C
orticosteroid 
1,777 (2.9) 
87 (1.4) 
566 (2.8) 
613 (3.0) 
511 (3.6) 
<0.001 
<0.001 
Statin 
36,498 (59.7) 
2,410 (37.4) 
11,492 (56.5) 
13,102 (64.5) 
9,494 (67.5) 
<0.001 
<0.001 
Anti-epileptic   
 
 
 
 
 
 
 
  C
arbem
azepine 
235 (0.38) 
11 (0.17) 
56 (0.28) 
87 (0.43) 
81 (0.58) 
<0.001 
<0.001 
  Phenytoin 
180 (0.29) 
6 (0.09) 
47 (0.23) 
67 (0.33) 
60 (0.43) 
 
 
M
edications at the tim
e of study entry, n (%
) 
O
AC
 at study entry 
32,079 (52.4) 
2,574 (40.0) 
10,730 (52.7) 
11,264 (55.5) 
7,511 (53.4) 
<0.001 
<0.001 
Any anti-platelet at study 
entry 
3,767 (6.2) 
123 (1.9) 
812 (4.0) 
1,377 (6.8) 
1,455 (10.3) 
<0.001 
<0.001 
D
O
AC
 at sub-therapeutic 
dose 
85 (0.14) 
7 (0.11) 
24 (0.12) 
22 (0.11) 
32 (0.23) 
0.015 
0.017 
a=non-param
etric test for trend (extension of W
ilcoxon rank-sum
 test). All others: C
hi-square 
A
bbreviations  D
O
AC
: direct oral anticoagulants; N
SAID
: non-steroidal anti-inflam
m
atory drugs; O
AC
: oral anticoagulation 
 
  
 
150 
7.4 Frailty and clinical outcomes in patients with AF 
7.4.1 All-cause mortality 
Overall, 6,143 (10.0%) patients died during the follow-up period, conferring a 
mortality rate of 83.8 (95% CI 81.7 to 85.9) /1000pys. 
 
Mortality rates were higher with increased frailty category, Figure 29. In the 
robust group, 2.6% (164) of patients died during the follow-up period. In the 
group with mild frailty, 5.1% (1,042) died, with moderate frailty 10.3% (2,096), 
and severe frailty 20.2% (2,841). All-cause mortality rates, standardised to 1000 
person-years were 20.3 (17.5 to 23.7); 41.5 (39.0 to 44.1); 86.2 (82.6 to 89.9); 
179.5 (173.0 to 186.2) /1000pys for robust, mild, moderate and severe frailty 
categories respectively. 
 
 
Figure 29: Kaplan-Meier graph showing all-cause mortality by frailty 
category in patients with AF, with 95% confidence interval. n=61,177  
  
 
151 
Mortality rates were positively correlated with age at study entry. For patients 
aged 65 to 70 years at study entry, the mortality rate was 23.3 (20.5 to 26.4) 
/1000pys, which increased by age category to a rate of 344.4 (312.3 to 379.7) 
/1000pys in the oldest category, 95 to 100 years of age. The steep rise in 
mortality rate with increasing age category is shown in Figure 30, and the rates 
of clinical outcomes by age category are reported in Table 31. 
 
Figure 30: Mortality rates /1000pys by age category in patients with AF, 
n=61,177 
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The association between frailty category and all-cause mortality was modelled 
using a Cox regression, and a positive, stepwise association between frailty 
status and all-cause mortality was demonstrated. Compared with the robust 
group, those in the mild, moderate and severe frailty groups had a HR for 
mortality of 2.0 (95% CI 1.7 to 2.4), 4.2 (3.6 to 4.9), and 8.7 (7.4 to 10.2) 
respectively, Figure 31.  
 
Adjustment for age, sex, smoking status, IMD quintile and GP practice identifier 
reduced the magnitude of the association, as did further adjustment for a past 
medical history of cancer. This indicates that the adjustment factors explain 
some of the difference between groups, but that a statistically significant 
difference in mortality by frailty category remained, Figure 31.
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Figure 31: A
ssociation betw
een frailty status and all-cause m
ortality in patients w
ith A
F, n=61,177  
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7.4.2 Ischaemic or unspecified stroke 
Overall, 617 patients (1.0%, 95% CI 0.9 to 1.1%) had a stroke during the follow-
up period, with a rate of first stroke event of 8.5 (95% CI 7.8 to 9.1) /1000pys. 
Of these, 45% (n=279) had an ischaemic stroke, and 55% (n=338) an 
unspecified stroke.  
 
The rate of first stroke event increased with increased frailty category. The 
standardised rates for the robust, mild, moderate and severe frailty groups were 
5.4 (4.0 to 7.2); 7.2 (6.2 to 8.3); 9.3 (8.2 to 10.6) and 10.7 (9.2 to 12.5) /1000pys 
respectively. There was overlap in the 95% confidence intervals between 
adjacent frailty categories, but a statistically significant difference between the 
robust and moderate category and severe category, Figure 32. 
 
 
Figure 32: First stroke event by frailty category. Patients with AF, n=61,177 
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Stroke rates were positively correlated with age, with a rate of 4.6 (3.5 to 6.1) 
/1000pys in those aged 65 to 69.9 years, and 23.3 (16.0 to 33.9) /1000pys in 
those aged 95-100. 
 
There was a stepwise increase in the unadjusted HR for stroke associated with 
increased frailty category (compared with the robust group), Figure 33. There 
was no statistically significant difference in HR between adjacent groups, but 
the HR for stroke was statistically different from the robust group in the 
moderate and severe frailty categories. However, this difference did not persist 
following adjustment, suggesting that the adjustment factors accounted for the 
difference in stroke rates between the groups. 
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7.4.3 Gastrointestinal bleeding event 
Overall, 583 patients (1.0%, 95% CI 0.88 to 1.04) had an GI bleeding event 
during the follow-up period. The rate was 8.0 (7.4 to 8.7) /1000pys, but 
increased by frailty category, with rates in the robust, mild, moderate and 
severe frailty categories of 4.5 (3.2 to 6.2); 5.8 (4.9 to 6.8); 9.0 (7.9 to 10.3); and 
11.8 (10.2 to 13.6) /1000pys respectively. The lines separate by frailty category 
in the Kaplan-Meier plot, Figure 34. 
 
 
Figure 34: First gastrointestinal bleeding event by frailty category. 
Patients with AF, n=61,177 
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Again, there was a positive association between frailty category and GI bleeding 
event, but the confidence intervals overlap between adjacent categories. 
Adjustment had only a minimal impact on the point estimate for the HR, which 
indicates that the adjustment factors explain little of the variance between 
groups in addition to frailty category, although there may be unmeasured 
confounding. 
 
There was no significant difference between the robust group and those with 
mild frailty in terms of GI bleed outcomes (unadjusted HR 1.29, 0.90 to 1.86). 
This effect remained consistent after adjustment for age, sex, smoking status, 
IMD quintile and GP practice ID (HR 1.32, 0.90 to 1.94). There was a significant 
difference between the robust group and the group with moderate frailty 
(unadjusted HR 2.00, 1.40 to 2.84, adjusted HR 2.02, 1.38 to 2.94) and 
between the robust group and the group with severe frailty (unadjusted HR 
2.60, 1.82 to 3.71; adjusted HR 2.71, 1.84 to 4.01), Figure 35. 
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Figure 35 : A
ssociation betw
een frailty status and gastrointestinal bleeding event  in patients w
ith A
F, n=61,177 
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7.4.4 Intracranial bleeding event 
There were comparatively few patients with a recorded IC bleeding event during 
the follow-up period: 0.2% (95% CI 0.19 to 0.26%, n=136) of the patients with 
AF, with a standardised rate of 1.9 (1.6 to 2.2) /1000pys. This ranged from 0.3 
(0.1 to 0.9) /1000pys in the group aged 65 to 70 years to 3.4 (1.3 to 9.1) per 
1000-person years in the group aged between 95 and 100 years.  
 
IC bleeding events were more common in patients with moderate or severe 
frailty. Rates /1000pys were 1.2 (0.7 to 2.3) in the robust group, 1.2 (0.9 to 1.8) 
in the group with mild frailty, 1.9 (1.4 to 2.5) in the group with moderate frailty, 
and 3.1 (2.4 to 4.1) in the group with severe frailty, Figure 36. 
 
 
 
Figure 36: First intracranial bleeding event by frailty category. Patients 
with AF, n=61,177 
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Compared to the robust group, there was no statistically significant difference in 
IC bleeding events in the group with mild or moderate frailty. There was a 
statistically significant difference for the severe frailty category compared with 
the robust group, with a HR of 2.5 (95% CI 1.3 to 4.9), although this was 
eliminated following adjustment (HR 1.5, 0.8 to 3.5), suggesting that the 
adjustment factors explained the difference between frailty categories, Figure 
37.
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7.4.5 Falls 
There were 2,707 participants that experienced a fall (4.4%, 95% CI 4.3 to 
4.6%), with a rate of 37.1 (95% CI 36.3 to 39.1) /1000pys. This increased with 
age, from 7.1 (5.6 to 8.9) /1000pys in patients aged 65 to 70 years to 118.6 
(99.9 to 140.8) /1000pys in patients aged 95 to 100 years. The rates were 
higher with increasing age, but the difference by age category was less than for 
other outcomes described. In patients aged 65 to 70, the rate was 5.1 (4.6 to 
5.6), compared with 10.3 (5.9 to 18.2) in those aged 95 to 100. 
 
Compared with the robust group, the HR for falls in mild frailty was 3.3 (95% CI 
2.5 to 4.4), adjusted 2.7 (1.9 to 3.6); moderate frailty 6.6 (4.9 to 8.7), adjusted 
4.1 (3.0 to 5.7); severe frailty 12.9 (9.7 to 17.2), adjusted 6.5 (4.8 to 8.8). 
 
7.4.6 Transient ischaemic attack 
Overall, 0.61% of participants had a TIA during the follow-up period (0.55 to 
0.67%, n=372). The rate in the oldest category was substantially higher than in 
the youngest category (3.0, 2.1 to 4.2/1000pys in those aged 65 to 70, and 
10.3, 5.9 to 18.2 1000pys in those aged 95 to 100). 
 
Compared with the robust group, the HR for TIA in mild frailty 1.15 (0.74 to 
1.77), adjusted 1.0 (0.7 to 1.6); moderate frailty 1.7 (1.1 to 2.6), adjusted 1.5 
(0.9 to 2.3); 2.3 (1.5 to 3.5), adjusted 1.8 (1.1 to 2.8). 
 
7.4.7 Summary of the association between frailty category and 
clinical outcomes, in patients with AF and without AF 
 
To demonstrate the differential association between frailty category and clinical  
outcomes, the hazard ratios that have been presented and discussed above are 
displayed in single plot for unadjusted estimates in Figure 38, and adjusted 
estimates in Figure 39.
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Finally, for comparison, plots showing the association between frailty status and 
clinical outcomes for the cohort of patients without AF are shown in Figure 40 
and Figure 41. These show the same direction of association as in the group 
without AF, and a stepwise increase in the HR for each outcome associated 
with frailty status. The unadjusted HR for mortality associated with frailty is 
higher in the group without AF than in the group with AF (unadjusted HR for 
mortality in the severe frailty category compared to robust: HR 10.0, 95% CI 9.5 
to 10.5 in patients without AF, and 8.7, 7.4 to 10.2 in patients with AF). After 
adjustment, the HR for mortality is similar, suggesting that the different 
association is explained by differences in the adjustment factors, age, sex, 
smoking, IMD, and GP practice (adjusted HR for mortality in the severe frailty 
category compared to robust: 4.3, 4.1 to 4.6 in patients without AF and 4.0, 3.4 
to 4.7 in patients with AF). 
 
There was no increased adjusted risk of stroke for patients with AF who were 
severely frail compared with robust patients (HR 1.2, 95% CI 0.9 to 1.8), 
however, for those without AF, severe frailty was associated with a 2.2-fold 
increased risk of stroke compared with those who were robust (HR 2.2, 1.9 to 
2.6). It was shown in the previous chapter that even after adjusting for 
differences in baseline characteristics and frailty category, AF was associated 
with an increased risk of stroke, HR 1.3 (1.2 to 1.4). This suggests that AF itself 
may confer a greater relative risk than frailty category. 
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Figure 40 : A
ssociation betw
een frailty status and clinical outcom
es, unadjusted, in patients w
ithout A
F. n=475,778 
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Figure 41: A
ssociation betw
een frailty status and clinical outcom
es, adjusted, in patients w
ithout A
F. n=475,778  
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7.5 Summary of key findings 
• Patients with AF and frailty tend to be older, have a longer history of AF, 
a greater proportion of women, higher levels of deprivation, and are more 
likely to live in a nursing home than patients who are robust. 
• Patients with AF had higher estimated risk of stroke (CHA2DS2-VASc) 
and bleeding (ATRIA) if they also had frailty.  
• Patients with frailty were more commonly prescribed a range of 
medications than those without frailty, including oral anticoagulation and 
anti-platelet medication at the time of study entry.  
• Frailty and increased age were associated with higher rates of each 
clinical outcome of interest, including mortality, stroke, intracranial 
bleeding and gastrointestinal bleeding. However, in a survival analysis, 
the adjusted estimates were only significantly different by frailty category 
for the outcomes of death and GI bleed. 
• There was a statistically significant difference in the association between 
each frailty category and mortality. This persisted despite adjustment for 
baseline characteristics. 
 
7.6 Conclusion 
Patients with AF and frailty tended to be older, with a longer history of AF. 
Frailty is associated with adverse clinical outcomes in patients with AF, 
including a higher risk of all-cause mortality, stroke, gastrointestinal and 
intracranial bleeding.  
 
In Chapter 8, the association between oral anticoagulation and clinical 
outcomes in patients with atrial fibrillation will be investigated. 
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Chapter 8 - Oral anticoagulation and clinical outcomes in 
patients with AF 
8.1 Chapter introduction 
In this chapter, the cohort of patients with AF will be divided into those that were 
anticoagulated and those that were not, and the baseline characteristics 
described and compared. The cohort will then be restricted to patients with a 
CHA2DS2-Vasc score of two or more. The association between OAC and 
clinical outcomes will be estimated, by frailty category. Finally, sensitivity 
analyses will be carried out in order to test some of the assumptions that have 
been made in this thesis, including the code-list used to define AF and stroke, 
and to account for persistence on OAC therapy. 
 
8.2 Chapter summary 
Of the patients with AF, there were 58,204 patients (95.1%) with a CHA2DS2-
Vasc score of two or more. Of these, 53.1% (n=30,916) were prescribed an 
OAC at study entry. Patients that were prescribed OAC tended to be younger, 
were more often male, with a longer duration of AF than patients that were not 
prescribed OAC. They were also less commonly taking an anti-platelet 
medication than patients that were prescribed OAC. Patients with frailty were 
more likely to be prescribed OAC than the robust group. DOAC accounted for 
24% of OAC prescriptions. 
 
OAC prescription was associated with a lower rate of all-cause mortality and 
stroke, but there was no statistically significant difference in the outcomes of GI 
bleed or IC bleeding event. OAC prescription was associated with a lower 
mortality rate in patients in each eFI category. When stratified by frailty status, 
OAC was associated with a decreased point estimate for the outcome of stroke, 
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but the confidence intervals were wide and crossed one in each category 
except moderate frailty. 
8.3 Participants 
The analytic cohort for this chapter consists of patients who were over the age 
of 65, with a history of atrial fibrillation at study entry, Figure 42. 
 
 
 
Figure 42: Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) diagram to show the derivation of the 
analytic cohort of patients with atrial fibrillation 
 
 
There was a history of AF at study entry in 61,177 patients (11.4%). Of these, 
32,079 (52.4%) were prescribed OAC at study entry. 
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8.3.1 Baseline characteristics of patients with AF by OAC status 
Of the patients with AF, 95.1% (n=58,204) had a CHA2DS2-Vasc score of two or 
more, and were considered ‘eligible’ for OAC.140 OAC was prescribed at study 
entry in 30,916 (53.1%) of patients with AF and a CHA2DS2-Vasc score of two 
or more. 
 
The median age of patients with AF was 79.7 (IQR 73.3 to 85.5) years. In 
patients with a CHA2DS2-Vasc score of 2 or more, the median age was 80.2 
(74.3 to 85.7) years, and among this group, patients prescribed OAC were on 
average 5 months younger than those not prescribed an OAC (80.1, IQR 74.6 
to 85.2 years compared with 80.5, 74.0 to 86.6 years, p<0.001). 
 
Of the patients with AF, 27,987 (45.8%) were women. Being female and over 65 
years of age confers two CHA2DS2-Vasc points, therefore there was no 
difference in the number of women after restricting the cohort to patients with 
AF and CHA2DS2-Vasc score of two or more, but the proportion of women 
increased to 48.1% due to the removal of 2,973 men from the cohort. In patients 
with AF and a CHA2DS2-Vasc score of two or more, 46.2% of those prescribed 
OAC were women, compared with 50.2% of those not prescribed OAC, 
p<0.001). Those prescribed OAC tended to be less deprived by IMD rank than 
those not prescribed OAC (12.5% in the most deprived quintile in those 
prescribed OAC compared with 13.7% of those not prescribed OAC). 
 
Of patients with AF and a CHA2DS2-Vasc score of two or more, 5,246 (9.0%) 
lived in a nursing home. The proportion living in a nursing home was lower in 
patients that were prescribed OAC than those that were not prescribed OAC 
(n=3,236 11.9% compared with n=2,010 6.5%, p<0.001).  Patients that were 
prescribed OAC tended to have a longer duration of AF prior to study entry than 
those that were not prescribed OAC (5.4, IQR 2.4 to 10.1 years compared with 
4.1, 1.9 to 8.4 years, p<0.001), Table 32. 
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8.3.2 Risk scores 
In patients with AF and CHA2DS2-Vasc score of two or more, the estimated risk 
of stroke was, on average, higher in patients that were prescribed OAC than in 
those that were not prescribed OAC (mean CHA2DS2-VASc score 3.8, SD 1.4; 
and 4.0, SD 1.4 respectively, p<0.001). The risk of bleeding was also higher - 
the median ATRIA score in the group that were prescribed OAC was 4 (IQR 2 
to 6), and in the group that was not prescribed OAC the median was 3 (2 to 6), 
p<0.001, Figure 43. 
 
 
Figure 43: Stroke and bleeding risk (CHA2DS2-VASc and ATRIA) scores by 
oral anticoagulation prescription status, in patients with CHA2DS2-
VASc score of two or more, n=58,204 
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Figure 44: Forest plot show
ing the difference in proportion (%
) w
ith recorded past m
edical history (PM
H
) betw
een those 
prescribed and not prescribed O
A
C
. Patients w
ith A
F and C
H
A
2D
S2 -VA
Sc score of tw
o or m
ore, n=58,204. 
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8.3.3 Past medical history 
Patients with AF and a CHA2DS2-VASc score of two or more less commonly 
had a recorded past medical history of memory loss if they were prescribed 
OAC at study entry (4.6% absolute difference between group prescribed OAC 
and not prescribed OAC, 95% CI 4.0 to 5.1%). They were also less likely to 
have a recorded history of peptic ulcer disease (difference of 1.1%, 0.7 to 
1.5%), anaemia (2.8%, 2.1 to 3.4%), cancer (1.0%, 0.7 to 1.9%), falls (2.3%, 1.7 
to 3.0%) and intra-cranial bleeding (1.5%, 1.3 to 1.7%), Figure 44. 
 
Patients with AF and a CHA2DS2-VASc score of two or more who were 
prescribed OAC at study entry more commonly had a recorded past medical 
history of chronic kidney disease (4.0% absolute difference, 95% CI 4.3 to 
5.8%), ischaemic heart disease (3.9%, 3.1 to 4.7%), stroke (3.7%, 3.1 to 4.2%), 
and transient ischaemic attack (2.9%, 2.5 to 3.4%). They also more commonly 
had a second indication for OAC prescription: in patients prescribed OAC, 4.2% 
(n=1,312) had a history of pulmonary embolism compared with 1.9% (n=508) of 
those that were not prescribed OAC (p<0.001). A history of deep vein 
thrombosis was recorded in 4.6% (n=1,413) of those prescribed an OAC, 
compared with 3.1% (n=851) of those that were not prescribed an OAC 
(p<0.001). 
 
8.3.4 Medication 
Patients with AF and a CHA2DS2-VASc score of two or more who were 
prescribed OAC were more commonly prescribed a statin in the year prior to 
study entry than those that were not prescribed OAC (64.6% compared with 
55.9%, p<0.001). Patients that were prescribed an OAC were less commonly 
prescribed proton pump inhibitors (38.3% of those prescribed OAC compared 
with 43.4% of those not prescribed OAC, p<0.001) or non-steroidal anti-
inflammatory medications (7.4% compared with 10.7%, p<0.001) in the year 
prior to study entry. 
 
At study entry, 2.1% (n=664) of patients that were prescribed an OAC were also 
prescribed an anti-platelet agent, compared with 11.2% (n=3,044) of patients 
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that were not prescribed an OAC (p<0.001). There was no statistically 
significant difference between the groups in the prescription rates of macrolide 
antibiotics, corticosteroids, carbamazepine or phenytoin in the year prior to 
study entry, Table 33. 
 
Table 33: Medication history by oral anticoagulation prescription at study 
entry status. Patients with AF and CHA2DS2-VASc score of two or 
more, n=58,204 
Variable Total  
n=58,204 
Prescribed 
OAC  
n=30,916 
Not 
prescribed 
OAC 
n=27,288 
p-
value* 
Medications in the previous year, n (%)    
Proton pump inhibitor 23,695 (40.7) 11,852 (38.3) 11,843 (43.4) <0.001 
Macrolide antibiotics 402 (0.69) 196 (0.63) 206 (0.75) 0.079 
NSAID 5,209 (9.0) 2,288 (7.4) 2,921 (10.7) <0.001 
Corticosteroid 1,684 (2.9) 901 (2.9) 783 (2.9) 0.747 
Statin 35,236 (60.5) 19,972 (64.6) 15,264 (55.9) <0.001 
Anti-epileptic       
  Carbemazepine 224 (0.38) 111 (0.36) 113 (0.41) 0.369 
  Phenytoin 176 (0.30) 85 (0.27) 91 (0.33) 
 
Medication at study entry, n (%) 
   
Any anti-platelet 3,688 (6.3) 644 (2.1) 3,044 (11.2) <0.001 
 
* p-value for the difference between group prescribed OAC and not prescribed OAC, Chi-
square. 
Abbreviation  OAC: oral anticoagulation 
 
 
8.3.5 Oral anticoagulation at study entry by frailty category 
Of patients with AF and a CHA2DS2-VASc score of two or more, 53.1% 
(n=30,916) were prescribed an OAC at study entry. This varied by electronic 
frailty index category: 41.7% (n=2,028) were prescribed OAC in the robust 
category; 53.2% (n=10,221) in the mild frailty category; 55.6% (n=11,167) in the 
moderate frailty category and 53.4% (n=7,500) in the severe frailty category, 
Figure 45. 
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Figure 45: Proportion of patients with AF and a CHA2DS2-VASc score of 
two or more that were prescribed OAC at study entry by electronic 
frailty index category, n=58,204 
 
The association between OAC status and frailty category was quantified using a 
logistic regression model, with OAC as the outcome and frailty category as the 
exposure. In comparison to the robust category, frailty was associated with 
higher odds of OAC prescription: mild frailty OR 1.6 (95% CI 1.5 to 1.7); 
moderate frailty OR 1.8 (1.6 to 1.9); severe frailty OR 1.6 (1.5 to 1.7). 
 
Adjustment for sex and IMD had a minimal effect on the estimates (OR 
associated with mild frailty 1.6, 95% CI 1.5 to 1.7; moderate frailty: 1.8, 1.7 to 
1.9; severe frailty: 1.7, 1.5 to 1.8. Further adjustment for concurrent medications 
increased the magnitude of the association between frailty and OAC 
prescription (OR associated with mild frailty: 1.7, 1.6 to 1.9; moderate frailty: 
2.1, 2.0 to 2.2; severe frailty: 2.1, 2.0 to 2.3). Additional adjustment for age, 
history of cancer, varices and previous GI or intra-cranial bleeding increased the 
magnitude of the association further (OR associated with mild frailty 1.8, 1.7 to 
2.0, moderate frailty: 2.3, 2.2 to 2.5, severe frailty: 2.5, 2.3 to 2.7), Figure 46.
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Figur e 46 : A
ssociation betw
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8.3.6 Oral anticoagulation agents at study entry 
Of those patients that were prescribed OAC at study entry, 76% (n=23,502) 
were prescribed warfarin and 24% (n=7,329) a DOAC, Table 34. The rates of 
DOAC prescription varied by frailty category, ranging from 21.6% of 
prescriptions in the robust group to 29.5% of OAC prescriptions in the group 
with severe frailty. Overall, rivaroxaban accounted for 74% of all DOAC 
prescriptions.  
 
Sinthrome, acenocoumarol and phenindione were prescribed uncommonly. 
Combined, these three medications accounted for less than 1% of all OAC 
prescriptions. 
 
8.4 Frailty and clinical outcomes 
The rates of clinical outcomes in all patients with AF have previously been 
reported (with any CHA2DS2-VASc score, Table 31). The rates for patients with 
AF and a CHA2DS2-VASc score of two or more are shown in Table 35. The 
stroke rates were similar in the two sub-groups (8.5, 95% CI 7.8 to 9.1 in all 
patients with AF, and 8.7, 8.1 to 9.5 in patients with a CHA2DS2-VASc score of 
two or more, p=0.568).  
 
Rates (/1000pys) of GI bleed, IC bleed, fall and TIA were similar between the 
whole cohort of patients with AF and patients with a CHA2DS2-VASc score of 
two or more (GI bleed: 8.0, 95% CI 7.4 to 8.7 vs 8.3, 7.6 to 9.0, p=0.572; IC 
bleed 1.9, 1.6 to 2.2 vs 1.9, 1.6 to 2.3, p=0.806; Fall 37.1, 36.3 to 39.1 vs 39.4, 
37.9 to 40.9, p=0.108; TIA 5.1, 4.6 to 5.6 vs 5.2, 4.7 to 5.8, p=0.764). The rates 
by frailty status are reported in Table 35, showing a positive association 
between eFI category and rates of clinical events, as shown in section 7.4. 
 
The all-cause mortality rate was higher in the cohort restricted to patients with a 
CHA2DS2-VASc score of two or more than in all patients with AF (87.4, 95% CI 
85.3 to 89.6, compared with 83.8, 81.7 to 85.9, p-value for difference in 
proportions = 0.014). The stroke rate was similar (8.5, 7.8 to 9.1 in all patients 
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with AF, and 8.7, 8.1 to 9.5 in patients with a CHA2DS2-VASc score of two or 
more, p=0.568).  
 
Rates of GI bleed, IC bleed, fall and TIA were similar between the whole cohort 
of patients with AF and patients with a CHA2DS2-VASc score of two or more (GI 
bleed: 8.0, 95% CI 7.4 to 8.7 vs 8.3, 7.6 to 9.0, p=0.572; IC bleed 1.9, 1.6 to 2.2 
vs 1.9, 1.6 to 2.3, p=0.806; Fall 37.1, 36.3 to 39.1 vs 39.4, 37.9 to 40.9, 
p=0.108; TIA 5.1, 4.6 to 5.6 vs 5.2, 4.7 to 5.8, p=0.764), Table 35. 
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  Table 35: R
ates of clinical outcom
es (/1000pys) in patients w
ith A
F and C
H
A
2 D
S
2 -VA
Sc score of 2 or m
ore by frailty status. 
n=58,204. 
 
All 
R
obust  
M
ild 
M
oderate 
Severe 
n 
58,204 
4,863 
19,198 
20,099 
14,044 
Person 
years follow
-
up 
69,610.31 
6079.80 
23,676.68 
24,053.19 
15,800.64 
 
n 
R
ate 
n 
R
ate 
n 
R
ate 
n 
R
ate 
n 
R
ate 
D
eath 
6,085 
87.4 (85.3-89.6) 
139 
22.9 (19.4-27.0) 
1,019 
43.0 (40.5-45.8) 
2,088 
86.8 (83.2-90.6) 
2,839 
179.7 (173.2-186.4) 
Stroke 
605 
8.7 (8.1-9.5) 
36 
5.9 (4.3-8.2) 
177 
7.5 (6.5-8.7) 
223 
9.3 (8.2-10.6) 
169 
10.8 (9.2-12.5) 
  Ischaem
ic  
271 
3.9 (3.5-4.4) 
21 
3.5 (2.3-5.3) 
78 
3.3 (2.6-4.1) 
105 
4.4 (3.6-5.3) 
67 
4.3 (3.3-5.4) 
  U
nspecified 
334 
4.8 (4.3-5.4) 
15 
2.5 (1.5-4.1) 
99 
4.2 (3.4-5.1) 
118 
4.9 (4.1-5.9) 
102 
6.5 (5.3-7.9) 
G
I bleed 
572 
8.3 (7.6-9.0) 
33 
5.5 (3.9-7.7) 
137 
5.8 (4.9-6.9) 
217 
9.1 (8.0-10.4) 
185 
11.8 (10.2-13.7) 
IC
 bleed 
133 
1.9 (1.6-2.3) 
9 
1.5 (0.8-2.9) 
29 
1.2 (0.9-1.8) 
46 
1.9 (1.4-2.6) 
49 
3.1 (2.4-4.1) 
Fall 
2,682 
39.4 (37.9-40.9) 
45 
7.1 (5.3-9.6) 
488 
20.9 (19.1-22.8) 
949 
40.4 (37.9-43.0) 
1,202 
79.6 (75.2-84.2) 
TIA 
361 
5.2 (4.7-5.8) 
22 
3.6 (2.4-5.5) 
86 
3.6 (3.0-4.5) 
134 
5.6 (4.7-6.6) 
119 
7.6 (6.3-9.1) 
Abbreviations  G
I: gastrointestinal; IC
: intracranial; TIA: transient ischaem
ic attack 
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8.5 Oral anticoagulation and clinical outcomes 
Overall, the standardised stroke rate for patients with AF and any CHA2DS2-
VASc score was 8.45 (95% CI 7.81 to 9.14) /1000pys. In patients that were not 
prescribed OAC at study entry, the rate was 9.66 (8.67 to 10.75) /1000pys, 
compared with 7.38 (6.57 to 8.29) /1000pys in the group that were prescribed 
OAC. The highest stroke rate was observed in patients that were not prescribed 
OAC at study entry and had a score of 7, in whom the rate was 23.56 (15.51 to 
35.78) /1000pys. 
 
No patients with a CHA2DS2-VASc score of nine had a stroke during the follow-
up period, and there were no stroke events recorded in patients that were 
prescribed OAC and had a CHA2DS2-VASc score of one. There were 12 
patients that experienced a stroke event with a CHA2DS2-VASc score of one 
who were not prescribed OAC (rate 5.30, 95% CI 3.01 to 9.33 /1000pys). 
 
For a given CHA2DS2-VASc score, stroke rates were lower in patients taking an 
OAC at study entry, as shown in Figure 47 and Table 36. However, there were 
a relatively small number of events for each CHA2DS2-VASc score category, 
and the confidence intervals were wide and often overlapping between those 
prescribed OAC and those that were not prescribed OAC. 
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Figure 47: Rate of stroke per 1000 patient years by CHA2DS2-VASc score 
and OAC status, n=61,177 
  
0
10
20
30
40
50
60
70
80
0 1 2 3 4 5 6 7 8 9
R
at
e 
of
 s
tro
ke
, /
10
00
py
s
CHA2DS2-VASC score
•   Not prescribed OAC 
•   Prescribed OAC 
  
 
190 
  
Ta
bl
e 
36
: S
tr
ok
e 
ra
te
s 
by
 O
A
C
 s
ta
tu
s,
 s
tr
at
ifi
ed
 b
y 
C
H
A
2D
S 2
-V
A
Sc
 s
co
re
 
C
H
A 2
D
S 2
-V
AS
c 
Al
l p
at
ie
nt
s 
w
ith
 A
F,
 n
=6
1,
17
7 
N
ot
 p
re
sc
rib
ed
 O
AC
, 
n=
29
,0
98
 
Pr
es
cr
ib
ed
 O
AC
, 
n=
32
,0
79
 
D
iff
er
en
ce
 b
et
w
ee
n 
gr
ou
p 
pr
es
cr
ib
ed
 
O
AC
 a
nd
 g
ro
up
 n
ot
 p
re
sc
rib
ed
 O
AC
 
Sc
or
e 
n=
 
St
ro
ke
 
ev
en
ts
 
R
at
e,
 /1
00
0p
ys
 
(9
5%
C
I) 
R
at
e,
 /1
00
0p
ys
 
(9
5%
C
I) 
R
at
e,
 /1
00
0p
ys
 
(9
5%
C
I) 
D
iff
er
en
ce
 in
 p
ro
po
rti
on
s 
(9
5%
C
I) 
p-
va
lu
e 
0 
0 
0 
- 
- 
- 
0 
- 
1 
2,
97
3 
12
 
3.
22
 (1
.8
3-
5.
68
) 
5.
30
 (3
.0
1-
9.
33
) 
0 
0.
00
03
 (0
.0
00
2,
 0
.0
00
5)
 
<0
.0
01
 
2 
9,
75
8 
71
 
5.
92
 (4
.6
9-
7.
46
) 
5.
05
 (3
.5
7-
7.
15
) 
6.
88
 (5
.0
3-
9.
41
) 
-0
.0
00
1 
(-0
.0
00
5,
 0
.0
00
4)
 
0.
73
2 
3 
15
,1
17
 
10
2 
5.
55
 (4
.5
7-
6.
74
) 
7.
51
 (5
.9
1-
9.
55
) 
3.
70
 (2
.6
6-
5.
15
) 
0.
00
10
 (0
.0
00
5,
 0
.0
01
6)
 
<0
.0
01
 
4 
15
,6
78
 
16
4 
8.
80
 (7
.5
5-
10
.2
5)
 
10
.6
1 
(8
.6
4-
13
.0
3)
 
7.
25
 (5
.7
6-
9.
12
) 
0.
00
08
 (0
.0
00
1,
 0
.0
01
5)
 
0.
03
1 
5 
9,
34
9 
13
1 
12
.0
4 
(1
0.
15
-1
4.
29
) 
14
.7
1 
(1
1.
58
-1
8.
69
) 
10
.1
2 
(7
.9
2-
12
.9
3)
 
0.
00
03
 (-
0.
00
03
, 0
.0
00
9)
 
0.
35
3 
6 
5,
61
4 
89
 
13
.8
7 
(1
1.
27
-1
7.
07
) 
14
.3
1 
(1
0.
37
-1
9.
75
) 
13
.5
7 
(1
0.
34
-1
7.
81
) 
-0
.0
00
3 
(-0
.0
00
8,
 0
.0
00
2)
 
0.
29
6 
7 
2,
14
3 
37
 
15
.5
7 
(1
1.
28
-2
1.
49
) 
23
.5
6 
(1
5.
51
-3
5.
78
) 
10
.4
0 
(6
.2
7-
17
.2
5)
 
0.
00
03
 (-
0.
00
01
, 0
.0
00
6)
 
0.
13
2 
8 
48
5 
11
 
20
.9
7 
(1
1.
61
-3
7.
87
) 
20
.4
5 
(7
.6
7-
54
.4
8)
 
21
.2
8 
(1
0.
15
-4
4.
64
) 
-0
.0
00
1 
(-0
.0
00
2,
 0
.0
00
1)
 
0.
47
6 
9 
60
 
0 
- 
- 
- 
0 
(0
,0
) 
- 
Al
l 
61
,1
77
 
61
7 
8.
45
 (7
.8
1-
9.
14
) 
9.
66
 (8
.6
7-
10
.7
5)
 
7.
38
 (6
.5
7-
8.
29
) 
0.
00
23
 (0
.0
00
9,
 0
.0
03
6)
 
0.
00
1 
A
bb
re
vi
at
io
n 
 O
AC
: o
ra
l a
nt
ic
oa
gu
la
tio
n 
 
  
 
191 
Overall, in patients with AF and a CHA2DS2-VASc score of two or more, all-
cause mortality rates were higher in patients that were not prescribed OAC 
compared to those that were prescribed OAC. There were 3,267 (12.0%) 
deaths in the group that were not prescribed OAC, with a mortality rate of 101.2 
(95% CI 97.8 to 104.7) per 1000 patient years. In comparison, there were 2,818 
deaths (9.12%) in the group that were prescribed OAC, with a rate of 75.50 
(72.76 to 78.34) per 1000 patient years (p<0.001).  
 
Rates of stroke were also lower in patients prescribed OAC than those that 
were not (10.0, 95% CI 8.9 to 11.1 per 1000 patient-years compared with 7.7, 
6.8 to 8.6 /1000pys, p<0.001). There was no statistically significant difference in 
the rates of GI bleed (7.8, 6.9 to 8.8 compared with 8.7 (7.8 to 9.7, p=0.170), or 
IC bleed (1.6, 1.2 to 2.1 compared with 2.2, 1.8 to 2.7, p=0.063) between 
patients that were prescribed OAC and those that were not, Figure 48.  
 
There was no statistically significant difference in the rates of falls and TIA by 
OAC prescription at study entry, Table 37. For completeness, the rates of 
clinical outcome events in all patients with AF, regardless of CHA2DS2-VASc 
score are also reported in Table 38. 
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In patients with AF and a CHA2DS2-VASc score of two or more, prescription of 
OAC at study entry was associated with a reduced hazard of all-cause mortality 
(unadjusted HR 0.75, 95% 0.71 to 0.79; adjusted 0.81, 0.77 to 0.85) and stroke 
(unadjusted HR 0.77, 0.66 to 0.90, adjusted 0.78, 0.67 to 0.92), but no 
significant association was shown between OAC status and IC bleed, GI bleed, 
falls, or TIA, Table 39.  
 
When stratified by frailty status, there was a statistically significant reduction in 
mortality associated with OAC therapy amongst the moderate and severe frailty 
groups. Overall, however, there was no evidence of an interaction effect by 
frailty category for any of the clinical outcomes. 
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8.6 Sensitivity analyses 
As described in section 5.7, a series of sensitivity analyses were carried out to 
test how robust the findings were to a stricter definition of AF using a more 
specific code-set, and account for the different duration of OAC therapy that 
patients were prescribed during the study. 
 
8.6.1 Recording of AF in the dataset 
Of the 37 CTV-3 codes used to identify AF in the cohort, four codes accounted 
for over 75% of the codes used: G5730 - Atrial fibrillation; 2432. - O/E - pulse 
irregularly irreg., 3272. - ECG: atrial fibrillation, and Xa2E8 - Paroxysmal atrial 
fibrillation. Table 40 shows how frequently each CTV-3 code was used to record 
AF in the 61,177 patients with AF. Within the EHR of the cohort, a CTV-3 code 
was used to identify AF on 244,782 occasions. The median number of times 
that a CTV-3 code was used to record the presence of AF in an individual was 3 
per patient (minimum 1, maximum 381, IQR 1 to 6). Often, different CTV-3 
codes for AF were used in the same individual (median of 2 different codes; 
minimum 1, maximum 10, IQR 1 to 2). 
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8.6.2 Evaluating the impact of a more specific AF code-set 
A more specific code-list for AF was developed (outlined in section 5.7.1), 
excluding the following codes from the AF definition:  
• XaaaD: Provision of written information about atrial fibrillation 
• XaLFh : Exception reporting: atrial fibrillation quality indicators 
• XaLFi: Excepted from atrial fibrillation quality indicators: Patient 
unsuitable 
• XaLFj: Excepted from atrial fibrillation quality indicators: Informed dissent 
• 2432: O/E - pulse irregularly irreg. 
 
After removing these codes to form a reduced AF cohort, the number of patients 
remaining with a diagnosis of AF reduced by 14% to 52,605. The remaining 
8,572 patients were excluded from the sensitivity analysis, Figure 49. 
 
 
Figure 49: Illustration of the derivation of the reduced analytical cohort for 
a sensitivity analysis using a more specific AF code set 
 
 
Baseline patient characteristics for the original AF cohort, compared to the 
reduced AF cohort showed that there were small but statistically significant 
differences between the groups. Patients in the reduced AF cohort were, on 
average, five months older than those in the excluded group (p<0.001). The 
reduced AF cohort had a lower proportion of women than the excluded group 
(45.4% compared with 47.8%, p<0.001), and tended to have higher levels of 
frailty than those the excluded group (median 9, IQR 7-12 eFI deficits compared 
with 8, IQR 6 to 11, p<0.001,Table 41). 
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The excluded group had a lower prescription rate of OAC than the original 
analytical cohort or the reduced cohort. In the original analytic cohort, 52.4% of 
patients were prescribed OAC. In the reduced analytical cohort, 60.3% were 
prescribed OAC, and in the excluded group, 4.4% were prescribed OAC (p-
value for the difference between excluded and reduced analytical cohort 
p<0.001, Table 41). 
 
Table 41: Baseline characteristics of patients with specific code-list for 
sensitivity analysis 
 Original 
analytical cohort 
n=61,177 
Reduced 
analytical cohort 
n=52,605 
Excluded patients 
n=8,572 
p-
value 
Age. Median (IQR) 79.7 (73.3-85.5) 79.8 (73.4-85.5) 79.33 (73.0-85.3) <0.001 
Female. n (%) 27,987 (45.8) 23,886 (45.4) 4,101 (47.8) <0.001 
Number of eFI 
deficits, median (IQR) 
9 (6-12) 9 (7-12) 8 (6-11)  
 
Frailty category. n (%) 
    
  Robust 6,443 (10.5) 5,153 (9.8) 1,290 (15.1) <0.001 
  Mild 2,352 (33.3) 17,286 (32.9) 3,066 (35.8) 
  Moderate 20,315 (33.2) 17,657 (33.6) 2,658 (31.0) 
  Severe 14,067 (23.0) 12,509 (23.8) 1,558 (18.2) 
Prescribed OAC. n(%) 32,079 (52.4) 31,699 (60.3) 380 (4.4) <0.001 
Abbreviations  IQR: interquartile range; OAC: oral anticoagulation 
 
Comparing outcome event rates between the reduced analytical cohort and the 
excluded group in patients with CHA2DS2-VASc score of two or more, each of 
the following clinical outcomes occurred more frequently in the reduced 
analytical cohort: all-cause mortality 91.5, 95% CI 89.2 to 94.0 /1000pys in 
reduced cohort and 62.7, 58.0 to 67.8 /1000pys in the excluded group, p<0.001; 
unspecified stroke: 5.1, 4.5 to 5.7 compared with 3.2, 2.3- to 4.5 /1000pys, 
p=0.006; GI bleeding event: 8.6, 7.9 to 9.4 compared with 6.4, 5.0 to 8.2 
/1000pys, p=0.012 and falls: 40.6, 39.0 to 42.2 compared with 32.6, 29.2 to 
36.4 /1000pys, p<0.001. 
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There were no statistically significant differences between the groups in rates of 
stroke overall, ischaemic stroke, or IC bleeding events or TIA (p-values for 
difference >0.05), Table 42. 
 
Table 42: Clinical outcome events by AF sensitivity analysis analytical 
cohort subgroups, in patients with CHA2DS2-VASc score of two or 
more. Rates, /1000pys (95% CI) 
 
Outcome 
Original 
analytical cohort 
n= 58,204 
Reduced 
analytical cohort 
n=50,010 
Excluded 
patients 
n= 8,194 
p-value* 
Death 87.4 (85.3-89.6) 91.5 (89.2-94.0) 62.7 (58.0-67.8) <0.001 
Stroke 8.7 (8.1-9.5) 8.9 (8.1-9.7) 8.0 (6.4-9.9) 0.197 
  Ischaemic  3.9 (3.5-4.4) 3.8 (3.3-4.3) 4.7 (3.6-6.3) 0.262 
  Unspecified 4.8 (4.3-5.4) 5.1 (4.5-5.7) 3.2 (2.3-4.5) 0.006 
GI bleed 8.3 (7.6-9.0) 8.6 (7.9-9.4) 6.4 (5.0-8.2) 0.012 
IC bleed 1.9 (1.6-2.3) 2.0 (1.6-2.4) 1.6 (1.0-2.6) 0.349 
Falls 39.4 (37.9-40.9) 40.6 (39.0-42.2) 32.6 (29.2-36.4) <0.001 
TIA 5.2 (4.7-5.8) 5.2 (4.7-5.8) 5.0 (3.8-6.6) 0.568 
*p-value for difference between the reduced analytical cohort and excluded patients 
Abbreviations  GI: gastrointestinal; IC: intracranial; TIA: transient ischaemic attack 
 
There was a step-wise increase in event rates by frailty category in both the 
reduced analytical cohort and the excluded patient group in the clinical 
outcomes of all-cause mortality, stroke, and falls. This pattern was not apparent 
in either group for ischaemic stroke. The stepwise increase was seen in the 
reduced analytical cohort, but not the excluded group in the outcomes of 
unspecified stroke, GI bleed, IC bleed. In the clinical outcome of TIA, a stepwise 
positive association was seen in the excluded group, but not the reduced 
analytical cohort, Table 43. 
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Table 43: R
ates of outcom
e events (/1000pys) in patients w
ith A
F and a C
H
A
2 D
S
2 -VA
SC
 score of tw
o or m
ore, by frailty status. 
R
esults show
n for the reduced analytical cohort (n=52,605) and the excluded group (n=8,194).   
 
All 
R
obust 
M
ild 
M
oderate 
Severe 
 
n 
R
ate 
R
ate 
R
ate 
R
ate 
R
ate 
D
eath 
 
 
 
 
 
 
Excluded group 
626 
62.7 (58.0-67.8) 
12.7 (7.9-20.5) 
34.1 (28.6-40.6) 
69.3 (60.7-79.1) 
146.7 (130.0-165.6) 
R
educed cohort 
5,459 
91.5 (89.2-94.0) 
25.7 (21.5-30.7) 
44.7 (41.8-47.7) 
89.4 (41.8-47.7) 
183.9 (176.9-191.1) 
Stroke 
 
 
 
 
 
 
Excluded group 
79 
8.0 (6.4-9.1) 
5.3 (2.5-11.1) 
6.3 (4.2-9.5) 
10.1 (7.1-14.3) 
9.5 (5.9-15.3) 
R
educed cohort 
526 
8.9 (8.1-9.7) 
6.1 (4.3-8.8) 
7.7 (6.6-9.1) 
9.2 (8.0-10.6) 
10.9 (9.3-12.8) 
Ischaem
ic stroke 
 
 
 
 
 
 
Excluded group 
47 
4.7 (3.6-6.3) 
1.5 (0.4-6.0) 
3.6 (2.1-6.1) 
7.2 (4.8-10.9) 
5.0 (2.6-9.7) 
R
educed cohort 
224 
3.8 (3.3-4.3) 
4.0 (2.6-6.3) 
3.3 (2.6-4.1) 
3.9 (3.2-4.9) 
4.2 (3.2-5.4) 
U
nspecified stroke 
 
 
 
 
 
 
Excluded group 
32 
3.2 (2.3-4.5) 
3.8 (1.6-9.0) 
2.7 (1.5-5.1) 
2.8 (1.5-5.4) 
4.5 (2.2-8.9) 
R
educed cohort 
302 
5.1 (4.5-5.7) 
2.1 (1.4-3.9) 
4.5 (3.6-5.5) 
5.2 (4.3-6.3) 
6.7 (5.5-8.2) 
G
astrointestinal bleed 
 
 
 
 
 
Excluded group 
64 
6.4 (5.0-8.2) 
6.0 (3.0-12.0) 
6.0 (4.0-9.2) 
4.4 (2.6-7.5) 
11.3 (7.3-17.5) 
R
educed cohort 
508 
8.6 (7.9-9.4) 
5.3 (3.6-7.8) 
5.8 (4.8-6.9) 
9.8 (8.5-11.3) 
11.9 (10.2-13.9) 
Intracranial bleed 
 
 
 
 
 
 
Excluded group 
16 
1.6 (1.0-2.6) 
0 
1.4 (0.6-3.3) 
1.3 (0.5-3.4) 
3.9 (1.9-8.2) 
R
educed cohort 
117 
2.0 (1.6-2.4) 
1.9 (1.0-3.6) 
1.2 (0.8-1.8) 
2.0 (1.5-2.7) 
3.0 (2.2-4.1) 
Fall 
 
 
 
 
 
 
Excluded group 
319 
32.6 (29.2-36.4) 
4.5 (2.0-10.0) 
19.6 (15.6-24.8) 
35.1 (29.1-42.4) 
77.3 (65.2-91.7) 
R
educed cohort 
2,363 
40.6 (39.0-42.2) 
7.8 (5.7-10.8) 
21.1 (19.2-23.2) 
41.2 (38.5-44.1) 
79.9 (75.3-84.8) 
TIA
 
 
 
 
 
 
 
Excluded group 
50 
5.0 (3.8-6.6) 
1.5 (0.4-6.0) 
4.7 (2.9-7.5) 
4.7 (2.8-7.8) 
9.0 (5.5-14.6) 
R
educed cohort 
311 
5.2 (4.7-5.8) 
4.2 (2.7-6.6) 
3.5 (2.7-4.4) 
5.7 (4.8-6.9) 
7.4 (6.1-9.0) 
 
  
 
206 
Repeating the survival analysis showed that the effect size for OAC was greater 
in the reduced analytical cohort than in the original cohort for the outcomes of 
all-cause mortality (unadjusted HR for mortality compared with patients not 
prescribed OAC 0.75, 95%CI 0.71 to 0.79 in original cohort, compared with 
0.63, 0.60 to 0.67) in the reduced cohort). There was also a greater reduction in 
stroke associated with prescription of OAC, although the confidence intervals 
overlap between the two groups (HR 0.77, 0.66 to 0.90 compared with 0.71, 
0.60 to 0.84), Figure 50. 
 
There was no difference in the association between OAC prescription and the 
hazard ratio for IC or GI bleeding between the original analytical cohort and the 
reduced analytical cohort. Adjusted estimates of the association between OAC 
prescription and clinical outcomes in the reduced analytical cohort are shown in 
Table 44. 
 
Table 44: Association between OAC at study entry and clinical events in 
patients with CHA2DS2-VASC score ³ 2, in the reduced analytical 
cohort. n=50,010 
 Unadjusted hazard ratio (95% CI) Adjusted hazard ratio (95% CI) 
 No OAC  
n=19,464 
OAC 
n=30,546 
p-
value* 
No OAC  
n=19,464 
OAC 
n=30,546 
p- 
value*  
Death 1 (ref) 0.63 (0.60-0.67) <0.001 1 (ref) 0.70 (0.66-0.74) <0.001 
Stroke 1 (ref) 0.7 (0.6-0.8) <0.001 1 (ref) 0.7 (0.6-0.9) <0.001 
GI 
bleed 
1 (ref) 1.0 (0.8-1.2) 0.924 1 (ref) 1.0 (0.9-1.2) 0.997 
IC bleed 1 (ref) 1.4 (0.9-2.1) 0.102 1 (ref) 1.4 (1.0-2.2) 0.078 
* p-value for difference in HR associated with prescription of OAC. 
Abbreviations  OAC: oral anticoagulation; GI: gastrointestinal; IC: intracranial 
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Figure 50: Sensitivity analysis show
ing the unadjusted association betw
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8.6.3 Evaluating the intention to treat assumption 
This section will report the characteristics of patients that did not persist on 
OAC, and investigate the impact of removing patients that were not persistent 
on OAC therapy in a sensitivity analysis. Of the 58,204 patients with AF and a 
CHA2DS2-VASC score of two or more, 34,030 (58.5%) were prescribed OAC at 
study entry. Of these, 28,356 (83.3%) persisted with an OAC prescription for the 
duration of follow-up, and 5,674 (16.7%) discontinued OAC during the study, 
Figure 51. 
 
Figure 51: Illustration of the derivation of the subgroups for a sensitivity 
analysis of OAC persistence 
 
In patients with AF and a CHA2DS2-VASC score of two or more, patients that 
discontinued OAC were older and tended to have higher baseline frailty 
category than those that were persistent on OAC (or were not prescribed OAC). 
The group that were not persistent on OAC had the greatest proportion of 
patients in the most deprived quintile (14.4% compared with 12.3% of the 
persistent group and 13.7% of the group that were not prescribed OAC), and 
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had the highest proportion living in a nursing home (13.8%, compared with 
5.5% in the persistent group and 12.1% in the group that were not prescribed 
OAC). The group that discontinued OAC had the highest proportion of patients 
with a history of GI bleed, but not IC bleed. 
 
Patients that persisted with OAC had the lowest proportion of patients taking 
anti-platelet medications at study entry, or be prescribed an anti-platelet during 
the study period (2.1% and 0.8%) compared with those that were not prescribed 
OAC (11.0% and 2.4%) or discontinued OAC (8.0% and 4.2%). Patients that 
were persistent on OAC also had the lowest proportion taking a PPI at entry, or 
prescribed a PPI during the study, Table 45. 
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It was shown in section 8.5 that prescription of OAC at study entry was 
associated with a reduced risk of stroke and all-cause mortality during the 
follow-up period. Persistent OAC was associated with a further reduction in the 
risk of death. OAC at study entry was associated with a HR of 0.75 (95% CI 
0.71-0.79), compared with a HR associated with persistent OAC (compared 
with no OAC) of 0.63 (0.60 to 0.67). Restricting the cohort to the reduced AF 
analytic cohort used in section 8.6.2 resulted in a further strengthening of the 
association between OAC and mortality reduction, with a HR of 0.52 (0.49 to 
0.55), Figure 52. Adjusted estimates showed the same pattern of association, 
Figure 53. 
 
The increased strength of association shown for mortality was also shown in 
stroke, although as in the main analysis, the confidence intervals overlap 
between groups. Compared to the reference group of patients not prescribed 
OAC, OAC at study entry was associated with a HR of 0.77 (95%CI 66 to 90); 
persistent OAC with a HR of 0.75 (0.62 to 0.90); and persistent OAC with a 
reduced AF analytic cohort was associated with a HR for stroke of 0.69 (0.56 to 
0.84). 
 
As in the main analysis, the sensitivity analyses showed no statistically 
significant association between OAC and bleeding events, as the confidence 
intervals of the hazard ratio cross one. 
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Figure 52: Forest plot show
ing the unadjusted results of the sensitivity analyses  
 
  
 
214 
 
  
Figure 53: Forest plot show
ing the results  of the sensitivity analyses, adjusted for age, sex, sm
oking status, IM
D
 
quintile, and G
P practice ID
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When stratified by eFI category, OAC prescription was associated with a 
reduction in all-cause mortality for mild, moderate and severe frailty categories, 
but there was no statistically significant reduction among patients in the robust 
category. Whilst the confidence intervals overlap between the groups, the point 
estimates suggest an inverse ‘dose response’ relationship in the reduction in 
mortality associated with OAC prescription and eFI category. A statistically 
significant reduction associated with OAC prescription in the robust category 
was only seen in the reduced AF analytical cohort with persistent OAC 
prescription. The HR for all-cause mortality associated with OAC prescription 
was 0.6 (95% CI 0.4 to 0.9) in this group, with no change in the estimate with 
adjustment, Figure 54. 
 
For the outcome of stroke, there was little difference in the HR across the 
different analyses. In each, the moderate frailty category was the only one in 
which there was a statistically significant reduction in stroke associated with 
OAC prescription, HR 0.59 (95% CI 0.45 to 0.77) for OAC prescription at study 
entry compared with a HR of 0.55 (0.40 to 0.77) in the reduced AF analytical 
cohort and persistent OAC prescription, Figure 55. 
 
There was no statistically significant difference in bleeding outcomes between 
the groups prescribed OAC or not prescribed OAC across each of the sensitivity 
analyses and eFI categories, Figure 56 and Figure 57. 
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Figure 54: Forest plot showing results of the sensitivity analyses for all-
cause mortality by electronic frailty index category 
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Figure 55: Forest plot showing results of the sensitivity analyses for 
stroke by electronic frailty index category 
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Figure 56: Forest plot showing results of the sensitivity analyses for 
gastrointestinal bleeding event by electronic frailty index category 
  
 
219 
 
 
Figure 57: Forest plot showing results of the sensitivity analyses for 
intracranial bleeding event by electronic frailty index category 
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8.7 Summary of key findings 
• Of patients that were eligible for OAC prescription according to NICE 
guidelines, OAC was prescribed in 30,916 (53.1%). 
• Patients that were prescribed OAC tended to be younger, were more 
often male, with a longer duration of AF, and had a slightly higher 
average CHA2DS2-VASc score than patients that were not prescribed 
OAC. They were also less likely to have a past medical history of falls, 
anaemia, cancer and memory loss than patients that were prescribed 
OAC. 
• Patients that were not prescribed OAC were more commonly prescribed 
an anti-platelet medication than patients that were prescribed OAC (2.1% 
compared with 11.2%, p<0.001). 
• Patients with frailty were more likely to be prescribed OAC than the 
robust group. 
• OAC prescription was associated with a lower rate of all-cause mortality 
and stroke, but there was no statistically significant difference in the 
outcomes of GI bleed or IC bleeding event. 
• OAC prescription was associated with a lower mortality rate in patients in 
each eFI category. When stratified by frailty status, OAC was associated 
with a decreased point estimate for the outcome of stroke, but the 
confidence intervals were wide and crossed one in each category except 
moderate frailty. 
• Sensitivity analyses showed that the direction of associations that were 
demonstrated in the main analyses were unchanged, and that restricting 
the cohort to a more specific definition of AF and accounting for 
persistence of OAC prescription increased the effect size of the 
association. 
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8.8 Conclusion 
Among patients with AF and a CHA2DS2-VASc score of two or more, those with 
frailty were more commonly prescribed OAC. OAC was associated with a 
greater reduction in all-cause mortality with increasing eFI category. OAC was 
associated with a reduction in stroke events overall, but when stratified by eFI 
category remained statistically significant only in the moderate frailty group. 
These findings were robust to sensitivity analyses that accounted for 
persistence on OAC and in a more specifically defined cohort of patients with 
AF. 
 
The findings of the thesis will be discussed in the context of the existing 
literature and critically evaluated in the next chapter, as will the strengths and 
limitations of the study. 
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Chapter 9 - Discussion 
 
9.1 Introduction 
 
Atrial fibrillation and frailty are increasing in prevalence, more frequently present 
in older people, and are associated with substantial morbidity and mortality.10, 
131, 136, 184, 187. Whilst each are important severally, this thesis has demonstrated, 
for the first time in a large national study of electronic health records, that in 
combination they are associated with particularly poor clinical outcomes. 
However, the scale of the problem is not matched by the current evidence base.  
 
My published systematic review and meta-analysis found that in people with AF, 
frailty is associated with an increased incidence of stroke, mortality, symptom 
severity, and length of hospital stay.185  Yet, there were no community-based 
studies that examined whether frailty modifies the association between the use 
of oral anticoagulation and subsequent clinical outcomes in people with AF. 
This thesis has contributed to addressing this knowledge gap 
 
In addition to the systematic review of the literature, I report analyses from a 
nationwide dataset of the electronic health records of over half a million older 
people registered in primary care. Guided by the gaps in knowledge identified in 
the literature review, the objectives of this study have been met by:  
 
1. Establishing the population prevalence of atrial fibrillation, stratified by 
frailty category 
2. Reporting prescription rates of OAC in patients with AF by eFI category 
3. Estimating the association between frailty and OAC prescription. 
4. Reporting rates of clinical outcomes (stroke, death and major bleeding) 
by eFI category and OAC status.  
5. Quantifying the association between OAC and clinical outcomes (stroke, 
death and major bleeding), and how it is modified by frailty. 
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By addressing each of these objectives, this study makes novel and important 
contributions to the understanding of the epidemiology, management and 
clinical outcomes of older people with frailty and AF. The key findings of the 
thesis will now be summarised and discussed in the context of the existing 
literature. The strengths and limitations of the study will then be critically 
appraised, and the implications of the results assessed.  
 
9.2 Summary of key and novel findings 
The findings of the literature review, and in particular the gaps in the existing 
evidence base, guided the questions that this thesis set out to address in the 
quantitative analysis. Key and novel findings from each component of the thesis 
will now be summarised. 
 
9.2.1 Systematic review and meta-analysis 
Twenty research articles were included in the systematic review. The main 
findings were that in patients with AF, those that also had frailty were at a higher 
risk of stroke, all-cause mortality, and a greater symptom burden. In those that 
were hospitalised with AF, those with frailty in addition tended to have a longer 
hospital admission. A diagnosis of AF was associated with a higher risk of 
frailty, falls, and physical performance decline compared to patients without AF.  
 
Data on the association between OAC prescription and frailty in patients with 
AF was conflicting in the literature. A meta-analysis was performed to 
synthesise the existing evidence. A single community-based study found that 
frailty was associated with increased OAC prescription. However, the findings 
were more complex amongst patients that were admitted to hospital. At hospital 
admission, frailty was associated with decreased OAC prescription. This 
represents prescribing decisions made in the community, and this finding may 
reflect a cohort of patients that are sicker (hence requiring hospitalisation) being 
less likely to be prescribed OAC. There was no statistically significant 
association between OAC prescription and frailty at hospital discharge.  
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9.2.2 Quantitative analysis 
Overall, the prevalence of AF in the primary care analytical cohort of 536,995 
patients aged 65 years or older was 11.4%. The prevalence of AF was higher 
with increasing frailty category, affecting 2.9% of robust patients, 11.2% of 
those with mild frailty, 22.2% with moderate, and 31.5% with severe frailty.  
 
Patients with AF and frailty tended to be older, with a longer history of AF and 
higher levels of deprivation. Patients with AF and frailty were also more 
commonly women and were more likely to live in a nursing home than patients 
in the robust group.  
 
The burden of frailty was higher in patients with AF than those without. AF was 
associated with higher all-cause mortality, bleeding events, falls and transient 
ischaemic attack compared to patients without AF (all p<0.001). In patients with 
AF, frailty was associated with a higher risk of all-cause mortality, stroke, 
gastrointestinal and intracranial bleeding. Patients with frailty had a higher 
estimated risk of stroke associated with AF than those in the robust category, 
but also had higher bleeding risk scores. They were also more commonly 
prescribed medications including anti-platelets, macrolide antibiotics, non-
steroidal anti-inflammatory drugs, corticosteroids and statins than the robust 
group. 
 
Among 58,204 patients aged 65 years or older with AF and a CHA2DS2-VASc 
score of two or more, OAC was prescribed in 30,916 (53.1%). Of these, 23.7% 
(n=7,329) were prescribed a DOAC. Patients that were prescribed OAC tended 
to be younger, were more often male, with a longer duration of AF, and had a 
slightly higher predicted stroke risk than patients that were not prescribed OAC. 
They were also less likely to have a past medical history of falls, anaemia, 
cancer and memory loss than patients that were prescribed OAC. Frailty was 
positively associated with OAC prescription, compared with the robust category. 
Compared with older people in the robust group, OAC prescription was more 
likely for people with mild frailty (OR 1.6, 95% CI 1.5 to 1.7), moderate frailty 
(OR 1.8, 1.6 to 1.9) and severe frailty (OR 1.6, 1.5 to 1.7) 
  
 
226 
Importantly, the prescription of OAC was associated with a greater reduction in 
all-cause mortality with increasing frailty, and with a reduction in stroke events 
overall. When stratified by frailty category, the reduction in stroke events 
associated with OAC prescription was only statistically significant in older 
people with moderate frailty. There was no statistically significant difference in 
the recorded bleeding events between patients that were and were not 
prescribed OAC. These findings were robust to sensitivity analyses that 
accounted for persistence on OAC and in an analysis using a stricter definition 
of AF. 
 
9.3 Findings in the context of the literature 
The main findings of the quantitative analysis will now be critically discussed it 
the context of the existing evidence base.  
 
9.3.1 Prevalence of AF 
In this study, the prevalence of AF at baseline was 11.4%, which is somewhat 
higher than that reported in the literature. In a study of opportunistic versus 
systematic screening for AF in UK primary care, Hobbs et al reported a baseline 
prevalence of AF identified from GP records of 7.2% of patients aged 65 years 
or older in 2001 who receiving routine care.335 The median age of the two 
cohorts was similar, at 73.8 (IQR 69.0 to 80.5) in this thesis compared with 74.1 
(IQR not reported) in the study by Hobbs et al. However, a recent study of 
temporal trends in AF prevalence showed that age and sex standardised AF 
prevalence has increased over time, from 2.14% (95% CI 2.11% to 2.17%) in 
2000 to 3.29% (95% CI 3.27% to 3.32%) in 2016,131 suggesting that the 
prevalence in patients aged 65 years or over in 2015 is likely to be higher than 
that reported in the Hobbs et al study, which was based on data from 2001.  
 
In an analysis of insurance claims data of 8.3 million patients in Germany, 
prevalence estimates for AF increased with age. AF was diagnosed in 1.8% of 
those aged 65 to 69 years; 7.6% aged 70 to 74 years; 11.0% aged 75 to 79 
years; 13.7% aged 80 to 84 years; 15.1% aged 85 to 89 years; and 12.7% of 
patients aged over 89 years.336 AF was identified from claims data if they had 
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received at least two outpatient diagnoses of AF in two different quarters of the 
year and/or had received at least one main AF diagnosis during inpatient 
treatment between 1 January 2007 and 12 December 2008. These inclusion 
criteria are more restrictive than in the thesis, as a single recorded episode of 
AF was sufficient to be included in the AF cohort which may explain the finding 
the higher prevalence estimates in this thesis: 4.5% aged 65 to 69 years; 8.2% 
aged 70 to 74 years; 13.0% aged 75 to 79 years; 18.3% aged 80 to 84 years; 
22.6% aged 85 to 90 years. The decision to take a more inclusive approach 
was made on the basis of evidence that the risk of stroke remains elevated 
even in patients with ‘resolved AF’,286 suggesting that AF is never really ‘cured’. 
This judgement is supported by findings that even following clinically successful 
radiofrequency pulmonary vein isolation (AF ablation) followed by a three month 
blanking period, 48% of patients continued to have episodes of AF lasting six 
minutes or more recorded by implantable loop recorder monitoring.337  
 
9.3.2 Prevalence of frailty 
A study comprising 493,737 participants in the UK Biobank (a population-based 
cohort, recruited between 2006 and 2010338) which used the phenotype criteria 
for frailty found that 15.9% of the population aged 65 to 73 years of age were 
classified pre-frail, and 18.5% as frail.339 However, it is known that there is a 
wide variation in the estimates of the population prevalence of frailty depending 
on the clinical setting and frailty measure.27 Secondly, there is evidence of a 
healthy participant bias in UK Biobank, meaning that patients with frailty are 
likely to be under-represented with in the dataset.338 
 
Unlike UK Biobank, ResearchOne, has inclusive enrolment criteria, and is less 
likely to have the same susceptibility to healthy participant bias.257 The most 
direct comparison for this study is therefore with the ResearchOne cohort used 
in the original eFI validation study, in which 50% of patients were categorised as 
fit, 35% with mild frailty, 12% with moderate frailty and 3% with severe frailty.11 
On average, patients tended to have a higher frailty category in this thesis: 41% 
were categorised as fit, 34% as mildly frail, 17% as moderately frail, and 8% as 
severely frail. The discrepancy may be related to improvements in recording of 
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deficits due to an increased awareness of frailty (and in particular functional 
impairment), but also due to population ageing and a general increase in frailty 
over the time period between 2008 and 2015. 
 
A greater proportion of AF patients were moderately and severely frail 
compared with patients without AF. Possible explanations for this include the 
higher average age of patients with AF compared to those without, and the 
possibility that patients with AF have clustering of cardiovascular risk factors 
relating to the AF diagnosis, and therefore to some extent reflects the model 
that was used to identify frailty.126 As identified in the literature review, the 
prevalence of frailty in patients with AF varies widely and is dependent on the 
setting and population included.27 For example, 6% of participants in a registry 
of outpatients with AF aged 18 years or over were classified as frail,202 whereas 
100% of patients with AF living in a nursing home were classified as frail.213 I 
believe this to be the first study to report prevalence of frailty in patients with AF 
using a large, national primary care cohort. 
 
9.3.3 Atrial fibrillation and mortality 
As has been shown in the general population,11 in this study mortality was 
significantly associated with frailty category. In addition, AF was an independent 
risk factor for mortality. In an unadjusted analysis, AF was associated with a 2.7 
fold increase in the risk of death, compared to those without AF (HR 2.7, 95% 
CI 2.6 to 2.8). After adjustment (for eFI category, age, sex, smoking status, IMD 
quintile and GP practice identifier), the HR reduced to 1.6 (1.55 to 1.64). There 
are two key conclusions from this. The first, is that there are significant 
differences between the groups with AF and those without in terms of baseline 
characteristics that are associated with mortality. The second, is that even after 
accounting for these differences, AF was associated with a significant mortality 
disadvantage. This is consistent with a nationwide case-control study of 
272,186 patients admitted to hospital in Sweden, in which the long-term 
adjusted all-cause mortality risk was higher among patients with AF compared 
with patients without AF.136 The Swedish study reported that in patients with a 
primary diagnosis of AF (rather than patients with AF secondary to another 
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identified cause), the adjusted HR for mortality in patients aged 65 to 74 years 
was 1.44 (1.29 to 1.61) in women and 1.18 (1.09 to 1.28) in men.136 In those 
aged 75 to 85 years, there appears to be a reduction in the mortality 
disadvantage associated with AF (HR 1.20, 1.14 to 1.26 in women; 1.01, 0.96 to 
1.06 in men), perhaps due to the development of other age-related competing 
risks for mortality, such as myocardial infarction or cancer, in the older age 
category. Importantly, the study did not go on to assess how frailty modifies the 
association with mortality, or consider additional outcomes 
 
9.3.4 Atrial fibrillation, stroke, and transient ischaemic attack 
The rates of TIA were only slightly higher in patients with AF than those without: 
5.1 events (95% CI 4.6 to 5.6) per 1000 person-years in patients with AF, and 
3.3 (3.2 to 3.5) per 1000 person-years in patients without AF, p<0.001. Rates 
vary within the literature, but in a recent epidemiological study rates were 
reported as 0.7 per 1000 person-years in patients aged 65 to 74 years, 1.41 per 
1000 person-years in those aged 75 to 84 years, and 2.29 per 1000 person-
years in patients aged 85 years or over.340 As the method of participant 
recruitment involved individual clinicians submitting patient’s details to the study 
team, this may have resulted in a non-representative population. Also, the 
diagnosis of TIA was subject to the patient having normal brain imaging (in 
order to exclude a stroke), which would not be known at the time a TIA was 
clinically diagnosed in general practice in ReserachOne. Further evidence that 
TIA rates in this thesis may be an overestimate is shown in a study showing that 
only 54% of patients referred to the TIA clinic have their diagnosis confirmed by 
the specialist team,301 suggesting that the reported TIA rates in the thesis 
should be interpreted with caution, and that stroke rates may be a more robust 
end-point. 
 
AF is a major risk factor for stroke, which is demonstrated in these data. In this 
study, AF was associated with a doubling of stroke risk (HR 2.1, 95% CI 1.9 to 
2.2). However, there were differences in the baseline characteristics of patients 
with AF compared to those without, and after adjustment for sex, smoking 
status, deprivation, age and GP practice, the relative increase in risk was 50% 
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(HR 1.5, 1.4 to 1.6). Further adjustment for electronic frailty index category 
reduced the estimate further to 30% (HR 1.3, 1.2 to 1.4). This final adjustment 
suggests that frailty explains some of the difference in stroke risk between 
patients with AF and without, independently of the other factors. The reasons 
for this association cannot be established from these data. Serum levels of 
factor VIII and fibrinogen are higher in patients with phenotype-defined frailty 
compared with non-frail patients.341 The elevated markers of blood clotting seen 
in patients with frailty may be implicated in the excess stroke risk observed in 
patients with frailty. The links between cardiovascular disease, multimorbidity 
and frailty are currently under investigation, and it has been hypothesized that 
inflammation may be part of a common root cause.342 
 
9.3.5 Atrial fibrillation and falls 
Falls are most likely under-reported in this study dataset (and, indeed, in similar 
community based national EHR datasets), since patients may not consult their 
GP following a fall. However, the finding of an increased falls rate in patients 
with AF compared to those without (38 per 1000 person-years compared with 
19 per 1000 person-years) is of interest, as falls have historically been a 
commonly reported reason for non-prescription of OAC.343, 344  In this dataset, 
20% of patients with AF and a CHA2DS2-Vasc score of two or more had a 
recorded past medical history of falls. In patients that were prescribed OAC, 
2.9% had a history of falls compared with 21.2% of those that were not 
prescribed OAC, p<0.001. This finding indicates that history of falls may have 
an important influence on anticoagulation prescribing decisions in AF.  
 
It may be appropriate to consider falls as part of the decision making process 
when considering OAC prescription, as there is evidence from a cohort study of 
patients that were admitted to hospital with recurrent falls had similar rates of 
bleeding injury if they were prescribed OAC as those that were not (12.8% vs 
12.7%, p=0.97), but patients prescribed OAC had significantly higher rates of 
mortality if they did have a bleeding injury 21.5% vs 6.9%, p<0.01).299 
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An influential and highly cited studyd that provided support for prescribing OAC 
to patients with recurrent falls was published in 1999.233 Man-Son-Hing et al 
sought to determine whether the risk of falling should influence the choice of 
antiplatelet or anticoagulation in older people with AF, and concluded that older 
people taking warfarin ‘must fall about 295 times in 1 year for warfarin to not be 
the optimal therapy’.233 The authors used a Markov model, where clinical events 
are represented by the transition between a series of discrete health states, and 
movement between states can be modelled based upon probabilities. However, 
there were a number of limitations to the clinical assumptions that may affect 
the validity of their conclusions. The modelled treatment strategies were not 
collectively exhaustive, encompassing just three variations of a wide range of 
clinical possibilities. For example, they include the strategy of ‘no treatment then 
switch to aspirin in the event of a TIA or reversible ischaemic neurologic deficit’, 
but not the use of warfarin in such a scenario. The disease-specific and 
treatment-related hazards were assumed to be constant over time, but this 
judgement was reached based upon studies of patients followed up for two 
years or less.  
 
An average case fatality rate for strokes was used across both treatments, and 
‘for simplicity’ major stroke disability was given an average of the utilities of a 
moderate and major disability. The utilities used were based upon a survey of 
69 patients with AF, but there is a high degree of inter-patient variability in 
views. Where 0 is death and 1 is full health, Gage et al found that 10% of 
respondents rated a major stroke with a utility of 0.5, while 83% rated it as equal 
to or worse than death.345 Perhaps these complex, subjective, and nuanced 
evaluations are not well reflected in the utility value for major disability used by 
Man-Son-Hing of 0.11. Interestingly a TIA, where symptoms and signs resolve 
within 24 hours, was assigned the same utility value as a minor stroke, despite 
the fact that in a stroke these deficits persist.346 An assumption was made that 
the probability of sub-dural haematoma (SDH) fatality was identical amongst 
those taking aspirin and those that were not, and that patients that survived a 
SDH or intracerebral haemorrhage were left with moderate disability. In fact, of 
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the 50% of people that survive an intracerebral haemorrhage, most are left with 
significant disability.347  
 
Many of these assumptions have the potential to overestimate the benefit and 
underestimate the harm associated with OAC, and therefore the conclusion that 
‘the risk of falling is not an important factor in the decision about whether to offer 
antithrombotic therapy to elderly patients with AF’ is not, in my view, 
substantiated by the evidence that the authors provide. NICE recommend that 
OAC prescription decisions should be tailored to the individual, and take into 
account their risks and preferences.348 An updated analysis using estimates 
based upon contemporary data that includes DOAC, and with a more nuanced 
evaluation of the utilities associated with stroke and associated disability is 
needed. 
 
9.3.6 Stroke rates in patents with atrial fibrillation 
In this study, stroke rates were lower than those reported in the literature. In all 
patients with AF regardless of CHA2DS2-VASc score, the stroke rate was 0.85 
(95% CI 0.78 to 0.91) per 100 person-years. Stroke rates were lower in patients 
that were prescribed OAC than those that were not (0.97, 0.87 to 1.08 
compared with 0.74, 6.57 to 8.29 per 100 person-years, p<0.001).  
 
The latest publication from the Global Anticoagulant Registry in the Field 
(GARFIELD-AF) reports stroke rates of 1.2 per 100 person-years.349 Although 
this study included 28,628 patients with AF, medication details were available in 
28,211, of whom 63.3% (n=17,872) were prescribed OAC, 24.5% (n=6,905) 
were prescribed antiplatelet alone, and 12.2% (n=3,444) were prescribed 
neither. The stroke rate was not reported by OAC prescription status, but the 
authors do report that OAC was associated with decreased all-cause mortality 
and stroke/systemic embolism (30% and 28% reduction in risk respectively) 
associated with OAC prescription. There was active ascertainment of clinical 
events, as patients were reviewed every four months. In contrast, there is 
evidence of under-reporting of a range of conditions in primary care records, 
including acute myocardial infarction and bleeding.242, 294 This may also be true 
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of stroke, particularly when relying on coded data in the absence of free-text 
comments.350 These limitations may in part explain the discrepancy between 
the thesis rates and those reported in GARFIELD-AF.  
 
An earlier cohort study from 2003 reported rates of stroke or systemic embolism 
of 1.2 per 100 person-years in patients prescribed warfarin, compared to 2.0 per 
100 patient-years in patients without OAC.207 Rates in the clinical trials range 
from 1.2 to 2.4 per 100 person-years in patients prescribed warfarin and 1.2 to 
2.1 per 100 person-years in patients prescribed DOAC.149-152 In addition to 
possible under-reporting in routine data that may account lower rates reported 
in the thesis, there were also differences in the definitions for clinical outcomes 
in the trials. Indeed, there are differences between the clinical trials, which 
means that they are not directly comparable. To improve comparability, the 
rates of stroke (not stroke and systemic embolism) will be briefly summarised. 
In ROCKET-AF study, the rates of ischaemic or unknown stroke was 1.4 per 
100 person-years in the Rivaroxaban arm, and 1.5 per 100 person-years in the 
warfarin arm.149 In RE-LY, the rates were 1.34 per 100 person-years in the 
Dabigatran 100mg group, 0.92 per 100 person-years in the Dabigatran 150mg 
group and 1.20 per 100 person-years in the warfarin group.150 Ischaemic stroke 
rates in the ENGAGE AF-TIMI 48 were 1.25 per 100 person-years in both the 
warfarin and Edoxaban arms.151 In the ARISTOTLE study, rates of ischaemic or 
uncertain type of stroke were 0.97 per 100 person-years in the Apixaban group 
and 1.05 per 100 person-years in the warfarin group.152 These rates are much 
closer to those reported in this study, suggesting that whilst it is likely that some 
events were not captured, the discrepancy is not large, considering that 
recording is based upon ‘real world’ clinical practice as opposed to a clinical trial 
setting. 
 
9.3.7 Prescription rates of oral anticoagulation 
In this study, among 58,204 patients with AF and a CHA2DS2-VASc score of 
two or more, OAC was prescribed in 53.1% (n=30,916). This proportion is 
similar to that reported elsewhere. In a UK primary care population of 13.1 
million patients, Cowan et al found that 132,099 patients had AF and a CHADS2 
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score of two or more.145 Of these, OAC was prescribed in 72,211 (54.7%). 
Although CHADS2 and CHA2DS2-VASc are not equivalent, a score of two in 
either is deemed ‘high risk’, and eligible for OAC prescription,157 and therefore 
comparison of prescription rates between the two is reasonable. The authors 
analysed data that was uploaded from general practices using the Guidance on 
Risk Assessment and Stroke Prevention in Atrial Fibrillation (GRASP-AF) tool 
up until 2012.  
 
The results from a study using Q-Research were similar. In patients with AF and 
a CHADS2 score of two or more, 53.0% were prescribed OAC in 2010.351 This 
had increased from 49.7% in 2007. In Danish registry data from 2007 to 2014, 
prescription of OAC was found to vary by geographical region in patients with 
AF and a CHA2DS2-VASc score of two or more, from 49.5% to 62.4%.352 
 
The concordance between OAC prescription rates and other sources of data 
suggests that the prescription data recorded within ResearchOne is likely to be 
representative of the general population. These rates are still lower than one 
might expect, given that a CHA2DS2-VASc score of two or more is associated 
with an annual stroke risk of at least 2.2%.157 Cowan et al identified that of 
those with a CHADS2 score of two or more, 14,987 (11.3%) were recorded as 
having refused or had a contraindication to OAC.145 However, this left 44,901 
patients (34.0%) that were not prescribed OAC therapy and without a recorded 
contraindication or refusal. It was noted that among patients that were not 
prescribed OAC, 79.9% were prescribed an antiplatelet drug. The authors 
comment that whilst this was not recommended by NICE at that time, it still met 
the requirements of the recommendations of the NHS Quality and Outcomes 
Framework, which may in part have influenced prescribing behaviour.145 
 
Previous qualitative work has shown a tendency for clinicians and patients to 
overestimate the risk (but also benefit) of OAC on stroke risk prevention in 
AF,353, 354 suggesting that there may be a role for improved communication of 
the efficacy and safety of OAC therapy.  Understanding the reasons for non-
prescription of OAC is likely to benefit from a mixed methods approach 
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including qualitative work within primary care to explore perceptions of risk and 
benefit in greater detail, alongside a granular quantitative analysis using 
detailed patient records. 
 
9.3.8 Oral anticoagulation prescription and frailty status 
The analyses presented within this thesis showed that patients with AF and 
frailty were more likely to be prescribed OAC than the robust group. To the best 
of my knowledge, this is the first study that uses a large cohort of primary care 
patients evaluate the association between frailty status and OAC prescription. It 
is also the only such study to date that used the eFI to identify frailty, so direct 
comparisons between other studies are not possible. However, this finding has 
previously been reported by Frewen et al, who showed that in mobile 
community-dwelling participants in The Irish Longitudinal Study on Ageing 
(TILDA) with AF (n=118), frailty as measured by the Fried criteria was 
associated with an increased probability of OAC prescription (OR 2.33, 95% CI 
1.03-5.23, adjusted for age, sex, and educational level).30, 212 TILDA is a 
prospective cohort study, and was designed to be representative of the Irish 
population. Sampling was in geographic clusters, and every member of the Irish 
population aged 50 years and older had an equal probability of being invited to 
participate.355 The results contrast with a recent study by Madhavan et al, which 
showed that patients with frailty were less likely to be prescribed OAC (67.5% of 
participants with frailty were prescribed OAC compared with 76.9% of 
participants without frailty, p<0.001).325 Their analysis was based upon 
participants in the Outcomes Registry for Better Informed Treatment of AF 
(ORBIT-AF), with a median age of 75.0 (IQR 67.0 to 82.0). Frailty was identified 
using the American Geriatric Society’s Geriatric Evaluation and Management 
Tool at enrolment (which is based upon the Fried criteria30). 
 
The methods used to identify frailty were similar in both studies, which aids 
comparisons between them. However, each had limitations. Whilst their 
recruitment process appears to be representative of the overall population, 
Frewen et al included just 118 participants with AF. They do not report the 
number of patients with frailty and AF, but the 95% confidence interval for their 
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OR is wide (and the lower limit is 1.03), reflecting the imprecision of the point 
estimate. Madhavan et al report that a small proportion (6%, n=575) of the 
participants with AF also had frailty, whereas in this thesis 89% (n=54,734) of 
the participants with AF had mild, moderate or severe frailty. The difference in 
apparent frailty burden between the studies is likely to be related to differences 
in frailty ascertainment and in the population sampled. There is only a moderate 
correlation between the eFI and the phenotype model in identifying frailty 
(Spearman’s rho = 0.51, 95% CI 0.42 to 0.59 356)  which limits comparability 
(frailty assessment will be discussed in detail in section 9.4.4.2). Secondly, 
there may be a “healthy participant effect”, where those that are enrolled in 
cohort studies may differ from the general population, as there may be a 
requirement to be physically fit enough to participate, and people that choose to 
take part may exhibit other health-conscious behaviours that may influence care 
provision and clinical outcomes.357  
 
It is not possible to establish why patients with frailty were more commonly 
prescribed OAC than those without frailty from these data. One possible 
contributing factor could be that patients with frailty tend to consult clinicians 
more frequently,358 which may potentially provide opportunities for OAC 
prescription. However, patients with AF that are not prescribed OAC are easily 
identified in EHR using automated tools such as GRASP-AF,145, 267 which would 
be expected to decrease reliance on opportunistic clinical encounters to target 
and initiate guideline indicated prescription of OAC in patients with a known 
history of AF. 
 
Patients that are admitted to hospital are a different population. As discussed in 
chapter 2, eight studies of hospital inpatients showed a range of estimates of 
the association between frailty and OAC prescription. Five studies reported that 
frailty was associated with decreased prescription of OAC,181, 190, 197 and three 
studies showed no statistically significant association.1, 193, 199, 200, 210 Meta-
analysis showed that at hospital admission frailty was associated with 
decreased OAC prescription, but there was no statistically significant 
association at the time of discharge.185 
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9.3.9 Efficacy of oral anticoagulation in patients with AF 
The analyses in this thesis showed that there was a 25% reduction in mortality 
(HR 0.75, 95%CI 0.71 to 0.79) and 23% reduction in stroke (HR 0.77, 0.66 to 
0.90) associated with OAC prescription. As OAC now has a substantial 
evidence-base of benefit for patients with AF in stroke prevention, there are no 
contemporary studies that compare OAC with placebo. In 1999, a meta-analysis 
was performed of six randomised trials (2,900 patients) published between 
1989 and 1993.359 This showed that adjusted dose warfarin was associated with 
a 62% (95% CI 48% to 72%) relative risk reduction of stroke, and a 26% (95% 
CI 4% to 43%) relative risk reduction in mortality compared with placebo.359 
However, these figures should not be directly compared with those reported in 
this thesis. Stroke incidence has reduced substantially over the intervening 
years. One study using GP records showed a 30% reduction in stroke incidence 
in the UK between 1999 and 2008.360 Similar trends have been observed in 
Sweden,361 despite population ageing. However, even when compared with trial 
outcomes of a similar era, it has been shown that the efficacy of warfarin 
appears to be lower in ‘real-world’ settings.362 This could be related to sub-
optimal compliance and difficulties in healthcare access.362 It is also possible 
that the active ascertainment of clinical outcomes that takes place in clinical 
trials allows events to be identified that are not captured in observational 
research.  
 
 
9.3.10 Efficacy and safety of oral anticoagulation in patients with AF 
and frailty 
In this thesis, frailty category did not have a statistically significant interaction in 
the association between OAC and the reported clinical outcomes, suggesting 
that the differences in safety and efficacy endpoints that are reported above are 
not significantly different across the frailty categories. Without accounting for 
OAC prescription, the risk of stroke was 40% higher in the mild frailty group 
than the robust group (HR 1.4, 1.0 to 1.9), 70% higher in the moderate group 
(HR 1.7, 1.3 to 2.4), and double in the severe frailty category (HR 2.0, 1.4 to 
2.8). However, the confidence intervals were wide, and only the moderate and 
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severe groups were statistically significantly different from the robust group. 
There was no statistically significant difference between the groups following 
adjustment for age, sex, smoking, deprivation and GP practice. 
 
Whilst there was a reduction in stroke risk associated with OAC, when stratified 
by frailty category the reduction only remained statistically significant in the 
group with moderate frailty. It may be that the number of events were sufficient 
to detect a difference between the groups prescribed OAC and those not 
prescribed OAC overall, but not when stratified, and that the attainment of pre-
specified statistical significance in the moderate frailty category is a product of 
chance. Alternatively, I have presented evidence in this thesis that patients in 
the moderate and severe categories of frailty are at higher risk of stroke, and 
therefore are most likely to derive benefit from treatment. It is conceivable that 
the benefit may be demonstrated only in the moderate frailty group because 
patients in the severe group are at proportionately higher risk of mortality (or 
had a stroke that resulted in death) as a competing event. Future work with a 
longer period of follow-up and access to hospital-linked data and death 
certificates would be useful to investigate this further, along with an a priori 
power calculation. 
 
The systematic literature review identified evidence that frailty in patients with 
AF was associated with a greater incidence of cardio-embolic stroke and all-
cause mortality compared to those without frailty.181 However, there were 
limited data on whether the association between OAC and clinical outcomes in 
patients with AF was different in patients in the presence of concurrent frailty. 
One study in the review addressed this question in a retrospective cohort study 
of community dwelling adults aged 65 years or over, although patients were 
selected for the study on the basis of a previous hospitalisation for AF. Pilotto et 
al reported lower mortality in patients with AF who were prescribed OAC 
compared to those that were not across the three categories of 
multidimensional prognostic index (overall at two years follow-up, for OAC 
prescription compared with no OAC prescription, HR 0.6, 95% CI 0.6 to 0.7).191  
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More recent evidence suggests that patients with AF and frailty may have a 
similar reduction in clinical outcome events as patients without frailty. Madhavan 
et al reported that although patients with frailty were less likely to be prescribed 
OAC, that ‘the benefits of OAC were similar in patients with and without 
frailty’.325 They reported that there was no interaction between OAC use and 
frailty and the association with mortality, major bleeding and a composite end 
point of stroke, non-central nervous system systemic embolism, TIA, myocardial 
infarction or cardiovascular death. However, the authors did not report the 
hazard ratios for the reduction in events associated with OAC by frailty status. 
They present (unadjusted) Kaplan-Meier curves showing that there is 
separation of the lines for patients without frailty associated with OAC. 
However, in patients with frailty the lines do not appear to separate for the 
outcome of all-cause mortality, and there is no discernable difference by OAC 
treatment in either group for the outcome of cardiovascular death, myocardial 
infarction, stroke/systemic embolism or TIA. The authors were contacted for 
extra information, but this was not provided. In the absence of numerically 
reported outcome data, it is difficult to reconcile the apparent discrepancies 
between the author’s conclusions and the survival plots. 
 
Whilst there was a lack of clinical trial data identified in the literature review, a 
post-hoc sub-group analysis of the ARISTOTLE trial was recently published by 
Alexander et al.363 They categorised patients aged 55 years or older by the 
number of comorbidities they had at baseline: no multi-morbidity (0–2 comorbid 
conditions), moderate multi-morbidity (3–5 comorbid conditions), and high multi-
morbidity (≥6 comorbid conditions). They found that the adjusted rates of stroke 
or systemic embolism, death, and major bleeding increased with multi-morbidity 
category (compared with no multi-morbidity, moderate multi-morbidity was 
associated with HR for stroke or systemic embolism of 1.4, 95% CI 1.2 to 1.6; 
and high multi-morbidity HR 1.9, 1.6 to 2.3). The authors report that there was 
no interaction in relation to efficacy or safety of apixaban, as the difference in 
outcome rates between the warfarin and apixaban groups was not statistically 
significant overall. However, these findings should be interpreted with a degree 
of caution.  
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Firstly, selection bias is likely, whereby patients that are entered into an RCT 
may be fitter than a general population.  
Secondly, whilst the paper refers to frailty, what is actually measured is the 
number of co-morbidities a patient had at baseline, out of seventeen. The 
reason for the selection of the included co-morbidities or the cut-off points is not 
described by the authors. Such decisions are particularly susceptible to bias 
given the post-hoc nature of the analysis.  
Thirdly, the inclusion criteria age was 55 years or older, a threshold that is not 
commonly used for an entry point to consider frailty, and this choice is not 
explained. The overall age distribution of the cohort is not reported in the study, 
but as expected, the median age increased with multimorbidity group: 69 years 
(IQR 63 to 75) in the ‘no multi-morbidity’ group; 71 years (65 to 77) for 
‘moderate’ and 74 years (68 to 79) in the ‘high’ multimorbidity group.  
Fourthly, the characteristics of patients allocated to each treatment arm 
(Apixaban and warfarin) are not reported for comparison.  
Finally, the absence of a statistically significant difference between the warfarin 
and Apixaban arms does not mean that there is not a difference between the 
groups. In the absence of a reported power calculation, it is possible that the 
study was underpowered to detect a difference as a consequence of the 
relatively small number of events.  
On the basis of this analysis, a linked editorial concludes that ‘in the absence of 
contradictory evidence, the key message stands: OAC prescription should not 
be deterred by presence of multi-morbidities or frailty’, although the authors do 
call for the pooling of similar trial evidence.364  
 
9.4 Strengths and limitations  
This, to the best of my knowledge, is the first study to use a large, national 
dataset from primary care to investigate AF, frailty and clinical outcomes. As 
has been discussed, the population of patients with frailty and AF is growing, 
and yet evidence to guide optimal management of this vulnerable group is 
lacking. This study and its outputs are genuinely novel, and the questions that 
this thesis has addressed are of clinical importance.  
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The study was inclusive, with a cohort of over 500,000 older people. This large 
dataset increases the probability that the findings are generalisable to patients 
aged 65 years and over across the UK, and increases the precision of 
estimates, particularly when quantifying rare events such as intracranial 
bleeding. Whilst traditional prospective cohort studies potentially introduce 
healthy participator bias, routine data is likely to be representative of the overall 
clinical population, and better represents the data available to a treating 
clinician. The dataset is contemporaneous, with follow-up until April 2017, and 
reflects modern-day clinical practice in a real-world setting. This increases the 
likelihood that the findings are generalisable to current patients. 
 
Generally, randomised controlled trials provide the strongest evidence of an 
association between an intervention and outcome, and are considered the ‘gold 
standard’.365 A key strength of a randomised design is a lower susceptibility to 
bias, by ensuring that participants in the different groups are comparable at the 
study baseline, and that the only systematic difference between them is the 
clinical intervention that is under investigation.365 However, a RCT does not give 
insights into clinical practice in a ‘real world’ setting, and under-representative 
recruitment of older patients with more advanced frailty has limited the 
generalisability of existing studies to this population.78 There is therefore an 
important role for the cohort study, but the limitations of observational research 
must be acknowledged. Sources of bias associated with cohort studies may 
include missing data, ascertainment bias, contamination, selection bias and 
bias by indication.366 The limitations of this study specifically will now be 
discussed in the context of the literature. 
 
9.4.1 The dataset 
9.4.1.1 Coverage 
SystmOne has wide population coverage extending to 34% of general practices 
in England and Wales, and is second only to EMIS (56% of practices).276 It may 
therefore be considered nationwide and population-representative. However, 
whilst a third of primary care patients in England and Wales are registered with 
SystmOne, geographical coverage is heterogeneous. For example, it is not 
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used by any practices in some Clinical Commissioning Groups in the North 
West of England, the West Midlands, London and the South East of England.276 
This geographical clustering has the potential to introduce systematic bias 
through local variations in population demographics, referral pathways, links 
with secondary care and clinical commission group level prescribing guidelines. 
The computing and coding systems themselves may be related to heterogeneity 
in clinical recording between different software providers, and therefore any 
associated research databases, as demonstrated in a study showing that there 
is variation in the recording of quality of care indicators by which clinical 
computer system was in use at the general practice.367 These factors may 
influence the external validity of the findings of EHR from a single research 
database. A way of mitigating the risk of inductive fallacy is to undertake 
external validation in a second dataset, potentially in a different healthcare 
system. The duration of follow-up that was available in the dataset will be 
discussed in section 9.4.6. 
 
9.4.1.2 Opt-out 
Patients that ‘opt out’ of inclusion in research databases using EHR may be 
systematically different from those that assent to use of their records, which 
may introduce bias. Unfortunately, despite requests to ResearchOne, data are 
not available on the number or characteristics of patients that have opted out 
inclusion in ResearchOne. However, national figures from NHS Digital show 
that opt out rates in general are low – currently 2.8% of patients registered with 
a practice within a Clinical Commissioning Group in England have registered to 
opt out of sharing their identifiable data outside of NHS Digital for purposes 
beyond direct care.368 Whilst there is substantial variation in opt out rates 
between Clinical Commissioning Groups, in 95.2% of groups the proportion of 
patients opting out is 5% or less.368 Thus it is unlikely that this had a substantive 
impact on the reliability of the findings of this study. Moreover, I have included 
GP practice as a confounder in the time to event models, which accounts for 
variations between practices that may be a result of different opt-out rates 
between areas.   
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9.4.1.3 Missing data 
Missing data may be considered according to four categories:  
1. Missing completely at random: the probability that a data point is missing 
is not related to any other variable; 
2. Missing at random: the probability that a data point is missing does not 
depend on the value of the data-point after accounting for other known 
variables;  
3. Not missing at random: the probability that a data point is missing 
depends on the value of that data point or of another unmeasured 
variable.328  
4. Missing by design: planned missing data designs may involve randomly 
assigning participants to have missing items or measurement occasions 
in order to reduce participant burden and the cost of data collection.369 
 
Various approaches can be used to account for missing data if they are missing 
at random or completely at random, such as using a complete case analysis or 
by multiple imputation, which has the advantage of maintaining statistical power 
and mitigating potential biases introduced by excluding missing data.328 Missing 
data in EHR present particular challenges, however, as positive recording 
datasets are frequently used. For some variables, the absence of a recording 
equates to the absence of the event. For example, if a patient does not have a 
recorded prescription for OAC in a practice that uses electronic prescribing then 
it is highly unlikely that the patient is taking OAC. This is not an unreasonable 
assumption, as OAC are prescription-only medications,154 and repeat 
prescriptions are provided through primary care. However, it has been shown 
that recording of clinical outcome events in cardiovascular disease is 
incomplete in primary care records.370 For example, the absence of a CTV-3 
coded diagnosis of AF from a patient’s EHR does not mean that AF is absent 
from the patient. It is possible a diagnosis has been made in secondary care 
and has not entered the primary care record, that the diagnosis was recorded 
incorrectly in the primary care record, or was entered as free-text which is not 
available in the research database. It is also possible that the condition of 
interest may be phenotypically manifest, but not yet been diagnosed. 
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For this study, the only variables where it was possible to truly identify missing 
data were sex, age, and IMD rank. There was missing data for IMD rank, which 
was a co-variate in the adjusted models, in 6% of records. A complete case 
analysis was used for the adjusted models, which will have reduced statistical 
power to detect a difference between groups. However, there was no change in 
the direction of the associations between adjusted and unadjusted models. 
Future work may consider making use of multiple imputation to maintain the 
sample size, and could include the number of healthcare encounters as a 
predictor variable to account for the fact that each encounter gives an 
opportunity for documentation.370 This will be discussed further in the following 
section. The use of multiple linked sources of outcome data would reduce the 
probability of under-recording of key events that may otherwise be ‘missing’.294  
 
9.4.1.4 Informed presence bias 
The fact that patients that feature in EHR is not random, but rather indicates 
that the subject is ill, leads to the possibility of informed presence bias,371 
whereby more frequent interactions with healthcare professionals may give 
more opportunities for illnesses to be identified. In a trial, occurrence of a 
clinical event is often actively sought for each participant at set time intervals, so 
that the recorded incidence is not contingent on the participant’s engagement 
with the healthcare sector. However, in this study a positive recording dataset 
was used, meaning that if a patient did not seek healthcare, then no diagnosis 
would be recorded. Frailty is associated with increased healthcare utilisation, 
which may introduce a differential effect between groups. For example, people 
aged 65 years or older who were enrolled in the Irish longitudinal study on 
ageing visited their GP an average of 5 times in the year prior to enrolment 
(95% CI 4.8 to 5.2). However, this varied by frailty index category, whereby the 
robust group made an average of 3.0 (2.8 to 3.2) visits; pre-frail made 4.9 (4.7 
to 5.2) visits; and frail made 7.5 (6.9 to 8.1) visits.358 The implications of this will 
be discussed in section 9.4.4.2. 
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9.4.2 Definition of AF 
Atrial fibrillation and flutter has been analysed as a single entity throughout this 
work. However, there are clinically important distinctions based upon the pattern 
and duration of arrhythmia, and whether the patient has any concomitant 
valvular disease. These limitations will now be discussed in more detail. 
 
9.4.2.1 Sub-types of atrial fibrillation 
In this thesis, patients with atrial fibrillation/flutter were considered eligible for 
OAC prescription regardless of AF subtype (paroxysmal, persistent, long-
standing persistent or permanent 126). This is in line with NICE and ESC 
guidelines, which do not differentiate between the subtypes in their OAC 
recommendations.126, 140 However, there is some evidence that AF burden may 
influence stroke risk. In a post hoc analysis of the AMADEUS (Evaluating the 
Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With 
Atrial Fibrillation) trial, 46% (n=2,072) of the participants had non-permanent 
AF, and 54% (n=2,484) had permanent AF.372 Permanent AF was associated 
with a 59% higher risk of cardiovascular death or stroke/systemic embolism 
than non-permanent AF, (HR 1.59, 95% CI 1.04-2.44). The authors do not, 
however, report how patients were categorised into the permanent and non-
permanent groups. There was the potential for misclassification bias, as there is 
evidence that the classification of AF by a clinician into paroxysmal or persistent 
has poor correlation with objectively measured persistence as measured by 
implantable cardiac devices (Cohen's kappa 0.12, 0.05 to 0.18).138 The decision 
of the authors to use pooled data from both arms of the trial may have been 
reasonable, as the AMADEUS study concluded that idraparinux was non-
inferior to warfarin in terms of efficacy (although it did cause significantly more 
bleeding).373 Nevertheless, the post hoc nature of the study increases the 
susceptibility to bias, and no sensitivity analysis is reported stratified by drug 
treatment.372   
 
A pre-specified analysis of The ENGAGE AF-TIMI 48 trial (Effective 
Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation–
Thrombolysis in Myocardial Infarction 48) showed that the group with 
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paroxysmal AF had fewer recorded thromboembolic events than the persistent 
and permanent AF groups (1.49, 1.83 and 1.95 per 100 person-years 
respectively), an effect that was observed even after adjustment for baseline 
variables.374 
 
An observational study, from the Stockholm Cohort of AF, found that in 855 
patients with paroxysmal AF and 1,126 with permanent AF, there was no 
significant difference in ischaemic stroke over 3.6 years follow-up between 
individuals who had paroxysmal AF and individuals who had permanent AF 
(adjusted HR 1.07, 95% CI 0.71 to 1.61)e without a prior stroke.375 A similar 
study of individuals from the Loire Valley of France showed that pattern of AF 
was were not independently associated with stroke and thromboembolism (in 
multivariate analysis, paroxysmal AF was associated with HR 1.13, 0.76 to 
1.70, and permanent with HR 1.44, 0.96–2.16).376 Both studies have the same 
potential for misclassification bias with regard to AF type that was previously 
discussed.138 
 
Overall, the evidence that AF subtype may influence stroke is conflicting, and 
inclusion as a co-variate in this study would have been associated with a high 
risk of misclassification. This is due to inaccuracies in clinical categorisation,138 
and the dynamic and progressive nature of AF which may evolve in pattern from 
paroxysmal to persistent to permanent.139 The resolution of the data within 
ResearchOne is likely to be insufficient to differentiate between AF subtypes. 
For example, the code for ‘persistent AF’ was recorded in 0.41% of EHRs, 
whereas the code for ‘atrial fibrillation’ featured in 32.0%. The ESC conclude 
that the evidence that AF burden may influence stroke risk is weak, and “should 
not be a major factor” in management decisions,126 which supports the 
pragmatic approach taken in this thesis. 
 
The management of thromboembolic risk in AF differs between valvular and 
non-valvular AF, as discussed in section 1.4.6. Valvular AF usually refers to AF 
 
e Adjusted for age, sex, heart failure, hypertension, diabetes mellitus, mitral stenosis, 
previous myocardial infarction, and warfarin treatment on the latest documented 
contact or on the occasion of the event. 
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in the presence of a mechanical heart valve replacement or moderate/severe 
mitral stenosis. These are conditions that are associated with an increased 
thromboembolic risk, and therefore patients tend to have more intensive OAC 
therapy.126, 153 DOACs are not currently licenced in this clinical situation.154 As a 
consequence, patients with non-valvular AF are likely to be at increased risk of 
thromboembolic stroke, but also of bleeding complications as a consequence of 
more intensive therapy (this will be discussed further in section 9.4.5). However, 
it was not possible to differentiate between these different categories in the 
dataset, as the CTV-3 codes in use were not sufficiently specific. This is unlikely 
to have had a large impact on the results of this study, as the prevalence of 
valvular AF is relatively low. The PREFER in AF registry (Prevention of 
thromboembolic events – European Registry in Atrial Fibrillation) recorded 
valvular AF at baseline in just 1.9% of AF cases recruited in the UK.377 
 
9.4.3 Duration of AF 
Patients with higher eFI categories tended to have a longer duration of AF 
history in this study, which may theoretically have contributed to increased 
event rates in that group. It is known that persistence of AF leads to structural 
remodelling of the atria, characterized by chamber enlargement and tissue 
fibrosis.128 These changes increase the burden of atrial substrate, thereby 
sustaining the arrhythmia,127 and left atrial enlargement, in particular, has been 
associated with an increased risk of thrombus formation.125 Thus, the duration 
of AF prior to study entry could have been included as a potential confounder.  
 
The decision was taken a priori to not standardise for AF duration, on the basis 
that the quality of recording of first event was unknown, and this may have 
introduced bias that was differential across different ages as clinical records 
gradually became computerised. Should the onset of AF be accurate one could 
have included duration of AF as an adjustment within each model, but also 
undertaken analyses that examined time from diagnosis to first clinical outcome 
event. 
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Secondly, stroke risk is a dynamic phenomenon. There is evidence that even 
brief periods of atrial tachyarrhythmia identified by implantable cardiac devices 
are associated with an increased risk of stroke. A pooled analysis of 10,016 
patients with such devices showed that one hour of AF was associated with a 
HR for ischaemic stroke of 2.1 (95% CI 1.2 to 3.6), but the risk of stroke was 
increased after just five minutes of arrhythmia (HR 1.8, 1.02 to 3.02).378 
However, a definitive temporal relationship between episodes of AF and stroke 
is yet to be established. The Asymptomatic AF and Stroke Evaluation in 
Pacemaker Patients and the AF Reduction Atrial Pacing Trial (ASSERT) 
showed that of the 51 patients who experienced a stroke or systemic embolism 
during follow-up, only 4 (8%) had subclinical AF detected by their device in the 
30 days prior to their stroke.379 The Apixaban for the Reduction of Thrombo-
Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation 
(ARTESiA) trial aims to identify whether OAC is beneficial in this setting.380 
 
Thirdly, there is a risk of over-adjustment by including prior duration of AF, 
which is a component of the eFI, as a confounder in the Cox regression model. 
Future work could include sensitivity analyses to evaluate the impact of duration 
of AF on the associations measured. 
 
9.4.4 Ascertainment of exposures and outcomes 
9.4.4.1 Coding 
Coding of the source clinical data within general practice is likely to be 
imperfect. In the Newcastle 85+ Study, health assessment identified 
participants with clinical evidence of disease that was not in the medical notes, 
including hypertension, ischaemic heart disease and AF.370 It is possible that 
these were diagnoses that were previously unidentified, or alternatively that 
these diagnoses were known but not correctly recorded in the primary care 
records.273, 367 This could have led to systematic underestimation of the 
conditions of interest. Secondly, differentiating between a current condition and 
a past medical history of a condition is problematic in a positive recording 
dataset. This is unlikely to have been a significant limitation in this study, as 
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resolved AF was considered in the AF category, and outcome events were 
analysed by the first recorded episode. 
 
The code-lists used within the study to identify every condition of interest were 
carefully identified using existing code lists and hand searching the NHS clinical 
code list browser, with decisions made for inclusion or exclusion based upon 
clinical expertise. Still, these judgements are subjective and subject to the 
potential for error. In future work, code lists should be defined using a more 
formal approach. Watson et al recommend using a three-stages.381 Firstly, 
clearly define the clinical feature of interest. Next, use software to 
comprehensively search all available codes that are potentially of interest. 
Finally, they suggest using a modified Delphi process to reach consensus 
including a measure of uncertainty, which can be used for sensitivity analysis. 
This approach is rigorous, but time-consuming, and unfortunately was not 
feasible within the time constraints of this project. Instead, I have adopted an 
approach recommended by Bhattarai et al: my reporting of case definitions has 
been transparent, and I have conducted a sensitivity analysis with an 
alternative, more stringent, code-list.273 
 
The sensitivity analysis restricting the cohort to a more specific definition of AF 
showed no change in the direction of associations that were demonstrated in 
the main analyses but did increase the effect size of the association. The 
probable effect of excluding the five CTV-3 codes outlined was to limit the 
cohort to those most likely to benefit from OAC. By removing patients with an 
irregularly irregular pulse may have taken patients out of the cohort that had 
ventricular ectopy rather than AF and were therefore did not have an indication 
for OAC. It may also have removed patients that were too unwell to attend the 
GP for a confirmatory ECG, who may also be less likely to benefit from OAC, 
but in this case due to competing risks for death. Removing patients that had 
been provided with written information about AF could have led to a purer AF 
cohort, as being given written information does not necessarily mean that 
individual has a diagnosis of AF – it could be that they had an affected relative 
and were interested in learning more. These patients would therefore not have 
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an indication for OAC themselves. The exclusion of patients that had exception 
reports for QOF as their only identifying feature of AF were excluded, as it was 
felt that this alone was insufficient to diagnose AF. This will have had the effect 
of removing some patients that did not have AF, but also of removing patients 
that had valid clinical reasons for not being prescribed OAC. In each case, 
restricting the cohort was likely to strengthen the observed association, which is 
what was observed. 
 
This finding lends support to the conclusions of the main analyses, but in my 
view, should not supplant the main analysis. Firstly, post-hoc changes of the 
analytical plan have the potential to introduce bias. Secondly, one of the key 
objectives was to evaluate whether frailty modifies the association between 
OAC and clinical outcomes in patients with AF in an unrestricted population of 
people aged 65 or over. For this question, it is important to be as inclusive as 
possible. As frailty itself has been identified as a reason by physicians for non-
prescription of OAC,382 excluding patients where a clinical decision of ineligibility 
has been made is likely to exclude some of the core group of particular interest. 
Rather, future work could include a subgroup analysis of patients that were 
deemed ineligible, and their characteristics and clinical outcomes described in 
detail. 
 
9.4.4.2 Frailty 
Whilst there is general acceptance that frailty describes a ‘state of increased 
vulnerability to poor resolution of homoeostasis after a stressor event, which 
increases the risk of adverse outcomes’,10 there is currently no consensus on 
how to operationalise the concept into clinical practice. This study used the eFI 
to identify patients with frailty. The reasons for this choice were that the eFI has 
been validated both in ResearchOne and externally, has robust predictive 
validity for outcomes of mortality, hospitalisation and nursing home admission, 
and has been nationally implemented.11, 219 As previously discussed, the eFI is 
based upon the cumulative deficit model of frailty as a theoretical framework.10, 
36 The phenotype model offers an alternative approach to considering frailty,30 
and could be a useful addition to any future prospective work. The inclusion of a 
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frailty index with a greater weighting for functional impairment, which contributes 
only one deficit to the eFI, may also yield interesting insights.356 
 
Recent work has shown that whilst the eFI is a strong predictor of mortality at a 
population level, but at an individual level single time point frailty scores have a 
low predictive value for mortality in older adults.383 However, the eFI is not 
solely a tool for mortality prediction, but an instrument for identifying patients 
that are particularly vulnerable to a range of adverse outcomes. Mortality is a 
useful outcome to measure the predictive validity of a frailty index because it is 
available, dichotomous, non-arbitrary and relevant.37 
 
In this study, frailty was treated as a categorical variable throughout using the 
cut-points defined within the eFI.11 However, there is potentially large clinical 
heterogeneity within each category, particularly in the severe frailty category 
which encompasses patients that may be medically stable and also patients 
that are terminally ill.11, 60 Using the eFI as a continuous variable would have 
accounted for this to some extent. Many studies in the literature take an 
alternative approach and consider frailty as binary, or use the categories of 
robust, pre-frail and frail. In this study, the decision to use the eFI categories as 
validated in the original work means that the results may be readily interpreted, 
and will hopefully be more easily translated into clinical practice.  
 
As discussed previously, there is an association between the number of times 
that a patient encounters a healthcare professional and their underlying health 
state.358 At each encounter, there is a new opportunity for a diagnosis to be 
added to the EHR, which could potentially be a deficit of a frailty index. It is 
therefore feasible that the association reported by Roe et al (discussed in 
section 9.4.1.4) between frailty category and healthcare provider utilisation in 
the 12 months prior to frailty assessment is as a consequence of deficits 
accumulated during those appointments.358  Similarly, in this thesis there may 
have been systematic differences in the recording of clinical events between 
patients with different categories of frailty due to differences in the number of 
times they encounter healthcare professionals. This is particularly relevant to 
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the case ascertainment of AF which is frequently a sub-clinical phenomenon,138 
and may therefore lead to a relatively greater rate of AF diagnosis in patients 
with frailty. Any potential biases in recording related to health seeking behaviour 
is likely to be lower in the clinical outcomes of this study, as they are sufficiently 
serious that healthcare professionals are likely to have been involved (stroke, 
intracranial or gastrointestinal bleeding, death), and therefore recorded in the 
EHR. In future work, one could consider the impact of the number of healthcare 
encounters as a sensitivity analysis.371 This was not undertaken as a part of this 
thesis, as the size of the dataset and the complexity of the structure with which 
events are recorded meant that this was not feasible within the timeframe. 
 
9.4.5 Oral anticoagulation 
The recording of medication prescriptions in ResearchOne was highly detailed, 
allowing analysis of the impact of OAC persistence on clinical outcomes. A 
further strength of this study was the inclusion of DOAC, which make up an 
increasing proportion of OAC prescriptions.188 In this study, 23.7% (n=7,329 of 
patients that were prescribed OAC at study entry were prescribed a DOAC. This 
is important in an era of rapid change in DOAC usage – In CPRD and 
QResearch, warfarin use declined between 2011 and 2016 from accounting for 
98% of OAC prescriptions to 23%. The rate that different DOAC agents were 
prescribed was highly dynamic during that interval – for example, Dabigatran 
was licenced in 2008, reached a peak of 10% of all OAC prescriptions in 2013, 
but this dropped to 3% in 2016 as Rivaroxaban and Apixaban became more 
common choices.188 
 
There were limitations to the approach taken to analyse OAC data. Prescription 
information was available, but we did not have data on treatment concordance. 
This limitation is shared with most clinical trials and other observational 
studies.149-152, 188 It is known that warfarin management generally is suboptimal - 
a meta-analysis showed that patients taking warfarin spent just 63.6% of time 
(95% CI 61.6 to 65.6) with an INR in the therapeutic range.384 However, we did 
not have access to INR data as part of this study to account for this. Nor did we 
have access to blood results or weight measurements that would have allowed 
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an analysis to assess the appropriateness of DOAC dose adjustments, 
therefore an assumption was made that the dosing was correct for the 
individual. This assumption is not ideal, as there is evidence from registry data 
that almost a third of patients may not be on the correct dose of DOAC.385 In the 
absence of INR results or the data needed to check dose adjustments, a 
decision was taken to treat OAC as binary – prescribed OAC, or not prescribed 
OAC. This is a limitation, as there is evidence that different agents are 
associated with different efficacy and safety profiles.188 As prescription of 
parenteral anticoagulation is not recommended in chronic AF, only oral agents 
were included.126, 140, 289, 386  
 
In order to reflect real world practice, patients with prior use of OAC before AF 
onset were not deselected, and so there are patients in the AF cohort with other 
concomitant indications for OAC such as pulmonary embolism or deep vein 
thrombosis. Nonetheless, the OAC prescription or target therapeutic range 
would be the same as that for AF.154, 386 In patients with a mechanical heart 
valve, a greater intensity of OAC with warfarin is indicated. In patient with AF 
alone, the target INR is usually 2.5. An INR target of 2.5 is also recommended 
in patients with a modern mechanical valve replacement in the aortic position, 
meaning that the risk of bleeding is theoretically the same as for AF alone.  
However, in patients with one of the older mechanical valves (Lillehei-Kaster, 
Omniscience, Starr-Edwards, Bjork-Shiley and other tilting-disc valves) in the 
mitral position, the recommended target INR is 4, which is associated with a 
greater risk of bleeding complications.386 As discussed in section 9.4.2.1, it was 
not possible to identify patients with valvular AF within the cohort, but patients 
with mechanical heart valves are likely to account for around 1.9% of patients 
with AF in the UK,377 of whom a small number are likely to have a first 
generation mechanical heart valve, and no evidence has been identified that 
shows a differential prevalence of valvular AF by frailty category. In view of 
these factors, it seems unlikely that the findings of this study would be 
significantly affected by the limitations in the available OAC data that has been 
outlined. 
 
  
 
254 
9.4.6 Outcomes 
The major outcomes studied in this thesis are clearly and transparently defined, 
and are relevant to patients with AF as well as clinical practice.292 The results of 
the analyses have been discussed in the context of the literature in section 9.3. 
 
Limitations in the ascertainment of the clinical outcomes were discussed in 
section 9.4.4. Additional limitations include a relatively short follow-up period 
(mean of 15 months), but the large sample size meant that 671,135 person-
years of data were available for analysis of which 74,238 person-years of 
follow-up were in patients with AF. During the study, 24,254 participants died 
(4.5%). Cardiovascular-specific death rates would be useful additions to future 
work, as it is possible that in this analysis patients were censored from follow-up 
due to death, when the cause of death was a stroke. This is particularly 
important in an older population with frailty, who have competing risks for 
mortality. A further limitation as a consequence of the relatively short duration of 
follow-up is that inaccuracy in the date of death has a proportionally larger 
effect. In this study, mortality was established from clinical records, rather than 
data linked to the Office for National Statistics (ONS). This has the potential for 
inaccuracy: a study of 118,571 deaths using a CPRD dataset linked to ONS 
death records found that in 7.8% of cases the recorded dates differed between 
the two sources by more than two weeks.387 In this study, there was the addition 
limitation of the ‘rounding’ of the date of death to comply with Health Research 
Authority guidance for confidentiality.293 
 
The decision to evaluate time to first event, rather than including multiple events 
in the analysis is a commonly used,349 but cautious approach. An alternative 
would be to consider codes that were recorded within a pre-specified timeframe 
as belonging to the same clinical event. However, in the absence of a linked 
dataset this approach is highly subjective and may introduce bias. Future work 
using a linked dataset would mitigate this, as a new episode of any of the main 
outcome events is likely to be marked by an admission to hospital. A linked 
dataset is also likely to enable more complete ascertainment of clinical outcome 
events. Recent work in patients with AF using CPRD data linked to hospital 
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episodes statistics has shown that coding of inpatient bleeding events in their 
primary care record was incomplete.294 Overall, just 39% of intra-cranial bleeds 
and 14% of gastrointestinal bleeds were coded in their primary care record in 
the subsequent 12 weeks. In these CPRD data, the probability of having a 
bleed recorded in the primary care record were higher in patients that were 
prescribed an OAC compared with those that were not prescribed an OAC (OR 
2.3, 95%CI 1.6 to 3.2).294 This discrepancy between groups has the potential to 
introduce bias, although an apparent excess of bleeding events in the group 
prescribed OAC was not identified in this thesis. Future work could also 
investigate how well systemic embolism is represented in primary care data, as 
inclusion of this outcome would make the results more easily comparable with 
the clinical trials, as mentioned in section 9.3.6.149-152 
 
9.4.7 Confounding by indication 
Where a variable is an independent risk factor for the outcome, is associated 
with the exposure, and is not an intermediate variable between the exposure 
and the outcome, then the variable is considered a confounder.388 In this study, 
adjustments were made to account for differences in potential confounders 
between groups, such as age, sex and deprivation. Confounding by indication is 
where the clinical indication for selecting a treatment also affects the 
outcome.388 An example of this is severity of illness, where more severe cases 
have a worse clinical outcome, and illness severity also affects a clinician’s 
choice of treatment. In this study, patients with the most advanced 
multimorbidity may be at highest risk of stroke, and the presence of advanced 
multimorbidity may also affect whether or not a clinician prescribes OAC, which 
gives rise the potential for confounding by indication. This presents a challenge 
when investigating the impact of frailty, as differences in baseline risk of 
adverse clinical events are fundamental to the concept.10 This study 
demonstrated that patients with frailty were more likely to be prescribed OAC 
than those without frailty, but that there was no statistically significant interaction 
by frailty category in the association between OAC prescription and the 
reduction in stroke and all-cause mortality, whereas the reverse may be 
expected if there was substantial confounding by indication. Further work could 
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use propensity score analysis to account for systematic differences (except for 
frailty category) between patients that were prescribed OAC and those that 
were not, with weighting of the survival models by propensity score.389, 390 This 
advanced statistical analysis is beyond the scope of this project, and therefore 
the risk of confounding by indication must be acknowledged as a limitation. 
 
9.5 Implications of the study 
 
To the best of my knowledge, this thesis reports the first systematic review of 
the existing evidence in AF and frailty, and is the first study to report the 
utilisation and clinical outcomes of OAC in patients with frailty in an unselected 
primary care cohort.  
 
The thesis reports the burden of AF and frailty, and the clinical characteristics of 
patients with these conditions. This may be of use to policy makers and care 
providers in planning the provision of health and care services for this large and 
growing population. In particular, this study has shown that AF affects over one 
in ten people aged 65 years or over in a community setting. A diagnosis of AF is 
associated with a greater burden of frailty, and a higher incidence of adverse 
clinical outcomes than in people without AF, including all-cause mortality, 
stroke, and bleeding events. In people aged 65 years or over with AF, frailty 
was associated with a greater risk of mortality, stroke, intracranial bleeding and 
gastrointestinal bleeding. In this cohort, frailty was associated with an increased 
rate of OAC prescription.  
 
In those aged 65 years or older with AF and a CHA2DS2-Vasc score of two or 
more, OAC prescription was associated with a lower rate of all-cause mortality 
and stroke. However, there was no statistically significant difference in the 
outcomes of gastrointestinal or intracranial bleeding between those prescribed 
OAC and those that were not. 
 
Of note, 89% of those aged 65 years or over with AF have concomitant frailty, 
suggesting a high degree of clinical complexity amongst this group. In the face 
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of multiple competing health priorities, single-organ guidelines may be 
challenging for clinicians to implement. They may also feel that the 
recommendations may not be applicable to patients with frailty due to limitations 
in the studies on which they are based. However, in this study, OAC was 
associated with improved mortality and stroke rates, with no statistically 
significant interaction by frailty category. Overall, just over half of patients that 
were considered eligible for OAC were prescribed OAC, suggesting that 
existing clinical guidelines on stroke prophylaxis are not being followed.  
 
My findings of a reduction in stroke and all-cause mortality associated with 
OAC, without an apparent increase in bleeding complications is of clinical 
importance, and is in line with the recently published post-hoc analysis of the 
ARISTOTLE study,363 although both studies may be underpowered to detect a 
difference between the groups in these rare events. However, the data from this 
thesis and the above analysis lend support to the suggestion that in the 
absence of contradictory evidence, the presence of frailty should not 
necessarily deter prescription of OAC.364 Ultimately, the most robust estimates 
of the risks and benefits of OAC in older people with frailty would come from a 
randomised trial with the inclusion of pre-specified, formal frailty measurement. 
However, as OAC is an established therapy with a robust evidence base for 
stroke prevention in AF, the inclusion of a placebo arm would not be considered 
ethical. A pragmatic approach may be to construct a frailty index using existing 
DOAC trial data, and to investigate whether outcomes differed by frailty status. 
 
Plans are in place for dissemination of the work. Two manuscripts are in 
preparation reporting the results of the quantitative analysis, and an abstract is 
being presented at the European Society of Cardiology Congress in Paris in 
August 2019. The systematic review and meta-analysis has been published in 
Age and Ageing,185 and the findings were presented at the British Geriatric 
Society Conference in April 2019. 
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9.6 Recommendations for future research 
In my opinion, key recommendations for further research that have emerged 
during this MD thesis include: 
1. An investigation into the factors associated with prescription, 
discontinuation and switching between OACs in older people. 
2. A study of the health trajectories of older people with frailty with and 
without AF, stratified by OAC prescription. 
3. Research into the impact of recurrent falls on the risk-benefit balance 
associated with OAC in patients with AF. 
4. Exploration of whether the mortality benefit associated with OAC is 
explained solely by a reduction in stroke and systemic embolism, or 
whether factors such as a reduction in other thromboembolic events such 
as pulmonary embolism are also significant. 
5. Using a linked-dataset with a longer duration of follow-up to externally 
validate the findings of this study. 
6. To include frailty assessment in future trials of OAC 
7. To construct a frailty index from existing trial data, and investigate 
whether outcomes differ by frailty category. 
 
There is scope for developing the work outlined in this thesis further using the 
existing dataset. In particular, the highly granular prescription data within 
ResearchOne could be used to characterise and explore the patterns of patient-
level OAC usage in clinical practice in more detail, and identify factors 
associated with prescription, discontinuation, and switching between agents. 
Qualitative work aimed at identifying the key reasons for non-prescription of 
OAC by clinicians in an era of DOAC agents would be useful alongside this 
work, to understand reasons for the discrepancy between guideline-indicated 
OAC use and the real-life experience that has been described in this thesis.  
 
Trajectories of frailty in patients with AF compared to those without AF could be 
investigated, using this dataset to quantify the rate of deficit accumulation. 
These analyses could be stratified by OAC prescription. The large amount of 
historic data could also be used to identify predictors of both frailty and AF, and 
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therefore identify patients at particularly high risk of developing these 
conditions. If this was in parallel with ongoing international projects aimed at 
modifying individual level risk factors for AF and slowing progression of frailty, 
then this could be of clinical value in an era of personalised medicine.391 
 
The extent to which recurrent falls should influence OAC prescribing is currently 
unclear.233, 299 Yet, recurrent falls is a commonly encountered clinical problem in 
patients with AF.203, 392 Research to quantify the burden of harm associated with 
OAC in patients with AF according to robustly ascertained annualised falls rates 
would be valuable to clinicians and patients in order to guide risk and benefit 
estimation in patients with AF and recurrent falls.   
 
We have secured funding for further study that will build upon the work set out 
in this thesis using a dataset linked to hospital admissions and a longer period 
of follow-up. Outcome data in a linked dataset are likely to be more reliable and 
representative than in a single primary care source,294, 387 and will be important 
validation work for the results of this thesis. Access to death certificate data 
would allow a more detailed analysis of cause-specific mortality. This could be 
used to investigate the extent to which OAC may be contributing to a reduction 
in causes of death other than stroke or systemic embolus, such as pulmonary 
embolism. A linked dataset would enable more accurate ascertainment and 
severity assessment of bleeding events, which is a key consideration. 
Ultimately, observational studies of this type have significant limitations due to 
the presence of bias and residual confounding. The best way to address these 
would be to include frailty assessment in future trials of OAC. 
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9.7 Conclusion 
 
This is the first study to investigate AF and frailty in a large primary care 
population of older people in the UK. In a cohort of over half a million patients, 
this thesis identified that AF and frailty commonly co-exist and are associated 
with particularly poor clinical outcomes. Despite a relatively high calculated risk 
of stroke amongst patients with AF, OAC was prescribed in just over half of 
those that were eligible, and in whom a DOAC was prescribed in 24%. Patients 
with AF and frailty were more commonly prescribed OAC than those without 
frailty. Prescription of oral anticoagulation was associated with a greater 
reduction in all-cause mortality with increasing frailty category, and with a 
reduction in stroke events overall. There was no statistically significant 
difference in the recorded bleeding events between patients that were and were 
not prescribed OAC. 
 
There is strong evidence from the systematic review and quantitative analysis 
that frailty is an important adverse prognostic factor in older people with AF. 
However, in this study as in others, appropriate prescription of OAC 
substantially reduced the risk of death and stroke, without a statistically 
significant increase in the risk of harm. Future work using a dataset linked to 
hospital admissions data is likely to give more robust ascertainment of bleeding 
events but will not be free of the potential biases inherent to observational 
research. A randomised clinical trial is ultimately required to evaluate the risks 
and benefits of OAC for stroke prophylaxis in older people with AF and frailty, 
however, this study found no evidence that OAC should be withheld on the 
basis that they also have frailty.  
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Appendix A CHA2DS2-Vasc codes 
 
The correspondence below is from Dr John Parry, the Clinical Director of 
SystmOne. This definition of CHA2DS2-Vasc was used in the quantitative 
analysis. 
  
What follows are the definitions of CHADSVASc terms as approved by Professor G Lip, 
Professor of Cardiovascular Medicine at Birmingham University and lead author of the 
leading paper on CHADSVASc. 
  
C: Patients who have had a recent decompensated heart failure irrespective of ejection 
fraction OR symptomatic / asymptomatic moderate or severe left ventricle impairment 
or dysfunction (by any cardiac imaging). 
 H: History of hypertension or uncontrolled blood pressure. Identified via coded event, 
antihypertensive medication or most recent blood pressure for untreated hypertension 
of >= 160/90. 
A: Age >= 75 
D:Diabetes – Type I or II. The duration is irrelevant. There is currently no data on 
diabetes resolved, neonatal and gestational diabetes. 
S: All strokes – both ischemic or haemorrhagic; TIAs included. Note: Stroke caused by 
injury / trauma from RTA not included.  Systemic embolism – arterial yes but not 
venous for the purposes of this score (venous was included in the original research but 
should not be considered a risk factor). 
V: Established myocardial infarction, peripheral artery disease, imaging showing 
complex aortic plaque or h/o angioplasty. This also includes carotid surgery, gangrene, 
leg angioplasty and leg amputation. Note that there is no distinction between STEMI / 
non-STEMI. Ischemic heart disease alone is not sufficient as the limited data appears 
to show that mild coronary-arterial trauma is not sufficiently a risk factor. Codes for 
angina should be ignored as these are often incorrectly recorded. 
  
Mechanical heart valves / bio-prosthesis should be taken as exceptional and so should 
be considered separately. These patients usually have consultant review but it is 
important that GPs choose medication correctly (e.g. warfarin only for mechanical heart 
valve). 
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A: Patient age is >= 65 or <75 
Sc: Sex Category. There is no data on gender reassignment. 
In SystmOne, we use the following codes as approximations for these definitions. 
These approximations have also been approved by Professor G Lip. 
- C - G58.. (and its children) Heart failure 
- H - XE0Ub (and its children) Hypertension 
- A - Age Patient is over 75 
- D - C10.. (and its children) Diabetes mellitus 
- S - The below codes and their children:     
  XE0VK   Transient ischaemic attack 
 X00D1   Cerebrovascular accident 
  XE0VS   Arterial embolus and thrombosis 
  XaDyM     Head and neck arterial embolus 
  X203k     Coronary embolus 
  X202x     Pulmonary thromboembolism 
  L432.     Obstetric blood-clot pulmonary embolism 
  Xa6YU     Coeliac artery embolus 
  Xa07T     Mesenteric embolus 
  Xa6Yb     Suprarenal artery embolus 
  K1380     Renal artery embolus 
  X203m     Aortic bifurcation embolus 
  XaDtF     Upper limb arterial embolus 
  XaDtI     Lower limb arterial embolus 
  Xa3fY     Peripheral arterial embolism 
- V - The below codes and their children: 
  X200E     Myocardial infarction 
  Xa0lV     Peripheral vascular disease 
  G71..     Aortic aneurysm 
  XE0VR     Intermittent claudication 
 - A – Age Patient is 65 years or older and below 75 
Sc – Patient’s gender is set as female. If any other gender is set, this will not add to the 
CHADSVASc score. 
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Appendix B Research ethic committee letter 
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Appendix C CTV-3 code lists 
The code lists below are those that featured in the ResearchOne extract, and 
were used to define the variables of interest. 
 
Activity 
limitation Y3502 Allowance / DLA applied for 
 13O5. Attendance allowance 
 13VC. Disability 
 9EB5. DS 1500 Disability living allowance completed 
 Y1558 Blue Badge disabled driver 
 Y3501 Already receiving attendance allowance / DLA 
 13V8. Has disabled driver badge 
 Y0700 Physical - motor disability    
Alcohol excess XE0b4 Alcoholic cirrhosis of liver 
 E23z. Alcohol dependence syndrome NOS 
 E010. Delirium tremens 
 J613. Alcoholic liver damage unspecified 
 E01y0 Alcohol withdrawal syndrome 
 E230. Acute alcoholic intoxication in alcoholism 
 8BA8. Alcohol detoxification 
 J611. Acute alcoholic hepatitis 
 XaKAC Alcohol consumption counselling 
 8H35. Admitted to alcohol detoxification centre 
 XaPPv Brief intervention for excessive alcohol consumptn completed 
 XE1YQ Chronic alcoholism 
 Xa1yZ Alcohol abuse 
 Xa2lt Persistent alcohol abuse 
 X3071 Alcoholic liver disease 
 XaBDY [V] Alcohol use 
 ZV6D6 [V]Alcohol abuse counselling and surveillance 
 Ua1Mm Alcohol withdrawal regime 
 Xa25J Alcoholic dementia 
 X306r Alcoholic hepatitis 
 E01.. Alcoholic psychoses 
 Xa17e Alcoholic hallucinosis 
 XE1YX Nondependent alcohol abuse 
 XaPty Brief intervention for excessive alcohol consumptn declined 
 XaX4S Extended interven for excessive alcohol consumption declined 
 XE0dF Alcoholic liver damage NOS 
 E2312 Episodic chronic alcoholism 
 J610. Alcoholic fatty liver 
 Ua1Ml Alcohol reduction programme 
 E231z Chronic alcoholism NOS 
 X20Bo Alcohol-related macrocytosis 
 XaPwp Declined referral to specialist alcohol treatment service 
 SM0z. Alcohol causing toxic effect NOS 
 XaLWu [X]Alcohol withdrawal-induced seizure 
 E011. Korsakov psychosis 
 X006u Alcohol-induced epilepsy 
 E250z Nondependent alcohol abuse NOS 
 XaPPy Extended intervention for excessive alcohol consumptn complt 
 E2500 Nondependent alcohol abuse, unspecified 
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 E01yz Other alcoholic psychosis NOS 
 E2313 Chronic alcoholism in remission 
 E2311 Continuous chronic alcoholism 
 E014. Pathological alcohol intoxication 
 XaIN4 Under care of community alcohol team 
 X0053 Wernicke encephalopathy 
 Eu104 [X]Men & behav dis due alcohl: withdrawl state with delirium 
 Xa7On Alcoholism counselling 
 XaJni Alcohol disorder monitoring 
 Eu103 [X]Mental and behav dis due to use alcohol: withdrawal state 
 E2302 Episodic acute alcoholic intoxication in alcoholism 
 E01z. Alcoholic psychosis NOS 
 XE1ZF [X]Mental & behav dis due to use alcohol: psychotic disorder 
 XaamS In-house alcohol detoxification 
 XaA1V Ethanol abuse 
 E2310 Unspecified chronic alcoholism 
 E2300 Acute alcoholic intoxication, unspecified, in alcoholism 
 F11x0 Alcoholic encephalopathy 
 E2502 Nondependent alcohol abuse, episodic 
 E011z Alcohol amnestic syndrome NOS 
 E015. Alcoholic paranoia 
 XE1Xu Other alcoholic dementia 
 XE1ZG [X]Men & behav dis due alcoh: resid & late-onset psychot dis 
 Eu106 [X]Mental and behav dis due to use alcohol: amnesic syndrome 
 E2501 Nondependent alcohol abuse, continuous 
 XE1ZE [X]Mental and behav dis due to use alcohol: dependence syndr 
 Eu101 [X]Mental and behav dis due to use of alcohol: harmful use 
 E0112 Wernicke-Korsakov syndrome 
 E01y. Other alcoholic psychosis 
 X00Rk Alcoholic dementia NOS 
 SM0.. Alcohol causing toxic effect 
 XaLrN Alcohol abuse monitoring 
 E0111 Korsakov's alcoholic psychosis with peripheral neuritis 
 XaBE3 Chronic alcoholic hepatitis 
 ZV113 [V]Personal history of alcoholism 
 Xa1bS Othello syndrome 
 E0120 Chronic alcoholic brain syndrome 
 Eu10z [X]Ment & behav dis due use alcohol: unsp ment & behav dis 
 Eu10y [X]Men & behav dis due to use alcohol: oth men & behav dis 
 XSBcu Alcohol rehabilitation 
 X3072 Alcoholic fibrosis and sclerosis of liver 
 E2503 Nondependent alcohol abuse in remission 
 XaLsx Delivery of rehabilitation for alcohol addiction 
 XaKAo Alcohol counselling by other agencies 
 X3073 Alcoholic hepatic failure 
 E2303 Acute alcoholic intoxication in remission, in alcoholism 
 E230z Acute alcoholic intoxication in alcoholism NOS 
 XacTX Emergency dept attendanc related to personl alcohl consumptn 
 XaPmB Advised to contact primary care alcohol worker 
 du5.. Acamprosate calcium    
Anaemia C2620 Folic acid deficiency 
 XE13c Iron deficiency anaemia 
 D00.. Iron deficiency anaemias (& [hypochromic - microcytic]) 
 XM05A Anaemia 
 42T2. Serum vitamin B12 low 
 66E5. B12 injections - at surgery 
 i312. Hydroxocobalamin 1mg/1mL injection 
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 XE2ro Pernicious anaemia 
 XE13b Deficiency anaemias 
 XE140 Anaemia unspecified 
 X20Bw Microcytic anaemia 
 42R41 Ferritin level low 
 C2621 Cobalamin deficiency 
 D00zz Iron deficiency anaemia NOS 
 D011z Other vitamin B12 deficiency anaemia NOS 
 Xa7n0 Normocytic anaemia 
 Xa9Aw Vitamin B12-deficient megaloblastic anaemia 
 Dyu06 [X]Vitamin B12 deficiency anaemia, unspecified 
 D001. Iron deficiency anaemia due to dietary causes 
 X20Bu Anaemia of chronic disorder 
 D00y1 Microcytic hypochromic anaemia 
 1451 H/O: anaemia - iron deficient 
 XE13g Other vitamin B12 deficiency anaemias 
 XE13h Vitamin B12 deficiency anaemia due to dietary causes 
 D000. Anaemia due chron blood loss: [iron defic] or [normocytic] 
 XE13x Acute posthaemorrhagic anaemia 
 X20CA Megaloblastic anaemia due to dietary causes 
 XE14W B12 deficiency anaemia (& other) 
 X20Bv Anaemia of renal disease 
 X20C6 Macrocytic anaemia 
 XaCLx Anaemia secondary to renal failure 
 D010. Pernicious anaemia (& [Biermers][congen def intrins factor]) 
 D21z. Anaemia: [unsp][secondary NOS][normocyt/macrocyt unsp cause] 
 XE13d Iron deficiency anaemia due to chronic blood loss 
 Dyu00 [X]Other iron deficiency anaemias 
 D214. Chronic anaemia 
 D00z2 Idiopathic hypochromic anaemia 
 D00y. (Kelly-Paterson's)/(Plumm-Vinson's)/(oth sp iron def anaem) 
 X20Br Secondary anaemia NOS 
 X20C8 Megaloblastic anaemia 
 D012z Folate deficiency anaemia NOS 
 D2z.. Other anaemias NOS 
 D0... Deficiency anaemiasm (& [asiderotic] or [sideropenic]) 
 Dyu02 [X]Other vitamin B12 deficiency anaemias 
 D00z. Unspecified iron deficiency anaemia 
 D1114 Drug-induced haemolytic anaemia 
 1452 H/O: Anaemia vit.B12 deficient 
 D1... Haemolytic anaemia 
 Xaa65 Recurrent anaemia 
 i1... Oral iron for iron-deficiency anaemias 
 D11.. Acquired haemolytic anaemia 
 1453 H/O: haemolytic anaemia 
 X20Bp Normocytic anaemia due to unspecified cause 
 i2... Parenteral iron for iron-deficiency anaemias 
 D012. Folate-deficient megaloblastic anaemia 
 145.. H/O: blood disorder (& [anaemia]) 
 XE13o Autoimmune haemolytic anaemia 
 D01.. Anaemia: [megaloblastic] or [other deficiency] 
 X20C9 Megaloblastic anaemia NOS 
 XaCLy Anaemia secondary to chronic renal failure 
 XaYv2 Refractory anaemia with multilineage dysplasia 
 D014. Protein-deficiency anaemia 
 Dyu22 [X]Anaemia in other chronic diseases classified elsewhere 
 D00yz Other specified iron deficiency anaemia NOS 
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 D20.. Aplastic anaemia 
 XE14S (Anaem: [iron def][microcyt]) or (Kelly-Pat) or (Plumm-Vins) 
 X20C7 Macrocytic anaemia of unspecified cause 
 Dyu03 [X]Other folate deficiency anaemias 
 D011. Vitamin B12 deficiency anaemia (& pleural) 
 D210. Sideroblastic anaemia 
 Dyu01 [X]Other dietary vitamin B12 deficiency anaemia 
 1454 H/O: anaemia NOS 
 D0130 Combined B12 and folate deficiency anaemia 
 D0110 Vit B12 def anaem: [diet][Imersl-Grasbeck][Imerslund][Vegan] 
 D104. (Thalassaemia (& Mediterr anaemia)) or (leptocytosis, hered) 
 X20CK Refractory anaemia 
 D21.. Other and unspecified anaemia 
 D2010 Aplastic anaemia due to chronic disease 
 Dyu1. [X]Haemolytic anaemias 
 XE13i Folate deficiency anaemia due to dietary causes 
 XE13e Other specified iron deficiency anaemia 
 D212. Anaemia in neoplastic disease 
 D110. (Autoimmun haemolyt anaemia) or (Coombs positive haemolysis) 
 D106. Sickle cell anaemia 
 X20Ce Warm autoimmune haemolytic anaemia 
 B9371 Refractory anaemia with sideroblasts 
 BBmA. [M] Refractory anaemia with sideroblasts 
 D0z.. Deficiency anaemias NOS 
 D21yz Other specified anaemia NOS 
 D110z Autoimmune haemolytic anaemia NOS 
 D1111 Microangiopathic haemolytic anaemia 
 XE14U Anaemia: [deficiency excluding iron] or [megaloblastic] 
 D01z0 [X]Megaloblastic anaemia NOS 
 D0111 Vit B12 defic anaemia due to malabsorption with proteinuria 
 D2y.. Other specified anaemias 
 XE13f Other deficiency anaemias 
 XE14i Other anaemias 
 D210z Sideroblastic anaemia NOS 
 Xa9FH Normocytic anaemia following acute bleed 
 Xa3ev Nutritional anaemias NOS 
 XaM6S Hypoplastic haemolytic and renal anaemia drugs Band 1 
 D0122 Folate deficiency anaemia, drug-induced 
 ByuHC [X]Refractory anaemia, unspecified 
 Xa36n Cold autoimmune haemolytic anaemia 
 D01z. Anaemia NOS: [other deficiency] or [megaloblastic] 
 D1060 Sickle cell anaemia of unspecified type 
 Dyu24 [X]Other specified anaemias 
 D20z. Aplastic anaemia NOS 
 D1z.. Haemolytic anaemias NOS 
 D1y.. Other specified haemolytic anaemias 
 Xa0Sf Refractory anaemia with excess blasts 
 Dyu0. [X]Nutritional anaemias 
 D104z (Mediterranean anaemia) or (thalassaemia NOS) 
 D2017 Transient hypoplastic anaemia 
 D013. Other specified megaloblastic anaemia NEC 
 B9372 Refractory anaemia with excess of blasts 
 D21yy Other specified other anaemia 
 D2... Aplastic and other anaemias 
 D00z1 Chlorotic anaemia 
 D0y.. Other specified deficiency anaemias 
 D00z0 Achlorhydric anaemia 
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 D1100 Primary cold-type haemolytic anaemia 
 D013z Other specified megaloblastic anaemia NEC NOS 
 XE13q Constitutional aplastic anaemia 
 XE13w Acquired aplastic anaemia NOS 
 D1101 Primary warm-type haemolytic anaemia 
 D0123 Folate deficiency anaemia due to malabsorption 
 X20CG Combined deficiency anaemia 
 XE13t Acquired aplastic anaemia 
 XE13j Other deficiency anaemias NOS 
 D0121 Anaemia: [folate def or megaloblast, diet cause]/[goat milk] 
 D01y. Other specified nutritional deficiency anaemia 
 D1110 Mechanical haemolytic anaemia 
 D0124 Folate deficiency anaemia due to liver disorders 
 D2011 Anaemia: [aplast due drug][hypoplast due drug or chem subst] 
 D204. Idiopathic aplastic anaemia 
 D2014 Aplastic anaemia due to toxic cause 
 D11z. Acquired haemolytic anaemia NOS 
 D1102 Secondary cold-type haemolytic anaemia 
 Dyu15 [X]Other autoimmune haemolytic anaemias 
 D2101 Acquired sideroblastic anaemia 
 XaBC5 [M] Refractory anaemia with excess of blasts 
 XaBDS Anaemia in ovarian carcinoma 
 Dyu23 [X]Other sideroblastic anaemias    
Atrial fibrillation 3272 ECG: atrial fibrillation 
 G5730 Atrial fibrillation 
 2432 O/E - pulse irregularly irreg. 
 XaOfa Persistent atrial fibrillation 
 XaIIT Atrial fibrillation monitoring 
 XaMGD Atrial fibrillation annual review 
 XaLFj Excepted from atrial fibrillation qual indic: Inform dissent 
 XaOft Permanent atrial fibrillation 
 XaDv6 H/O: atrial fibrillation 
 Xa2E8 Paroxysmal atrial fibrillation 
 G5731 Atrial flutter 
 Xa7nI Controlled atrial fibrillation 
 X202R Lone atrial fibrillation 
 XaLFz Atrial fibrillation resolved 
 XaEga Rapid atrial fibrillation 
 G573. Atrial fibrillation and flutter 
 XaLFi Except from atr fib quality indicators: Patient unsuitable 
 3273 ECG: atrial flutter 
 XaaUH Paroxysmal atrial flutter 
 XE0Wk (Atrial fibrillation) or (atrial flutter) 
 G573z Atrial fibrillation and flutter NOS 
 XaMDG Atrial fibrillation monitoring first letter 
 XaXrZ Referral to atrial fibrillation clinic 
 XaeUP Chronic atrial fibrillation 
 XaNRA History of atrial flutter 
 XaLFh Exception reporting: atrial fibrillation quality indicators 
 XaMFn Atrial fibrillation monitoring telephone invite 
 XaeUQ Typical atrial flutter 
 XaMDF Atrial fibrillation monitoring administration 
 XaMDH Atrial fibrillation monitoring second letter 
 XaMDI Atrial fibrillation monitoring third letter 
 X202S Non-rheumatic atrial fibrillation 
 7936A Implant intravenous pacemaker for atrial fibrillation 
 XaZdc Atrial fibrillation care pathway 
  
 
301 
 XaMDK Atrial fibrillation monitoring verbal invite 
 XaeUR Atypical atrial flutter    
Bleeding 
disorder XE24o Thrombocytopenia 
 D306. Disseminated intravascular coagulation 
 X20FX Essential thrombocythaemia 
 D30.. Coagulation disorder 
 XM1V8 Autoimmune thrombocytopenia 
 XE146 Idiopathic thrombocytopenic purpura 
 D315. Thrombocytopenia NOS 
 D3y0. Essential thrombocytosis 
 Xa8Hh Thrombocytopenic disorder 
 XaAz4 Heterozygous factor V Leiden mutation 
 X20FJ Immune thrombocytopenic purpura 
 D3130 Idiopathic purpura (& thrombocytopenic) 
 D304. von Willebrand's disease 
 X20FY Reactive thrombocytosis 
 XE145 Primary thrombocytopenia 
 XaBBu Idiopathic thrombocythaemia 
 D31.. Purpura and other haemorrhagic conditions 
 XaAyb Factor V Leiden mutation 
 X20EZ Dysfibrinogenaemia 
 D314. Secondary thrombocytopenia 
 X20Ej Thrombophilia 
 D3141 Thrombocytopenia due to drugs 
 XM0qK Haemophilia - disorder 
 D300. Congenital factor VIII deficiency 
 Xa0hN Anticoagulant excess without bleeding 
 D3z.. Clotting or bleeding disorder NOS 
 D311. Platelet defects: [qualitative][Bernard-Soulier thrombopath] 
 Xa9Ay Thrombocytopenic purpura 
 D309. Protein S deficiency 
 D3035 Factor XII deficiency 
 D3036 Factor XIII deficiency 
 X20F8 Essential thrombocytopenia NOS 
 X20EV Fibrinogen abnormality 
 X20Ek Antithrombin deficiency 
 D3133 [X]Essential thrombocytopenia NOS 
 D30z. Coagulation defect NOS 
 G756. Thrombotic thrombocytopenic purpura 
 D1111 Microangiopathic haemolytic anaemia 
 D3050 Haemorrhagic disorder due to antithrombinaemia 
 D1113 Haemolytic uraemic syndrome 
 XaAz3 Homozygous factor V Leiden mutation 
 XE14o (Other coagulation defects) or (Dissemin intravascular coag) 
 Q450. Haemorrhagic disease of the newborn 
 D31z. Haemorrhagic condition NOS 
 D3033 Factor VII deficiency 
 XE1g9 Haemorrhagic disease (& [perinatal]) 
 Xa0hM Anticoagulant-induced bleeding 
 XE149 Secondary thrombocytopenia NOS 
 D308. Haemophilia carrier 
 D302. Factor XI deficiency 
 Dyu32 [X]Other primary thrombocytopenia 
 Xa36j Heparin-induced thrombocytopenia 
 D303y Congenital deficiency of other clotting factor OS 
 X20F5 Acquired platelet disorder 
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 D3032 Factor V deficiency 
 D301. Congenital factor IX deficiency 
 D3031 Deficiency of factor II &/or prothrombin 
 XE148 Primary thrombocytopenia NOS 
 XE143 Qualitative platelet defects 
 G756z Thrombotic microangiopathy NOS 
 Dyu30 [X]Other specified coagulation defects 
 X20EE Haemophilia A carrier 
 D3034 Factor X deficiency 
 X20EX Hypofibrinogenaemia 
 X20EL Congenital von Willebrand's disease 
 D3y.. Other specified disorders of clotting or bleeding 
 D3070 Deficiency of coagulation factor due to liver disease 
 D3051 Haemorrhagic disorder due to hyperheparinaemia 
 D313y Other specified primary thrombocytopenia 
 X20F2 Cyclooxygenase deficiency 
 X20FG Hereditary thrombocytopenia NEC 
 Xa0lB Afibrinogenaemia 
 D311z Qualitative platelet deficiency NOS 
 XE147 Congenital thrombocytopenic purpura 
 XaB8v Idiopathic factor VIII deficiency 
 X20Et Bernard-Soulier syndrome 
 D303. Congenital deficiency of other clotting factors 
 X20EH Factor IX deficiency 
 X20FK Autoimmune thrombocytopenic purpura 
 D305z Haemorrhagic disorder due to circulating anticoagulants NOS 
 D305. Haemorrhagic disorder due to circulating anticoagulants 
 D31y. Other specified haemorrhagic conditions 
 D314y Other specified secondary thrombocytopenia 
 D31yz Other specified haemorrhagic condition NOS 
 XaYgo Hereditary thrombophilia 
 D3072 Acquired factor II deficiency 
 XE2rp Post-transfusion thrombocytopenic purpura 
 X20EN Congenital von Willebrand's disease type II 
 X20EP Acquired von Willebrand's disease 
 XE141 Factor II deficiency 
 X20EM Congenital von Willebrand's disease type I 
 X20EF Haemophilia A with inhibitor    
Cancer B34.. Malignant neoplasm of female breast 
 C332z Paraproteinaemia NOS 
 X78gO Adenocarcinoma of colon 
 B46.. Malignant tumour of prostate 
 XaIyc Cancer care review 
 B1101 Malignant neoplasm of cardio-oesophageal junction of stomach 
 X78Xw Squamous cell carcinoma of vulva 
 Xa9Jk Metastasis to lower limb lymph node 
 B3... [Mal neop][carc] bone (& [sarc]), connect tiss, skin, breast 
 B4y.. Malignant neoplasm of genitourinary organ OS 
 Xa9Jm Metastasis to intrapelvic lymph node 
 Byu6. [X]Malignant neoplasm of breast 
 B641. Chronic lymphoid leukaemia 
 XaZdn Diffuse large B-cell lymphoma 
 B133. Malignant tumour of sigmoid colon 
 B496. Malignant tumour of ureteric orifice 
 X78Y6 Carcinoma of prostate 
 Xa0KG Malignant tumour of lung 
 XE1vc Malignant neoplasm of bronchus or lung NOS 
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 XE1vb Malignant neoplasm of upper lobe, bronchus or lung 
 B134. Malignant neoplasm of caecum (& carcinoma) 
 B13.. Malignant tumour of colon 
 X78ef Malignant tumour 
 B650. Acute myeloid leukaemia 
 B65.. Myeloid leukaemia 
 X78iu Malignant tumour of kidney 
 Xa0G9 Squamous cell carcinoma of tongue 
 B17.. Malignant tumour of pancreas 
 Xa0TG Diffuse malignant lymphoma - large cell 
 B307. Malignant neoplasm of long bones of leg 
 Xa0DF Adenocarcinoma of oesophagus 
 X78j2 Transitional cell carcinoma of bladder 
 B49z. Malignant neoplasm of urinary bladder NOS 
 XE1vW Malignant tumour of rectum 
 X78it Malignant tumour of urinary tract 
 B49.. Malignant tumour of urinary bladder 
 XaFrL Local recurrence of malignant tumour of urinary bladder 
 XaYii Extranod marg zone B-cell lymphom mucosa-assoc lymphoid tiss 
 Xa36r Carcinoma of cervix 
 Xa34H Carcinoma of sigmoid colon 
 X78gM Carcinoma of caecum 
 X78QP Squamous cell carcinoma of lung 
 B577. Metastasis to liver 
 B2221 Malignant neoplasm of upper lobe of lung 
 B34z. Malignant neoplasm of female breast NOS 
 X78gA Carcinoma of stomach 
 XaYim Follicular lymphoma grade 3b 
 B060. Malignant tumour of tonsil 
 B4A1z Malignant neoplasm of renal pelvis NOS 
 ByuDC [X]Diffuse non-Hodgkin's lymphoma, unspecified 
 Xa0l6 Paraproteinaemia 
 Xa0Ge Carcinoma of larynx 
 X78eE Malignant tumour of head and neck 
 X78gN Malignant tumour of large intestine 
 Xa0SY Myelodysplastic syndrome 
 B61.. Hodgkin's disease 
 B65y1 Acute promyelocytic leukaemia 
 Xa97q Malignant tumour of liver 
 X78gK Malignant tumour of intestine 
 XE11b Monoclonal paraproteinaemia 
 X78XO Endometrial carcinoma 
 X78OK Adenocarcinoma of rectum 
 B627. Non-Hodgkin's lymphoma - disorder 
 XaDc7 Carcinoma of descending colon 
 XE20N Multiple myeloma etc. 
 B630. Myeloma 
 X78io Teratoma of testis 
 Xa0SP Myeloproliferative disorder 
 B934. Polycythaemia rubra vera 
 XaBmX Adenocarcinoma of uterus 
 XE1xL Carcinoma of colon 
 X78Yx Clear cell carcinoma of kidney 
 B585. Metastasis to bone 
 Xa0Dp Malignant glioma of brain 
 XaFr7 Local recurrence of malignant tumour of lung 
 X78QS Non-small cell lung cancer 
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 B340z Malignant neoplasm of nipple or areola of female breast NOS 
 Xa0bT Intraduct carcinoma of breast 
 B5811 Metastasis to bladder 
 Xa0GC Squamous cell carcinoma of floor of mouth 
 B58y5 Metastasis to prostate 
 Xa3eL Carcinoma of breast - upper, inner quadrant 
 XaFrI Local recurrence of malignant tumour of colon 
 Xa84V Adenocarcinoma of sigmoid colon 
 B16.. Malignant tumour of biliary tract 
 Xa0bU Lobular carcinoma of breast 
 B141. Malignant neoplasm of rectum (& carcinoma) 
 Xa0QP B-cell chronic lymphocytic leukaemia 
 XE1xT Ca sigmoid colon 
 B13z. Malignant neoplasm of colon (& NOS) 
 Xa3AC Metastasis to colon of unknown primary 
 B35.. Malignant neoplasm of male breast 
 X78YK Carcinoma of glans penis 
 XE2t9 [X]Non-Hodgkin's lymphoma, unspecified type 
 X78cP Follicular thyroid carcinoma 
 B580. Metastasis to kidney 
 XE1vQ Malignant neoplasm of oesophagus NOS 
 B10.. Malignant tumour of oesophagus 
 X78QG Adenocarcinoma of lung 
 XaFrw Metastasis from malignant tumour of lung 
 B570. Metastasis to lung 
 B53.. Malignant tumour of thyroid gland 
 X78JO Carcinoma of submandibular gland 
 Xa980 Metastasis to lymph node 
 X78kl Metastasis to omentum 
 XaDc9 Carcinoma of splenic flexure 
 B58y0 Metastasis to breast 
 XacSF Prostate cancer care review 
 B302. Malignant neoplasm of vertebral column 
 ByuDE [X]Unspecified B-cell non-Hodgkin's lymphoma 
 Xa0ko Mixed seminoma teratoma of testis 
 X78ip Seminoma of testis 
 B4A00 Hypernephroma 
 B6275 Malignant lymphoma - mixed small and large cell 
 X78g3 Carcinoma of oesophagus 
 XE1vl Malignant tumour of adrenal gland 
 Xa36T Metastasis to vertebral column 
 Xa0Rn Chronic lymphocytic prolymphocytic leukaemia syndrome 
 X78cQ Papillary thyroid carcinoma 
 X78j1 Carcinoma of bladder 
 B4A1. Malignant tumour of renal pelvis 
 Xa982 Metastatic malignant disease 
 XaFr8 Local recurrence of malignant tumour of breast 
 B47.. Malignant tumour of testis 
 XE1vj Malignant neoplasm of vulva unspecified 
 B170. Malignant tumour of head of pancreas 
 X78Wk Endometrioid carcinoma ovary 
 X78WR Paget's disease of nipple 
 B440. Malignant tumour of ovary 
 B41.. Malignant neoplasm of cervix uteri (& carcinoma) 
 X78Xg Adenocarcinoma of cervix 
 B587. Metastasis to adrenal gland 
 XaFrJ Local recurrence of malignant tumour of rectum 
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 Xa9Jc Metastasis to head and neck lymph node 
 B5761 Metastasis to peritoneum 
 X78jy Malignant tumour of endocrine gland 
 Xa0T2 Diffuse low grade B-cell lymphoma 
 B344. Malignant neoplasm of upper-outer quadrant of female breast 
 XaBA5 Osteosarcoma of bone 
 X78iC Malignant tumour of female genital organ 
 X78e9 Malignant tumour of unknown origin 
 XE1vU Malignant tumour of caecum 
 B564z Secondary and unspec malig neop of inguinal and leg LN NOS 
 Xa0QI Lymphoproliferative disorder 
 Xa0GA Squamous cell carcinoma of gum 
 B1503 Hepatocellular carcinoma 
 B621z Mycosis fungoides NOS 
 Xa8Jb T-cell lymphoma 
 B621. Mycosis fungoides 
 B01.. Malignant tumour of tongue 
 B1... Malig neoplasm digest organs and peritoneum (& [carcinoma]) 
 XaYij Follicular lymphoma grade 1 
 X78if Malignant tumour of penis 
 Xa36a IgA myeloma 
 XE1vi Malignant tumour of cervix 
 B135. Malignant tumour of appendix 
 B4A.. Malignant renal neoplasm (& [other unspecif urinary organs]) 
 B22.. Malignant neoplasm of trachea, bronchus and lung 
 Xa99k Malignant lymphoma 
 X78Q8 Squamous cell carcinoma of bronchus 
 X78Q2 Squamous cell carcinoma of trachea 
 XM0ps Malignant melanoma of eye 
 XaDc8 Carcinoma of hepatic flexure 
 B47z. Malign neoplasm of testis: [NOS] or [seminoma] or [teratoma] 
 XM0pb Tonsil carcinoma 
 B624. Hairy cell leukaemia 
 XaFrD Local recurrence of malignant tumour of oesophagus 
 B21.. Malignant tumour of larynx 
 X78QI Carcinoid tumour of lung 
 Xa0T3 High grade B-cell lymphoma 
 Xa3eQ Carcinoma of breast NOS 
 X78Xf Squamous cell carcinoma of cervix 
 B691. Chronic myelomonocytic leukaemia 
 B4A0. Malignant tumour of kidney parenchyma 
 XE2vP Malignant neoplasm of genitourinary organ 
 B04y. Malignant neoplasm of other sites of floor of mouth 
 X78gL Malignant tumour of small intestine 
 B136. Malignant tumour of ascending colon 
 XaDc5 Carcinoma of ascending colon 
 X78bw Malignant melanoma of choroid 
 X78ke Metastasis to spleen 
 X77nQ Neuroendocrine carcinoma 
 XaEJf Squamous cell carcinoma of bronchus in left upper lobe 
 Xa0Dj Malignant melanoma of rectum 
 B616. Hodgkin's disease, lymphocytic depletion 
 Xa3Bc Metastasis to lymph node of unknown primary 
 B130. Malignant tumour of hepatic flexure 
 Xa0QQ B-cell chronic lymphocytic leukaemia variant 
 B2241 Malignant neoplasm of lower lobe of lung 
 Xa0WG Primary malignant tumour of peritoneum 
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 B4302 Malignant neoplasm of endometrium of corpus uteri 
 Xa34F Carcinoma of anal canal 
 Xa0DG Squamous cell carcinoma of oesophagus 
 X78el Squamous cell carcinoma of lip 
 B5831 Metastasis to spinal cord 
 XaEfj Cystadenocarcinoma of ovary 
 Xa0Sz Cutaneous/peripheral T-cell lymphoma 
 B140. Malignant tumour of rectosigmoid junction 
 XE1vY Malignant tumour of gallbladder 
 Xa0GN Squamous cell carcinoma of palate 
 X78Hz Carcinoma of lingual tonsil 
 XaFrH Local recurrence of malignant tumour of pancreas 
 X78gd Carcinoma of pancreas 
 XaFrp Metastasis from malignant tumour of pancreas 
 XaEJg Squamous cell carcinoma of bronchus in right lower lobe 
 B121. Malignant tumour of jejunum 
 B454. Malign neoplasm of vulva: [unspecified] or [primary cancer] 
 Xa3A5 Metastasis to lung of unknown primary 
 Xa3AE Metastasis to liver of unknown primary 
 B5830 Metastasis to brain 
 XE1wp Tongue carcinoma 
 X78e2 Leukaemia 
 XaFrM Local recurrence of malignant tumour of prostate 
 X78QN Small cell carcinoma of lung 
 B640. Acute lymphoid leukaemia 
 XaBAn Carcinomatosis 
 XaB1p Metastatic adenocarcinoma of unknown origin 
 XaFro Metastasis from malignant tumour of colon 
 B010. Malignant tumour of base of tongue 
 Xa0LD Malignant tumour of middle ear 
 B4A2. Malignant tumour of ureter 
 XaDc6 Carcinoma of transverse colon 
 XaFrx Metastasis from malignant tumour of thyroid 
 Xa3eK Ca breast - nipple/central 
 XaYv2 Refractory anaemia with multilineage dysplasia 
 XaDbr Cholangiocarcinoma of biliary tract 
 B670. (Acute erythraemia+erythroleukaemia) or( Di Guglielmo's dis) 
 Xa983 Disseminated malignancy 
 XaPQD Mantle cell lymphoma 
 B627C Follicular lymphoma: [non-Hodgkin's] or [NOS] 
 XE2vS Malignant brain tumour 
 XaEJi Squamous cell carcinoma of bronchus in right upper lobe 
 X78Wo Undifferentiated carcinoma of ovary 
 B43.. Malignant tumour of body of uterus 
 Xa0T1 Low grade B-cell lymphoma 
 B342. Malignant neoplasm of upper-inner quadrant of female breast 
 Xa9Ji Metastasis to upper limb lymph node 
 B174. Malignant tumour of Islets of Langerhans 
 B4301 Malignant neoplasm of fundus of corpus uteri 
 B18y3 Malignant neoplasm of omentum 
 B651z Chronic myeloid leukaemia NOS 
 B651. Chronic myeloid leukaemia 
 B430z Malignant neoplasm of corpus uteri NOS 
 B341. Malignant neoplasm of central part of female breast 
 X78fO Malignant tumour of pharynx 
 XaFru Metastasis from malignant tumour of breast 
 ByuHD [X]Myelodysplastic syndrome, unspecified 
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 B3121 Malig neop of connective and soft tissue thigh and upper leg 
 X78Qc Malignant mesothelioma of pleura 
 Xa3AJ Metastasis to bone of unknown primary 
 X78es Malignant tumour of oral cavity 
 X78cR Mixed follicular and papillary thyroid carcinoma 
 XE1vV Malignant neoplasm of colon NOS 
 B340. Malignant neoplasm of nipple and areola of female breast 
 Xa9Jo Metastasis to multiple lymph nodes 
 Xa0SN Non-secretory myeloma 
 XaBB3 Plasma cell leukaemia 
 XaBAp Bronchioloalveolar adenocarcinoma of lung 
 XE1vZ Malignant tumour of respiratory and intrathoracic organ 
 X78lF Carcinoma of other and unspecified sites 
 B64.. Lymphoid leukaemia 
 B586. Metastasis to ovary 
 B162. Malignant tumour of ampulla of Vater 
 XE1vp Nodular lymphoma 
 X78Xx Malignant melanoma of vulva 
 Byu51 [X]Mesothelioma, unspecified 
 X78g1 Malignant tumour of digestive organ 
 B620z Nodular lymphoma NOS 
 XE2vQ Malig neop of kidney and other unspecified urinary organs 
 X78QJ Carcinoma of lung parenchyma 
 XaELK Seminoma of descended testis 
 X78fC Malignant tumour of salivary gland 
 Xa0bK Malignant seminoma of mediastinum 
 B501. Malignant tumour of orbit 
 XaYjI Primary cutaneous CD30 antigen positive large T-cell lymphom 
 Xa36b IgG myeloma 
 Xaa1N Clinical stage A chronic lymphocytic leukaemia 
 Xa0Dr Glioblastoma multiforme of brain 
 XaZdD Follicular lymphoma grade 3 
 Xa0T4 Follicular low grade B-cell lymphoma 
 X78j4 Squamous cell carcinoma of bladder 
 Xa7n9 Transitional cell carcinoma of ureter 
 B08.. Malignant tumour of hypopharynx 
 X00eS Retinoblastoma 
 Xa0bS Malignant lymphoma of breast 
 C331. Monoclonal paraproteinaemia (& gammopathy) 
 Xa0DX Gastric lymphoma 
 B41y1 Malignant neoplasm of squamocolumnar junction of cervix 
 Xa0TS Large cell anaplastic lymphoma 
 X78LV Malignant tumour of vocal cord 
 XM0pZ Palate carcinoma 
 B0551 Malignant tumour of palate 
 Xa0Ei Carcinoma of fallopian tube 
 B441. Malignant tumour of fallopian tube 
 X78Vj Liposarcoma 
 B40.. Malignant neoplasm of uterus, part unspecified 
 XM1Pr Cerebral metastasis 
 Xa3BZ Metastasis to brain of unknown primary 
 B050. Malignant tumour of buccal mucosa 
 B112. Malignant tumour of pyloric antrum 
 B14.. Malignant neoplasm of rectum, rectosigmoid junction and anus 
 B120. Malignant tumour of duodenum 
 XaFrR Local recurrence of malignant tumour of soft tissue 
 Xa0Rp Splenic lymphoma with villous lymphocytes 
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 B51z. Malignant neoplasm of brain NOS 
 X78QK Large cell carcinoma of lung 
 X78XN Sarcoma of uterus 
 B0100 Malignant neoplasm of base of tongue dorsal surface 
 XE2rk Malignant neoplasm of lip, oral cavity and pharynx 
 XaFsw Hereditary nonpolyposis colon cancer 
 Xa97z Malignant tumour of unknown origin or ill-defined site 
 XaFrN Local recurrence of malignant tumour of cervix 
 X78PC Extrahepatic bile duct carcinoma 
 Xa9AA Plasmacytoma - disorder 
 XaB1g Carcinoma of head of pancreas 
 X78PX Carcinoma of ampulla of Vater 
 B63.. Multiple myeloma and immunoproliferative disease 
 B200. Malignant tumour of nasal cavity 
 B1z0. Malignant neoplasm of intestinal tract, part unspecified 
 B6... Malig neoplasm lympha & haemopoiet tiss (& [histiocyt tiss]) 
 B213z Malignant neoplasm of laryngeal cartilage NOS 
 Xa0TE Diffuse high grade B-cell lymphoma 
 B572. Metastasis to pleura 
 XaBBN Malignant lymphoma - lymphoplasmacytic 
 B020. Malignant tumour of parotid gland 
 XaIt4 Benign paraproteinaemia 
 B224. Malignant neoplasm of lower lobe, bronchus or lung 
 XE1zj (Carcinoma bladder) or (bladder Ca) 
 B11z. Malignant neoplasm of stomach NOS 
 XaB8h Squamous cell carcinoma of mouth 
 B10z. (Malignant neoplasm of oesophagus NOS or oesophageal cancer 
 B4Az. Malignant neoplasm of kidney or urinary organs NOS 
 Xaa1O Clinical stage B chronic lymphocytic leukaemia 
 B02z. Malignant neoplasm of major salivary gland NOS 
 B07.. Malignant tumour of nasopharynx 
 Xa1oQ Carcinoma of vocal cord 
 XE1yD Ca larynx - NOS 
 XE1y7 Ca larynx - glottis 
 X78kk Carcinomatosis of peritoneal cavity 
 Xa0DQ Late gastric cancer 
 Xa0bQ Sarcoma of breast 
 B44.. Malignant neoplasm of ovary and other uterine adnexa 
 B8yy0 Carcinoma in situ of thyroid 
 X78id Malignant tumour of male genital organ 
 Xa3eR Carcinoma genital organs 
 XE1vk Malignant neoplasm of testis NOS 
 B211. Malignant tumour of supraglottis 
 B21z. Malignant neoplasm of larynx NOS 
 B05z. Malignant neoplasm of mouth NOS 
 B132. Malignant tumour of descending colon 
 XM0Ac Carcinoma of base of tongue 
 B06.. Malignant tumour of oropharynx 
 B04.. Malignant tumour of floor of mouth 
 Xa0T9 Monocytoid B-cell lymphoma 
 B613. Lymphocyte-rich classical Hodgkin lymphoma 
 XE1vd Malignant tumour of bone and articular cartilage 
 B61z. Hodgkin's disease NOS 
 B150z Primary malignant neoplasm of liver NOS 
 B511. Malignant neoplasm of frontal lobe 
 B137. Malignant tumour of splenic flexure 
 X78gY Carcinoma gallbladder 
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 B303. Malignant neoplasm of ribs, sternum and clavicle 
 C332. Other paraproteinaemias 
 B22y. Malignant neoplasm of other sites of bronchus or lung 
 B22z. Malig neopl lung: [of bronchus or lung NOS] or [lung cancer] 
 Xa3eG Carcinoma liver/biliary system NOS 
 B5z.. Malignant neoplasm of other and unspecified site NOS 
 XaBAu Pseudomyxoma peritonei 
 X78Q7 Malignant tumour of bronchus 
 B602z Burkitt's lymphoma NOS 
 B2220 Malignant neoplasm of upper lobe bronchus 
 Xa0TX Follicular malignant lymphoma - large cell 
 Xa0WH Malignant peritoneal local recurrence 
 X78Wi Serous papillary cystadenocarcinoma ovary 
 B4A3. Malignant tumour of urethra 
 Xa0T8 Mucosa-associated lymphoma 
 B210. Malignant tumour of glottis 
 B0720 Malignant tumour of pharyngeal recess 
 B550z Malignant neoplasm of head, neck and face NOS 
 B58y3 Metastasis to vagina 
 B41z. Malignant neoplasm of cervix uteri NOS 
 X78Pq Malignant tumour of peritoneum 
 XaBAk Malignant mastocytosis 
 ByuDA [X]Oth spcf mal neoplsm/lymphoid,haematopoietic+rltd tissue 
 XaCJ1 Primary malignant neoplasm of unknown site 
 Xa97y Malignant tumour of vulva 
 B202. Malignant tumour of maxillary sinus 
 B937W (Myelodysplastic syndrome, unspecified) or (myelodysplasia) 
 X78Wl Clear cell tumour of ovary 
 B56z. Secondary and unspec malig neop lymph nodes NOS 
 XE2vj Malignant hydatidiform mole 
 B4501 Malignant neoplasm of vaginal vault 
 X78YR Carcinoma of foreskin 
 B142. Malignant neoplasm of anal canal (& anal carcinoma) 
 XaBLv Malignant neoplasm of epiglottis NOS 
 B26.. Malignant neoplasm, overlap lesion of resp & intrathor orgs 
 XE1zf Ca penis 
 XE1yF (Bronchus carc) or (lung carc) or (Ca trachea/bronchus/lung) 
 Xa0SB Large granular lymphocytic leukaemia 
 B02.. Malignant tumour of major salivary gland 
 B105. Malignant tumour of lower third of oesophagus 
 B615. Hodgkin's disease, mixed cellularity 
 B11y. Malignant neoplasm of other specified site of stomach 
 B620. (Nodular lymphoma: Brill-Symmers) or (reticulosarc foll/nod) 
 B131. Malignant tumour of transverse colon 
 ByuD8 [X]Other specified leukaemias 
 B34y. Malignant neoplasm of other site of female breast 
 XE2xB Secondary and unspecified malignant neoplasm of lymph nodes 
 XE1y9 Ca larynx - supraglottis 
 B3401 Malignant neoplasm of areola of female breast 
 B50.. Malignant tumour of eye 
 X2032 Pulmonary tumour embolism 
 B213. Malignant tumour of laryngeal cartilage 
 B053. Malignant tumour of soft palate 
 XE1yB Ca larynx - subglottis 
 B052. Malignant tumour of hard palate 
 X78j7 Malignant tumour of nervous system 
 ByuD3 [X]Other specified types of non-Hodgkin's lymphoma 
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 ByuD1 [X]Other types of follicular non-Hodgkin's lymphoma 
 B602. Burkitt's lymphoma - disorder 
 B014. Malignant neoplasm of anterior 2/3 of tongue unspecified 
 XE1wv (Ca oro/naso/hypopharynx) or (carc: [pharynx] or [tonsil]) 
 XaBLx Plasmacytoma NOS 
 XE1yT (Ca bone/artic cart) or (bone carc) or (sarc bone/art cart) 
 Xa0SL Light chain myeloma 
 XaELI Lambda light chain myeloma 
 XE1zd Ca vulva: [clitoral Ca] or [labial Ca] 
 XE1xH Ca greater curvature - stomach 
 B653. Myeloid sarcoma 
 B110. Malignant tumour of cardia 
 B35zz Malignant neoplasm of male breast NOS 
 B040. Malignant tumour of anterior floor of mouth 
 Xa3eM Carcinoma of breast - lower, inner quadrant 
 XaELL Teratoma of descended testis 
 B150. Primary malignant neoplasm of liver 
 B143. Malignant neoplasm of anus unspecified 
 B550. Malignant neoplasm of head, neck and face 
 B486. Malignant tumour of scrotum 
 B55.. Malignant neoplasm of other and ill-defined sites 
 XE1xN Ca hepatic flexure - colon 
 B58.. Secondary [malig neopl] or [carcinoma] of other specif sites 
 XE1vX Malignant tumour of anal canal 
 B0zz. Malignant neoplasm of lip, oral cavity and pharynx NOS 
 XE1zl Ca kidney/other urinary organs 
 XE20J (Lymphatic tissue carcinoma) or (lymphoma) 
 B2003 Malignant tumour of nasal vestibule 
 Byu20 [X]Malignant neoplasm of bronchus or lung, unspecified 
 Xa3Bd Disseminated malignancy of unknown primary 
 B45z. Malignant neoplasm of female genital organ NOS 
 B6531 Granulocytic sarcoma 
 XE2vO Malig neop of bone, connective tissue, skin and breast 
 B45.. Malig neop of other and unspecified female genital organs 
 B31.. Malignant neoplasm of connective and other soft tissue 
 B62x. Malignant lymphoma otherwise specified 
 XE20X Malignant neoplasm NOS (& sarcoma NOS) 
 XE1xR Ca descending colon 
 B553z Malignant neoplasm of pelvis NOS 
 B517. Malignant neoplasm of brainstem 
 B681. Chronic leukaemia NOS 
 X78Wj Mucinous cystadenocarcinoma of ovary 
 XE1wj Malignant neoplasms (& carcinoma) 
 B152. Malignant neoplasm of liver unspecified 
 X78fH Malignant tumour of ear, nose and throat 
 Xa0SI Plasma cell disorder 
 X78cS Anaplastic thyroid carcinoma 
 X78M7 Malignant tumour of neck 
 Xa0TD Follicular malignant lymphoma - small cleaved cell 
 XM0Ad Metastasis to large intestine 
 X78NL Carcinoma of duodenum 
 B3022 Malignant neoplasm of lumbar vertebra 
 XE2vT Secondary malignant neoplasm of other specified sites 
 B006. Malignant neoplasm of overlapping lesion of lip 
 B540. Malignant neoplasm of adrenal gland (& phaeochromocytoma) 
 B5602 Secondary and unspec malig neop superficial cervical LN 
 B495. Malignant tumour of bladder neck 
  
 
311 
 X78Mg Carcinoma of lower third of oesophagus 
 B481. Malignant tumour of glans penis 
 B117. Malignant neoplasm, overlapping lesion of stomach 
 B450. Malignant tumour of vagina 
 B345. Malignant neoplasm of lower-outer quadrant of female breast 
 B113. Malignant tumour of fundus of stomach 
 B43z. Malignant neoplasm of body of uterus NOS 
 XaFrE Local recurrence of malignant tumour of stomach 
 XE1z9 Ca breast-upper,inner quadrant 
 B6277 Diffuse non-Hodgkin's lymphoblastic (diffuse) lymphoma 
 B30z. Malignant neoplasm of bone and articular cartilage NOS 
 B01z. Malignant neoplasm of tongue NOS 
 B18.. Malignant tumour of peritoneum and retroperitoneum 
 XE1wn Carcinoma of lip 
 Xa0SD B-cell acute lymphoblastic leukaemia 
 X78YP Malignant tumour of skin of penis 
 X78kT Metastasis to respiratory and intrathoracic organ 
 B58y2 Secondary malignant neoplasm of cervix uteri 
 Xa3AH Metastasis to peritoneum of unknown primary 
 XE2vR Malignant neoplasm of other and unspecified sites 
 XE1zX Ca ovary/other uterine adnexa 
 B301. Malignant neoplasm of mandible 
 X78ei Carcinoma of bone, connective tissue, skin and breast 
 B58yz Secondary malignant neoplasm of other specified site NOS 
 Xa0Ri Malignant white blood cell disorder 
 Xa3eF Carcinoma liver/biliary system 
 B626. Malignant mast cell tumours 
 XE1xX Ca ascending colon 
 B31z. Malignant neoplasm of connective and soft tissue, site NOS 
 XE1xP Ca transverse colon 
 X78WP Inflammatory carcinoma of breast 
 B4701 Malignant tumour of retained testis 
 X78ks Metastasis to urinary tract 
 B081. Malignant tumour of pyriform fossa 
 X78ci Parathyroid carcinoma 
 XaFzu Malignant neoplasm of bone 
 XE1xV (Ca caecum) or (caecum carcinoma) 
 XE1zv Malign tumour eye: [Ca eye][malign melanoma][retinoblastoma] 
 XE1wt (Ca gum, + rest of mouth) or (carc: [cheek][mouth][palate]) 
 XE1zb Malig tumour testis: [carcinoma] or [seminoma] or [teratoma] 
 XaFrc Metastases by primary malignancy 
 B516. Malignant neoplasm of cerebellum 
 B4... Malignant neoplasm of genitourinary organ (& [carcinoma]) 
 B221. Malignant neoplasm of main bronchus 
 B5... Malignant neopl other unspecified sites: (& [[carcinoma]) 
 B240. Malignant tumour of thymus 
 B4100 Malignant neoplasm of endocervical canal 
 B6300 Malignant plasma cell neoplasm, extramedullary plasmacytoma 
 B5632 Secondary and unspec malig neop infraclavicular lymph nodes 
 B41y. Malignant neoplasm of other site of cervix 
 B1500 Primary carcinoma of liver 
 XE1vn Disseminated malignancy NOS 
 Byu57 [X]Malignant neoplasm of peritoneum, unspecified 
 B494. Malignant neoplasm of posterior wall of urinary bladder 
 B305D Malignant neoplasm of phalanges of hand 
 B601z Lymphosarcoma NOS 
 B20y. Malig neop other site nasal cavity, middle ear and sinuses 
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 B200z Malignant neoplasm of nasal cavities NOS 
 B514. Malignant neoplasm of occipital lobe 
 X78QO Oat cell carcinoma of lung 
 X78OP Malignant tumour of anus 
 B03.. Malignant tumour of gum 
 B507. Malignant tumour of lacrimal gland 
 Xa3eP Carcinoma of breast - axillary tail 
 X78Xq Carcinoma of vagina 
 Xa0So Acute myelofibrosis 
 X78VS Malignant mesothelioma of peritoneum 
 B5630 Secondary and unspec malig neop axillary lymph nodes 
 B5633 Secondary and unspec malig neop pectoral lymph nodes 
 X78NB Carcinoma of lesser curve of stomach 
 B5619 Secondary and unspec malig neop pulmonary lymph nodes 
 XM1Ps Cerebral tumour - malignant 
 X78Wm Borderline epithelial tumour 
 XE1vO Malignant tumour of lip 
 X78bN Malignant melanoma of conjunctiva 
 B492. Malignant neoplasm of lateral wall of urinary bladder 
 B12.. Malignant neoplasm of small intestine and duodenum 
 B160. Malignant neoplasm of gallbladder (& carcinoma) 
 X78VQ Malignant tumour of mesothelial tissue 
 Xa9Jg Metastasis to intra-abdominal lymph node 
 B5500 Malignant neoplasm of head NOS 
 B115. Malignant neoplasm of lesser curve of stomach unspecified 
 B172. Malignant tumour of tail of pancreas 
 B173. Malignant tumour of pancreatic duct 
 B690. Acute myelomonocytic leukaemia 
 X78hk Malignant infiltration of skin 
 B43y. Malignant neoplasm of other site of uterine body 
 XaFr6 Local recurrence of malignant tumour of thyroid gland 
 B343. Malignant neoplasm of lower-inner quadrant of female breast 
 B583z Secondary malignant neoplasm of brain or spinal cord NOS 
 B5760 Metastasis to retroperitoneum 
 X78WT Malignant phyllodes tumour of breast 
 X78X8 Malignant germ cell tumour of ovary 
 X77nT Carcinoid bronchial adenoma 
 B560z Secondary unspec malig neop lymph nodes head/face/neck NOS 
 ByuC0 [X]Malignant neoplasm of other specified sites 
 X78hq Malignant tumour of mesothelial and soft tissue 
 Xa0Rk T-cell chronic lymphocytic leukaemia 
 Xa9AM Acute leukaemia 
 B64y1 Prolymphocytic leukaemia 
 Xa3eO Carcinoma breast - lower, outer quadrant 
 B110z Malignant neoplasm of cardia of stomach NOS 
 XM1Oc Carcinoma ventral surface of tongue 
 Xa0QD Anaplastic astrocytoma of brain 
 B3y.. Malig neop of bone, connective tissue, skin and breast OS 
 ByuC7 [X]Secondary malignant neoplasm of other specified sites 
 XaB1i Carcinoma of tail of pancreas 
 XE1xJ Ca stomach NOS 
 B63z. Immunoproliferative neoplasm or myeloma NOS 
 B69.. Myelomonocytic leukaemia 
 Byu5. [X]Malignant neoplasm of mesothelial and soft tissue 
 XE20B Secondary Ca NOS 
 ByuC2 [X]2ndry+unspcf malignant neoplasm lymph nodes/multi regions 
 Xa3BN Metastasis to kidney of unknown primary 
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 XE1y5 Ca pancreas NOS 
 B58y6 Metastasis to testis 
 Xa0Sq Tumour lysis syndrome 
 B5400 Malignant tumour of adrenal cortex 
 B6278 Diffuse non-Hodgkin's lymphoma undifferentiated (diffuse) 
 XE1zt Ca uterus NOS: [carcinoma] or [cancer] 
 X78QT Pancoast tumour 
 XE1wr Ca major saliv gland) or (carc: [parotid][subling][submand]) 
 B300B Malignant neoplasm of turbinate 
 B13y. Malignant neoplasm of other specified sites of colon 
 XaB1h Carcinoma of body of pancreas 
 B17z. Malignant neoplasm of pancreas NOS 
 B68z. Leukaemia NOS 
 C333. Macroglobulinaemia 
 X78l5 Metastasis to thyroid 
 Xaa1P Clinical stage C chronic lymphocytic leukaemia 
 Xa3BH Metastasis to breast of unknown primary 
 Xa0St Hodgkin's disease, lymphocytic predominance - nodular 
 B013. Malignant neoplasm of ventral surface of tongue 
 B627B Other types of follicular non-Hodgkin's lymphoma 
 B601. Lymphosarcoma 
 B6z.. Malignant neoplasm lymphatic or haematopoietic tissue NOS 
 ByuDD [X]Oth and unspecif peripheral & cutaneous T-cell lymphomas 
 B512. Malignant neoplasm of temporal lobe 
 B67.. Other specified leukaemia 
 X78l8 Local tumour spread 
 XaB1e Retroperitoneal sarcoma 
 X78QF Malignant tumour of lung parenchyma 
 Xa9FC Malignant lymphoma, follicular centre cell 
 XaEJe Squamous cell carcinoma of bronchus in left lower lobe 
 B543. Malignant tumour of pineal gland 
 B5512 Malignant neoplasm of intrathoracic site NOS 
 XE1x5 Ca oesophagus NOS 
 B552. Malignant tumour of abdomen 
 B063. Malignant tumour of vallecula 
 B6151 Hodgkin's mixed cellularity of lymph nodes head, face, neck 
 Byu81 [X]Malignant neoplasm/overlapping lesion/male genital organs 
 X309D Cystadenocarcinoma of pancreas 
 B4A10 Malignant tumour of renal calyx 
 B506. Malignant tumour of choroid 
 B49y. Malignant neoplasm of other site of urinary bladder 
 B222z Malignant neoplasm of upper lobe, bronchus or lung NOS 
 B057. Overlapping lesion of other and unspecified parts of mouth 
 B614z Hodgkin's disease, nodular sclerosis NOS 
 B3115 Malignant neoplasm of connective and soft tissue of thumb 
 XE203 Secondary nodes NOS 
 B490. Malignant tumour of trigone of urinary bladder 
 B3001 Malignant neoplasm of frontal bone 
 B055z Malignant neoplasm of palate NOS 
 XE1va Malignant tumour of middle ear and mastoid 
 Xa0bR Malignant lymphoma of thyroid gland 
 Xa0eC Erythraemia 
 B5000 Malignant tumour of ciliary body 
 X78gc Malignant tumour of exocrine pancreas 
 X78l3 Metastasis to choroid 
 X78bc Malignant melanoma of iris 
 B571. Metastasis to mediastinum 
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 B614. Hodgkin's disease, nodular sclerosis 
 B6214 Mycosis fungoides of lymph nodes of axilla and upper limb 
 Xa99l Malignant lymphoma - small lymphocytic 
 B58y1 Metastasis to uterus 
 XaZdF Follicular lymphoma grade 2 
 X78l7 Secondary carcinoma of other specified sites 
 B012. Malignant neoplasm of tongue, tip and lateral border 
 XaA0C Adenocarcinoma of ileum 
 B31z0 Kaposi's sarcoma of soft tissue 
 B3060 Malignant neoplasm of ilium 
 XaBAo Linitis plastica 
 XaFrK Local recurrence of malignant tumour of kidney 
 XaOrB Siewert type III adenocarcinoma 
 X78Wz Malignant granulosa cell tumour of ovary 
 B12z. Malignant neoplasm of small intestine NOS 
 B171. Malignant tumour of body of pancreas 
 XE20R Leukaemia: [lymphoid][monocytic][myeloid][specif cell type] 
 B161. Malignant tumour of extrahepatic bile duct 
 B103. Malignant tumour of upper third of oesophagus 
 XaOrV Siewert type I adenocarcinoma 
 Xa3rj Secondary carcinoma NOS 
 B180. Malignant retroperitoneal tumour 
 B6135 Hodgkin's, lymphocytic-histiocytic pred inguinal and leg 
 B411. Malignant neoplasm of exocervix 
 B410. Malignant neoplasm of endocervix 
 B5001 Malignant tumour of iris 
 XE1zn Ca kidney/urinary organs NOS 
 X78eg Carcinoma of genitourinary organ 
 Byu9. [X]Malignant neoplasm of urinary tract 
 Byu1. [X]Malignant neoplasm of digestive organs 
 XaabR Bowel scope (flexible sigmoidoscopy) screen: cancer detected 
 X78ej Carcinoma of lip, oral cavity and pharynx 
 X78l1 Metastasis to eye 
 B545z Malignant neoplasm of aortic body or paraganglia NOS 
 X78cT Medullary thyroid carcinoma 
 X78ek Malignant tumour of oral cavity, lips, salivary glands 
 B56.. (Lymph node metast) or (sec unsp malig neop lymph nodes) 
 B48z. Malignant neoplasm of penis and other male genital organ NOS 
 B55y0 Malignant neoplasm of back NOS 
 B505. Malignant tumour of retina 
 B451. Malignant neoplasm of labia majora 
 X78Q1 Adenoid cystic carcinoma of trachea 
 X00ZB Malignant melanoma of eyelid 
 B3400 Malignant neoplasm of nipple of female breast 
 X78b0 Adenoid cystic carcinoma of lacrimal gland 
 B522. Malignant tumour of spinal cord 
 X78Wh Malignant epithelial tumour of ovary 
 Xa9Je Metastasis to intrathoracic lymph node 
 Xa0U5 Malignant lymphoma of testis 
 B6200 Nodular lymphoma of unspecified site 
 Xa3BL Metastasis to ovary of unknown primary 
 XE1zR Ca cervix uteri - exocervix 
 Xa0ik Malignant infiltration of soft tissue 
 B480. Malignant tumour of foreskin 
 B31y. Malig neop connective and soft tissue other specified site 
 B3104 Malignant neoplasm of tarsus of eyelid 
 B4303 Malignant neoplasm of myometrium of corpus uteri 
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 XaYj4 Acute myeloid leukaemia with myelodysplasia-related changes 
 B491. Malignant tumour of vault of bladder 
 B5502 Malignant neoplasm of nose NOS 
 B563. Secondary and unspec malig neop axilla and upper limb LN 
 Xa3AG Metastasis to spleen of unknown primary 
 B114. Malignant tumour of body of stomach 
 B57.. Secondary malign neoplasm of resp &/or digest syst (& carc) 
 Byu8. [X]Malignant neoplasm of male genital organs 
 B591. Other malignant neoplasm NOS 
 B106. Malignant neoplasm, overlapping lesion of oesophagus 
 XE1wl (Ca lip, oral, pharynx) or (oral carcinomas) 
 XE1y3 Ca tail of pancreas 
 X78fN Malignant tumour of nasal sinuses 
 B5505 Malignant neoplasm of supraclavicular fossa NOS 
 B14z. Malignant neoplasm rectum,rectosigmoid junction and anus NOS 
 B300. Malignant neoplasm of bones of skull and face 
 Xa3Bb Metastasis to adrenal gland of unknown primary 
 B503. Malignant tumour of conjunctiva 
 B222. Malig neopl of upper lobe/bronchus/lung: (& [Pancoast synd]) 
 B1110 Malignant neoplasm of prepylorus of stomach 
 B67y. Other and unspecified leukaemia 
 B483. Malignant neoplasm of penis, part unspecified 
 B304z Malig neop of scapula and long bones of upper arm NOS 
 B493. Malignant neoplasm of anterior wall of urinary bladder 
 XM0pv Secondary malignant neoplasm of unknown site 
 B054. Malignant tumour of uvula 
 XE1vm Secondary malig neop of respiratory and digestive systems 
 B5420 Malignant tumour of pituitary gland 
 B5504 Malignant neoplasm of neck NOS 
 XaFr4 Local recurrence of malignant tumour of tongue 
 B4510 Malignant neoplasm of greater vestibular (Bartholin's) gland 
 B060z Malignant neoplasm tonsil NOS 
 B0z0. Malignant neoplasm of pharynx unspecified 
 B223. Malignant neoplasm of middle lobe, bronchus or lung 
 B031. Malignant tumour of lower gingiva 
 Xa97u Malignant tumour of soft tissue of shoulder 
 Byu2. [X]Malignant neoplasm of respiratory and intrathoracic orga 
 Xa3BX Metastasis to bladder of unknown primary 
 XE205 (Sec Ca sp site) or (metast sp site) or (sec Ca known site) 
 B430. Malignant neoplasm of corpus uteri, excluding isthmus 
 B18y5 Malignant neoplasm of pelvic peritoneum 
 B2... Malign neopl resp tract and intrathor organs (& [carcinoma]) 
 XaQbT Poikiloderma vasculare atrophicans 
 B68.. Leukaemia of unspecified cell type 
 B3040 Malignant neoplasm of scapula 
 B5810 Metastasis to ureter 
 B061. Malignant tumour of tonsillar fossa 
 ByuD. [X]Malignant neoplasms of lymphoid, haematopoietic and rela 
 X78IG Carcinoma of anterior part of floor of mouth 
 B2211 Malignant neoplasm of hilus of lung 
 Xa97s Malignant tumour of soft tissue 
 B2001 Malignant neoplasm of nasal conchae 
 B48.. Malignant neoplasm of penis and other male genital organs 
 B122. Malignant tumour of ileum 
 B111. Malignant tumour of pylorus 
 XaELM Teratoma of undescended testis 
 B1111 Malignant neoplasm of pyloric canal of stomach 
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 B525. Malignant neoplasm of cauda equina 
 B2133 Malignant neoplasm of thyroid cartilage 
 B3113 Malignant neoplasm of connective and soft tissue of hand 
 XE1x3 Ca lower third oesophagus 
 B34yz Malignant neoplasm of other site of female breast NOS 
 B30.. Malig neopl bone and artic cartilag (& [chondroma][osteoma]) 
 B59.. Malignant neoplasm of unspecified site 
 B450z Malignant neoplasm of vagina NOS 
 B576z Secondary malig neop of retroperitoneum or peritoneum NOS 
 B082. Malignant tumour aryepiglottic fold - hypopharyngeal aspect 
 Byu90 [X]Malignant neoplasm of urinary organ, unspecified 
 B61z3 Hodgkin's disease NOS of intra-abdominal lymph nodes 
 X78kd Metastasis to pancreas 
 B06z. Malignant neoplasm of oropharynx NOS 
 B541. Malignant tumour of parathyroid gland 
 XaYin Cutaneous follicle centre lymphoma 
 X78bM Squamous cell carcinoma of conjunctiva 
 B300A Malignant neoplasm of maxilla 
 B412. Malignant neoplasm, overlapping lesion of cervix uteri 
 ByuA2 [X]Malignant neoplasm of meninges, unspecified 
 B61z1 Hodgkin's disease NOS of lymph nodes of head, face and neck 
 B553. Malignant tumour of pelvis 
 X78N1 Carcinoma of pyloric antrum 
 X78Zc Malignant tumour of urethral stump 
 B5450 Malignant neoplasm of glomus jugulare 
 X78IR Carcinoma of hard palate 
 B6205 Nodular lymphoma of lymph nodes of inguinal region and leg 
 B5608 Secondary and unspec malig neop anterior cervical LN 
 X78Ib Carcinoma of uvula 
 XaYgm Primary mediastinal (thymic) large B-cell lymphoma 
 B453. Malignant neoplasm of clitoris 
 B51y0 Malignant neoplasm of corpus callosum 
 B471. Malignant neoplasm of descended testis 
 B564. Secondary and unspec malig neop inguinal and lower limb LN 
 B452. Malignant neoplasm of labia minora 
 B64yz Other lymphoid leukaemia NOS 
 B574z Secondary malig neop of small intestine or duodenum NOS 
 B07z. Malignant neoplasm of nasopharynx NOS 
 Byu7. [X]Malignant neoplasm of female genital organs 
 XE1y1 Ca body of pancreas 
 XE1zh (Epidid carc) or (Ca epidid/spermat cord) or (sperm cord Ca) 
 B5750 Secondary malignant neoplasm of colon 
 XaYip Sarcoma of dendritic cells 
 B138. Malignant neoplasm, overlapping lesion of colon 
 X78Wn Mixed epithelial tumour of ovary 
 B21y. Malignant neoplasm of larynx, other specified site 
 B2210 Malignant neoplasm of carina of bronchus 
 B521z Malignant neoplasm of cerebral meninges NOS 
 B5105 Malignant neoplasm of thalamus 
 B220z Malignant neoplasm of trachea NOS 
 B220. Malignant tumour of trachea 
 XaOqX Siewert type II adenocarcinoma 
 B4300 Malignant neoplasm of cornu of corpus uteri 
 X78l2 Metastasis to orbit 
 X309C Malignant cystic tumour of exocrine pancreas 
 XaJM3 Osteosarcoma - disorder 
 B6276 Diffuse non-Hodgkin's immunoblastic (diffuse) lymphoma 
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 B431. Malignant neoplasm of isthmus of uterine body 
 B056. Malignant tumour of retromolar area 
 Xa0Di Malignant melanoma of anus 
 Xa3AF Metastasis to pancreas of unknown primary 
 B3070 Malignant neoplasm of femur 
 XE1wg [X]Mesothelioma of other sites 
 Xa0Sk Acute myeloblastic leukaemia 
 XE2vN Malignant neoplasm of common bile duct 
 B583. Secondary malignant neoplasm of brain and spinal cord 
 B600. Reticulosarcoma 
 B1611 Malignant neoplasm of hepatic duct 
 Xa0S9 T-cell prolymphocytic leukaemia 
 ByuB. [X]Malignant neoplasm of thyroid and other endocrine glands 
 B100. Malignant tumour of cervical part of oesophagus 
 Xa3A7 Metastasis to heart of unknown primary 
 X78kb Metastasis to gastrointestinal tract 
 B08z. Malignant neoplasm of hypopharynx NOS 
 X78Yz Papillary cystadenocarcinoma of kidney 
 B3031 Malignant neoplasm of sternum 
 X78kV Metastasis to bronchus 
 B3101 Malignant tumour of soft tissue of face 
 B111z Malignant neoplasm of pylorus of stomach NOS 
 B59z. Malignant neoplasm of unspecified site NOS 
 B3071 Malignant neoplasm of fibula 
 X78e6 Malignant tumour of spleen 
 Xa0Tr Peripheral T-cell lymphoma - pleomorphic small cell 
 B3030 Malignant neoplasm of rib 
 B104. Malignant tumour of middle third of oesophagus 
 B203. Malignant tumour of ethmoid sinus 
 B6140 Hodgkin's disease, nodular sclerosis of unspecified site 
 B6133 Hodgkin's, lymphocytic-histiocytic pred intra-abdominal node 
 Xa9AO Chronic leukaemia 
 X78g2 Malignant tumour of oesophagus, stomach and duodenum 
 B482. Malignant tumour of body of penis 
 B320. Malignant melanoma of lip 
 X78ky Metastasis to pituitary 
 B561. Secondary and unspec malig neop intrathoracic lymph nodes 
 B3123 Malig neop of connective and soft tissue of lower leg 
 B6210 Mycosis fungoides of unspecified site 
 B55yz Malignant neoplasm of specified site NOS 
 B6021 Burkitt's lymphoma of lymph nodes of head, face and neck 
 B14y. Malig neop other site rectum, rectosigmoid junction and anus 
 XaB47 Atypical hairy cell leukaemia 
 B540z Malignant neoplasm of adrenal gland NOS 
 B212. Malignant tumour of subglottis 
 B2231 Malignant neoplasm of middle lobe of lung 
 B653z Myeloid sarcoma NOS 
 B5531 Malignant neoplasm of presacral region 
 B161z Malignant neoplasm of extrahepatic bile ducts NOS 
 B151. Malignant neoplasm of intrahepatic bile ducts 
 XE1zp (Carcinoma brain) or (brain Ca) or (cerebral tumour - malig) 
 XaELJ Seminoma of undescended testis 
 B1100 Malignant neoplasm of cardiac orifice of stomach 
 X78IW Carcinoma of soft palate 
 B3124 Malignant neoplasm of connective and soft tissue of foot 
 B064. Malignant neoplasm of anterior epiglottis 
 B021. Malignant tumour of submandibular gland 
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 XE1vS Malignant tumour of lesser curve of stomach 
 B6274 Malignant lymphoma - small cleaved cell 
 Xa97p Malignant tumour of anterior two-thirds of tongue 
 B2000 Malignant neoplasm of cartilage of nose 
 X78WQ Cancer en cuirasse 
 B16y. Malignant neoplasm other gallbladder/extrahepatic bile duct 
 B5103 Malignant neoplasm of globus pallidus 
 B1zy. Malignant neoplasm other spec digestive tract and peritoneum 
 ByuD0 [X]Other Hodgkin's disease 
 B16z. Malignant neoplasm gallbladder/extrahepatic bile ducts NOS 
 B680. Acute leukaemia NOS 
 B3100 Malignant tumour of soft tissue of head 
 B18y. Malignant neoplasm of specified parts of peritoneum 
 XaFrz Metastasis from malignant tumour of tongue 
 B6130 Hodgkin's, lymphocytic-histiocytic predominance unspec site 
 B15.. Malignant neoplasm of liver and intrahepatic bile ducts 
 Xa0TY Low grade T-cell lymphoma 
 X78NG Carcinoma of greater curve of stomach 
 Xa0Ro Richter's syndrome 
 B2240 Malignant neoplasm of lower lobe bronchus 
 B1511 Malignant neoplasm of interlobular biliary canals 
 B346. Malignant neoplasm of axillary tail of female breast 
 B23z. Malignant neoplasm of pleura NOS 
 B661. Chronic monocytic leukaemia 
 B5654 Secondary and unspec malig neop obturator lymph nodes 
 XaC2J Malignant neoplasm of lip, unspecified 
 B67z. Other specified leukaemia NOS 
 B6020 Burkitt's lymphoma of unspecified site 
 B592. Malignant neoplasms of independent (primary) multiple sites 
 B080. Malignant tumour of postcricoid region 
 B581. Secondary malignant neoplasm of other urinary organs 
 B51y. Malignant neoplasm of other parts of brain 
 Xa9A0 Nephroblastoma 
 Byu12 [X]Malignant neoplasm of intestinal tract, part unspecified 
 B5503 Malignant neoplasm of jaw NOS 
 Byu70 [X]Malignant neoplasm of uterine adnexa, unspecified 
 X77nj Klatskin's tumour 
 X78kg Metastasis to soft tissue 
 B18z. Malignant neoplasm of retroperitoneum and peritoneum NOS 
 B5613 Secondary and unspec malig neop ant mediastinal lymph nodes 
 B016. Malignant tumour of lingual tonsil 
 Byu82 [X]Malignant neoplasm of male genital organ, unspecified 
 B05.. Malignant neoplasm of other and unspecified parts of mouth 
 B066. Malignant neoplasm of lateral wall of oropharynx 
 B013z Malignant neoplasm of ventral tongue surface NOS 
 B6y.. Malignant neoplasm lymphatic or haematopoietic tissue OS 
 B10y. Malignant neoplasm of other specified part of oesophagus 
 B410z Malignant neoplasm of endocervix NOS 
 B64y. Other lymphoid leukaemia 
 B01y. Malignant neoplasm of other sites of tongue 
 B15z. Malignant neoplasm of liver and intrahepatic bile ducts NOS 
 B3122 Malig neop connective and soft tissue of popliteal space 
 X78OX Malignant tumour of anorectal junction 
 Xa99n Diffuse malignant lymphoma - centroblastic 
 X78XB Embryonal carcinoma of ovary 
 X30L8 Lymphoma of kidney 
 X78ca Adrenal carcinoma 
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 X78ap Malignant tumour of acoustic vestibular nerve 
 B48y0 Malignant tumour of seminal vesicle 
 XE1xD Ca Body - stomach 
 B517z Malignant neoplasm of brainstem NOS 
 XE2vi Acute erythraemia and erythroleukaemia 
 B544. Malignant neoplasm of carotid body 
 XaYis Atypical chronic myeloid leukaemia, BCR/ABL negative 
 X78kX Secondary lymphangitic carcinoma 
 B660. Acute monocytic leukaemia 
 B64y2 Adult T-cell leukaemia 
 B55y1 Malignant neoplasm of trunk NOS 
 B5501 Malignant neoplasm of cheek NOS 
 B5100 Malignant neoplasm of basal ganglia 
 B5510 Malignant neoplasm of axilla NOS 
 XM1FE Combined hepatocellular carcinoma and cholangiocarcinoma 
 B6011 Lymphosarcoma of lymph nodes of head, face and neck 
 Xa3AK Metastasis to vertebral column of unknown primary 
 B223z Malignant neoplasm of middle lobe, bronchus or lung NOS 
 B560. Secondary and unspec malig neop lymph nodes head/face/neck 
 B022. Malignant tumour of sublingual gland 
 B055. Malignant neoplasm of palate unspecified 
 B510. Malignant neoplasm cerebrum (excluding lobes and ventricles) 
 B004. Malignant neoplasm of lip unspecified, inner aspect 
 B35z. Malignant neoplasm of other site of male breast 
 XE1vr Chronic erythraemia 
 B5640 Secondary and unspec malig neop superficial inguinal LN 
 XaYeq Secondary malignant neoplasm of liver intrahepatic bile duct 
 Xa0bb Endometrioid carcinoma of prostate 
 B06yz Malignant neoplasm of other specified site of oropharynx NOS 
 B06y. Malignant neoplasm of oropharynx, other specified sites 
 B451z Malignant neoplasm of labia majora NOS 
 XaEY9 Malignant neoplasm of mesentery 
 B562z Secondary and unspec malig neop intra-abdominal LN NOS 
 B3150 Malignant neoplasm of connective and soft tissue of buttock 
 B573. Secondary malignant neoplasm of other respiratory organs 
 B512z Malignant neoplasm of temporal lobe NOS 
 B25.. Malig neo, overlapping lesion of heart, mediastinum & pleura 
 X78kf Metastasis to bone marrow 
 B03z. Malignant neoplasm of gum NOS 
 B6208 Nodular lymphoma of lymph nodes of multiple sites 
 B224z Malignant neoplasm of lower lobe, bronchus or lung NOS 
 Xa0T7 Malignant lymphomatous polyposis 
 Byu71 [X]Malignant neoplasm/other specified female genital organs 
 B062z Malignant neoplasm of tonsillar fossa NOS 
 X78Wy Malignant sex cord tumour of ovary 
 B23.. Malignant tumour of pleura 
 B347. Malignant neoplasm, overlapping lesion of breast 
 ByuC. [X]Malignant neoplasm of ill-defined, secondary and unspeci 
 B306z Malignant neoplasm of pelvis, sacrum or coccyx NOS 
 B5751 Secondary malignant neoplasm of rectum 
 XaYi5 Diffuse follicle centre lymphoma 
 B0z.. Malig neop other/ill-defined sites lip, oral cavity, pharynx 
 B05y. Malignant neoplasm of other specified mouth parts 
 B41yz Malignant neoplasm of other site of cervix NOS 
 B622. Sezary's disease 
 B302z Malignant neoplasm of vertebral column NOS 
 B205. Malignant tumour of sphenoid sinus 
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 XE1x9 Ca pylorus - stomach 
 B64z. Lymphoid leukaemia NOS 
 XE1vT Malignant tumour of greater curve of stomach 
 Xa0TZ High grade T-cell lymphoma 
 B66.. Monocytic leukaemia 
 B6131 Hodgkin's, lymphocytic-histiocytic pred of head, face, neck 
 B5812 Metastasis to urethra 
 B5511 Malignant neoplasm of chest wall NOS 
 ByuD4 [X]Other malignant immunoproliferative diseases 
 Xa3eT Carcinoma of genital organs NOS 
 B504. Malignant tumour of cornea 
 B4A11 Malignant tumour of pelviureteric junction 
 B562. Secondary and unspec malig neop intra-abdominal lymph nodes 
 B576. Secondary malig neop of retroperitoneum and peritoneum 
 Byu73 [X]Malignant neoplasm of female genital organ, unspecified 
 X78MW Carcinoma of upper third of oesophagus 
 B487. Malignant neoplasm, overlapping lesion of penis 
 ByuD2 [X]Other types of diffuse non-Hodgkin's lymphoma 
 Xa3BG Metastasis to soft tissue of unknown primary 
 B3102 Malignant tumour of soft tissue of neck 
 X78bk Malignant melanoma of ciliary body 
 B6207 Nodular lymphoma of spleen 
 B61z7 Hodgkin's disease NOS of spleen 
 XaYj0 Chronic myelogenous leukaemia, BCR/ABL positive 
 X78g0 Carcinoma of respiratory tract and intrathoracic organs 
 B3z.. Malig neop of bone, connective tissue, skin and breast NOS 
 B45y0 Malignant neoplasm of overlapping lesion of vulva 
 B304. Malignant neoplasm of scapula and long bones of upper arm 
 B612. Hodgkin's sarcoma 
 B11yz Malignant neoplasm of other specified site of stomach NOS 
 B3103 Malignant neoplasm of cartilage of ear 
 B521. Malignant neoplasm of cerebral meninges 
 B312. Malig neop of connective and soft tissue of hip and leg 
 B316. Malig neop of connective and soft tissue trunk unspecified 
 B04z. Malignant neoplasm of floor of mouth NOS 
 B5y.. Malignant neoplasm of other and unspecified site OS 
 B030. Malignant tumour of upper gingiva 
 X78Lx Malignant tumour of laryngeal ventricle 
 Xa0Tj Lymphoepithelioid lymphoma 
 XE1xZ Ca splenic flexure - colon 
 B6165 Hodgkin's lymphocytic depletion lymph nodes inguinal and leg 
 B201. Malig neop auditory tube, middle ear and mastoid air cells 
 B50y. Malignant neoplasm of other specified site of eye 
 B5623 Secondary and unspec malig neop common iliac lymph nodes 
 B062. Malignant tumour of tonsillar pillar 
 Xa0Dd Lymphoma of intestine 
 B55y. Malignant neoplasm of other specified sites 
 B1zz. Malignant neoplasm of digestive tract and peritoneum NOS 
 B3112 Malignant neoplasm of connective and soft tissue of fore-arm 
 B6273 Diffuse malignant lymphoma - small non-cleaved cell 
 B116. Malignant neoplasm of greater curve of stomach unspecified 
 B4z.. Malignant neoplasm of genitourinary organ NOS 
 X78kn Metastasis to female genital organ 
 X78Oz Sarcoma of liver 
 B1z1z Malignant neoplasm of spleen NOS 
 B124. Malignant neoplasm, overlapping lesion of small intestine 
 B5003 Malignant neoplasm of sclera 
  
 
321 
 X78kc Metastasis to small intestine 
 X78QR Lymphomatoid granulomatosis of lung 
 B221z Malignant neoplasm of main bronchus NOS 
 B674. Acute panmyelosis 
 XM00E Malignant tumour of lower labial mucosa 
 B555. Malignant neoplasm of lower limb NOS 
 B6010 Lymphosarcoma of unspecified site 
 B431z Malignant neoplasm of isthmus of uterine body NOS 
 XaYjf Subcutaneous panniculitic T-cell lymphoma 
 Xa0SH T-cell acute lymphoblastic leukaemia 
 B017. Malignant overlapping lesion of tongue 
 B5622 Secondary and unspec malig neop inferior mesenteric LN 
 B520z Malignant neoplasm of cranial nerves NOS 
 XaFrG Local recurrence of malignant tumour of liver 
 B3153 Malig neopl of connective and soft tissue - sacrum or coccyx 
 B20z. Malignant neoplasm of accessory sinus NOS 
 B6241 Leukaemic reticuloend of lymph nodes of head, face and neck 
 B6510 Chronic eosinophilic leukaemia 
 B6123 Hodgkin's sarcoma of intra-abdominal lymph nodes 
 B5605 Secondary and unspec malig neop submandibular lymph nodes 
 B3000 Malignant neoplasm of ethmoid bone 
 B0010 Malignant neoplasm of lower lip, external 
 B350. Malignant neoplasm of nipple and areola of male breast 
 B12y. Malignant neoplasm of other specified site small intestine 
 B2131 Malignant neoplasm of cricoid cartilage 
 Xa0SX Atypical chronic myeloid leukaemia 
 X78aB Pituitary carcinoma 
 B163. Malignant neoplasm, overlapping lesion of biliary tract 
 XE1yV Ca skull/face/jaw bone 
 X78WS Familial cancer of breast 
 B510z Malignant neoplasm of cerebrum NOS 
 X78Pf Malignant tumour of endocrine pancreas 
 Byu72 [X]Malignant neoplasm/overlapping lesion/feml genital organs 
 X78b3 Mucoepidermoid tumour of lacrimal gland    
Cerebrovascular 
disease XE0VK Transient ischaemic attack 
 XaEGq Stroke NOS 
 X00D1 Cerebrovascular accident 
 XaAsI Referral to stroke service 
 662M. Stroke monitoring 
 XaJYc Referral to stroke clinic 
 XaJkS Stroke / transient ischaemic attack referral 
 14AB. H/O: TIA 
 XaAsJ Admission to stroke unit 
 G65z. Transient cerebral ischaemia NOS 
 XaJ4b Excepted from stroke quality indicators: Patient unsuitable 
 XaJ4c Excepted from stroke quality indicators: Informed dissent 
 XaJwA Stroke/transient ischaemic attack monitoring status 
 X00DA Lacunar infarction 
 G6... Cerebrovascular disease 
 X00DI Haemorrhagic cerebral infarction 
 XaKSH Haemorrhagic stroke monitoring 
 XE2te H/O: CVA/stroke 
 XSAbR Stroke rehabilitation 
 G66.. CVA - cerebrovascular accident (& unspecified [& stroke]) 
 XaLKH Seen in stroke clinic 
 XaIzF Stroke annual review 
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 XE2aB Stroke and cerebrovascular accident unspecified 
 XE0X2 (Cereb infarc)(cerebrovas acc)(undef stroke/CVA)(stroke NOS) 
 XM1R3 H/O: stroke 
 XA0BD Traumatic subdural haematoma 
 G634. Carotid artery stenosis 
 XaAsR Seen by stroke service 
 G667. Left sided cerebral hemisphere cerebrovascular accident 
 X00D7 Partial anterior cerebral circulation infarction 
 F4236 Amaurosis fugax 
 X00DR Stroke of uncertain pathology 
 G640. Cerebral thrombosis 
 14A7. H/O: CVA &/or stroke 
 XaJDX Did not attend stroke clinic 
 G6711 Chronic cerebral ischaemia 
 X00D6 Total anterior cerebral circulation infarction 
 S620. Haemorrh: [closed traum subarach] or [mid mening follow inj] 
 XM1R2 H/O: CVA 
 X003j Vascular parkinsonism 
 X00DT Posterior circulation stroke of uncertain pathology 
 G61.. Intracerebral haemorrhage (& [cerebrovasc accident due to]) 
 G664. Cerebellar stroke syndrome 
 XE0VF Cerebral parenchymal haemorrhage 
 S628. Traumatic subdural haemorrhage 
 XaBL3 H/O: Stroke in last year 
 XaJi5 Ref to multidisciplinary stroke function improvement service 
 G65y. Other transient cerebral ischaemia 
 X00DS Anterior circulation stroke of uncertain pathology 
 G64.. Cereb art occl (& [cerebvasc acc][stroke]) or (cereb infarc) 
 XA0BH Traumatic subarachnoid haemorrhage 
 XaKba Stroke/transient ischaemic attack monitoring verbal invitati 
 XE0VL Cerebral atherosclerosis 
 Gyu6C [X]Sequelae of stroke,not specfd as h'morrhage or infarction 
 XE2w4 Non-traumatic subdural haematoma 
 XaLtA Delivery of rehabilitation for stroke 
 XaR8M Did not attend stroke review 
 XaKcm Stroke/transient ischaemic attack monitoring invitation 
 XaMGv Stroke/transient ischaemic attack monitoring telephone invte 
 XaJuX Stroke/transient ischaemic attack monitoring second letter 
 XaJuY Stroke/transient ischaemic attack monitoring third letter 
 G663. Brainstem stroke syndrome 
 Xa0Ml Central post-stroke pain 
 G65z1 Intermittent cerebral ischaemia 
 XE0X0 (Trans isch attacks) or (vert-basil insuf) or (drop attacks) 
 XaR68 Stroke 6 month review 
 XA0BE Traumatic intracranial subdural haematoma 
 G621. Subdural haemorrhage - nontraumatic 
 XE1m2 Traumatic intracranial haemorrhage 
 XA0BI Traumatic intracranial subarachnoid haemorrhage 
 S622. Closed traumatic subdural haemorrhage 
 XA0BG Traumatic intracerebral haemorrhage 
 Xa1hE Extension of cerebrovascular accident 
 X00E5 Spinal cord stroke 
 Xa1uU Non-traumatic intracranial subdural haematoma 
 XE1m3 Closed traumatic subarachnoid haemorrhage 
 G670. Atherosclerosis: [precerebral] or [cerebral] 
 G682. Sequelae of other non-traumatic intracranial haemorrhage 
 XaFsk Traumatic subdural haematoma without open intracranial wound    
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Chronic kidney 
disease XaLHI Chronic kidney disease stage 3 
 XaO3w Chronic kidney disease stage 3A without proteinuria 
 XaO3t Chronic kidney disease stage 3 with proteinuria 
 XaNbo Chronic kidney disease stage 3B 
 XaO3u Chronic kidney disease stage 3 without proteinuria 
 4677 Urine protein test = ++++ 
 XaO3y Chronic kidney disease stage 3B without proteinuria 
 XaO3z Chronic kidney disease stage 4 with proteinuria 
 XaLFm Except chronic kidney disease qual indic: Patient unsuitable 
 XaMGE Chronic kidney disease annual review 
 XaLHJ Chronic kidney disease stage 4 
 XaO40 Chronic kidney disease stage 4 without proteinuria 
 XaO3v Chronic kidney disease stage 3A with proteinuria 
 XaNbn Chronic kidney disease stage 3A 
 XaIyz Diabetes mellitus with persistent microalbuminuria 
 XaIzR Type II diabetes mellitus with persistent microalbuminuria 
 XaIz0 Diabetes mellitus with persistent proteinuria 
 X30In Chronic renal impairment 
 R110. [D]Proteinuria 
 XaO3x Chronic kidney disease stage 3B with proteinuria 
 XaLHK Chronic kidney disease stage 5 
 XaO41 Chronic kidney disease stage 5 with proteinuria 
 XaIzQ Type II diabetes mellitus with persistent proteinuria 
 C1090 Type II diabetes mellitus with renal complications 
 C104. Diabetes mellitus: [with renal manifestatn] or [nephropathy] 
 K05.. Renal failure: [chronic] or [end stage] 
 XaO42 Chronic kidney disease stage 5 without proteinuria 
 XaLFn Exc chronic kidney disease quality indicators: Inform dissen 
 C104z Diabetes mellitus with nephropathy NOS 
 XaXTz H/O: chronic kidney disease 
 PD13. Multicystic kidney 
 C1093 Type II diabetes mellitus with multiple complications 
 XaF05 Type II diabetes mellitus with nephropathy 
 C1080 Type I diabetes mellitus with renal complications 
 XE10G Diabetes mellitus with renal manifestation 
 XaF04 Type I diabetes mellitus with nephropathy 
 XaIzM Type 1 diabetes mellitus with persistent proteinuria 
 XaIzN Type 1 diabetes mellitus with persistent microalbuminuria 
 C104y Other specified diabetes mellitus with renal complications    
Chronic 
obstructive 
pulmonary 
disease H3... Chronic obstructive lung disease 
 XaYZO COPD self-management plan review 
 Xa35l Acute infective exacerbation chronic obstruct airway disease 
 XaEIY Severe chronic obstructive pulmonary disease 
 H3122 Acute exacerbation of chronic obstructive airways disease 
 XaEIW Moderate chronic obstructive pulmonary disease 
 XaEIV Mild chronic obstructive pulmonary disease 
 XaZd1 Acute non-infective exacerbation of COPD 
 X101i Chron obstruct pulmonary dis wth acute exacerbation, unspec 
 XaXCb Chronic obstructive pulmonary disease 6 monthly review 
 XaXCa Chronic obstructive pulmonary disease 3 monthly review 
 H3z.. Chronic obstructive airways disease NOS 
 XaZoz Seen in chronic obstructive pulmonary disease clinic 
 Hyu31 [X]Other specified chronic obstructive pulmonary disease 
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 XaY0w Referral to COPD community nursing team 
 H312z Obstructive chronic bronchitis NOS 
 XaJFu Admit COPD emergency 
 XaIND End stage chronic obstructive airways disease 
 XaN4a Very severe chronic obstructive pulmonary disease 
 H3y0. Chronic obstruct pulmonary dis with acute lower resp infectn 
 XaZp7 Chronic obstructive pulmonary disease rescue pack declined 
 XaZ6U On chronic obstructive pulmonary disease supprtv cre pathway 
 H3y.. Other specified chronic obstructive airways disease    
Cirrhosis XE0b4 Alcoholic cirrhosis of liver 
 X307L Cirrhosis of liver 
 J6160 Primary biliary cirrhosis 
 X307M Cirrhosis of liver NOS 
 X307O Cryptogenic cirrhosis 
 J6617 Primary sclerosing cholangitis 
 XE0b5 Cirrhosis - non-alcoholic 
 X307W Fibrosis of liver 
 J616. Biliary cirrhosis 
 J615. (Cirrhosis - non alcoholic) or (portal cirrhosis) 
 J6155 Macronodular cirrhosis 
 J61.. Cirrhosis and chronic liver disease 
 J615z (Liver cirrhos: [named vars] or [NOS]) or (hepat fibrosis) 
 J612. Cirrhosis: [florid] or [alcoholic] 
 X307Q Micronodular cirrhosis 
 XE0bA Non-alcoholic cirrhosis NOS 
 Xa9C7 Cardiac cirrhosis 
 XaC1d Oesophageal varices in alcoholic cirrhosis of the liver 
 J616z Biliary cirrhosis NOS 
 X307Z Hepatic sclerosis 
 XE0dJ Biliary cirrhosis (& [primary]) 
 XaBM6 Oesophageal varices in cirrhosis of the liver 
 X307b Hepatic fibrosis with hepatic sclerosis 
 X307X Congenital hepatic fibrosis 
 J615H Infectious cirrhosis NOS 
 X3072 Alcoholic fibrosis and sclerosis of liver 
 J615y Portal cirrhosis unspecified 
 J6356 Toxic liver disease with fibrosis and cirrhosis of liver 
 X3073 Alcoholic hepatic failure 
 X307R Portal cirrhosis 
 J6161 Secondary biliary cirrhosis 
 J6152 Mixed portal cirrhosis 
 J6153 Diffuse nodular cirrhosis 
 J6150 Unilobular portal cirrhosis    
Deep vein 
thrombosis Xa9Bs Deep vein thrombosis of lower limb 
 14A81 H/O: Deep Vein Thrombosis 
 X205n Ileofemoral deep vein thrombosis 
 XaBMc [V] Personal history deep vein thrombosis 
 L413. Antenatal deep vein thrombosis 
 Xacvd Unprovoked deep vein thrombosis 
 SP122 Postoperative deep vein thrombosis 
 XE0xL Postnatal deep vein thrombosis 
 XE0XS (Deep ven thromb leg)(nonpuer milk-leg)(deep thrombophl leg) 
 L414. DVT: [postnatal] or [obstetric phlegmasia alba dolens] 
 XaaBG On deep vein thrombosis care pathway 
 XaQIV Deep venous thrombosis of peroneal vein 
 XaZ43 Recurrent deep vein thrombosis 
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 L4140 Postnatal deep vein thrombosis unspecified 
 L414z Postnatal deep vein thrombosis NOS 
 Xacve Provoked deep vein thrombosis 
 L4130 Antenatal deep vein thrombosis unspecified 
 XaIIo Deep vein thrombosis of leg related to air travel 
 L4131 Antenatal deep vein thrombosis - delivered 
 XaJxo Deep vein thrombosis of leg related to intravenous drug use 
 X205m Lower venous segment thrombosis 
 X76Lh Phlegmasia caerula dolens 
 L413z Antenatal deep vein thrombosis NOS 
 L4142 Postnatal deep vein thrombosis with postnatal complication 
 Xa1aj Phlegmasia alba dolens - obstetric 
 L4132 Antenatal deep vein thrombosis with antenatal complication    
Diabetes XaMFF Referral for diabetic retinopathy screening 
 66A4. Diabetic on oral treatment 
 Y3579 Diabetic review 
 66A.. Diabetic monitoring 
 X40J5 Type II diabetes mellitus 
 66AS. Diabetic annual review 
 C10.. Diabetes mellitus 
 XaIIj Diabetic retinopathy screening 
 XaJO9 Under care of diabetic foot screener 
 XaJYg Diabetes clinical management plan 
 9OL1. Attends diabetes monitoring 
 XaIyt Diabetic peripheral neuropathy screening 
 XaBLn Self-monitoring of blood glucose 
 XaJ4Q Exception reporting: diabetes quality indicators 
 XaJ5j Patient on maximal tolerated therapy for diabetes 
 66AD. Fundoscopy - diabetic check 
 F420. Diabetic retinopathy 
 XaKwQ Diabetic 6 month review 
 C101. Diabetic ketoacidosis 
 XaPQH Diabetic foot screen 
 F4200 Background diabetic retinopathy 
 XaIuE Diabetic foot examination 
 XaJLa Diabetic retinopathy 12 month review 
 66A5. Diabetic on insulin 
 C100. Diabetes mellitus with no mention of complication 
 XaE46 Referral to diabetes nurse 
 XaELQ Type II diabetes mellitus without complication 
 XaE5c Diabetic macular oedema 
 XaJ4i Excepted from diabetes quality indicators: Informed dissent 
 C1001 Diab mell: [adult ons, no ment comp][mat onset][non-ins dep] 
 C1097 Type II diabetes mellitus - poor control 
 XaJK3 Diabetic medicine 
 XaIP5 Non proliferative diabetic retinopathy 
 XaJOi O/E - right eye preproliferative diabetic retinopathy 
 XaXZR H/O: diabetes mellitus type 2 
 XaJOk O/E - right eye proliferative diabetic retinopathy 
 XaE5V Severe non proliferative diabetic retinopathy 
 XaJOj O/E - left eye preproliferative diabetic retinopathy 
 XaE5U Moderate non proliferative diabetic retinopathy 
 XaIyz Diabetes mellitus with persistent microalbuminuria 
 XaJLb Diabetic retinopathy 6 month review 
 XaXZv H/O: diabetes mellitus type 1 
 X40J6 Insulin treated Type 2 diabetes mellitus 
 XE1T3 Diabetic - poor control 
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 66AH0 Conversion to insulin 
 66AZ. Diabetic monitoring NOS 
 XaE5T Mild non proliferative diabetic retinopathy 
 XaJ4h Excepted from diabetes qual indicators: Patient unsuitable 
 F4640 Diabetic cataract 
 XaIzR Type II diabetes mellitus with persistent microalbuminuria 
 XE12M Diabetes with other complications 
 42W3. Hb. A1C > 10% - bad control 
 66AR. Diabetes management plan given 
 XaKT5 Diabetic patient unsuitable for digital retinal photography 
 XaCES HbA1 - diabetic control 
 XaIz0 Diabetes mellitus with persistent proteinuria 
 Y1286 Diabetic Clinic 
 C106. Diab mell + neuro manif: (& [amyotroph][neurop][polyneurop]) 
 XaIIe Diabetes care by hospital only 
 XaFn8 Type II diabetes mellitus with arthropathy 
 XaIzQ Type II diabetes mellitus with persistent proteinuria 
 XaIeK O/E - Left diabetic foot - ulcerated 
 X40J4 Type I diabetes mellitus 
 C1090 Type II diabetes mellitus with renal complications 
 C104. Diabetes mellitus: [with renal manifestatn] or [nephropathy] 
 C1096 Type II diabetes mellitus with retinopathy 
 F3721 Chronic painful diabetic neuropathy 
 X00Ah Diabetic distal sensorimotor polyneuropathy 
 XE12A Diabetes mellitus: [adult onset] or [noninsulin dependent] 
 F1711 Diabetic autonomic neuropathy 
 C1087 Type I diabetes mellitus with retinopathy 
 C1010 Type 1 diabetes mellitus with ketoacidosis 
 F420z Diabetic retinopathy NOS 
 C1094 Type II diabetes mellitus with ulcer 
 F3720 Acute painful diabetic neuropathy 
 XaFmA Type II diabetes mellitus with diabetic cataract 
 C104z Diabetes mellitus with nephropathy NOS 
 XaXbW Symptomatic diabetic peripheral neuropathy 
 XE128 Diabetes mellitus (& [ketoacidosis]) 
 XE10F Diabetes mellitus, adult onset, no mention of complication 
 F3722 Asymptomatic diabetic neuropathy 
 XaKyX Type II diabetes mellitus with gastroparesis 
 XE12G Diabetes + eye manifestation (& [cataract] or [retinopathy]) 
 C10B0 Steroid-induced diabetes mellitus without complication 
 M2710 Ischaemic ulcer diabetic foot 
 XaELP Type I diabetes mellitus without complication 
 XE15k Diabetic polyneuropathy 
 C1091 Type II diabetes mellitus with ophthalmic complications 
 XE10H Diabetes mellitus with neurological manifestation 
 XaFn9 Type II diabetes mellitus with neuropathic arthropathy 
 XE12I Diabetes + neuropathy (& [amyotrophy]) 
 C1093 Type II diabetes mellitus with multiple complications 
 X40JJ Diabetes mellitus autosomal dominant type 2 
 XaJQp Type II diabetes mellitus with exudative maculopathy 
 F372. Diabetic neuropathy &/or diabetic polyneuropathy 
 C1092 Type II diabetes mellitus with neurological complications 
 XaF05 Type II diabetes mellitus with nephropathy 
 C10y. Diabetes mellitus with other specified manifestation 
 C1089 Type I diabetes mellitus maturity onset 
 C1061 Diabetes mellitus, adult onset, + neurological manifestation 
 XaEnq Type II diabetes mellitus with polyneuropathy 
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 X00Al Diabetic mononeuropathy 
 C1088 Type I diabetes mellitus - poor control 
 C1080 Type I diabetes mellitus with renal complications 
 C100z Diabetes mellitus NOS with no mention of complication 
 C10zz Diabetes mellitus NOS with unspecified complication 
 XE10G Diabetes mellitus with renal manifestation 
 C106z Diabetes mellitus NOS with neurological manifestation 
 C102. Diabetes mellitus with hyperosmolar coma 
 C1011 Type 2 diabetes mellitus with ketoacidosis 
 C105. Diabetes mellitus with ophthalmic manifestation 
 C1081 Type I diabetes mellitus with ophthalmic complications 
 XaKyW Type 1 diabetes mellitus with gastroparesis 
 XaJSr Type 1 diabetes mellitus with exudative maculopathy 
 XaF04 Type I diabetes mellitus with nephropathy 
 XE10I Diabetes mellitus with peripheral circulatory disorder 
 X00Aj Diabetic chronic painful polyneuropathy 
 XaIzM Type 1 diabetes mellitus with persistent proteinuria 
 XaIzN Type 1 diabetes mellitus with persistent microalbuminuria 
 C101z Diabetes mellitus NOS with ketoacidosis 
 X00Ai Diabetic acute painful polyneuropathy 
 C1095 Type II diabetes mellitus with gangrene 
 C1083 Type I diabetes mellitus with multiple complications 
 XaFWI Type II diabetes mellitus with hypoglycaemic coma 
 XaJUI Diabetes mellitus induced by non-steroid drugs 
 C102z Diabetes mellitus NOS with hyperosmolar coma 
 XaOPu Latent autoimmune diabetes mellitus in adult 
 Xa0lK Diabetic (femoral mononeuropathy) & (Diabetic amyotrophy) 
 C104y Other specified diabetes mellitus with renal complications 
 C107z Diabetes mellitus NOS with peripheral circulatory disorder 
 XaFm8 Type I diabetes mellitus with diabetic cataract 
 XaEnp Type II diabetes mellitus with mononeuropathy 
 C105z Diabetes mellitus NOS with ophthalmic manifestation 
 C1082 Type I diabetes mellitus with neurological complications 
 C107. Diabetes mellitus with: [gangrene] or [periph circul disord] 
 C101y Other specified diabetes mellitus with ketoacidosis 
 C108y Other specified diabetes mellitus with multiple comps 
 XaFWG Type I diabetes mellitus with hypoglycaemic coma 
 C103. Diabetes mellitus with ketoacidotic coma 
 XM1Qx Diabetes mellitus with gangrene 
 XaEnn Type I diabetes mellitus with mononeuropathy 
 XaFn7 Type II diabetes mellitus with peripheral angiopathy 
 f8... Diabetic neuropathy treatment [no drugs here] 
 X40JI Diabetes mellitus autosomal dominant 
 C10z. Diabetes mellitus with unspecified complication 
 C105y Other specified diabetes mellitus with ophthalmic complicatn 
 C1086 Type I diabetes mellitus with gangrene 
 C106y Other specified diabetes mellitus with neurological comps 
 C1085 Type I diabetes mellitus with ulcer    
Falls 16D.. Falls 
 TC... Accidental fall 
 Xa1GP Recurrent falls 
 Xa6uH Elderly fall 
 TCz.. Accidental falls NOS 
 TC5.. Fall on same level from slipping, tripping or stumbling 
 XaLqJ Referral to falls service 
 XaMGj Referral to elderly falls prevention clinic 
 Xa6uG Observation of falls 
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 Y3356 Unable to get off floor 
 YA756 Has pendant alarm services 
 XaN4s Provision of telecare community alarm service    
Gastrointestinal 
bleed, lower J5730 Rectal haemorrhage 
 X30Bj Bleeding per rectum 
 XaJuv Painless rectal bleeding 
 J573. (Haemorrhage of rectum & anus) or (PR - bleeding per rectum) 
 XE0d3 Anal &/or rectal haemorrhage 
 XaJuu Painful rectal bleeding 
 G8480 Bleeding haemorrhoids NOS 
 X76fy Bleeding pile 
 J5731 Anal haemorrhage 
 X30Bk Fresh blood passed per rectum 
 G8450 External bleeding haemorrhoids 
 X76fR Bleeding from anus 
 X30Bi Lower gastrointestinal haemorrhage 
 G8420 Internal bleeding haemorrhoids 
 XE0b0 Haemorrhage of rectum and anus 
 J573z Haemorrhage of rectum and anus NOS 
 X30Ct Stomal bleeding    
Gastrointestinal 
bleed, 
unspecified J68.. Gastrointestinal haemorrhage 
 XaB3J Recurrent gastrointestinal bleeding 
 XaB3K Massive gastrointestinal bleed 
 J68z. Gastrointestinal bleeding (& [unspecified]) 
 XE0bJ Gastrointestinal haemorrhage unspecified 
 J68z1 Intestinal haemorrhage NOS 
 J68zz Gastrointestinal tract haemorrhage NOS 
 Xa00e Sepsis-associated gastrointestinal haemorrhage    
Gastrointestinal 
bleed, upper J680. Haematemesis 
 XE0rB Vomiting blood - fresh 
 X30Bh Bleeding duodenal ulcer 
 X30Be Upper gastrointestinal haemorrhage 
 XaBfG Haematemesis - cause unknown 
 G850. Bleeding oesophageal varices 
 J1201 Acute duodenal ulcer with haemorrhage 
 J68z0 Gastric haemorrhage NOS 
 J1211 Chronic duodenal ulcer with haemorrhage 
 X30Bg Bleeding gastric ulcer 
 J1101 Acute gastric ulcer with haemorrhage 
 J1111 Chronic gastric ulcer with haemorrhage 
 XaB5h Haemorrhagic oesophagitis 
 J11y1 Unspecified gastric ulcer with haemorrhage 
 Xa7TU Oesophageal bleeding 
 J1103 Acute gastric ulcer with haemorrhage and perforation 
 Xa363 Vomiting stale blood 
 J1113 Chronic gastric ulcer with haemorrhage and perforation 
 XaBel Bleeding stress ulcer of stomach 
 J11y3 Unspecified gastric ulcer with haemorrhage and perforation 
 760J4 Balloon tamponade of oesophagus    
Haematuria K1972 Microscopic haematuria 
 XE0e5 Haematuria 
 XE0rU Blood in urine - haematuria 
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 K1973 Frank haematuria 
 K1971 Painful haematuria 
 K1970 Painless haematuria 
 XaB5q Haematuria NOS 
 X76YJ Bleeding from urethra 
 Xa1uK Persistent microscopic haematuria 
 Xa1uJ Recurrent frank haematuria 
 Xa1uL Recurrent microscopic haematuria 
 X30Pw Traumatic haematuria 
 Xa1uM Persistent haematuria 
 K197. Haematuria (& [traumatic] or [essential]) 
 1A45. Blood in urine (& symptom) 
 Xa1uN Recurrent haematuria 
 Xa1uI Persistent frank haematuria 
 XE0un Blood in urine - haematuria (& [symptom]) 
 X30Q0 Chemical haematuria 
 K0A2. Recurrent and persistent haematuria 
 K1974 Clot haematuria 
 X30Px Loin pain - haematuria syndrome 
 X30Ih Benign familial haematuria 
 X30Pz Upper urinary tract haematuria 
 K0A23 Recur+persist haemuria df mesangial prolif glomerulnephritis 
 K0A20 Recurrent+persistnt haematuria minor glomerular abnormality    
Haemoptysis R063. [D]Haemoptysis 
 XE0qp Blood in sputum - haemoptysis 
 172.. Blood in sputum - haemoptysis [& symptom] 
 R0630 [D]Cough with haemorrhage 
 Xa7vG Bloodstained sputum 
 R063z [D]Haemoptysis NOS 
 Xa7vH Blood streaked sputum 
 Xa7vI Frank blood in sputum 
 XaZy3 Massive haemoptysis 
 R0631 [D]Pulmonary haemorrhage NOS 
 XM0zJ Pulmonary haemorrhage   [D]    
Heart failure XaJ98 Echocardiogram shows left ventricular systolic dysfunction 
 XaIIq Left ventricular systolic dysfunction 
 XE2QG Left ventricular failure 
 XaJ9H New York Heart Association classification - class II 
 G58.. Heart failure 
 XaLN7 Heart failure review completed 
 G580. Heart failure: [right] or [congestive] 
 XaKNa Seen by community heart failure nurse 
 XaKNN Seen in heart failure clinic 
 G5801 Chronic congestive heart failure 
 XM1Qn Impaired left ventricular function 
 XaMJA Excepted heart failure quality indicators: Patient unsuitabl 
 XaKNX Referral to heart failure nurse 
 XE0V8 Biventricular failure 
 1736 Paroxysmal nocturnal dyspnoea 
 G581. (L ventric:[fail][imp func]) or (card asth) or (ac pulm oed) 
 XaIQN Heart failure annual review 
 XaWyi Heart failure with normal ejection fraction 
 G5800 Acute congestive heart failure 
 XE0V9 Heart failure NOS 
 G582. Acute heart failure 
 XaMJB Excepted heart failure quality indicators: Informed dissent 
 X202l Right ventricular failure 
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 XaJ9I New York Heart Association classification - class III 
 XaLon Heart failure 6 month review 
 14A6. H/O: heart failure 
 XaO5n Congestive heart failure due to valvular disease 
 XaIIU Congestive heart failure monitoring 
 G58z. Heart: [weak] or [failure NOS] 
 XE0Wo (Conges card fail)(dropsy)(card insuf)(R hrt fail)(LV fail) 
 XaXgq Referral to heart failure exercise programme declined 
 XE0WE Heart disease: [arteriosclerotic] or [chronic ischaemic NOS] 
 XaLCj Referred by heart failure nurse specialist 
 XaIL7 New York Heart Assoc classification heart failure symptoms 
 X102Y Acute cardiac pulmonary oedema 
 XaLNA Heart failure care plan discussed with patient 
 XaKNW Admit heart failure emergency 
 XaIpn Heart failure confirmed 
 XaMGu Heart failure monitoring third letter 
 XaQdP Heart failure self management plan 
 XaNUf Heart failure education 
 XaEgY Refractory heart failure 
 XaLGJ Did not attend practice nurse heart failure clinic 
 G5y4z Post cardiac operation heart failure NOS 
 XaBwi H/O: Heart failure in last year 
 XaMHD Did not attend heart failure clinic 
 XaLMw Heart failure information given to patient 
 XaLMx Referral to heart failure exercise programme 
 X202k Heart failure as a complication of care 
 bm... Vasodilators in heart failure [no drugs here]    
Hypertension XE0Ub Hypertension 
 XE0Uc Essential hypertension 
 XaJ4e Excepted from hypertension qual indicators: Patient unsuit 
 G2... Hypertensive disease 
 XaJ4P Exception reporting: hypertension quality indicators 
 XaJ4f Excepted from hypertension qual indicators: Informed dissent 
 XE0Ud Essential hypertension NOS 
 XaQaV Lifestyle advice regarding hypertension 
 14A2. H/O: hypertension 
 G2z.. Hypertensive disease NOS 
 9N1y2 Seen in hypertension clinic 
 F4211 Hypertensive retinopathy 
 6628 Poor hypertension control 
 G20.. High blood pressure (& [essential hypertension]) 
 G201. Benign essential hypertension 
 Gyu21 [X]Hypertension secondary to other renal disorders 
 G20z. Hypertension NOS (& [essential]) 
 G24.. Secondary hypertension 
 G202. Systolic hypertension 
 662F. Hypertension treatm. started 
 6627 Good hypertension control 
 XSDSb Diastolic hypertension 
 Xa8HD On treatment for hypertension 
 Xa0Cs Labile hypertension 
 XaJYi Hypertension clinical management plan 
 Xa3fQ Malignant hypertension 
 XaIy8 Moderate hypertension control 
 G24z1 Hypertension secondary to drug 
 XE0W8 (Hypertensive disease) or (hypertension) 
 G200. Malignant essential hypertension 
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 Xa0kX Renovascular hypertension 
 G24z. Secondary hypertension NOS 
 G24z0 Secondary renovascular hypertension NOS 
 G240. Malignant secondary hypertension 
 G22z. (Renal hypertension) or (hypertensive renal disease NOS) 
 G241z Secondary benign hypertension NOS 
 G240z Secondary malignant hypertension NOS 
 G244. Hypertension secondary to endocrine disorders 
 G241. Secondary benign hypertension 
 Gyu20 [X]Other secondary hypertension    
Hyperthyroidism 4422 Thyroid hormone tests high 
 XE104 Thyrotoxicosis 
 1431 H/O: hyperthyroidism 
 C022. Toxic multinodular goitre 
 XaZtG Subclinical hyperthyroidism 
 X40H0 Thyrotoxicosis on thyroxine therapy 
 X40Gt Borderline thyrotoxicosis 
 X40Gj Toxic goitre 
 C02.. ([Thyrotoxicosis] or [hyperthyroidism]) or (toxic goitre) 
 X40Go Toxic nodular goitre 
 X40Gk Thyrotoxicosis due to Graves' disease 
 C1343 TSH deficiency 
 C02zz Thyrotoxicosis NOS 
 C02z. Thyrotoxicosis without mention of goitre or other cause 
 XE122 Thyrotoxicosis: [+/- goitr][tox goitr][Graves dis][thyr nod] 
 XaKcQ Hyperthyroidism resolved 
 C022z Toxic multinodular goitre NOS 
 C02z0 Thyrotoxicosis without mention of goitre or cause no crisis 
 X40Gs T3 toxicosis 
 X40H2 Amiodarone-induced thyrotoxicosis 
 X40Gl Thyrotoxicosis due to Hashimoto's thyroiditis 
 Cyu13 [X]Other thyrotoxicosis 
 XE106 Thyrotoxicosis of other specified origin 
 XaJDU Did not attend hyperthyroidism clinic 
 Xa3eb Thyrotoxicosis with or without goitre 
 C024. Thyrotoxicosis from ectopic thyroid nodule 
 C0220 Toxic multinodular goitre with no crisis 
 XE105 Toxic diffuse goitre 
 C023. Toxic nodular goitre unspecified 
 C021. Toxic uninodular goitre 
 C023z Toxic nodular goitre NOS 
 C02yz Thyrotoxicosis of other specified origin NOS 
 X40Gq Toxic thyroid nodule 
 X40H1 Iodine-induced thyrotoxicosis 
 C0200 Toxic diffuse goitre with no crisis 
 X40Gz Iatrogenic thyrotoxicosis 
 X40Gn Thyrotoxicosis due to acute thyroiditis 
 C021z Toxic uninodular goitre NOS 
 C02y0 Thyrotoxicosis of other specified origin with no crisis 
 X40Gw Thyrotoxicosis in pregnancy 
 C02z1 Thyrotoxicosis without mention of goitre, cause with crisis 
 C0201 Toxic diffuse goitre with crisis 
 X40H5 Thyrotoxicosis due to TSHoma 
 C0230 Toxic nodular goitre unspecified with no crisis 
 C020z Toxic diffuse goitre NOS 
 X40Gu Autonomous thyroid function 
 C0221 Toxic multinodular goitre with crisis 
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 C02y. Thyrotoxicosis: [other specified origin] or [factitia] 
 X40H3 Thyroid crisis 
 C0210 Toxic uninodular goitre with no crisis 
 X40H4 Thyrotoxicosis due to inappropriate TSH secretion    
Intracranial 
haemorrhage G613. Cerebellar haemorrhage 
 G61z. Intracerebral haemorrhage NOS 
 XM0rV Cerebral haemorrhage 
 XE0VF Cerebral parenchymal haemorrhage 
 Gyu6F [X]Intracerebral haemorrhage in hemisphere, unspecified 
 XaBM4 Left sided intracerebral haemorrhage, unspecified 
 X00DQ Brainstem haemorrhage 
 G614. Pontine haemorrhage 
 X00DO Thalamic haemorrhage 
 XE0Wy Cerebral haemorrhage NOS 
 G612. Basal ganglia haemorrhage 
 X00DP Lacunar haemorrhage 
 G611. Internal capsule haemorrhage 
 G617. Intracerebral haemorrhage, intraventricular 
 XaBM5 Right sided intracerebral haemorrhage, unspecified 
 G610. Cortical haemorrhage 
 X00DM Lobar cerebral haemorrhage 
 G616. External capsule haemorrhage 
 X00DN Subcortical cerebral haemorrhage 
 G618. Intracerebral haemorrhage, multiple localised 
 G615. Bulbar haemorrhage    
Ischaemic heart 
disease XaIwY Acute non-ST segment elevation myocardial infarction 
 XE2uV Ischaemic heart disease 
 G33.. Angina 
 7928 Percutaneous balloon angioplasty of coronary artery 
 X200E Myocardial infarction 
 XE0Uh Acute myocardial infarction 
 X2009 Unstable angina 
 G33z. Angina pectoris NOS 
 G3z.. Ischaemic heart disease NOS 
 792.. Coronary artery operations (& bypass) 
 14A5. H/O: angina pectoris 
 662K0 Angina control - good 
 X00tE Coronary artery bypass grafting 
 X2008 Stable angina 
 XaIOW Coronary heart disease review 
 G34y1 Chronic myocardial ischaemia 
 X00tU Insertion of coronary artery stent 
 XaI9h Coronary heart disease annual review 
 G308. Inferior myocardial infarction NOS 
 X2006 Triple vessel disease of the heart 
 Xa7nH Exercise-induced angina 
 XE2aA Old myocardial infarction 
 G30z. Acute myocardial infarction NOS 
 G340. Coronary (atheroscl or artery dis) or triple vess dis heart 
 G3... Ischaemic heart disease (& [arteriosclerotic]) 
 Y3657 H/O: Ischaemic heart disease 
 G30.. (Myocard inf (& [ac][silent][card rupt])) or (coron thromb) 
 322.. ECG: myocardial ischaemia 
 XaNxN Admit ischaemic heart disease emergency 
 14A.. H/O: cardiovasc disease (& [heart disord][myocard problem]) 
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 3222 ECG:shows myocardial ischaemia 
 322Z. ECG: myocardial ischaemia NOS 
 X200C Myocardial ischaemia 
 XM0rN Coronary atherosclerosis 
 Xa0wX Central crushing chest pain 
 Ua1eH Ischaemic chest pain 
 662K3 Angina control - worsening 
 662K1 Angina control - poor 
 X200B Coronary spasm 
 X200c Cardiac syndrome X 
 XE0WA Myocardial infarction (& [acute]) or coronary thrombosis 
 14A4. H/O: myocardial infarct at greater than 60 
 XaFx7 Diab mellit insulin-glucose infus acute myocardial infarct 
 X75rV Crushing chest pain 
 G3y.. Other specified ischaemic heart disease 
 G30yz Other acute myocardial infarction NOS 
 G30y. Other acute myocardial infarction 
 XE0WC Acute/subacute ischaemic heart disease NOS 
 Gyu30 [X]Other forms of angina pectoris 
 X200d Post-infarction ventricular septal defect 
 XaFsH Transient myocardial ischaemia 
 G34z. Other chronic ischaemic heart disease NOS 
 G361. Atrial septal defect/curr comp folow acut myocardal infarct 
 Y6999 H/O: myocardial infarct >60 
 XE0WG Chronic ischaemic heart disease NOS 
 XaNMH Cardiovascular disease annual review declined 
 G31y2 Subendocardial ischaemia 
 G36.. Certain current complication follow acute myocardial infarct 
 G34yz Other specified chronic ischaemic heart disease NOS 
 bl... Vasodilators used in angina pectoris 
 G31yz Other acute and subacute ischaemic heart disease NOS    
Memory 
impairment F110. Alzheimer's disease 
 XaMGF Dementia annual review 
 X002w Dementia 
 XaJua Referral to memory clinic 
 XE1Xs Vascular dementia 
 2841 Confused 
 1461 H/O: dementia 
 X75xH Poor short-term memory 
 XaMJC Dementia monitoring 
 X75xU Memory impairment 
 1B1A. Memory disturbance (& amnesia (& symptom)) 
 Eu00. [X]Dementia in Alzheimer's disease 
 XaNbm Seen in memory clinic 
 Eu002 [X]Dementia in Alzheimer's dis, atypical or mixed type 
 Ua196 Minor memory lapses 
 E004z Arteriosclerotic dementia NOS 
 XaLFo Excepted from dementia quality indicators: Patient unsuitabl 
 Ua197 Memory lapses 
 XE1Z6 [X]Unspecified dementia 
 E2A10 Mild memory disturbance 
 Xa3f0 Confusional state 
 XaLFp Excepted from dementia quality indicators: Informed dissent 
 E0020 Senile dementia with paranoia 
 X00RS Mild cognitive disorder 
 XaMGG Dementia monitoring second letter 
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 XaMGI Dementia monitoring third letter 
 Xa0lH Multi-infarct dementia 
 X75xG Amnesia for recent events 
 E2A11 Organic memory impairment 
 X0030 Dementia in Alzheimer's disease with late onset 
 XaPpE Lacks capacity to give consent (Mental Capacity Act 2005) 
 Xa25J Alcoholic dementia 
 X00RT Age-associated memory impairment 
 X003A Lewy body disease 
 X003V Mixed cortical and subcortical vascular dementia 
 XaKyY [X]Lewy body dementia 
 X00R2 Senile dementia 
 X0034 Frontotemporal dementia 
 X002x Dementia in Alzheimer's disease with early onset 
 Eu041 [X]Delirium superimposed on dementia 
 F21y2 Binswanger's disease 
 Xa0sE Dementia of frontal lobe type 
 XE1bq Memory disturbance: [mild] 
 XaMGK Dementia monitoring telephone invite 
 X75xD Amnesia for remote events 
 XaJPy Anti-dementia drug therapy 
 XaMFy Dementia monitoring administration 
 X003R Vascular dementia of acute onset 
 Eu00z [X]Dementia in Alzheimer's disease, unspecified 
 R00z0 [D]Amnesia (retrograde) 
 X003W Semantic dementia 
 Eu023 [X]Dementia in Parkinson's disease 
 Eu01z [X]Vascular dementia, unspecified 
 3A40. Memory: present year not known 
 XaE74 Senile dementia of the Lewy body type 
 3AA1. Memory: address recall unsucc. 
 Eu01y [X]Other vascular dementia 
 Xa1GB Cerebral degeneration presenting primarily with dementia 
 X75xC Poor long-term memory 
 E001. Presenile dementia 
 E000. Uncomplicated senile dementia 
 Eu02z [X] Dementia: [unspecified] or [named variants (& NOS)] 
 XaLFf Exception reporting: dementia quality indicators 
 E012. Alcoholic dementia: [other] or [NOS] 
 E0021 Senile dementia with depression 
 E0041 Arteriosclerotic dementia with delirium 
 E0010 Uncomplicated presenile dementia 
 XaJBQ Global deterioration scale: assessment of prim deg dementia 
 3A70. Memory: important event not kn 
 Ua190 Distortion of memory 
 X003T Subcortical vascular dementia 
 XE1Xu Other alcoholic dementia 
 3A91. Memory: count down unsuccess. 
 3A60. Memory: present month not knwn 
 Xa3ez Other senile/presenile dementia 
 E041. Dementia in conditions EC 
 X00Rk Alcoholic dementia NOS 
 3A30. Memory: present place not knwn 
 E004. Arteriosclerotic dementia (including [multi infarct dement]) 
 E0040 Uncomplicated arteriosclerotic dementia 
 3A20. Memory: present time not known 
 X002m Amyotrophic lateral sclerosis with dementia 
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 Eu022 [X]Dementia in Huntington's disease 
 E003. Senile dementia with delirium 
 E001z Presenile dementia NOS 
 Eu011 [X]Dementia: [multi-infarct] or [predominantly cortical] 
 Xa2Ve Impairment of registration 
 Eu02y [X]Dementia in other specified diseases classif elsewhere 
 3A10. Memory: own age not known 
 3A80. Memory: import.person not knwn 
 3A50. Memory: own DOB not known 
 XE1aG Dementia (& [presenile] or [senile]) 
 Eu02. [X]Dementia in other diseases classified elsewhere 
 E002. Senile dementia with depressive or paranoid features 
 E0013 Presenile dementia with depression 
 X003P Acquired immune deficiency syndrome dementia complex 
 X003X Patchy dementia 
 Eu020 [X]Dementia in Pick's disease 
 Ub1T6 Language disorder of dementia 
 XaKUo Disturbance of memory for order of events 
 E0011 Presenile dementia with delirium 
 E0042 Arteriosclerotic dementia with paranoia 
 E002z Senile dementia with depressive or paranoid features NOS 
 E0012 Presenile dementia with paranoia 
 E0043 Arteriosclerotic dementia with depression    
Myocardial 
infarction XaIwY Acute non-ST segment elevation myocardial infarction 
 G301z Anterior myocardial infarction NOS 
 X200E Myocardial infarction 
 XE0Uh Acute myocardial infarction 
 X2009 Unstable angina 
 G308. Inferior myocardial infarction NOS 
 14A3. H/O: myocardial infarct at less than 60 
 G301. Other specified anterior myocardial infarction 
 G300. Acute anterolateral myocardial infarction 
 G30z. Acute myocardial infarction NOS 
 G30.. (Myocard inf (& [ac][silent][card rupt])) or (coron thromb) 
 G305. Lateral myocardial infarction NOS 
 323.. ECG: myocardial infarction 
 G307. Acute subendocardial infarction 
 G310. Post-myocardial infarction syndrome 
 G302. Acute inferolateral myocardial infarction 
 323Z. ECG: myocardial infarct NOS 
 G303. Acute inferoposterior infarction 
 XE0WA Myocardial infarction (& [acute]) or coronary thrombosis 
 14A4. H/O: myocardial infarct at greater than 60 
 G35.. Subsequent myocardial infarction 
 G304. Posterior myocardial infarction NOS 
 G30yz Other acute myocardial infarction NOS 
 G30y. Other acute myocardial infarction 
 XE0WC Acute/subacute ischaemic heart disease NOS 
 X200d Post-infarction ventricular septal defect 
 G361. Atrial septal defect/curr comp folow acut myocardal infarct 
 G350. Subsequent myocardial infarction of anterior wall 
 G366. Thrombosis atrium,auric append&vent/curr comp foll acute MI 
 Gyu34 [X]Acute transmural myocardial infarction of unspecif site 
 G351. Subsequent myocardial infarction of inferior wall 
 G36.. Certain current complication follow acute myocardial infarct 
 G364. Ruptur chordae tendinae/curr comp fol acute myocard infarct 
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 G31yz Other acute and subacute ischaemic heart disease NOS    
Obesity XaJJH Body mass index 40+ - severely obese 
 XM00v Obese build 
 XabHx Obese class I (body mass index 30.0 - 34.9) 
 222A. O/E - obese 
 X76dX Obese abdomen 
 XabHy Obese class II (body mass index 35.0 - 39.9) 
 XabHz Obese class III (BMI equal to or greater than 40.0)    
Peptic ulcer J12.. Duodenal ulcer 
 J11.. Gastric ulcer (& [prepyloric] or [pyloric]) 
 XE0aQ Gastric ulcer NOS 
 J13.. Ulcer: [peptic (PU) site unspecified] or [stress NOS] 
 J120z Acute duodenal ulcer NOS 
 XM0sI Perforated peptic ulcer 
 XM1RO H/O: gastric ulcer 
 J12z. Duodenal ulcer NOS 
 XE0aP Gastric ulcer 
 14C1. H/O: peptic ulcer (& [duodenal] or [gastric]) 
 J120. Acute duodenal ulcer 
 X302b Duodenal ulcer disease 
 J11z. Gastric: [erosions] or [multiple ulcers] or [ulcer NOS] 
 XE0qB H/O: peptic ulcer 
 J1202 Acute duodenal ulcer with perforation 
 X30Bh Bleeding duodenal ulcer 
 XaELE Multiple gastric ulcers 
 1956 Peptic ulcer symptoms 
 X302Q Perforation of duodenal ulcer 
 XM0BZ Peptic ulcer disease 
 J13z. Peptic ulcer NOS 
 J1020 Gastro-oesophageal reflux disease with ulceration 
 J121. Chronic duodenal ulcer 
 XaMO7 Non steroidal anti inflammatory drug induced duodenal ulcer 
 XaMO5 Non steroidal anti inflammatory drug induced gastric ulcer 
 J1301 Acute peptic ulcer with haemorrhage 
 XaB9d Repair of perforated pyloric ulcer 
 J131. Chronic peptic ulcer 
 Xa6ot Prepyloric gastric ulcer 
 J111. Chronic gastric ulcer 
 76270 Closure of perforated duodenal ulcer 
 XM1RN H/O: duodenal ulcer 
 J124. Recurrent duodenal ulcer 
 Xa84h Pyloric ulcer 
 XE0aS Gastrojejunal ulcer 
 J110. Acute gastric ulcer 
 J12y1 Unspecified duodenal ulcer with haemorrhage 
 J12y. Unspecified duodenal ulcer 
 X302c Peptic ulcer of duodenum 
 J1201 Acute duodenal ulcer with haemorrhage 
 J130. Acute peptic ulcer 
 X302F Chronic peptic ulcer of duodenum 
 J13y. Unspecified peptic ulcer 
 X302X Peptic ulcer of stomach 
 X20VN Oversewing perforated gastric ulcer 
 X301o Perforation of gastric ulcer 
 J12y2 Unspecified duodenal ulcer with perforation 
 J110z Acute gastric ulcer NOS 
 J1211 Chronic duodenal ulcer with haemorrhage 
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 J17y8 Healed gastric ulcer leaving a scar 
 XE0aR Peptic ulcer - (PU) site unspecified 
 J1200 Acute duodenal ulcer without mention of complication 
 J1100 Acute gastric ulcer without mention of complication 
 X30Bg Bleeding gastric ulcer 
 J1212 Chronic duodenal ulcer with perforation 
 J12y0 Unspecified duodenal ulcer without mention of complication 
 J13yz Unspecified peptic ulcer NOS 
 J1210 Chronic duodenal ulcer without mention of complication 
 761Jy Other specified operation on gastric ulcer 
 J11y. Unspecified gastric ulcer 
 761J0 Closure of perforated gastric ulcer 
 J121y Chronic duodenal ulcer unspecified 
 J14.. Ulcer: [gastrojej]/[anast]/[gastrocol]/[jej]/[margin]/[stom] 
 J1311 Chronic peptic ulcer with haemorrhage 
 J110y Acute gastric ulcer unspecified 
 J12yz Unspecified duodenal ulcer NOS 
 J120y Acute duodenal ulcer unspecified 
 761J. Gastric ulcer operation 
 X20Vu Oversewing perforated duodenal ulcer 
 XE0c1 Perforated DU (& [acute]) 
 X301J Chronic peptic ulcer of stomach 
 ZV127 [V]Pers hist digest syst disease (& [pept ulcer (& [duod])]) 
 J121z Chronic duodenal ulcer NOS 
 XaBmb Bleeding peptic ulcer 
 XaB8q Oversewing of bleeding duodenal ulcer 
 J1102 Acute gastric ulcer with perforation 
 7627z Operation on duodenal ulcer NOS 
 J1101 Acute gastric ulcer with haemorrhage 
 X301E Acute peptic ulcer of stomach 
 J11yz Unspecified gastric ulcer NOS 
 7627 Duodenal ulcer operation 
 XaLWq Anti-platelet induced gastric ulcer 
 J1111 Chronic gastric ulcer with haemorrhage 
 J111z Chronic gastric ulcer NOS 
 XaLdV Oversew of blood vessel of duodenal ulcer 
 J13y2 Unspecified peptic ulcer with perforation 
 J130z Acute peptic ulcer NOS 
 J1203 Acute duodenal ulcer with haemorrhage and perforation 
 76271 Suture of duodenal ulcer not elsewhere classified 
 J131y Chronic peptic ulcer unspecified 
 761Jz Operation on gastric ulcer NOS 
 XE0bz Perforated GU (& [acute]) 
 J12yy Unspec duodenal ulcer; unspec haemorrhage and/or perforation 
 XaB2R Suture of duodenal ulcer 
 XE0c3 Ulcer: [peptic NOS]/[gastrojejunal]/[stomal]/[anastomotic] 
 XaMO6 Non steroidal anti inflammatory drug induced gastric ulc NOS 
 XaFBq Endoscopic injection haemostasis of duodenal ulcer 
 J1302 Acute peptic ulcer with perforation 
 XaB9e Omental patch repair of perforated pyloric ulcer 
 XaCLu [V] Personal history of gastric ulcer 
 J11y0 Unspecified gastric ulcer without mention of complication 
 J1114 Chronic gastric ulcer with obstruction 
 J1310 Chronic peptic ulcer without mention of complication 
 J14z. Gastrojejunal ulcer NOS 
 J131z Chronic peptic ulcer NOS 
 J130y Acute peptic ulcer unspecified 
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 XaBlw Gastric ulcer sample 
 J1300 Acute peptic ulcer without mention of complication 
 7627y Other specified operation on duodenal ulcer 
 XaB15 Laparoscopic closure of perforated gastric ulcer 
 J13y1 Unspecified peptic ulcer with haemorrhage 
 J11y1 Unspecified gastric ulcer with haemorrhage 
 J1112 Chronic gastric ulcer with perforation 
 J1110 Chronic gastric ulcer without mention of complication 
 XaFBs Endoscopic injection haemostasis of gastric ulcer 
 XaMO8 Non steroidal anti inflammatory drug induced duoden ulc NOS 
 XaLWs Anti-platelet induced duodenal ulcer 
 X301F Acute drug-induced ulcer of stomach 
 J1401 Acute gastrojejunal ulcer with haemorrhage 
 J1312 Chronic peptic ulcer with perforation 
 Xa3ti Perforated peptic ulcer closure 
 J1103 Acute gastric ulcer with haemorrhage and perforation 
 Xa3u7 Stomach ulcer excision 
 XaBel Bleeding stress ulcer of stomach 
 X301G Stress ulcer of stomach 
 J14y. Unspecified gastrojejunal ulcer 
 J57y8 Primary ulcer of intestine 
 J12y4 Unspecified duodenal ulcer with obstruction 
 X302A Acute peptic ulcer of duodenum 
 J12y3 Unspecified duodenal ulcer with haemorrhage and perforation 
 XE0Cr Closure of gastric ulcer NEC 
 J111y Chronic gastric ulcer unspecified 
 J11y2 Unspecified gastric ulcer with perforation 
 J1214 Chronic duodenal ulcer with obstruction 
 J1213 Chronic duodenal ulcer with haemorrhage and perforation    
Peripheral 
vascular 
disease XaBL8 O/E - Absent right foot pulses 
 24F9. O/E - L.dorsalis pedis absent 
 24E9. O/E - R.dorsalis pedis absent 
 X203T Lower limb ischaemia 
 XaJD3 O/E - Right dorsalis pedis abnormal 
 G73z. Peripheral vascular disease NOS 
 X203Q Peripheral ischaemia 
 X203R Upper limb ischaemia 
 G73.. (Peri vasc dis (& [isch][oth])) or (isch leg) or (peri isch) 
 XaVyB History of peripheral vascular disease 
 X203S Critical upper limb ischaemia 
 X203U Critical lower limb ischaemia 
 XaE3G Critical ischaemia of foot 
 M2710 Ischaemic ulcer diabetic foot 
 X203M Arterial ischaemia 
 Xa0IV Consistencies 
 XE10I Diabetes mellitus with peripheral circulatory disorder 
 C107. Diabetes mellitus with: [gangrene] or [periph circul disord] 
 XM1Qx Diabetes mellitus with gangrene 
 G670. Atherosclerosis: [precerebral] or [cerebral] 
 XaFn7 Type II diabetes mellitus with peripheral angiopathy 
 C1086 Type I diabetes mellitus with gangrene    
Pulmonary 
embolism XE0Um Pulmonary embolus 
 G4010 Postoperative pulmonary embolus 
 X202x Pulmonary thromboembolism 
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 XaOYV Recurrent pulmonary embolism 
 X202y Acute massive pulmonary embolism 
 L43.. Obstetric pulmonary embolism 
 X202z Subacute massive pulmonary embolism 
 L43z1 Obstetric pulmonary embolism NOS - delivered 
 L43z0 Obstetric pulmonary embolism NOS, unspecified 
 L432. Obstetric blood-clot pulmonary embolism 
 L43z. Obstetric pulmonary embolism NOS    
Smoking Ub0oq Non-smoker 
 XE0oh Never smoked tobacco 
 1371 Non-smoker (& [never smoked tobacco]) 
 Y6628 Ex smoker 
 XaQUC Non-smoker annual review 
 XE0op Ex-cigarette smoker amount unknown 
 Ub1tI Cigarette consumption 
 137R. Smoker 
 Ub1na Ex-smoker 
 XE0oq Cigarette smoker 
 Xa1bv Ex-cigarette smoker 
 137K. Stopped smoking 
 1379 Ex-moderate smoker (10-19/day) 
 1374 Moderate cigarette smoker (10-19 cigs/day) 
 137G. Trying to give up smoking 
 Ub0p3 Age at starting smoking 
 137C. Keeps trying to stop smoking 
 XaIQj Negotiated date for cessation of smoking 
 137.. [Tobacco consumption] or [smoker - amount smoked] 
 137M. Rolls own cigarettes 
 XaIQk Smoking status at 4 weeks 
 XaBSp Smoking restarted 
 1375 Heavy cigarette smoker (20-39 cigs/day) 
 137A. Ex-heavy smoker (20-39/day) 
 137H. Pipe smoker 
 137F. Ex-smoker - amount unknown 
 1378 Ex-light smoker (1-9/day) 
 XaLQh Wants to stop smoking 
 XaIth Smoking cessation programme start date 
 XaIQl Smoking status between 4 and 52 weeks 
 137B. Ex-very heavy smoker (40+/day) 
 137O. Ex-cigar smoker 
 XaIkY Not interested in stopping smoking 
 137J. Cigar smoker 
 Ub1tJ Cigar consumption 
 1377 Ex-trivial smoker (<1/day) 
 137T. Date ceased smoking 
 137L. Current non-smoker 
 XaIkW Thinking about stopping smoking 
 Ub0p1 Time since stopped smoking 
 Ub1tK Pipe tobacco consumption 
 1373 Light cigarette smoker (1-9 cigs/day) 
 1372 (Trivial smoker - < 1 cig/day) or (occasional smoker) 
 Ub0oo Tobacco smoking behaviour 
 137Z. Tobacco consumption NOS 
 YA602 Contented smoker 
 XE0og Tobacco smoking consumption 
 XaK28 Carbon monoxide reading at 4 weeks 
 Ub1tR Occasional cigarette smoker 
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 XE0ol Ex-moderate cigarette smoker (10-19/day) 
 XaWNE Failed attempt to stop smoking 
 XE0on Ex-very heavy cigarette smoker (40+/day) 
 XE0om Ex-heavy cigarette smoker (20-39/day) 
 Ub1tT Moderate cigarette smoker 
 XaQ8V Ex roll-up cigarette smoker 
 1376 Very heavy cigarette smoker (40+ cigs/day) 
 XaIkX Ready to stop smoking 
 XaQzw Recently stopped smoking 
 Ub1tU Heavy cigarette smoker 
 Ub0p2 Total time smoked 
 XaIr7 Smoking free weeks 
 Ub1tV Very heavy cigarette smoker 
 XE0ok Ex-light cigarette smoker (1-9/day) 
 XE0oi Trivial cigarette smoker (less than one cigarette/day) 
 137N. Ex-pipe smoker 
 Ub1tS Light cigarette smoker 
 XaIQi Smoking cessation milestones 
 137P. Smoker (& cigarette) 
 XaW0h Practice based smoking cessation programme start date 
 XaItg Reason for restarting smoking 
 XaIQm Smoking status at 52 weeks 
 XE0oj Ex-trivial cigarette smoker (<1/day) 
 XaXUL Lost to smoking cessation follow-up 
 Y7110 Heavy smoker - 20-39 cigs/day 
 XaJX2 Minutes from waking to first tobacco consumption 
 XE1b4 Tobacco dependence (& [dependent smoker]) 
 Y0983 Smoking status at 4 weeks - Smoker 
 137Q. Smoking: [started] or [restarted] 
 XE0or Smoking started 
 XaZIE Waterpipe tobacco consumption 
 XE0oo Tobacco smoking consumption unknown 
 137D. Admitted tobacco cons untrue ? 
 Y9843 Very heavy smoker - 40+cigs/d 
 Ub1tW Chain smoker 
 XaXPX Smoking status at 12 weeks 
 XaIuQ Cigarette pack-years    
Stroke - 
haemorrhage G613. Cerebellar haemorrhage 
 G61z. Intracerebral haemorrhage NOS 
 G61.. Intracerebral haemorrhage (& [cerebrovasc accident due to]) 
 XE0VF Cerebral parenchymal haemorrhage 
 XaBM4 Left sided intracerebral haemorrhage, unspecified 
 X00DQ Brainstem haemorrhage 
 G614. Pontine haemorrhage 
 X00DO Thalamic haemorrhage 
 G612. Basal ganglia haemorrhage 
 X00DP Lacunar haemorrhage 
 G611. Internal capsule haemorrhage 
 XaBM5 Right sided intracerebral haemorrhage, unspecified 
 G610. Cortical haemorrhage 
 X00DM Lobar cerebral haemorrhage 
 G616. External capsule haemorrhage 
 X00DN Subcortical cerebral haemorrhage 
 G618. Intracerebral haemorrhage, multiple localised 
 G615. Bulbar haemorrhage    
Stroke - infarct Xa00I Occipital cerebral infarction 
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 X00DA Lacunar infarction 
 Xa0kZ Cerebral infarction 
 X00DI Haemorrhagic cerebral infarction 
 X00D8 Posterior cerebral circulation infarction 
 X00D7 Partial anterior cerebral circulation infarction 
 Xa00K Brainstem infarction 
 G640. Cerebral thrombosis 
 X00D3 CVA - cerebral artery occlusion 
 X00D6 Total anterior cerebral circulation infarction 
 Xa00J Cerebellar infarction 
 XaBED Right sided cerebral infarction 
 XaBEC Left sided cerebral infarction 
 XaJgQ Infarction of basal ganglia 
 XaB4Z Multiple lacunar infarcts 
 XE0VJ Cerebral infarction NOS 
 X00DC Pure sensory lacunar infarction 
 XaQbK Pure motor lacunar syndrome 
 X00D5 Anterior cerebral circulation infarction 
 G6410 Cerebral infarction due to embolism of cerebral arteries 
 G64z. Infarct (& [cerebell] or [cerebral NOS] or [brainstem NOS]) 
 Gyu64 [X]Other cerebral infarction 
 G6400 Cerebral infarction due to thrombosis of cerebral arteries 
 X00D9 Brainstem infarction NOS 
 Xa00M Wallenberg syndrome 
 Gyu63 [X]Cerebrl infarctn due/unspcf occlusn or sten/cerebrl artrs 
 G6760 Cereb infarct due cerebral venous thrombosis, non-pyogenic 
 X00DK Posterior cerebral circulation haemorrhagic infarction 
 Gyu6G [X]Cereb infarct due unsp occlus/stenos precerebr arteries 
 G63y1 Cerebral infarction due to embolism of precerebral arteries 
 X00DJ Anterior cerebral circulation haemorrhagic infarction 
 G63y0 Cerebral infarct due to thrombosis of precerebral arteries 
 X00DB Pure motor lacunar infarction 
 X00DD Pure sensorimotor lacunar infarction 
 Xa00P Weber syndrome 
 X00D4 Infarction - precerebral    
Stroke - 
unspecified XaEGq Stroke NOS 
 X00D1 Cerebrovascular accident 
 G66.. CVA - cerebrovascular accident (& unspecified [& stroke]) 
 XE2aB Stroke and cerebrovascular accident unspecified 
 XE0X2 (Cereb infarc)(cerebrovas acc)(undef stroke/CVA)(stroke NOS) 
 G667. Left sided cerebral hemisphere cerebrovascular accident 
 X00DR Stroke of uncertain pathology 
 G668. Right sided cerebral hemisphere cerebrovascular accident 
 X00DT Posterior circulation stroke of uncertain pathology 
 G664. Cerebellar stroke syndrome 
 X00DE Lacunar ataxic hemiparesis 
 X00DS Anterior circulation stroke of uncertain pathology 
 G663. Brainstem stroke syndrome 
 Xa00L Benedict syndrome 
 X00DF Dysarthria-clumsy hand syndrome 
 Xa1hE Extension of cerebrovascular accident 
 XaQbM Pure sensory lacunar syndrome    
Sub-dural 
haematoma Xa0AB Subdural haematoma 
 XA0BD Traumatic subdural haematoma 
 XaA99 Chronic intracranial subdural haematoma 
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 XaEIh Subdural haemorrhage 
 S628. Traumatic subdural haemorrhage 
 XE2w4 Non-traumatic subdural haematoma 
 XA0BE Traumatic intracranial subdural haematoma 
 XaKK3 Subdural haemorrhage NOS 
 S622. Closed traumatic subdural haemorrhage 
 S6226 Subdural h'ge inj no open intracran wnd+LOC unspec duration 
 Xa1uU Non-traumatic intracranial subdural haematoma 
 XaFsk Traumatic subdural haematoma without open intracranial wound 
 XaFsl Traumatic subdural haematoma with open intracranial wound 
 S6221 Subdural h'ge inj no open intracranial wound+no loss consc    
Subarachnoid 
haemorrhage Xa1uW Subarachnoid haemorrhage 
 G60z. Subarachnoid haemorrhage NOS 
 XA0BH Traumatic subarachnoid haemorrhage 
 Gyu61 [X]Other subarachnoid haemorrhage 
 S6201 Subarachnoid h'ge inj no open intracran wnd+no loss consc 
 XE2bF Spontaneous subarachnoid haemorrhage 
 Xa01k Subarachnoid haemorrhage from post communic artery aneurysm 
 Xa01l Subarachnoid haemorrhage from basilar artery aneurysm 
 Xa01b Subarachnoid haemorrhage from multiple aneurysms 
 Gyu6E [X]Subarachnoid haemorrh from intracranial artery, unspecif 
 Xa01j 
Subarachnoid haemorrhage from ant communicat artery 
aneurysm 
 Xa01h Subarachnoid haemorrhage frm middle cerebral artery aneurysm 
 XA0BI Traumatic intracranial subarachnoid haemorrhage 
 S6200 Subarachnoid h'ge inj no open intracran wound + unspec consc 
 Xa0N7 Angiogram-negative subarachnoid haemorrhage 
 Xa01i Subarachnoid haemorrhage from post cerebral artery aneurysm 
 X00Dg Subarachnoid haemorrhage due to ruptured aneurysm 
 Xa01m Subarachnoid haemorrhage from post inf cerebell artery aneur 
 Xa01c Subarachnoid haemorrhage from ant cerebral artery aneurysm 
 XE1m3 Closed traumatic subarachnoid haemorrhage 
 S621. Open traumatic subarachnoid haemorrhage 
 G601. Subarachnoid haemorrhage from carotid siphon and bifurcation 
 G606. Subarachnoid haemorrhage from vertebral artery 
 Xa01o Subarachnoid haemorrhage from carotid artery aneurysm 
 Gyu60 [X]Subarachnoid haemorrhage from other intracranial arteries    
Transient 
ischaemic 
attack XE0VK Transient ischaemic attack 
 G65z. Transient cerebral ischaemia NOS 
 G65.. (Drop attack) or (trans cereb isch) or (verteb-basil insuff) 
 X00DU Carotid territory transient ischaemic attack 
 X00DW Vertebrobasilar insufficiency 
 XaEGK Transient ischaemic attacks 
 F4236 Amaurosis fugax 
 G661. Anterior cerebral artery syndrome 
 Fyu55 [X]Other transnt cerebral ischaemic attacks+related syndroms 
 G660. Middle cerebral artery syndrome 
 G65y. Other transient cerebral ischaemia 
 X00DV Vertebrobasilar territory transient ischaemic attack 
 G662. Posterior cerebral artery syndrome 
 G6510 Vertebrobasilar artery syndrome 
 G651. Vertebral artery syndrome 
 XE0X0 (Trans isch attacks) or (vert-basil insuf) or (drop attacks) 
 G650. Basilar artery syndrome 
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 G654. Multiple and bilateral precerebral artery syndromes 
 G653. Carotid artery syndrome hemispheric    
Valvular disease X2011 Aortic stenosis 
 X2017 Aortic regurgitation 
 XE0Ux Mitral regurgitation 
 P6y0. Subaortic stenosis 
 G5414 Aortic valve stenosis with insufficiency 
 X2013 Calcific aortic stenosis - bicuspid valve 
 P641. Bicuspid aortic valve 
 X201L Pulmonary regurgitation 
 G541. Aortic valve disease 
 X777c Aortic valve calcification 
 XE0UZ Mitral stenosis 
 G5411 Aortic stenosis, non-rheumatic 
 XM00K Tricuspid regurgitation 
 XSDVN Aortic valve sclerosis 
 X200s Mitral restenosis 
 G110. Mitral stenosis (& [rheumatic]) 
 XE0UY Mitral valve disease 
 G11.. Mitral valve diseases (& [rheumatic]) 
 G5413 Aortic stenosis alone, cause unspecified 
 X7786 Mitral valve annular calcification 
 X77wI Dilatation of mitral annulus 
 X200u Mitral valve prolapse 
 X778h Aortic root dilatation 
 X777q Mitral cusp prolapse 
 X777i Senile sclerosis of aortic cusp 
 G5410 Aortic incompetence, non-rheumatic 
 X200r Rheumatic mitral stenosis 
 G5412 Aortic incompetence alone, cause unspecified 
 X201G Functional tricuspid regurgitation 
 G540. Mitral valve: [regurgitation] or [prolapse] 
 G5433 Pulmonary stenosis, cause unspecified 
 G541z Aortic valve disorders NOS 
 G5401 Mitral incompetence, cause unspecified 
 G5420 Tricuspid incompetence, non-rheumatic 
 X77wL Mitral leaflet abnormality 
 X77wQ True cleft of mitral leaflet 
 X777u Mitral valve appearance 
 X778A Mitral valve posterior leaflet prolapse 
 G11z. Mitral valve disease NOS 
 X201I Pulmonary valve stenosis 
 XE0Vq Rheumatic mitral valve disease (& [chronic]) 
 Xa0D0 Mitral valve anterior leaflet prolapse 
 X201C Tricuspid valve disease 
 Xa7tG Aortic valve vegetations 
 Xa7tH Mitral valve vegetations 
 XaI9k Non-rheumatic aortic sclerosis 
 X777a Aortic cusp regurgitation 
 G540z Mitral valve disorders NOS 
 G111. Rheumatic mitral regurgitation 
 G1404 Tricuspid insufficiency, cause unspecified 
 G5400 Non-rheumatic mitral regurgitation 
 P63.. Congenital aortic valve stenosis 
 Xa3fK Chronic rheumatic mitral valve 
 X2015 Senile aortic stenosis 
 X777b Aortic valve appearance 
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 Xa0Ct Isolated aortic stenosis 
 G112. Mitral stenosis with insufficiency 
 G121. Rheumatic aortic regurgitation 
 X77zp Aortic valve dysplasia 
 G120. Rheumatic aortic stenosis 
 G5431 Pulmonary stenosis, non-rheumatic 
 G5yy1 Papillary muscle degeneration 
 P61.. Congenital tricuspid atresia and stenosis 
 G543. Pulmonary valve disease 
 G5432 Pulmonary incompetence, cause unspecified 
 G12.. Rheumatic aortic valve disease 
 G140. Tricuspid valve disease NEC 
 P602z Congenital pulmonary stenosis NOS 
 G543z Pulmonary valve disorders NOS 
 G113. Non-rheumatic mitral valve stenosis 
 G5430 Pulmonary incompetence, non-rheumatic 
 Xa3fM Rheumatic mitral disease NOS 
 XE0Vu Rheumatic aortic valve disease (& [chronic]) 
 X777Y Prosthetic aortic valve regurgitation 
 G5yy0 Papillary muscle atrophy 
 G1401 Rheumatic tricuspid regurgitation 
 G542. Tricuspid valve disorders, non-rheumatic 
 XE0WW Pulmonary regurgitation (& [non-rheumatic]) 
 XE0Vs Rheumatic mitral insufficiency (& [stenosis with]) 
 Gyu10 [X]Other mitral valve diseases 
 X7782 Rheumatic mitral valve changes 
 P602. Congenital pulmonary valve stenosis 
 X77wD Mitral valve dysplasia 
 P62.. Ebstein's anomaly of tricuspid valve 
 X77wE Mitral leaflet dysplasia 
 X201B Congenital aortic valve abnormality 
 XE0WU Tricuspid incompetence (& [non-rheumatic]) 
 Gyu56 [X]Other aortic valve disorders 
 X201F Congenital tricuspid regurgitation 
 X77zv Aortic valve cusp abnormality 
 P65.. Congenital mitral stenosis 
 X2010 Congenital mitral valve abnormality 
 XE1KO Supravalvar aortic stenosis 
 X777o Prosthetic mitral valve regurgitation 
 X201D Tricuspid stenosis 
 G12z. Rheumatic aortic valve disease NOS 
 Gyu5A [X]Aortic valve disorders in diseases classified elsewhere 
 P600. Pulmonary valve anomaly, unspecified 
 X77zx Accessory tissue on aortic valve cusp 
 X200x Post-infarction mitral papillary muscle rupture 
 P60.. Congenital pulmonary valve abnormality 
 P652. Parachute malformation of mitral valve 
 G141. Rheumatic pulmonary valve disease 
 XE2bE Mitral chordae rupture 
 X201M Congenital pulmonary regurgitation 
 G542z Tricuspid valve disorders NOS 
 X7787 Torn mitral leaflet 
 P64z. Congenital aortic valve insufficiency NOS 
 G141z Rheumatic pulmonary valve disease NOS 
 X77vm Tricuspid valve dysplasia 
 X777W Aortic stenosis with doming 
 X7783 Rheumatic mitral valve leaflet changes 
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 X77vw Tricuspid valve prolapse 
 G122. Rheumatic aortic stenosis with insufficiency 
 G5434 Pulmonary valve stenosis with insufficiency 
 P66.. Congenital mitral regurgitation 
 X777d Aortic valve fibrosis 
 G1403 Tricuspid stenosis, cause unspecified 
 G5421 Tricuspid stenosis, non-rheumatic 
 X200w Mitral regurgitation due to dysfunct subvalvular apparatus 
 Gyu59 [X]Mitral valve disorders in diseases classified elsewhere 
 Gyu11 [X]Other rheumatic aortic valve diseases 
 P651. Fused commissure of the mitral valve 
 P6yyC Fusion of mitral valve cusps 
 G140z Rheumatic tricuspid valve disease NOS 
 X2019 Aortic regurgitation due to cystic medial necrosis of aorta 
 Gyu5B [X]Tricuspid valve disorders/diseases CE 
 Gyu58 [X]Other pulmonary valve disorders 
 G1402 Rheumatic tricuspid stenosis and insufficiency 
 G364. Ruptur chordae tendinae/curr comp fol acute myocard infarct 
 Gyu57 [X]Other non-rheumatic tricuspid valve disorders 
 G1410 Rheumatic pulmonary valve stenosis 
 X77vt Tricuspid leaflet abnormality 
 P64.. Congenital aortic valve insufficiency 
 X7801 Aortic valve cusp prolapse 
 Gyu5f [X]Non-rheumatic tricuspid valve disorder, unspecified 
 Xa7rx Tricuspid valve vegetations 
 Gyu55 [X]Other non-rheumatic mitral valve disorders 
 P60zz Other pulmonary valve anomaly NOS    
Varices X2063 Oesophageal varices 
 X20UK Operation on oesophageal varices 
 G857. Gastric varices 
 G850. Bleeding oesophageal varices 
 760C5 Fibreoptic oesophagoscopy and banding of oesophageal varices 
 XaE6u Oesophageal varices NOS 
 760F4 Rigid oesophagoscopy and banding of oesophageal varices 
 76094 Open injection sclerotherapy to oesophageal varices 
 G8520 Oesophageal varices with bleeding in diseases EC 
 760C3 Fibreoptic oesophagoscopy & injection sclerotherapy varices 
 7609z Open operation on oesophageal varices NOS 
 XaC1d Oesophageal varices in alcoholic cirrhosis of the liver 
 G851. Oesophageal varices without bleeding 
 G852. Oesophageal varices in diseases EC 
 Gyu94 [X]Oesophageal varices in diseases classified elsewhere 
 XaBM6 Oesophageal varices in cirrhosis of the liver 
 76093 Local ligation of oesophageal varices 
 Xa9G4 Duodenal varices 
 X20Ui Sclerotherapy of oesophageal varices 
 7609 Open operations on oesophageal varices 
 G8521 Oesophageal varices without bleeding in diseases EC 
 G852z Oesophageal varices in diseases EC NOS 
 X206R Ruptured varix 
 
 
 
